Introduction		O
of		O
a		O
methyl		B-IUPAC
group		B-MODIFIER
in		O
the		O
2		O
-		O
position		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		O
substituted		B-MODIFIER
indole		O
resulted		O
in		O
further		O
increase		O
of		O
selectivity		O
for		O
the		O
5		O
-		O
HT2		O
receptor		O
.		O
Due		O
to		O
the		O
existence		O
of		O
several		O
chiral		O
centers		O
on		O
this		O
molecule		O
,		O
upon		O
the		O
formation		O
of		O
[		O
99mTc		O
]		O
TRODAT		O
-		O
1		O
complex		O
(		O
2		O
)		O
several		O
diastereomers		O
could		O
be		O
created		O
.		O
Thus		O
,		O
simple		O
replacement		O
of		O
the		O
terminal		O
propenyl		B-IUPAC
system		B-MODIFIER
[		O
C		O
(		O
16,17,18		O
)		O
]		O
in		O
7		O
with		O
a		O
cyclopropyl		B-IUPAC
group		B-MODIFIER
produced		O
acid		O
8		O
[		O
(		B-IUPAC
2E		I-IUPAC
,		I-IUPAC
4E		I-IUPAC
,		I-IUPAC
6E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethylthiochroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
methylene		I-IUPAC
-		I-IUPAC
4,6		I-IUPAC
-		I-IUPAC
heptadienoic		I-IUPAC
acid		I-IUPAC
with		O
markedly		O
reduced		O
activity		O
.		O
Thus		O
(		O
S		O
)		O
-		O
6b		O
has		O
a		O
lipophilicity		O
that		O
will		O
allow		O
a		O
relatively		O
higher		O
uptake		O
into		O
the		O
brain		O
compared		O
to		O
sulpiride		O
.		O
The		O
nigrostriatal		O
toxin		O
1		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1,2,3,6		I-IUPAC
-		I-IUPAC
tetrahydropyridine		I-IUPAC
(		O
MPTP		O
)		O
is		O
biotransformed		O
by		O
brain		O
monoamine		O
oxidase		O
(		O
MAO		O
)		O
to		O
an		O
unstable		O
dihydropyridinium		O
intermediate		O
that		O
reacts		O
with		O
cyanide		O
ion		O
to		O
form		O
an		O
alpha		B-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
tetrahydropyridine		I-IUPAC
adduct		O
and		O
,		O
in		O
the		O
absence		O
of		O
cyanide		O
ion		O
,		O
undergoes		O
disproportionation		O
to		O
the		O
1		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenylpyridinium		I-IUPAC
species		O
MPP+		O
and		O
MPTP		O
.		O
All		O
N		O
(		O
4		O
)		O
-		O
hydroxy		O
-		O
dCMP		O
(		O
6a		O
,		O
b		O
,		O
d		O
-		O
h		O
)		O
and		O
dUMP		O
analogues		O
studied		O
were		O
competitive		O
vs		O
dUMP		O
inhibitors		O
of		O
the		O
enzyme		O
.		O
We		O
have		O
prepared		O
fluoroalkyl		O
analogs		O
of		O
QNB		O
,		O
which		O
are		O
amenable		O
to		O
labeling		O
with		O
18F		O
,		O
for		O
potential		O
imaging		O
applications		O
with		O
positron		O
emission		O
tomography		O
.		O
Structure		O
-		O
activity		O
relationships		O
within		O
this		O
series		O
of		O
compounds		O
are		O
discussed		O
.		O
In		O
the		O
cocaine		O
discrimination		O
test		O
,		O
all		O
analogues		O
showed		O
full		O
or		O
at		O
least		O
50%		O
generalization		O
with		O
the		O
exception		O
of		O
3p		O
,		O
which		O
did		O
not		O
show		O
generalization		O
.		O
In		O
the		O
absence		O
of		O
a		O
spacer		O
(		O
1		O
)		O
,		O
the		O
analogue		O
exhibited		O
dual		O
delta		O
-		O
agonism		O
(		O
pEC		O
(		O
50		O
)		O
,		O
7.28		O
)		O
and		O
delta		O
-		O
antagonism		O
(		O
pA		O
(		O
2		O
)		O
,		O
7.90		O
)		O
.		O
Requisite		O
heterocycles		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
7c		O
)		O
,		O
3		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
7d		O
)		O
,		O
3		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
7e		O
)		O
,		O
and		O
4		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
7f		O
)		O
were		O
synthesized		O
by		O
known		O
procedures		O
from		O
4		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyridinone		I-IUPAC
(		O
6		O
)		O
.		O
[		O
Cys		O
(		O
Acm		O
)		O
2		O
,		O
D		O
-		O
Trp		O
(		O
Boc		O
)		O
4		O
,		O
Lys		O
(		O
Boc		O
)		O
5		O
,		O
Thr		O
(		O
tBu		O
)		O
6		O
,		O
Cys		O
(		O
Acm		O
)		O
7		O
,		O
des		B-IUPAC
(		I-IUPAC
threoninol		I-IUPAC
)		I-IUPAC
]		I-IUPAC
-		I-IUPAC
octreotide		I-IUPAC
was		O
assembled		O
by		O
Fmoc		O
solid		O
-		O
phase		O
synthesis		O
and		O
the		O
intramolecular		O
disulfide		O
bond		O
formed		O
by		O
treatment		O
of		O
the		O
resin		O
-		O
bound		O
peptide		O
with		O
thallium		O
trifluoroacetate		O
[		O
Tl		O
(		O
Tfa		O
)		O
3		O
]		O
.		O
1,3		B-IUPAC
-		I-IUPAC
Dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
13		O
were		O
prepared		O
from		O
2		B-IUPAC
-		I-IUPAC
aminopyridine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acids		I-IUPAC
(		O
7		O
,		O
10		O
)		O
via		O
Curtius		O
rearrangement		O
.		O
Strips		O
of		O
rabbit		O
bladder		O
neck		O
were		O
employed		O
as		O
a		O
predictive		O
assay		O
for		O
antagonism		O
in		O
the		O
human		O
lower		O
tract		O
.		O
None		O
of		O
the		O
DNA		O
polymerases		O
examined		O
were		O
able		O
to		O
incorporate		O
this		O
compound		O
into		O
the		O
growing		O
DNA		O
chain		O
.		O
Four		O
polyamine		O
conjugates		O
are		O
synthesized		O
,		O
two		O
of		O
terephthalic		O
acid		O
[		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
)		I-IUPAC
benzoylspermine		I-IUPAC
(		O
7		O
)		O
and		O
its		O
methyl		O
ester		O
(		O
6		O
)		O
]		O
and		O
two		O
of		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dihydroxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
thiazolecarboxylic		I-IUPAC
acid		I-IUPAC
[		O
(		O
S		O
)		O
-		O
4'		O
-		O
(		O
HO		O
)		O
-		O
DADFT		O
]		O
[		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
12		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5,9		I-IUPAC
-		I-IUPAC
diazadodecyl		I-IUPAC
-		I-IUPAC
oxy		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
thiazolecarboxylic		I-IUPAC
acid		I-IUPAC
(		O
10		O
)		O
and		O
its		O
ethyl		O
ester		O
(		O
9		O
)		O
]		O
.		O
The		O
activity		O
of		O
the		O
title		O
compounds		O
was		O
determined		O
in		O
vitro		O
against		O
Gram		O
-		O
positive		O
and		O
Gram		O
-		O
negative		O
bacteria		O
,		O
and		O
the		O
in		O
vivo		O
efficacy		O
of		O
selected		O
derivatives		O
was		O
determined		O
using		O
a		O
mouse		O
infection		O
model		O
.		O
The		O
three		O
-		O
atom		O
-		O
bridged		O
analogue		O
4		O
was		O
somewhat		O
more		O
inhibitory		O
to		O
human		O
TS		O
than		O
methotrexate		O
(		O
MTX		O
)		O
.		O
The		O
new		O
compounds		O
,		O
bearing		O
a		O
branched		O
(		O
4		O
)		O
or		O
a		O
geometrically		O
constrained		O
benzyl		B-IUPAC
/		O
phenylethyl		B-IUPAC
amide		I-IUPAC
side		B-MODIFIER
chain		I-MODIFIER
(		O
5-8		O
)		O
,		O
represent		O
the		O
continuation		O
of		O
our		O
research		O
on		O
N		B-IUPAC
-		I-IUPAC
benzylindol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylglyoxylylamides		I-IUPAC
1		O
(		O
Da		O
Settimo		O
et		O
al.		O
,		O
1996		O
)		O
,		O
N'		B-IUPAC
-		I-IUPAC
phenylindol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylglyoxylohydrazides		I-IUPAC
2		O
(		O
Da		O
Settimo		O
et		O
al.		O
,		O
1998		O
)		O
,		O
and		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylglyoxylyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
derivatives		B-MODIFIER
3		O
(		O
Primofiore		O
et		O
al.		O
,		O
1989		O
)		O
.		O
Nine		O
compounds		O
with		O
BZ		O
receptor		O
IC50		O
binding		O
affinity		O
values		O
equal		O
or		O
superior		O
to		O
diazepam		O
were		O
evaluated		O
in		O
secondary		O
screening		O
.		O
Provided		O
these		O
types		O
of		O
purines		O
and		O
pyrimidines		O
do		O
not		O
exhibit		O
undesirable		O
toxicity		O
,		O
they		O
may		O
be		O
superior		O
to		O
O6		B-IUPAC
-		I-IUPAC
benzylguanine		I-IUPAC
as		O
chemotherapeutic		O
adjuvants		O
for		O
enhancing		O
the		O
effectiveness		O
of		O
antitumor		O
drugs		O
for		O
which		O
the		O
mechanism		O
of		O
action		O
involves		O
modification		O
of		O
the		O
O6		O
-		O
position		O
of		O
DNA		O
guanine		O
residues		O
.		O
Substituted		O
indole		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxamides		I-IUPAC
and		O
indole		B-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carboxamides		I-IUPAC
have		O
been		O
found		O
to		O
be		O
potent		O
and		O
selective		O
antagonists		O
of		O
the		O
peptidoleukotrienes		O
.		O
The		O
initial		O
purpose		O
of		O
this		O
work		O
was		O
to		O
determine		O
the		O
influence		O
of		O
different		O
groups		O
in		O
position		O
3		O
.		O
2		O
microM		O
)		O
was		O
shown		O
to		O
reside		O
exclusively		O
in		O
8		O
(		O
IC50		O
=		O
0.11		O
+		O
/		O
-		O
0.01		O
microM		O
;		O
EC50		O
=		O
0.71		O
+		O
/		O
-		O
0.11		O
microM		O
)		O
,		O
whereas		O
9		O
did		O
not		O
interact		O
significantly		O
with		O
AMPA		O
receptors		O
,		O
either		O
as		O
an		O
agonist		O
or		O
as		O
an		O
antagonist		O
.		O
The		O
data		O
indicated		O
that		O
a		O
considerable		O
degree		O
of		O
structural		O
variation		O
is		O
possible		O
while		O
still		O
retaining		O
nanomolar		O
affinity		O
at		O
sigma		O
receptors		O
.		O
All		O
radioactive		O
compounds		O
were		O
substrates		O
for		O
MGMT		O
,		O
as		O
demonstrated		O
using		O
a		O
competitive		O
repair		O
assay		O
.		O
Neither		O
the		O
chromophore		O
,		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylbutyl		I-IUPAC
]		I-IUPAC
ammonium		I-IUPAC
chloride		I-IUPAC
(		O
2		O
)		O
,		O
nor		O
the		O
side		O
-		O
chain		O
moiety		O
,		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydroxyhexanedioic		I-IUPAC
acid		I-IUPAC
(		O
4		O
)		O
,		O
as		O
separate		O
fragments		O
alone		O
showed		O
any		O
significant		O
activity		O
.		O
As		O
for		O
BTCP		O
,		O
all		O
of		O
the		O
compounds		O
tested		O
showed		O
Ki		O
values		O
&		O
gt		O
;		O
10,000		O
nM		O
for		O
displacement		O
of		O
[		O
3H		O
]		O
TCP		O
from		O
rat		O
brain		O
homogenates		O
.		O
Radiochemical		O
yields		O
,		O
with		O
respect		O
to		O
initial		O
[		O
18F		O
]		O
fluoride		O
ion		O
radioactivity		O
,		O
were		O
68-72%		O
(		O
decay		O
-		O
corrected		O
)		O
and		O
49-52%		O
(		O
non		O
-		O
decay		O
-		O
corrected		O
)		O
,		O
and		O
the		O
specific		O
radioactivities		O
at		O
EOB		O
were		O
4-7		O
Ci		O
/		O
micromol		O
(		O
148-259		O
GBq		O
/		O
micromol		O
)		O
.		O
Screening		O
of		O
the		O
compounds		O
was		O
with		O
one		O
of		O
two		O
assays		O
.		O
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
mandelate		I-IUPAC
.		O
The		O
ring		O
closure		O
of		O
3		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
5		B-PARTIUPAC
-		I-PARTIUPAC
cyclopentanecarboxamido		I-PARTIUPAC
-		I-PARTIUPAC
and		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
benzoylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
aminouracils		I-IUPAC
requires		O
drastic		O
reaction		O
conditions		O
.		O
O		O
(		O
6		O
)		O
-		O
Substituted		O
guanine		B-IUPAC
derivatives		B-MODIFIER
are		O
powerful		O
agents		O
used		O
for		O
tumor		O
cell		O
sensitization		O
by		O
inhibition		O
of		O
the		O
DNA		O
repair		O
enzyme		O
O		O
(		O
6		O
)		O
-		O
methylguanine		O
-		O
DNA		O
methyltransferase		O
(		O
MGMT		O
)		O
.		O
Biochemistry		O
1986		O
,		O
25		O
,		O
3021-3031		O
)		O
.		O
In		O
the		O
2,4		O
series		O
,		O
activity		O
against		O
aniline		O
hydroxylase		O
was		O
poor		O
or		O
absent		O
in		O
most		O
cases		O
.		O
The		O
key		O
compounds		O
11a		O
,		O
b		O
were		O
conveniently		O
obtained		O
by		O
Stille		O
coupling		O
between		O
2,5		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butylstannyl		I-IUPAC
)		I-IUPAC
furan		I-IUPAC
and		O
the		O
corresponding		O
heteroaryl		O
halides		O
.		O
The		O
effect		O
of		O
the		O
compounds		O
was		O
time		O
-		O
,		O
pH		O
-		O
,		O
and		O
concentration		O
-		O
dependent		O
,		O
with		O
&		O
gt		O
;		O
50%		O
and		O
&		O
gt		O
;		O
80%		O
estrogen		O
-		O
binding		O
sites		O
inactivated		O
at		O
0		O
degrees		O
C		O
and		O
pH		O
8.5		O
,		O
for		O
the		O
less		O
active		O
and		O
more		O
active		O
compounds		O
,		O
respectively		O
;		O
the		O
corresponding		O
IC50		O
values		O
varied		O
from		O
approximately		O
20		O
nM		O
to		O
approximately		O
10		O
microM		O
.		O
C		O
-		O
terminal		O
modification		O
primarily		O
affected		O
mu		O
-		O
opioid		O
receptor		O
affinities		O
,		O
which		O
increased		O
maximally		O
1700		O
-		O
fold		O
relative		O
to		O
the		O
prototype		O
delta		O
-		O
antagonist		O
H		O
-		O
Dmt		O
-		O
Tic		O
-		O
NH		O
(		O
2		O
)		O
and		O
differentially		O
modified		O
bioactivity		O
.		O
In		O
general		O
the		O
synthetic		O
route		O
involved		O
the		O
coupling		O
of		O
diethyl		B-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
prop		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ynylamino		I-IUPAC
)		I-IUPAC
benzoyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamate		I-IUPAC
with		O
the		O
appropriate		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
quinazoline		I-IUPAC
followed		O
by		O
deprotection		O
with		O
mild		O
alkali		O
.		O
Employing		O
a		O
recently		O
developed		O
q		O
-		O
jumping		O
molecular		O
dynamics		O
(		O
MD		O
)		O
simulation		O
method		O
,		O
which		O
allows		O
us		O
to		O
consider		O
the		O
flexibility		O
of		O
both		O
the		O
ligands		O
and		O
the		O
receptor		O
in		O
docking		O
studies		O
,		O
we		O
predicted		O
the		O
binding		O
models		O
of		O
phorbol		B-IUPAC
-		I-IUPAC
13		I-IUPAC
-		I-IUPAC
acetate		I-IUPAC
,		O
phorbol		B-IUPAC
-		I-IUPAC
12,13		I-IUPAC
-		I-IUPAC
dibutyrate		I-IUPAC
(		O
PDBu		O
)		O
,		O
indolactam		O
V		O
(		O
ILV		O
)		O
,		O
ingenol		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzoate		I-IUPAC
,		O
and		O
thymeleatoxin		O
to		O
PKC		O
.		O
Ring		O
substitution		O
(		O
e.g.		O
,		O
4		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
)		O
of		O
the		O
4		B-IUPAC
-		I-IUPAC
phenylethylnyl		I-IUPAC
group		B-MODIFIER
did		O
not		O
provide		O
enhanced		O
selectivity		O
,		O
as		O
it		O
did		O
for		O
the		O
4		B-IUPAC
-		I-IUPAC
styryl		I-IUPAC
-		O
substituted		B-MODIFIER
dihydropyridines		B-IUPAC
.		O
Several		O
compounds		O
were		O
tested		O
as		O
spinal		O
anesthetics		O
.		O
Generally		O
,		O
the		O
(		O
R		O
)		O
-		O
enantiomers		O
displayed		O
higher		O
affinity		O
for		O
the		O
5		O
-		O
HT1A		O
receptor		O
than		O
the		O
corresponding		O
(		O
S		O
)		O
-		O
enantiomers		O
.		O
Phosphates		O
of		O
the		O
aliphatic		O
alcohol		O
5e		O
could		O
be		O
obtained		O
by		O
both		O
methods		O
in		O
similar		O
yields		O
.		O
These		O
6		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
compounds		B-MODIFIER
are		O
of		O
interest		O
as		O
novel		O
nAChR		O
probes		O
and		O
potential		O
metabolites		O
of		O
candidate		O
insecticides		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitroimidazole		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
picolyl		I-IUPAC
)		I-IUPAC
acetamide		I-IUPAC
on		O
further		O
reaction		O
with		O
m		B-IUPAC
-		I-IUPAC
chloroperbenzoic		I-IUPAC
acid		I-IUPAC
produced		O
the		O
corresponding		O
N		O
-		O
oxide		O
.		O
The		O
7		B-IUPAC
-		I-IUPAC
hydroxypyrazolo		I-IUPAC
[		I-IUPAC
1,5		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
-		I-IUPAC
pyrimidines		I-IUPAC
were		O
not		O
as		O
active		O
.		O
Therefore		O
enantiomers		O
of		O
the		O
selected		O
hydroxamic		O
derivatives		O
of		O
cis		B-PARTIUPAC
-		I-PARTIUPAC
and		O
trans		B-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
cyclohexanedicarboxylic		I-IUPAC
acid		I-IUPAC
were		O
prepared		O
by		O
two		O
different		O
chiral		O
synthetic		O
routes		O
and		O
evaluated		O
in		O
vitro		O
for		O
their		O
ACE		O
inhibitor		O
potencies		O
.		O
Among		O
dihydroflavonol		O
analogues		O
,		O
the		O
2		B-IUPAC
-		I-IUPAC
styryl		I-IUPAC
instead		O
of		O
the		O
2		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
substituent		B-MODIFIER
,		O
in		O
15		O
,		O
afforded		O
selectivity		O
for		O
human		O
A3		O
vs		O
rat		O
A1		O
or		O
A2A		O
receptors		O
.		O
In		O
an		O
in		O
vivo		O
mouse		O
model		O
for		O
T		O
.		O
Incubation		O
of		O
AdoHcy		O
hydrolase		O
with		O
7		O
or		O
15		O
resulted		O
in		O
irreversible		O
inactivation		O
and		O
release		O
of		O
bromide		O
ion		O
.		O
Reaction		O
of		O
2		O
with		O
diethanolamine		O
under		O
various		O
conditions		O
and		O
different		O
solvents		O
resulted		O
in		O
the		O
corresponding		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
acetyl		I-IUPAC
]		I-IUPAC
precursors		O
,		O
which		O
were		O
subsequently		O
treated		O
with		O
SOCl2		O
to		O
yield		O
the		O
target		O
compounds		O
.		O
x		O
4		O
)		O
or		O
240		O
mg		O
/		O
kg		O
(		O
q		O
.		O
Potency		O
of		O
the		O
CAM		O
-		O
HOPO		O
ligands		O
for		O
in		O
vivo		O
chelation		O
of		O
Pu		O
(		O
IV		O
)		O
resembled		O
that		O
of		O
structurally		O
hexadentate		B-IUPAC
tris		I-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxypyridinonate		I-IUPAC
)		I-IUPAC
and		O
tris		B-IUPAC
(		I-IUPAC
sulfocatecholate		I-IUPAC
)		I-IUPAC
ligands		O
and		O
functionally		O
hexadentate		O
tetrakis		B-IUPAC
-		I-IUPAC
(		I-IUPAC
sulfocatecholate		I-IUPAC
)		I-IUPAC
and		O
tetrakis		B-IUPAC
(		I-IUPAC
carboxycatecholate		I-IUPAC
)		I-IUPAC
ligands		O
.		O
The		O
acetate		O
8		O
was		O
condensed		O
with		O
thymine		O
,		O
5		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
uracils		B-IUPAC
and		O
cytosines		B-IUPAC
,		O
6		B-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
,		O
and		O
6		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
fluoropurine		I-IUPAC
to		O
give		O
pyrimidine		O
and		O
purine		O
nucleosides		O
.		O
However		O
,		O
it		O
increased		O
the		O
rotorod		O
deficit		O
produced		O
by		O
ethanol		O
at		O
anxiolytic		O
doses		O
,		O
an		O
indication		O
of		O
alcohol		O
interaction		O
.		O
By		O
a		O
slightly		O
different		O
procedure		O
,		O
5		O
was		O
converted		O
in		O
two		O
steps		O
to		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
acetamidopropionic		I-IUPAC
acid		I-IUPAC
hydrobromide		I-IUPAC
(		O
7d		O
)		O
.		O
The		O
yields		O
of		O
Thf		O
-		O
FU		O
and		O
more		O
especially		O
of		O
Thf2		O
-		O
FU		O
were		O
greatly		O
dependent		O
on		O
the		O
relative		O
amount		O
of		O
SnCl4		O
,		O
and		O
0.01-0.1		O
equiv		O
of		O
the		O
catalyst		O
with		O
respect		O
to		O
Me3Si		O
-		O
FU		O
gave		O
the		O
best		O
results		O
.		O
This		O
has		O
led		O
to		O
an		O
increased		O
interest		O
in		O
the		O
development		O
of		O
RGD		O
compounds		O
with		O
high		O
affinity		O
and		O
improved		O
selectivity		O
for		O
integrin		O
receptors		O
.		O
When		O
compared		O
to		O
1		O
,		O
compound		O
21		O
as		O
well		O
as		O
its		O
analogue		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
methylenedioxyphthalazin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
(		I-IUPAC
2H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
16		O
)		O
show		O
a		O
longer		O
lasting		O
anticonvulsant		O
activity		O
.		O
The		O
synthesis		O
of		O
11		B-IUPAC
-		I-IUPAC
thiohomofolic		I-IUPAC
acid		I-IUPAC
(		O
2		O
)		O
has		O
been		O
accomplished		O
by		O
an		O
unambiguous		O
procedure		O
.		O
In		O
addition		O
,		O
selected		O
compounds		O
showed		O
potential		O
antipsychotic		O
effects		O
.		O
No		O
5,6		O
-		O
olefinic		O
bond		O
regeneration		O
was		O
observed		O
for		O
the		O
5		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
analogs		B-MODIFIER
.		O
The		O
most		O
active		O
heteroarotinoids		O
were		O
ester		O
10		O
[		O
methyl		B-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,2,4,4		I-IUPAC
-		I-IUPAC
tetramethylthiochroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoate		I-IUPAC
]		O
and		O
acid		O
11		O
[		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,2,4,4		I-IUPAC
-		I-IUPAC
tetramethyl		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzothiopyran		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
]		O
.		O
The		O
affinities		O
of		O
the		O
compounds		O
for		O
[		O
3H		O
]		O
raclopride		O
-		O
labeled		O
cloned		O
human		O
dopamine		O
(		O
DA		O
)		O
D2		O
and		O
D3		O
receptors		O
as		O
well		O
as		O
[		O
3H		O
]		O
-		O
8		O
-		O
OH		O
-		O
DPAT		O
-		O
labeled		O
rat		O
hippocampal		O
5		O
-		O
HT1A		O
receptors		O
were		O
determined		O
.		O
Most		O
of		O
the		O
compounds		O
were		O
less		O
potent		O
than		O
theophylline		O
and		O
none		O
were		O
remarkably		O
selective		O
for		O
A1		O
-		O
or		O
A2		O
-		O
adenosine		O
receptors		O
.		O
A		O
series		O
of		O
thymidylate		O
synthetase		O
inhibitors		O
was		O
synthesized		O
,		O
some		O
of		O
which		O
were		O
potential		O
irreversible		O
inhibitors		O
.		O
The		O
p		B-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butylbenzyl		I-IUPAC
-		O
quaternized		B-MODIFIER
analogue		I-MODIFIER
very		O
strongly		O
inhibited		O
(		O
ED		O
(		O
50		O
)		O
&		O
lt		O
;		O
1		O
microM		O
)		O
growth		O
of		O
the		O
amastigote		O
stage		O
of		O
T		O
.		O
In		O
vivo		O
studies		O
in		O
mice		O
showed		O
that		O
the		O
pip		O
-		O
pip		O
complexes		O
are		O
significantly		O
less		O
toxic		O
than		O
cisplatin		O
.		O
A		O
quantitative		O
structure		O
-		O
activity		O
relationship		O
was		O
developed		O
between		O
these		O
two		O
series		O
that		O
correctly		O
predicted		O
the		O
potencies		O
of		O
six		O
additional		O
5		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
pyrazolo		B-IUPAC
[		I-IUPAC
4,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
that		O
were		O
synthesized		O
during		O
the		O
course		O
of		O
the		O
analysis		O
.		O
Evaluation		O
of		O
these		O
compounds		O
in		O
L1210		O
,		O
HFF		O
,		O
and		O
KB		O
cells		O
showed		O
that		O
the		O
sugar		O
-		O
modified		O
analogs		O
all		O
were		O
less		O
cytotoxic		O
than		O
their		O
corresponding		O
ribonucleoside		O
analogs		O
.		O
Preliminary		O
screening		O
indicated		O
methyl		B-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,2		I-IUPAC
-		I-IUPAC
trichloroethenyl		I-IUPAC
)		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carbamate		I-IUPAC
to		O
be		O
the		O
most		O
potent		O
derivative		O
in		O
the		O
series		O
.		O
(		B-IUPAC
5		I-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
methanone		I-IUPAC
(		O
12		O
)		O
possessed		O
marked		O
central		O
depressant		O
activity		O
without		O
anticonvulsant		O
activity		O
and		O
without		O
impairment		O
of		O
motor		O
functioning		O
.		O
The		O
remaining		O
target		O
compounds		O
,		O
11-17		O
,		O
were		O
very		O
weak		O
or		O
inactive		O
as		O
inhibitors		O
of		O
both		O
uptake		O
systems		O
.		O
Optimization		O
of		O
ring		O
size		O
and		O
composition		O
led		O
to		O
the		O
discovery		O
of		O
cyclo		O
(		O
1-3		O
)		O
[		O
Ac		O
-		O
DAsp		O
(		O
1		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DLys		O
(		O
3		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
DAla		O
(		O
10		O
)		O
]		O
GnRH		O
(		O
5		O
,		O
K		O
(		O
i		O
)		O
=		O
0.82		O
nM		O
)		O
,		O
cyclo		O
(		O
1,1		O
'		O
-		O
3		O
)		O
[		O
Ac		O
-		O
DAsp		O
(		O
1		O
)		O
(		O
Gly		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DOrn		O
(		O
3		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
DAla		O
(		O
10		O
)		O
]		O
GnRH		O
(		O
13		O
,		O
K		O
(		O
i		O
)		O
=		O
0.34		O
nM		O
)		O
,		O
cyclo		O
(		O
1		O
,		O
1'		O
-		O
3		O
)		O
[		O
Ac		O
-		O
DAsp		O
(		O
1		O
)		O
(		O
Gly		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DLys		O
(		O
3		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
DA		O
la		O
(		O
10		O
)		O
]		O
GnRH		O
(		O
20		O
,		O
K		O
(		O
i		O
)		O
=		O
0.14		O
nM		O
)		O
,		O
and		O
cyclo		O
(		O
1,1		O
'		O
-		O
3		O
)		O
[		O
Ac		O
-		O
DAsp		O
(		O
1		O
)		O
(		O
betaAla		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DOrn		O
(		O
3		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
DAla		O
(		O
10		O
)		O
]		O
GnRH		O
(		O
21		O
,		O
K		O
(		O
i		O
)		O
=		O
0.17		O
nM		O
)		O
,		O
which		O
inhibited		O
ovulation		O
significantly		O
at		O
doses		O
equal		O
to		O
or		O
lower		O
than		O
25		O
microgram		O
/		O
rat		O
.		O
An		O
enzymatically		O
activated		O
liposome		O
-		O
based		O
drug		O
-		O
delivery		O
concept		O
involving		O
masked		O
antitumor		O
ether		O
lipids		O
(		O
AELs		O
)		O
has		O
been		O
investigated		O
.		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
Nitrothien		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
was		O
synthesized		O
using		O
ceric		O
ammonium		O
nitrate		O
as		O
reagent		O
.		O
The		O
results		O
obtained		O
indicate		O
that		O
(		O
a		O
)		O
the		O
nature		O
of		O
the		O
substituent		O
in		O
position		O
1		O
has		O
an		O
important		O
influence		O
on		O
the		O
biological		O
activity		O
of		O
these		O
peptides		O
,		O
and		O
(		O
b		O
)		O
the		O
potency		O
of		O
antagonists		O
I		O
-		O
IV		O
(		O
all		O
less		O
potent		O
antagonists		O
than		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
sarcosine		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
threonine		I-IUPAC
]		I-IUPAC
angiotensin		I-IUPAC
II		I-IUPAC
)		O
is		O
very		O
much		O
influenced		O
by		O
the		O
length		O
and		O
branching		O
of		O
the		O
side		O
chain		O
in		O
position		O
8		O
.		O
However		O
,		O
this		O
series		O
had		O
IC		O
(		O
50		O
)		O
values		O
of		O
&		O
gt		O
;		O
100		O
microM		O
,		O
66.7		O
microM		O
,		O
and		O
15.5		O
microM		O
,		O
respectively		O
,		O
in		O
CHO		O
-		O
MG		O
cells		O
,		O
which		O
are		O
PAT		O
-		O
deficient		O
.		O
In		O
addition		O
,		O
45		O
also		O
protected		O
gerbils		O
from		O
hippocampal		O
neuronal		O
degeneration		O
produced		O
by		O
either		O
hypoxia		O
or		O
intrastriatal		O
quinolinic		O
acid		O
injection		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
cyanamido		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
haloethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
7,8		I-IUPAC
)		I-IUPAC
analogues		B-MODIFIER
of		O
arabinouridine		O
were		O
moderately		O
inhibitory		O
for		O
VZV		O
and		O
HSV		O
-		O
1		O
(		O
strain		O
KOS		O
)		O
,		O
whereas		O
compounds		O
10		O
and		O
11		O
were		O
inactive		O
against		O
herpes		O
viruses		O
.		O
2		B-IUPAC
-		I-IUPAC
Phenylquinazolinones		I-IUPAC
were		O
marginally		O
less		O
potent		O
than		O
the		O
corresponding		O
2		B-IUPAC
-		I-IUPAC
methylquinazolinones		I-IUPAC
,		O
but		O
the		O
introduction		O
of		O
an		O
electron		O
-		O
withdrawing		O
or		O
electron		O
-		O
donating		O
4'		O
-		O
substituent		O
on		O
the		O
2		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
ring		B-MODIFIER
invariably		O
increased		O
potency		O
.		O
This		O
suggested		O
that		O
hybrid		O
N6		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
and		O
2		B-IUPAC
-		I-IUPAC
thioether		I-IUPAC
ATP		I-IUPAC
derivatives		B-MODIFIER
might		O
be		O
potent		O
and		O
selective		O
for		O
certain		O
P2Y		O
-		O
receptors		O
,		O
as		O
was		O
shown		O
for		O
one		O
such		O
derivative		O
,		O
N6		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hexenylthio		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ATP		I-IUPAC
.		O
Compound		O
10		O
was		O
also		O
effective		O
in		O
suppressing		O
seizures		O
induced		O
in		O
Swiss		O
mice		O
by		O
maximal		O
electroshock		O
(		O
MES		O
)		O
or		O
pentylenetetrazole		O
(		O
PTZ		O
)		O
.		O
Zone		O
assays		O
in		O
several		O
tumor		O
cell		O
lines		O
show		O
that		O
active		O
compounds		O
are		O
cytotoxic		O
agents		O
with		O
little		O
selectivity		O
for		O
tumor		O
cells		O
.		O
These		O
[		O
(		O
11		O
)		O
C		O
]		O
ligands		O
could		O
pass		O
across		O
the		O
blood		O
-		O
brain		O
barrier		O
and		O
enter		O
the		O
rat		O
brain		O
(		O
0.17-0.32%		O
of		O
injected		O
dose		O
per		O
gram		O
wet		O
tissue		O
)		O
.		O
About		O
2000X		O
less		O
2		O
than		O
1		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
naphthoxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propanol		I-IUPAC
(		O
3		O
)		O
,		O
the		O
product		O
of		O
N		O
-		O
dealkylation		O
of		O
1		O
,		O
was		O
formed		O
.		O
Reduction		O
with		O
trimethyl		O
phosphite		O
of		O
the		O
furoxan		O
derivatives		O
afforded		O
the		O
corresponding		O
furazans		O
,		O
while		O
oxidation		O
with		O
an		O
equimolar		O
amount		O
of		O
30%		O
hydrogen		O
peroxide		O
in		O
acetic		O
acid		O
or		O
with		O
an		O
excess		O
of		O
81%		O
hydrogen		O
peroxide		O
in		O
trifluoroacetic		O
acid		O
afforded		O
the		O
corresponding		O
arylsulfinyl		B-IUPAC
and		O
arylsulfonyl		B-IUPAC
analogues		B-MODIFIER
,		O
respectively		O
.		O
The		O
protecting		O
groups		O
were		O
removed		O
with		O
boron		O
trichloride		O
and		O
the		O
resulting		O
aglycone		O
glycosidated		O
with		O
optically		O
active		O
N		B-IUPAC
,		I-IUPAC
O		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
trifluoroacetyl		I-IUPAC
)		I-IUPAC
daunosamine		I-IUPAC
bromide		I-IUPAC
and		O
silver		O
trifluoromethanesulfonate		O
.		O
Of		O
the		O
compounds		O
,		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
carbonyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroisoquinoline		I-IUPAC
was		O
found		O
to		O
possess		O
the		O
highest		O
activity		O
.		O
The		O
most		O
potent		O
type		O
5		O
compound		O
was		O
1		B-IUPAC
-		I-IUPAC
decyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
diethylcarbamoyl		I-IUPAC
)		I-IUPAC
piperidine		I-IUPAC
(		O
5a		O
)		O
.		O
Also		O
prepared		O
via		O
DEPC		O
coupling		O
was		O
a		O
mixture		O
of		O
the		O
four		O
possible		O
diastereomers		O
of		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
N10		I-IUPAC
-		I-IUPAC
methylpteroyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
cyanoglutamic		I-IUPAC
acid		I-IUPAC
(		O
gamma		O
-		O
cyanoMTX		O
)		O
.		O
Allenic		O
isomerization		O
of		O
6b		O
gave		O
compound		O
5c		O
.		O
A		O
variety		O
of		O
1		O
-		O
O		O
-		O
acetylated		O
pentose		O
sugar		O
derivatives		O
were		O
condensed		O
with		O
silylated		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
oxopyrido		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
,		O
followed		O
by		O
protection		O
,		O
to		O
afford		O
a		O
series		O
of		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
oxopyrido		I-IUPAC
[		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
nucleosides		B-MODIFIER
.		O
Indoles		O
substituted		B-MODIFIER
in		O
the		O
1		O
-		O
position		O
with		O
4		B-IUPAC
-		I-IUPAC
piperazinyl		I-IUPAC
had		O
generally		O
weaker		O
affinity		O
for		O
both		O
5		O
-		O
HT2		O
and		O
D2		O
receptors		O
compared		O
to		O
corresponding		O
4		B-PARTIUPAC
-		I-PARTIUPAC
piperidinyl		I-PARTIUPAC
-		I-PARTIUPAC
and		O
1,2,3,6		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
-		O
substituted		B-MODIFIER
indoles		B-IUPAC
.		O
In		O
contrast		O
,		O
II		O
bound		O
with		O
higher		O
affinity		O
to		O
muscarinic		O
receptors		O
in		O
brainstem		O
,		O
cerebellar		O
,		O
and		O
hypothalamic		O
nuclei		O
(		O
IC50		O
values		O
less		O
than		O
0.5		O
microM		O
)		O
than		O
to		O
receptors		O
in		O
thalamic		O
nuclei		O
(		O
IC50		O
values		O
between		O
0.5		O
and		O
2.0		O
microM		O
)		O
.		O
These		O
prodrugs		O
may		O
be		O
useful		O
for		O
prodrug		O
monotherapy		O
of		O
necrotic		O
tumors		O
that		O
liberate		O
beta		O
-		O
glucuronidase		O
or		O
for		O
antibody		O
-		O
directed		O
enzyme		O
prodrug		O
therapy		O
with		O
antibodies		O
that		O
can		O
deliver		O
beta		O
-		O
glucuronidase		O
to		O
target		O
tumor		O
cells		O
.		O
8,9		O
-		O
Dioxo		O
-		O
6		O
-		O
phenyl		O
-		O
1		O
-		O
aza		O
-		O
7		O
-		O
oxabicyclo		O
[		O
4.2.1		O
]		O
nonane		O
(		O
1		O
)		O
and		O
9,10		B-IUPAC
-		I-IUPAC
dioxo		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
aza		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
oxabicyclo		I-IUPAC
[		I-IUPAC
5.2.1		I-IUPAC
]		I-IUPAC
decane		I-IUPAC
(		O
2		O
)		O
,		O
examples		O
of		O
anti		O
-		O
Bredt		O
bicyclic		O
2,4		B-IUPAC
-		I-IUPAC
oxazolidinediones		I-IUPAC
,		O
were		O
investigated		O
as		O
anticonvulsants		O
in		O
mice		O
.		O
Two		O
complete		O
and		O
two		O
partial		O
structure		O
-		O
activity		O
relationship		O
scans		O
of		O
the		O
active		O
fragment		O
of		O
human		O
growth		O
hormone		O
-		O
releasing		O
hormone		O
,		O
[		O
Nle27		O
]		O
-		O
hGHRH		O
(		O
1-29		O
)		O
-		O
NH2		O
,		O
have		O
identified		O
potent		O
agonists		O
in		O
vitro		O
.		O
The		O
Ki		O
for		O
inhibition		O
of		O
human		O
DHFR		O
by		O
the		O
5		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
and		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deaza		I-IUPAC
analogues		B-MODIFIER
was		O
about		O
the		O
same		O
as		O
that		O
of		O
3		O
(		O
0.35		O
pM		O
)		O
,		O
11		O
-		O
fold		O
lower		O
than		O
that		O
of		O
aminopterin		O
(		O
AMT		O
,		O
1		O
)		O
,		O
and		O
15		O
-		O
fold		O
lower		O
than		O
that		O
of		O
methotrexate		O
(		O
MTX		O
,		O
2		O
)		O
.		O
Their		O
absolute		O
configurations		O
were		O
assigned		O
by		O
1H		O
NMR		O
analyses		O
.		O
This		O
paper		O
outlines		O
the		O
synthesis		O
of		O
selected		O
acid		O
mimics		O
of		O
the		O
non		O
-		O
peptide		O
CCK		O
-		O
B		O
selective		O
antagonist		O
CI		O
-		O
988		O
,		O
1		O
.		O
The		O
anticonvulsant		O
activity		O
of		O
all		O
compounds		O
was		O
assayed		O
against		O
audiogenic		O
seizures		O
induced		O
in		O
DBA		O
/		O
2		O
mice		O
.		O
No		O
compound		O
showed		O
death		O
when		O
dosed		O
at		O
100		O
mg		O
/		O
kg		O
;		O
however		O
,		O
most		O
compounds		O
did		O
show		O
signs		O
typical		O
of		O
dopamine		O
activity		O
.		O
A		O
variety		O
of		O
amine		O
complexes		O
with		O
1		B-IUPAC
-		I-IUPAC
boraadamatane		I-IUPAC
were		O
synthesized		O
and		O
subsequently		O
evaluated		O
for		O
an		O
antiproliferative		O
effect		O
on		O
CD81		O
-		O
enriched		O
cell		O
lines		O
to		O
provide		O
evidence		O
for		O
binding		O
and		O
activation		O
of		O
CD81		O
.		O
A		O
series		O
of		O
dioxolane		O
analogues		B-MODIFIER
based		O
on		O
dexoxadrol		O
(		O
(		B-IUPAC
4S		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
diphenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
piperidyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dioxolane		I-IUPAC
)		O
and		O
etoxadrol		O
(		O
(		B-IUPAC
2S		I-IUPAC
,		I-IUPAC
4S		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
piperidyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dioxolane		I-IUPAC
)		O
were		O
prepared		O
and		O
tested		O
for		O
their		O
ability		O
to		O
displace		O
[		O
3H		O
]		O
TCP		O
(		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
cyclohexyl		I-IUPAC
]		I-IUPAC
piperidine		I-IUPAC
)		O
from		O
PCP		O
(		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phenylcyclohexyl		I-IUPAC
)		I-IUPAC
piperidine		I-IUPAC
)		O
binding		O
sites		O
in		O
rat		O
brain		O
tissue		O
homogenates		O
.		O
Although		O
it		O
was		O
hypothesized		O
that		O
these		O
new		O
agents		O
might		O
possess		O
high		O
affinity		O
for		O
the		O
serotonin		O
5		O
-		O
HT2A		O
/		O
2C		O
receptor		O
subtypes		O
,		O
unexpected		O
affinity		O
for		O
muscarinic		O
receptors		O
was		O
observed		O
.		O
In		O
the		O
2H		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
category		O
the		O
parent		O
phenol		O
was		O
also		O
inactive		O
whereas		O
the		O
basic		O
ethers		O
16		O
and		O
26		O
were		O
modest		O
receptor		O
ligands		O
while		O
being		O
quite		O
active		O
as		O
antiestrogens		O
.		O
Prodrug		O
9b		O
was		O
found		O
to		O
be		O
stable		O
in		O
aqueous		O
solution		O
(		O
pH		O
7		O
)		O
but		O
readily		O
cleaved		O
by		O
phosphatases		O
to		O
liberate		O
5e		O
(		O
MSX		O
-		O
2		O
)		O
.		O
In		O
addition		O
,		O
molecular		O
electrostatic		O
potentials		O
have		O
been		O
calculated		O
for		O
selected		O
conformations		O
and		O
the		O
absolute		O
configuration		O
of		O
the		O
potent		O
5		O
-		O
HT		O
-		O
receptor		O
agonist		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cis		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
di		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylamino		I-IUPAC
)		I-IUPAC
tetralin		I-IUPAC
has		O
been		O
determined		O
,		O
by		O
X		O
-		O
ray		O
crystallography		O
of		O
the		O
synthetic		O
precursor		O
,		O
to		O
be		O
1S		O
,		O
2R		O
.		O
The		O
introduction		O
of		O
a		O
tetrahydropyrido		O
ring		O
with		O
bulky		O
hydrophobic		O
substituents		O
at		O
the		O
basic		O
nitrogen		O
provided		O
inhibitors		O
of		O
AChE		O
which		O
were		O
completely		O
inactive		O
toward		O
CEase		O
.		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Diethylamino		I-IUPAC
)		I-IUPAC
thieno1		I-IUPAC
,		I-IUPAC
3		I-IUPAC
\C5		I-IUPAC
\8F		I-IUPAC
xazin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
act		O
as		O
acyl		O
-		O
enzyme		O
inhibitors		O
of		O
HLE		O
,		O
similar		O
to		O
the		O
inhibition		O
of		O
serine		O
proteases		O
by		O
4H		B-IUPAC
-		I-IUPAC
3,1		I-IUPAC
-		I-IUPAC
benzoxazin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
.		O
Condensation		O
of		O
N6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
omega		I-IUPAC
-		I-IUPAC
aminoalkyl		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
of		O
AMP		O
with		O
N		B-IUPAC
-		I-IUPAC
hydroxysuccinimide		I-IUPAC
esters		I-IUPAC
of		O
omega		B-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
carbobenzyloxy		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
carboxylic		I-IUPAC
acids		I-IUPAC
gave		O
N6		O
-		O
(		O
CH2		O
)		O
nNHCO		O
(		O
CH2		O
)		O
mNH		O
-		O
Cbz		O
derivatives		O
of		O
AMP		O
which		O
,		O
upon		O
conversion		O
to		O
the		O
corresponding		O
derivatives		O
of		O
ATP		O
,		O
followed		O
by		O
removal		O
of		O
the		O
carbobenzyloxy		B-IUPAC
group		B-MODIFIER
and		O
iodoacetylation		O
,		O
as		O
described		O
above		O
,		O
gave		O
N6		O
-		O
(		O
CH2		O
)		O
nNHCO		O
(		O
CH2		O
)		O
mNHCOCH2I		O
-		O
ATP		O
derivatives		O
(		O
n		O
=		O
3		O
,		O
m		O
=		O
5		O
or		O
6		O
;		O
n		O
=		O
4		O
,		O
m		O
=		O
5		O
;		O
n		O
=		O
6		O
,		O
m		O
=		O
1		O
-		O
-		O
6		O
)		O
.		O
With		O
the		O
plasma		O
enzyme		O
,		O
the		O
ID50		O
values		O
were		O
II		O
,		O
1.6		O
X		O
10		O
(		O
-		O
4		O
)		O
M		O
;		O
III		O
,		O
5		O
X		O
10		O
(		O
-		O
5		O
)		O
M		O
;		O
V		O
,		O
1.2		O
X		O
10		O
(		O
-		O
4		O
)		O
M		O
;		O
VI		O
5		O
X		O
10		O
(		O
-		O
4		O
)		O
M		O
;		O
VII		O
5		O
X		O
10		O
(		O
-		O
5		O
)		O
M		O
;		O
VIII		O
,		O
5		O
X		O
10		O
(		O
-		O
4		O
)		O
M		O
.		O
Optimization		O
of		O
5		O
resulted		O
in		O
the		O
preparation		O
of		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
thien		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylmethoxy		I-IUPAC
)		I-IUPAC
)		I-IUPAC
phenylprope		I-IUPAC
noic		I-IUPAC
acid		I-IUPAC
18		O
(		O
RPR111723		O
)		O
which		O
had		O
an		O
IC50		O
in		O
the		O
binding		O
assay		O
of		O
80		O
nM		O
on		O
the		O
ETA		O
receptor		O
and		O
a		O
pKB		O
of		O
6.5		O
in		O
the		O
functional		O
assay		O
,		O
measured		O
on		O
rat		O
aortic		O
strips		O
.		O
(		O
R		O
)		O
-		O
11b		O
was		O
not		O
an		O
inhibitor		O
of		O
murine		O
liver		O
AADC		O
.		O
A		O
diverse		O
set		O
of		O
compounds		O
was		O
synthesized		O
and		O
evaluated		O
to		O
probe		O
the		O
role		O
of		O
the		O
acidic		O
hydrogen		O
of		O
the		O
aminosulfonyl		B-IUPAC
group		B-MODIFIER
of		O
1		O
in		O
imparting		O
this		O
selectivity		O
.		O
Two		O
of		O
the		O
compounds		O
possessed		O
Ki		O
values		O
of		O
about		O
2x		O
10		O
(		O
-		O
4		O
)		O
M		O
with		O
guanine		O
aminohydrolase		O
,		O
but		O
no		O
inhibition		O
of		O
xanthine		O
oxidase		O
was		O
observed		O
by		O
any		O
at		O
5		O
x		O
10		O
(		O
-		O
4		O
)		O
M		O
.		O
The		O
compounds		O
were		O
potent		O
inhibitors		O
of		O
growth		O
in		O
folate		O
-		O
dependent		O
bacteria		O
,		O
Streptococcus		O
faecium		O
and		O
Lactobacillus		O
casei		O
.		O
Furthermore		O
,		O
it		O
antagonizes		O
in		O
vivo		O
seizures		O
induced		O
by		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
AMPA		O
)		O
,		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
isoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
ATPA		O
)		O
,		O
and		O
kainate		O
(		O
KA		O
)		O
,		O
and		O
its		O
anticonvulsant		O
activity		O
is		O
reversed		O
by		O
pretreatment		O
with		O
aniracetam		O
.		O
An		O
alternate		O
synthesis		O
utilizing		O
1		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
p		I-IUPAC
-		I-IUPAC
(		I-IUPAC
carbomethoxy		I-IUPAC
)		I-IUPAC
thiophenoxy		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
butanone		I-IUPAC
(		O
11		O
)		O
and		O
4		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2,5,6		I-IUPAC
-		I-IUPAC
triaminopyrimidine		I-IUPAC
has		O
also		O
been		O
carried		O
out		O
.		O
The		O
(		O
malonato		O
)		O
platinum		O
(		O
II		O
)		O
complex		O
1m		O
and		O
the		O
(		O
glycolato		O
)		O
platinum		O
(		O
II		O
)		O
complexes		O
3d		O
-		O
g		O
were		O
selected		O
for		O
further		O
studies		O
based		O
on		O
the		O
greater		O
in		O
vivo		O
and		O
in		O
vitro		O
antitumor		O
activity		O
and		O
desirable		O
physical		O
properties		O
.		O
The		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
analogue		B-MODIFIER
of		O
this		O
new		O
heterocyclic		O
ring		O
system		O
was		O
similarly		O
prepared		O
from		O
3		B-IUPAC
-		I-IUPAC
aminopyrazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carbonitrile		I-IUPAC
.		O
The		O
5		B-PARTIUPAC
-		I-PARTIUPAC
and		O
8		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
analogues		B-MODIFIER
were		O
prepared		O
from		O
methyl		B-IUPAC
2		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phthalimidopentanoate		I-IUPAC
and		O
4		B-PARTIUPAC
-		I-PARTIUPAC
amino		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
deoxy		I-PARTIUPAC
-		I-PARTIUPAC
N10		I-PARTIUPAC
-		I-PARTIUPAC
formyl		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
deaza		I-PARTIUPAC
-		I-PARTIUPAC
and		O
-		B-PARTIUPAC
8		I-PARTIUPAC
-		I-PARTIUPAC
deazapteroic		I-PARTIUPAC
acid		I-PARTIUPAC
,		O
respectively		O
.		O
Although		O
generally		O
less		O
active		O
,		O
the		O
4,5,7		O
-		O
unsubstituted		O
,		O
4		O
-		O
mono		O
-		O
substituted		O
,		O
cis		O
-		O
and		O
trans		O
-		O
5,7		O
-		O
di		O
-		O
Me		O
-		O
substituted		O
,		O
and		O
cis		O
-		O
4,5		O
-		O
di		O
-		O
Me		O
-		O
substituted		O
analogues		O
of		O
1		O
also		O
exhibited		O
some		O
significant		O
desired		O
activity		O
.		O
We		O
conclude		O
that		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
azacyclic		I-IUPAC
)		I-IUPAC
chromans		I-IUPAC
appear		O
to		O
be		O
a		O
promising		O
new		O
class		O
of		O
nicotine		O
agonists		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
5,8		I-IUPAC
-		I-IUPAC
dideaza		I-IUPAC
analogue		B-MODIFIER
of		O
3		O
was		O
the		O
most		O
active		O
member		O
of		O
the		O
series		O
,		O
with		O
an		O
IC50		O
=		O
0.33		O
nM		O
versus		O
1.8		O
nM		O
for		O
3		O
and		O
15		O
nM		O
for		O
MTX		O
.		O
59		O
nM		O
at		O
human		O
A3		O
receptors		O
and		O
was		O
moderately		O
selective		O
for		O
that		O
subtype		O
.		O
The		O
most		O
potent		O
compound		O
was		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
(		I-IUPAC
5H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
with		O
an		O
IC50		O
of		O
6.4		O
x		O
10		O
(		O
-		O
6		O
)		O
M		O
.		O
(		O
N		O
)		O
-		O
Methanocarba		O
-		O
T		O
(		O
2		O
)		O
was		O
further		O
evaluated		O
as		O
a		O
component		O
of		O
a		O
short		O
oligodeoxynucleotide		O
(		O
ODN		O
)		O
phosphorothioate		O
(		O
5'		O
-		O
CTTCATTTTTTCTTC		O
-		O
3'		O
)		O
where		O
all		O
thymidines		O
were		O
replaced		O
by		O
2		O
.		O
Several		O
benzoxazole		B-IUPAC
-		O
and		O
1,2,4		B-IUPAC
-		I-IUPAC
oxadiazole		I-IUPAC
-		O
derived		O
analogues		B-MODIFIER
were		O
found		O
to		O
be		O
potent		O
inhibitors		O
of		O
aldose		O
reductase		O
from		O
human		O
placenta		O
and		O
were		O
orally		O
active		O
in		O
preventing		O
sorbitol		O
accumulation		O
in		O
rat		O
sciatic		O
nerve		O
,		O
in		O
an		O
acute		O
test		O
of		O
diabetic		O
complications		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
acylethynyl		I-IUPAC
)		I-IUPAC
uracils		I-IUPAC
have		O
also		O
shown		O
in		O
vitro		O
activity		O
against		O
CCRF		O
-		O
CEM		O
and		O
L1210/0		O
tumor		O
cell		O
lines		O
.		O
)		O
and		O
P		O
.		O
Several		O
novel		O
substituted		B-MODIFIER
tetrahydro		B-PARTIUPAC
-		I-PARTIUPAC
and		O
hexahydro		B-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
benzisothiazol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
one		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxides		I-IUPAC
and		O
thiadiazinones		B-IUPAC
were		O
prepared		O
and		O
examined		O
in		O
a		O
series		O
of		O
in		O
vitro		O
and		O
in		O
vivo		O
tests		O
to		O
determine		O
their		O
pharmacological		O
profile		O
.		O
A		O
series		B-MODIFIER
of		O
4		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
arylthio		I-IUPAC
)		I-IUPAC
furoxans		I-IUPAC
were		O
synthesized		O
by		O
oxidation		O
of		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
arylthio		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylglyoxymes		I-IUPAC
with		O
dinitrogen		O
tetroxide		O
.		O
The		O
configuration		O
of		O
the		O
cyclopentane		O
unit		O
determined		O
the		O
affinity		O
profile		O
:		O
a		O
1R		O
configuration		O
,		O
as		O
in		O
(		O
+		O
)		O
-		O
3		O
and		O
(		O
-		O
)		O
-		O
4		O
,		O
conferred		O
higher		O
affinity		O
at		O
alpha		O
(		O
1		O
)		O
-		O
adrenoreceptors		O
,		O
whereas		O
a		O
1S		O
configuration		O
,		O
as		O
in		O
(		O
-		O
)		O
-		O
3		O
and		O
(		O
+		O
)		O
-		O
4		O
,		O
produced		O
higher		O
affinity		O
for		O
5		O
-		O
HT		O
(		O
1A		O
)		O
receptors		O
.		O
All		O
compounds		O
were		O
tested		O
for		O
activity		O
against		O
HCMV		O
and		O
HSV		O
-		O
1		O
.		O
A		O
cyclic		O
3		O
-		O
keto		O
derivative		O
was		O
5		O
-		O
fold		O
more		O
potent		O
at		O
A3		O
receptors		O
than		O
a		O
related		O
open		O
-		O
ring		O
analogue		O
.		O
Substituted		B-MODIFIER
9H		B-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
indoles		I-IUPAC
(		O
beta		O
-		O
carbolines		O
)		O
,		O
identified		O
in		O
our		O
laboratory		O
as		O
potential		O
pharmacophores		O
for		O
designing		O
macrofilaricidal		O
agents		O
,		O
have		O
been		O
explored		O
further		O
for		O
identifying		O
the		O
pharmacophore		O
responsible		O
for		O
the		O
high		O
order		O
of		O
adulticidal		O
activity		O
.		O
From		O
salicyclic		O
acid		O
,		O
the		O
two		O
enantiomers		O
of		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methoxybenzamide		I-IUPAC
(		O
6b		O
)		O
were		O
prepared		O
in		O
a		O
five		O
-		O
step		O
synthesis		O
.		O
A		O
series		O
of		O
new		O
enantiomerically		O
pure		O
3		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyrans		I-IUPAC
(		O
3		B-IUPAC
-		I-IUPAC
aminochromans		I-IUPAC
)		O
has		O
been		O
synthesized		O
from		O
(		B-PARTIUPAC
R		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
.		O
The		O
3,4		B-IUPAC
-		I-IUPAC
dimethoxybenzoate		I-IUPAC
23		O
was		O
nearly		O
twice		O
as		O
active		O
as		O
codeine		O
in		O
the		O
mouse		O
hot		O
-		O
plate		O
assay		O
.		O
Interestingly		O
,		O
another		O
analogue		O
of		O
this		O
series		O
,		O
[		O
Dmt1		O
,		O
d		O
-		O
1		O
-		O
Nal4		O
]		O
endomorphin		O
-		O
1		O
,		O
turned		O
out		O
to		O
be		O
a		O
moderately		O
potent		O
mixed		O
mu		O
-		O
agonist		O
/		O
delta		O
-		O
antagonist		O
.		O
Therefore		O
,		O
(		O
i		O
)		O
to		O
develop		O
affinity		O
labels		O
of		O
the		O
receptor		O
not		O
susceptible		O
to		O
hydrolysis		O
and		O
(		O
ii		O
)		O
to		O
specify		O
the		O
structural		O
requirements		O
for		O
17		O
alpha		O
-		O
electrophilic		O
estradiol		O
derivatives		O
to		O
be		O
potent		O
affinity		O
labels		O
of		O
the		O
receptor		O
,		O
we		O
prepared		O
four		O
17		B-IUPAC
alpha		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
haloacetamido		I-IUPAC
)		I-IUPAC
alkyl		I-IUPAC
]		I-IUPAC
estradiols		I-IUPAC
.		O
All		O
of		O
these		O
compounds		O
were		O
cytotoxic		O
to		O
H		O
.		O
The		O
3		O
-		O
and		O
4		O
-		O
monosubstituted		O
and		O
the		O
3,4		O
-		O
disubstituted		O
benzoate		O
esters		O
were		O
examined		O
for		O
qualitative		O
structure		O
-		O
activity		O
relationships		O
with		O
respect		O
to		O
parameters		O
Esc		O
and		O
pi		O
.		O
(		B-IUPAC
5		I-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
methanone		I-IUPAC
(		O
4		O
)		O
also		O
has		O
a		O
favorable		O
anticonvulsant		O
depression		O
ratio		O
.		O
These		O
tetraamines		O
include		O
a		O
simple		O
linear		O
analogue		O
of		O
DESPM		O
,		O
N1		B-IUPAC
,		I-IUPAC
N12		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2,2,2		I-IUPAC
-		I-IUPAC
trifluoroethyl		I-IUPAC
)		I-IUPAC
spermine		I-IUPAC
(		O
FDESPM		O
)		O
,		O
the		O
cyclic		O
analogues		O
of		O
DESPM		O
,		O
N		B-IUPAC
,		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidinylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
diaminobutane		I-IUPAC
[		O
PIP		O
(		O
4,4,4		O
)		O
]		O
and		O
N		B-IUPAC
,		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidinyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
diaminobutane		I-IUPAC
[		O
PIP		O
(		O
5,4,5		O
)		O
]		O
,		O
and		O
their		O
aromatic		O
counterparts		O
,		O
N		B-IUPAC
,		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
diaminobutane		I-IUPAC
[		O
PYR		O
(		O
4,4,4		O
)		O
]		O
and		O
N		B-IUPAC
,		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
diaminobutane		I-IUPAC
[		O
PYR		O
(		O
5,4,5		O
)		O
]		O
.		O
The		O
ability		O
of		O
selected		O
3		B-IUPAC
-		I-IUPAC
hydroxypyridinones		I-IUPAC
to		O
facilitate		O
the		O
excretion		O
of		O
iron		O
in		O
bile		O
was		O
investigated		O
in		O
non		O
-		O
iron		O
-		O
overloaded		O
,		O
bile		O
duct		O
-		O
cannulated		O
rats		O
and		O
in		O
a		O
[		O
59Fe		O
]		O
ferritin		O
-		O
loaded		O
rat		O
model		O
.		O
An		O
antagonism		O
toward		O
the		O
negative		O
influence		O
exerted		O
by		O
endogenous		O
adenosine		O
on		O
the		O
heart		O
seems		O
to		O
be		O
involved		O
in		O
the		O
contractile		O
activity		O
of		O
compound		O
28		O
.		O
Fifteen		O
of		O
these		O
analogues		O
(		O
all		O
but		O
6		O
)		O
appear		O
as		O
potent		O
or		O
more		O
potent		O
in		O
vivo		O
oxytocin		O
antagonists		O
than		O
C		O
(		O
pA2		O
=		O
7.37		O
+		O
/		O
-		O
0.17		O
)		O
.		O
Additional		O
structure		O
-		O
activity		O
relationships		O
encompassing		O
a		O
variety		O
of		O
heterocyclic		O
side		O
chains		O
are		O
discussed		O
.		O
Its		O
p		O
-		O
methoxy		O
analogue		O
5c		O
is		O
a		O
mixed		O
inhibitor		O
of		O
norepinephrine		O
and		O
serotonin		O
reuptake		O
(		O
K		O
(		O
i		O
)		O
=		O
187		O
nM		O
at		O
the		O
NET		O
and		O
56		O
nM		O
at		O
the		O
SERT		O
)		O
.		O
The		O
macrofilaricidal		O
activity		O
was		O
initially		O
evaluated		O
in		O
vivo		O
against		O
Acanthoeilonema		O
viteae		O
.		O
6		O
-		O
[		O
5		O
-		O
(		O
4		O
-		O
Amidinophenyl		O
)		O
furan		O
-		O
2		O
-		O
yl		O
]		O
nicotinamidine		O
(		O
8a		O
)		O
was		O
synthesized		O
from		O
6		B-IUPAC
-		I-IUPAC
[		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
cyanophenyl		I-IUPAC
)		I-IUPAC
furan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
nicotinonitrile		I-IUPAC
(		O
4a		O
)		O
,		O
through		O
the		O
bis		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetoxyamidoxime		I-IUPAC
followed		O
by		O
hydrogenation		O
.		O
Twenty		O
-		O
six		O
compounds		O
derived		O
from		O
the		O
5		B-PARTIUPAC
-		I-PARTIUPAC
deaza		I-PARTIUPAC
-		I-PARTIUPAC
and		O
5,10		B-IUPAC
-		I-IUPAC
dideazaaminopterin		I-IUPAC
series		B-MODIFIER
of		O
aminopterin		O
analogues		O
were		O
evaluated		O
for		O
antiarthritic		O
activity		O
in		O
the		O
mouse		O
type		O
II		O
collagen		O
model		O
.		O
Against		O
Ma		O
DHFR		O
,		O
28		O
had		O
IC		O
(		O
50		O
)		O
and		O
SI		O
values		O
of		O
1.5		O
nM		O
and		O
430		O
,		O
respectively		O
,		O
compared		O
with		O
300		O
nM		O
and		O
610		O
for		O
TMP		O
.		O
In		O
contrast		O
,		O
the		O
most		O
potent		O
Pgp		O
inhibitors		O
were		O
found		O
among		O
AbA		O
analogues		O
with		O
[		O
betaHO		O
-		O
MeVal		O
(		O
9		O
)		O
]		O
residue		O
alterations		O
,		O
with		O
some		O
data		O
suggesting		O
a		O
negative		O
impact		O
of		O
the		O
[		O
L		O
-		O
Leu		O
(		O
8		O
)		O
-		O
L		O
-		O
betaHOMeVal		O
(		O
9		O
)		O
-		O
D		O
-		O
Hmp		O
(		O
1		O
)		O
]		O
gamma		O
-		O
turn		O
secondary		O
structure		O
on		O
Pgp		O
inhibitory		O
potential		O
.		O
Moreover		O
,		O
in		O
vivo		O
binding		O
of		O
the		O
methyl		O
homologue		O
[		O
(		O
11		O
)		O
C		O
]		O
8		O
in		O
the		O
monkey		O
brain		O
could		O
be		O
inhibited		O
by		O
PBR		O
-		O
selective		O
2		O
or		O
1		O
,		O
indicating		O
that		O
some		O
of		O
the		O
[		O
(		O
11		O
)		O
C		O
]		O
8		O
binding		O
was		O
due		O
to		O
PBR		O
.		O
Analogues		O
1		O
,		O
2		O
,		O
and		O
4-6		O
exhibit		O
no		O
detectable		O
antidiuretic		O
agonistic		O
activity		O
.		O
The		O
identification		O
of		O
triazolinone		O
-		O
based		O
sulfonamide		O
derivatives		O
combining		O
high		O
AT1		O
affinity		O
,		O
considerably		O
enhanced		O
AT2		O
potency		O
,		O
and		O
favorable		O
in		O
vivo		O
properties		O
provides		O
insights		O
relevant		O
to		O
the		O
design		O
of		O
dual		O
AT1		O
/		O
AT2		O
receptor		O
antagonists		O
.		O
The		O
C3		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
ester		I-IUPAC
derivative		B-MODIFIER
is		O
10		O
-		O
fold		O
less		O
active		O
than		O
H1		O
,		O
and		O
SQS		O
inhibitory		O
activity		O
similar		O
to		O
that		O
of		O
the		O
methyl		O
ester		O
was		O
retained		O
only		O
in		O
those		O
C3		O
-		O
heterocycle		O
-		O
substituted		O
H1		O
analogues		O
for		O
which		O
electrostatic		O
potential		O
maps		O
of		O
the		O
C3		O
-		O
substituent		O
were		O
closely		O
similar		O
to		O
that		O
of		O
a		O
methyl		O
ester		O
.		O
Agonist		O
effects		O
were		O
sensitive		O
to		O
blockade		O
by		O
the		O
selective		O
H		O
(		O
1		O
)		O
-		O
receptor		O
antagonist		O
mepyramine		O
(		O
pA		O
(		O
2		O
)		O
approximately		O
9		O
(		O
guinea		O
-		O
pig		O
)		O
and		O
pA		O
(		O
2		O
)		O
approximately		O
8		O
(		O
rat		O
aorta		O
)		O
)		O
.		O
Analogues		O
of		O
degarelix		O
were		O
synthesized		O
,		O
characterized		O
,		O
and		O
screened		O
for		O
the		O
antagonism		O
of		O
GnRH		O
-		O
induced		O
response		O
in		O
a		O
reporter		O
gene		O
assay		O
in		O
HEK		O
-		O
293		O
cells		O
expressing		O
the		O
human		O
GnRH		O
receptor		O
.		O
Reaction		O
of		O
2,3		B-IUPAC
-		I-IUPAC
dibromopropene		I-IUPAC
(		O
19		O
)		O
with		O
adenine		O
(		O
18		O
)		O
led		O
to		O
bromoalkene		O
20		O
,		O
which		O
was		O
benzoylated		O
to		O
give		O
N6		B-IUPAC
,		I-IUPAC
N6		I-IUPAC
-		I-IUPAC
dibenzoyl		I-IUPAC
derivative		B-MODIFIER
23		O
.		O
3		O
-		O
Deoxy		O
-		O
2,5		O
-		O
di		O
-		O
O		O
-		O
p		O
-		O
nitrobenzoyl		O
-		O
alpha		O
-		O
D		O
-		O
threo		O
-		O
entofuranosyl		O
bromide		O
(		O
1		O
)		O
reacted		O
with		O
mercuric		O
cyanide		O
to		O
give		O
2,5		B-IUPAC
-		I-IUPAC
anhydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
lyxo		I-IUPAC
-		I-IUPAC
hexononitrile		I-IUPAC
(		O
2		O
)		O
which		O
upon		O
acid		O
hydrolysis		O
of		O
the		O
CN		O
group		O
gave		O
acid		O
3		O
.		O
2		B-PARTIUPAC
-		I-PARTIUPAC
Chloro		I-PARTIUPAC
-		I-PARTIUPAC
,		O
2		B-PARTIUPAC
-		I-PARTIUPAC
bromo		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
2		B-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
fucose		I-IUPAC
(		O
9a		O
,		O
9b		O
,		O
and		O
13		O
,		O
respectively		O
)		O
have		O
been		O
prepared		O
by		O
addition		O
of		O
the		O
appropriate		O
halogen		O
to		O
3,4		B-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
fucal		I-IUPAC
,		O
followed		O
by		O
hydrolysis		O
of		O
the		O
anomeric		O
halogen		O
and		O
the		O
acetyl		O
groups		O
.		O
The		O
relative		O
activities		O
for		O
mRNA		O
induction		O
of		O
the		O
pS2		O
gene		O
in		O
MCF		O
-		O
7		O
cell		O
cultures		O
by		O
the		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxyalkyl		I-IUPAC
)		I-IUPAC
estrogens		I-IUPAC
closely		O
parallel		O
the		O
relative		O
binding		O
affinities		O
.		O
These		O
results		O
suggested		O
that		O
the		O
N		O
-		O
terminal		O
tripeptide		O
was		O
likely		O
to		O
assume		O
a		O
folded		O
conformation		O
favoring		O
the		O
close		O
proximity		O
of		O
the		O
side		O
chains		O
of		O
residues		O
1		O
and		O
3		O
.		O
All		O
of		O
the		O
test		O
compounds		O
were		O
potent		O
inhibitors		O
of		O
[		O
3H		O
]		O
-		O
5		O
-		O
HT		O
uptake		O
into		O
synaptosomes		O
in		O
vitro		O
,		O
with		O
the		O
S		O
enantiomer		O
of		O
6		O
being		O
most		O
active		O
.		O
This		O
compound		O
is		O
noncompetitive		O
with		O
the		O
ubiquinone		O
substrate		O
and		O
interacts		O
with		O
a		O
site		O
which		O
is		O
mutually		O
exclusive		O
with		O
that		O
of		O
rotenone		O
but		O
nonexclusive		O
with		O
that		O
of		O
piericidin		O
and		O
several		O
other		O
inhibitors		O
of		O
NADH		O
dehydrogenase		O
.		O
This		O
study		O
emphasizes		O
the		O
importance		O
of		O
the		O
metabolic		O
conversion		O
of		O
the		O
enantiomers		O
of		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylpiperidine		I-IUPAC
(		O
3		O
-		O
PPP		O
)		O
into		O
their		O
catechol		O
analogues		O
,		O
the		O
enantiomers		O
of		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydroxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylpiperidine		I-IUPAC
.		O
Selective		O
methylation		O
of		O
the		O
phenolic		B-MODIFIER
hydroxyl		B-IUPAC
group		B-MODIFIER
of		O
to		O
give		O
1		B-IUPAC
,		I-IUPAC
6		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylbutyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ammoniohexanoate		I-IUPAC
(		O
15		O
)		O
,		O
resulted		O
in		O
a		O
small		O
decrease		O
in		O
activity		O
.		O
These		O
data		O
support		O
the		O
hypothesis		O
that		O
mifentidine		O
,		O
like		O
cimetidine		O
,		O
acts		O
through		O
the		O
neutral		O
species		O
.		O
Good		O
penetration		O
into		O
the		O
CNS		O
was		O
documented		O
both		O
after		O
subcutaneous		O
and		O
peroral		O
administration		O
of		O
Lu		O
28-179		O
by		O
ex		O
vivo		O
binding		O
studies		O
.		O
A		O
similar		O
sequence		O
starting		O
from		O
methyl		B-IUPAC
N		I-IUPAC
(		I-IUPAC
delta		I-IUPAC
)		I-IUPAC
-		I-IUPAC
benzyloxycarbonyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
ornithine		I-IUPAC
led		O
to		O
2		B-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
[		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
oxopyrido		I-IUPAC
[		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methylamino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
isoindolyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
aminopentanoic		I-IUPAC
acid		I-IUPAC
(		O
3		O
)		O
and		O
the		O
(		B-IUPAC
6R		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
derivative		B-MODIFIER
4		O
.		O
The		O
diamines		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminoethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminoaceto		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
6'		I-IUPAC
-		I-IUPAC
xylidide		I-IUPAC
(		O
13		O
)		O
and		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminoethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
diethylamino		I-IUPAC
)		I-IUPAC
aceto		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
6'		I-IUPAC
-		I-IUPAC
xylidide		I-IUPAC
(		O
29		O
)		O
are		O
especially		O
promising		O
in		O
this		O
respect		O
.		O
Since		O
the		O
binding		O
conformation		O
of		O
residue		O
1		O
must		O
be		O
included		O
in		O
this		O
limited		O
conformational		O
intersection		O
,		O
its		O
elucidation		O
is		O
facilitated		O
.		O
Substitution		O
at		O
the		O
ortho		O
or		O
meta		O
positions		O
of		O
the		O
phenyl		O
rings		O
,		O
replacement		O
by		O
thiopheneyl		O
or		O
cyclohexyl		O
moieties		O
,		O
or		O
constraining		O
in		O
a		O
planar		O
phenanthrene		O
system		O
resulted		O
in		O
compounds		O
that		O
were		O
less		O
effective		O
inhibitors		O
of		O
ADP		O
-		O
induced		O
platelet		O
aggregation		O
.		O
Most		O
notably		O
,		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
fluoromethyl		I-IUPAC
)		I-IUPAC
piperazine		I-IUPAC
(		O
10		O
)		O
and		O
hexahydro		B-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
diazepine		I-IUPAC
(		O
16		O
,		O
fluorohomopiperazine		O
)		O
at		O
the		O
quinolone		O
C		O
-		O
7		O
position		O
produced		O
products		O
with		O
similar		O
in		O
vitro		O
antibacterial		O
activity		O
as		O
the		O
ciprofloxacin		O
reference		O
.		O
As		O
deduced		O
by		O
the		O
rotarod		O
test		O
,		O
all		O
the		O
compounds		O
exhibit		O
a		O
toxicity		O
lower		O
than		O
that		O
of		O
1		O
.		O
X		O
-		O
ray		O
analyses		O
of		O
1		O
and		O
2		O
are		O
reported		O
,		O
and		O
compound		O
1		O
is		O
the		O
first		O
example		O
in		O
which		O
the		O
cbdca		O
ligand		O
is		O
coordinated		O
to		O
a		O
ruthenium		O
center		O
.		O
This		O
publication		O
describes		O
the		O
synthesis		O
and		O
optimization		O
of		O
a		O
novel		O
series		O
of		O
stilbene		O
endothelin		O
antagonists		O
.		O
Three		O
analogs		O
,		O
5		O
(		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
17		I-IUPAC
-		I-IUPAC
methylmorphinan		I-IUPAC
)		O
,		O
14		O
(		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
17		I-IUPAC
-		I-IUPAC
methylmorphinan		I-IUPAC
)		O
,		O
and		O
15		O
(		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propoxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
17		I-IUPAC
-		I-IUPAC
methylmorphinan		I-IUPAC
)		O
were		O
found		O
to		O
possess		O
potent		O
anticonvulsant		O
activity		O
with		O
full		O
efficacy		O
(		O
ED50		O
25		O
,		O
5.6		O
,		O
and		O
3.9		O
mg		O
/		O
kg		O
,		O
sc		O
,		O
respectively		O
)		O
in		O
the		O
rat		O
supramaximal		O
electroshock		O
(		O
MES		O
)		O
test		O
.		O
Each		O
compound		O
was		O
characterized		O
with		O
respect		O
to		O
the		O
following		O
:		O
structure		O
,		O
(		B-IUPAC
hydroxyimino		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
acid		I-IUPAC
dissociation		O
constant		O
,		O
nucleophilicity		O
toward		O
trigonal		O
carbon		O
and		O
tetrahedral		O
phosphorus		O
,		O
octanol		O
-		O
buffer		O
partition		O
coefficient		O
,		O
reversible		O
inhibition		O
of		O
eel		O
acetylcholinesterase		O
(		O
AChE		O
)		O
,		O
and		O
in		O
vitro		O
reactivation		O
of		O
AChE		O
inhibited		O
by		O
ethyl		O
p		O
-		O
nitrophenyl		O
methylphosphonate		O
.		O
This		O
compound		O
does		O
not		O
bind		O
in		O
vivo		O
to		O
alpha7		O
nicotinic		O
or		O
5HT3		O
receptors		O
.		O
The		O
1		O
:		O
1		O
diastereomeric		O
mixtures		O
thus		O
obtained		O
were		O
separated		O
by		O
chromatography		O
,		O
using		O
poly		O
(		O
D		O
-		O
phenylglycine		O
)		O
as		O
the		O
chiral		O
stationary		O
phase		O
.		O
gondii		O
DHFR		O
.		O
A		O
family		O
of		O
analogues		O
of		O
des		O
-		O
AA		O
(		O
1,2,5		O
)		O
-		O
[		O
DTrp		O
(		O
8		O
)		O
/		O
D2Nal		O
(		O
8		O
)		O
]		O
-		O
SRIF		O
that		O
contain		O
a		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aminomethylphenylalanine		I-IUPAC
(		O
IAmp		O
)		O
at		O
position		O
9		O
was		O
identified		O
that		O
has		O
high		O
affinity		O
and		O
selectivity		O
for		O
human		O
somatostatin		O
receptor		O
subtype		O
1		O
(		O
sst1		O
)		O
.		O
Incubation		O
of		O
5		B-IUPAC
-		I-IUPAC
hydroxytryptamine		I-IUPAC
(		O
1		O
)		O
with		O
L		O
-		O
cysteine		O
and		O
pig		O
or		O
bovine		O
brain		O
microsomes		O
and		O
an		O
NADPH		O
-		O
generating		O
system		O
or		O
with		O
synaptosomes		O
results		O
in		O
the		O
rapid		O
formation		O
of		O
the		O
(		B-MODIFIER
2R		I-MODIFIER
,		I-MODIFIER
4R		I-MODIFIER
)		I-MODIFIER
-		I-MODIFIER
and		O
(		B-MODIFIER
2S		I-MODIFIER
,		I-MODIFIER
4R		I-MODIFIER
)		I-MODIFIER
-		I-MODIFIER
epimers		I-MODIFIER
of		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
thiazolidine		I-IUPAC
.		O
Although		O
this		O
substituent		O
may		O
play		O
a		O
minor		O
role		O
in		O
orienting		O
the		O
conformation		O
of		O
the		O
5		O
-		O
methoxy		O
group		O
in		O
derivatives		O
such		O
as		O
4		O
and		O
5		O
,		O
there		O
appears		O
to		O
be		O
some		O
other		O
,		O
as		O
yet		O
unknown		O
,		O
critical		O
receptor		O
interaction		O
.		O
The		O
affinity		O
of		O
(		O
S		O
)		O
-		O
FIPCT		O
and		O
(		O
R		O
)		O
-		O
FIPCT		O
for		O
SERT		O
was		O
127		O
-		O
and		O
20		O
-		O
fold		O
lower		O
,		O
respectively		O
,		O
than		O
for		O
DAT		O
.		O
A		O
comparison		O
of		O
the		O
conformations		O
of		O
these		O
analogues		O
with		O
those		O
displayed		O
by		O
Leu5		O
-		O
enkephalin		O
has		O
also		O
been		O
made		O
,		O
and		O
unexpected		O
similarities		O
have		O
been		O
revealed		O
.		O
The		O
presence		O
of		O
an		O
additional		O
methyl		O
group		O
at		O
the		O
C		O
-		O
2		O
position		O
(		O
R3		O
in		O
3		O
)		O
of		O
the		O
cis		B-IUPAC
-		I-IUPAC
(		I-IUPAC
+		I-IUPAC
/		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
analog		B-MODIFIER
resulted		O
in		O
enhancement		O
of		O
in		O
vitro		O
5		O
-		O
HT1A		O
receptor		O
binding		O
affinity		O
,		O
with		O
the		O
(		O
2		O
beta		O
,		O
3a		O
alpha		O
,		O
9a		O
alpha		O
)		O
-		O
(		O
+		O
/		O
-		O
)		O
-		O
isomer		O
displaying		O
potency		O
35		O
times		O
greater		O
than		O
the		O
(		O
2		O
alpha		O
,		O
3a		O
alpha		O
,		O
9a		O
alpha		O
)		O
-		O
(		O
+		O
/		O
-		O
)		O
-		O
isomer		O
.		O
Although		O
there		O
existed		O
extensive		O
metabolizers		O
and		O
poor		O
metabolizers		O
in		O
Sprague		O
-		O
Dawley		O
rats		O
administrated		O
6,7		B-IUPAC
-		I-IUPAC
dimethoxyquinazoline		I-IUPAC
derivatives		B-MODIFIER
(		O
1b		O
and		O
1c		O
)		O
,		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
)		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
methoxyquinazoline		I-IUPAC
analogue		B-MODIFIER
16k		O
showed		O
no		O
metabolic		O
polymorphism		O
.		O
On		O
the		O
basis		O
of		O
the		O
high		O
potency		O
of		O
8		B-IUPAC
-		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dialkylxanthines		I-IUPAC
,		O
the		O
parent		O
compounds		O
were		O
8		B-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
carboxymethyl		I-IUPAC
)		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
derivatives		B-MODIFIER
of		O
theophylline		O
and		O
1,3		B-IUPAC
-		I-IUPAC
dipropylxanthine		I-IUPAC
.		O
The		O
ampicillin		O
derivative		O
7b		O
(		O
HKI		O
9924154		O
)		O
and		O
the		O
corresponding		O
amoxicillin		O
derivative		O
8		O
(		O
HKI		O
9924155		O
)		O
represent		O
the		O
most		O
active		O
compounds		O
.		O
Removal		O
of		O
the		O
p		B-IUPAC
-		I-IUPAC
methoxybenzyl		I-IUPAC
and		O
allyl		B-IUPAC
groups		B-MODIFIER
gave		O
2,4,5		B-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
myo		I-IUPAC
-		I-IUPAC
inositol		I-IUPAC
which		O
was		O
phosphitylated		O
with		O
bis		B-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
(		I-IUPAC
diisopropylamino		I-IUPAC
)		I-IUPAC
phosphine		I-IUPAC
to		O
give		O
the		O
fully		O
protected		O
trisphosphite		O
triester		O
.		O
2,4		B-IUPAC
-		I-IUPAC
Diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
sulfanylpyrimidine		I-IUPAC
gave		O
,		O
on		O
treatment		O
with		O
diisopropyl		B-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
chloroethoxy		I-IUPAC
)		I-IUPAC
methylphosphonate		I-IUPAC
in		O
the		O
presence		O
of		O
NaH		O
and		O
subsequent		O
deprotection		O
,		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonomethoxy		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
sulfanyl		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
.		O
The		O
most		O
active		O
member		O
of		O
the		O
series		O
is		O
the		O
dihydrodiol		B-IUPAC
derivative		B-MODIFIER
of		O
6		B-IUPAC
-		I-IUPAC
methylcholanthrene		I-IUPAC
,		O
which		O
contains		O
a		O
bay		O
region		O
methyl		B-IUPAC
group		B-MODIFIER
.		O
In		O
the		O
delayed		O
-		O
type		O
hypersensitivity		O
(		O
DTH		O
)		O
mouse		O
model		O
,		O
a		O
model		O
of		O
skin		O
inflammation		O
,		O
a		O
5%		O
solution		O
of		O
7d		O
reduced		O
edema		O
by		O
69%		O
compared		O
to		O
control		O
animals		O
.		O
The		O
latter		O
is		O
presumably		O
formed		O
by		O
dephosphorylation		O
of		O
FdUMP		O
by		O
plasma		O
5'		O
-		O
nucleotidases		O
or		O
phosphatases		O
.		O
Confirmed		O
in		O
vitro		O
cytotoxic		O
activity		O
that		O
parallels		O
antimicrobial		O
activity		O
was		O
found		O
for		O
juncusol		O
(		O
1a		O
)		O
,		O
desvinyljuncusol		O
(		O
2h		O
)		O
,		O
2		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
9,10		I-IUPAC
-		I-IUPAC
dihydrophenanthrene		I-IUPAC
(		O
3h		O
)		O
,		O
and		O
the		O
quaternary		B-MODIFIER
dimethyl		B-IUPAC
[		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
ammonium		I-IUPAC
salts		B-MODIFIER
2d		O
and		O
3d		O
in		O
a		O
human		O
lymphoblastic		O
leukemia		O
cell		O
culture		O
(		O
CCRF		O
-		O
CEM		O
,		O
IC50		O
=		O
nt		O
,		O
9.3		O
,		O
nt		O
,		O
0.9		O
and		O
1.4		O
microgram		O
/		O
mL		O
,		O
respectively		O
)		O
,		O
B		O
-		O
16		O
mouse		O
melanoma		O
cell		O
culture		O
(		O
IC50		O
=		O
12.5		O
,		O
17.5		O
,		O
27.7		O
,		O
0.3		O
,		O
and		O
0.5		O
microgram		O
/		O
mL		O
,		O
respectively		O
)		O
,		O
and		O
L		O
-		O
1210		O
mouse		O
lymphocytic		O
leukemia		O
cell		O
culture		O
(		O
IC50		O
=		O
13.8		O
,		O
10.2		O
,		O
24.5		O
,		O
1.3		O
,		O
and		O
3.7		O
micrograms		O
/		O
mL		O
,		O
respectively		O
)		O
.		O
The		O
3		B-IUPAC
-		I-IUPAC
halogenated		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylhistamines		I-IUPAC
(		O
halogen		O
=		O
Br		O
(		O
35		O
)		O
and		O
I		O
(		O
36		O
)		O
)		O
were		O
equipotent		O
with		O
histamine		O
,		O
while		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
)		I-IUPAC
histamine		I-IUPAC
(		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
trifluoromethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
ethanamine		I-IUPAC
(		O
39		O
)		O
)		O
was		O
significantly		O
more		O
potent		O
than		O
histamine		O
(		O
39		O
:		O
pD2		O
=		O
6.81		O
,		O
relative		O
activity		O
=		O
128%		O
)		O
.		O
A		O
bulky		O
N5		B-IUPAC
-		I-IUPAC
diphenylacetyl		I-IUPAC
derivative		B-MODIFIER
,		O
13		O
,		O
displayed		O
a		O
Ki		O
value		O
of		O
0		O
.		O
The		O
first		O
two		O
templates		O
studied		O
in		O
previous		O
investigations		O
corresponded		O
to		O
2		B-IUPAC
-		I-IUPAC
deoxyribonolactone		I-IUPAC
(		O
template		O
I		O
)		O
and		O
4,4		B-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
gamma		B-IUPAC
-		I-IUPAC
butyrolactone		I-IUPAC
(		O
template		O
II		O
)		O
,		O
with		O
the		O
latter		O
producing		O
potent		O
protein		O
kinase		O
C		O
(		O
PK		O
-		O
C		O
)		O
ligands		O
with		O
low		O
nanomolar		O
binding		O
affinities		O
.		O
High		O
activity		O
(		O
greater		O
than		O
100%		O
ILS		O
)		O
was		O
likewise		O
shown		O
by		O
the		O
bis		B-PARTIUPAC
(		I-PARTIUPAC
2,5		I-PARTIUPAC
-		I-PARTIUPAC
dimethylbenzyl		I-PARTIUPAC
)		I-PARTIUPAC
,		O
bis		B-PARTIUPAC
(		I-PARTIUPAC
2,6		I-PARTIUPAC
-		I-PARTIUPAC
dichlorobenzyl		I-PARTIUPAC
)		I-PARTIUPAC
,		O
and		O
di		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
picolyl		I-IUPAC
esters		I-IUPAC
of		O
MTX		O
and		O
by		O
the		O
bis		B-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylbutyl		I-IUPAC
)		I-IUPAC
ester		I-IUPAC
of		O
DCM		O
.		O
Compound		O
5		O
was		O
the		O
more		O
potent		O
with		O
activity		O
against		O
human		O
cytomegalovirus		O
and		O
herpes		O
simplex		O
virus		O
type		O
1		O
.		O
However		O
,		O
the		O
pKa		O
of		O
the		O
nitrogens		O
in		O
the		O
groups		O
differ		O
;		O
thus		O
,		O
the		O
extent		O
of		O
protonation		O
and		O
the		O
charge		O
characteristics		O
among		O
the		O
members		O
of		O
the		O
groups		O
differ		O
.		O
Receptor		O
-		O
binding		O
studies		O
suggest		O
that		O
this		O
activity		O
was		O
not		O
a		O
consequence		O
of		O
activity		O
at		O
either		O
benzodiazepine		O
or		O
NMDA		O
-		O
type		O
glutamate		O
receptors		O
.		O
Reaction		O
of		O
N		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
2,6		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
benzoquinone		I-IUPAC
imine		I-IUPAC
with		O
hydrochloric		O
acid		O
gave		O
3'		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
6'		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
hydroxyacetanilide		I-IUPAC
,		O
whereas		O
ethanethiol		O
,		O
aniline		O
,		O
and		O
ethanol		O
gave		O
tetrahedral		O
adducts		O
resulting		O
from		O
addition		O
to		O
the		O
imine		O
carbon		O
.		O
In		O
regard		O
to		O
6,7		B-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
groups		B-MODIFIER
,		O
ethoxy		O
analogues		O
showed		O
potent		O
activity		O
(		O
IC		O
(		O
50		O
)		O
of		O
16b		O
is		O
0.04		O
microM		O
;		O
IC		O
(		O
50		O
)		O
of		O
17a		O
is		O
0.01		O
microM		O
)		O
and		O
further		O
extension		O
of		O
the		O
alkyl		O
group		O
reduced		O
activity		O
.		O
1c		O
was		O
moderately		O
stable		O
in		O
aqueous		O
buffers		O
over		O
the		O
pH		O
range		O
1-7.4		O
(		O
T1/2		O
&		O
gt		O
;		O
30		O
h		O
)		O
.		O
Compound		O
13		O
does		O
not		O
affect		O
[		O
3H		O
]		O
glycine		O
binding		O
at		O
the		O
strychnine		O
-		O
insensitive		O
glycine		O
binding		O
site		O
,		O
and		O
[		O
3H		O
]		O
MK801		O
binding		O
studies		O
showed		O
that		O
the		O
(		B-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
tetrazole		I-IUPAC
,		O
even		O
if		O
is		O
formed		O
,		O
would		O
probably		O
have		O
no		O
effect		O
on		O
the		O
activity		O
of		O
tetrazol		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ylglycine		I-IUPAC
at		O
the		O
NMDA		O
receptor		O
.		O
The		O
5,5		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanone		I-IUPAC
proved		O
to		O
be		O
the		O
better		O
template		O
for		O
the		O
construction		O
of		O
DAG		O
surrogates		O
that		O
were		O
demonstrated		O
to		O
have		O
high		O
binding		O
affinities		O
for		O
the		O
biological		O
target		O
,		O
protein		O
kinase		O
C		O
(		O
PK		O
-		O
C		O
)		O
.		O
We		O
also		O
report		O
a		O
revision		O
of		O
our		O
previous		O
comparative		O
molecular		O
field		O
analysis		O
(		O
CoMFA		O
)		O
study		O
of		O
the		O
PAT		O
ligands		O
that		O
yields		O
a		O
highly		O
predictive		O
model		O
for		O
66		O
compounds		O
with		O
a		O
cross		O
-		O
validated		O
R		O
(		O
2		O
)		O
(		O
q		O
(		O
2		O
)		O
)		O
value		O
of		O
0.67		O
.		O
On		O
the		O
other		O
hand		O
,		O
formamides		O
32		O
(		O
N		B-IUPAC
-		I-IUPAC
heptyl		I-IUPAC
)		O
and		O
33		O
(		O
N		B-IUPAC
-		I-IUPAC
octyl		I-IUPAC
)		O
,		O
in		O
addition		O
to		O
inhibiting		O
the		O
type		O
I		O
enzyme		O
(		O
IC50s		O
=		O
9.57		O
and		O
16.9		O
nM		O
,		O
respectively		O
)		O
,		O
showed		O
also		O
strong		O
inhibitory		O
activity		O
(		O
IC50s		O
=		O
14.0		O
and		O
18.4		O
nM		O
,		O
respectively		O
)		O
for		O
human		O
type		O
II		O
5		O
alpha		O
-		O
reductase		O
,		O
in		O
comparison		O
to		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1'		I-IUPAC
,		I-IUPAC
1'		I-IUPAC
-		I-IUPAC
dimethylethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aza		I-IUPAC
-		I-IUPAC
5		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
androst		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ene		I-IUPAC
-		I-IUPAC
17		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
MK		O
-		O
906		O
;		O
IC50		O
=		O
4.53		O
nM		O
)		O
.		O
Also		O
,		O
the		O
active		O
imidazo		B-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
3		O
was		O
shown		O
to		O
cause		O
the		O
accumulation		O
of		O
cells		O
at		O
mitosis		O
.		O
The		O
present		O
survey		O
indicates		O
that		O
in		O
many		O
cases		O
such		O
reagents		O
may		O
be		O
difficult		O
of		O
access		O
when		O
data		O
are		O
not		O
available		O
regarding		O
structural		O
or		O
physicochemical		O
features		O
of		O
the		O
target		O
enzyme		O
adjacent		O
to		O
its		O
catalytic		O
site		O
.		O
Cathepsin		O
B		O
was		O
weakly		O
inhibited		O
by		O
most		O
compounds		O
in		O
this		O
study		O
.		O
It		O
displayed		O
a		O
potency		O
5		O
-		O
fold		O
higher		O
than		O
that		O
shown		O
by		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
7,8		I-IUPAC
-		I-IUPAC
methylenedioxy		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
benzodiazepine		I-IUPAC
(		O
1		O
,		O
GYKI		O
52466		O
)		O
,		O
a		O
well		O
-		O
known		O
noncompetitive		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
AMPA		O
)		O
receptor		O
antagonist		O
.		O
This		O
was		O
demonstrated		O
by		O
assays		O
with		O
mutants		O
deficient		O
in		O
components		O
of		O
the		O
iron		O
transport		O
systems		O
.		O
HBr		O
)		O
was		O
found		O
to		O
be		O
more		O
potent		O
as		O
an		O
inhibitor		O
of		O
the		O
NADH		O
:		O
UBQ		O
activity		O
(		O
IC50		O
=		O
15-17		O
microM		O
)		O
than		O
the		O
6		B-IUPAC
-		I-IUPAC
thienylimidazoles		I-IUPAC
such		O
as		O
10		O
.		O
The		O
new		O
leads		O
with		O
potent		O
H3		O
receptor		O
antagonist		O
activity		O
belong		O
to		O
a		O
series		O
of		O
derivatives		O
of		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propanol		I-IUPAC
with		O
carbamate		O
(		O
4-7		O
)		O
,		O
ester		O
(		O
8-16		O
)		O
,		O
and		O
ether		O
(		O
17-22		O
)		O
as		O
functional		O
groups		O
.		O
The		O
diamidines		O
8a		O
,		O
8c		O
,		O
and		O
14b		O
gave		O
IC		O
(		O
50		O
)		O
values		O
versus		O
T		O
.		O
Correlations		O
between		O
antibacterial		O
potency		O
of		O
all		O
the		O
synthesized		O
7		B-IUPAC
-		I-IUPAC
azetidinylquinolones		I-IUPAC
and		O
naphthyridines		O
and		O
their		O
calculated		O
electronic		O
properties		O
and		O
experimental		O
capacity		O
factors		O
were		O
established		O
.		O
Thus		O
,		O
hydroxylation		O
of		O
norspermine		O
analogues		O
appears		O
to		O
be		O
a		O
way		O
to		O
maintain		O
the		O
compounds		O
'		O
antiproliferative		O
activity		O
while		O
reducing		O
their		O
toxicity		O
.		O
All		O
members		O
of		O
the		O
series		O
were		O
designed		O
to		O
have		O
a		O
1,3		O
-		O
dioxolane		O
ring		O
moiety		O
in		O
their		O
carrier		O
ligands		O
to		O
increase		O
water		O
solubility		O
.		O
The		O
high		O
antiradiation		O
activity		O
and		O
low		O
toxicity		O
of		O
sodium		B-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxypropyl		I-IUPAC
hydrogen		I-IUPAC
phosphorothioate		I-IUPAC
(		O
1		O
)		O
suggested		O
the		O
introduction		O
of		O
hydroxyl		B-IUPAC
groups		B-MODIFIER
into		O
other		O
types		O
of		O
radioprotective		O
phosphorothioates		O
.		O
PET		O
study		O
determined		O
that		O
the		O
[		O
(		O
11		O
)		O
C		O
]		O
ligands		O
preferably		O
accumulate		O
in		O
the		O
occipital		O
cortex		O
of		O
the		O
monkey		O
brain		O
,		O
a		O
region		O
with		O
a		O
high		O
density		O
of		O
PBR		O
in		O
the		O
primate		O
brain		O
.		O
Molecular		O
mechanical		O
calculations		O
on		O
AMPA		O
,		O
ATPA		O
,		O
and		O
ABPA		O
using		O
the		O
program		O
MM2		O
showed		O
that		O
conformations		O
of		O
AMPA		O
,		O
ABPA		O
,		O
and		O
especially		O
ATPA		O
by		O
rotation		O
of		O
the		O
amino		O
acid		O
side		O
chain		O
have		O
energy		O
barriers		O
.		O
Assuming		O
that		O
the		O
interaction		O
between		O
these		O
racemic		O
compounds		O
and		O
PK		O
-		O
C		O
is		O
stereospecific		O
,		O
the		O
potency		O
of		O
the		O
active		O
enantiomer		O
is		O
anticipated		O
to		O
double		O
.		O
Individual		O
substitution		O
of		O
the		O
nine		O
most		O
potent		O
peptides		O
identified		O
from		O
the		O
Ala		O
series		O
with		O
the		O
helix		O
promoter		O
alpha		B-IUPAC
-		I-IUPAC
aminoisobutyric		I-IUPAC
acid		I-IUPAC
(		O
Aib		O
)		O
produced		O
similar		O
results		O
,		O
except		O
for		O
[		O
Aib8		O
]		O
(		O
doubling		O
vs		O
[		O
Ala8		O
]		O
)		O
,		O
[		O
Aib9		O
]		O
(		O
having		O
vs		O
[		O
Ala9		O
]		O
)		O
,		O
and		O
[		O
Aib15		O
]		O
(		O
10		O
-		O
fold		O
decrease		O
vs		O
[		O
Ala15		O
]		O
)		O
.		O
The		O
antitumor		O
activity		O
of		O
various		O
platinum		O
(		O
II		O
)		O
complexes		O
of		O
1,2		B-IUPAC
-		I-IUPAC
cyclohexanediamine		I-IUPAC
and		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
cyclohexylamine		I-IUPAC
isomers		O
against		O
leukemia		O
P388		O
was		O
evaluated		O
by		O
means		O
of		O
the		O
platinum		O
analogue		O
study		O
protocol		O
recommended		O
by		O
the		O
National		O
Cancer		O
Institute		O
.		O
This		O
study		O
identified		O
these		O
structural		O
classes		O
as		O
novel		O
DNA		O
-		O
PK		O
inhibitors		O
and		O
delineated		O
initial		O
structure		O
-		O
activity		O
relationships		O
against		O
DNA		O
-		O
PK		O
.		O
On		O
the		O
basis		O
of		O
our		O
recent		O
findings		O
that		O
[		B-IUPAC
188Re		I-IUPAC
]		I-IUPAC
tricarbonyl		I-IUPAC
(		I-IUPAC
cyclopentadienylcarbonate		I-IUPAC
)		I-IUPAC
rhenium		I-IUPAC
(		O
[		O
188Re		O
]		O
CpTR		O
-		O
COOH		O
)		O
was		O
recognized		O
as		O
an		O
aromatic		O
compound		O
and		O
was		O
metabolized		O
as		O
such		O
in		O
the		O
body		O
,		O
[		O
99mTc		O
]		O
cyclopentadienyltricarbonyltechnetium		O
(		O
[		O
99mTc		O
]		O
CpTT		O
)		O
was		O
conjugated		O
at		O
the		O
omega		O
-		O
position		O
of		O
pentadecanoic		O
acid		O
to		O
prepare		O
[		O
99mTc		O
]		O
CpTT		O
-		O
PA		O
.		O
The		O
first		O
stage		O
of		O
acid		O
hydrolysis		O
of		O
these		O
four		O
oxazaphosphorines		O
is		O
a		O
P		O
-		O
N		O
bond		O
cleavage		O
of		O
the		O
six		O
-		O
membered		O
ring		O
leading		O
to		O
the		O
phosphoramidic		O
acid		O
monoesters		O
(		O
2a		O
-		O
d		O
)		O
of		O
type		O
R'		O
HN		O
(		O
CH		O
(		O
2		O
)		O
)		O
(		O
3		O
)		O
OP		O
(		O
O		O
)		O
(		O
OH		O
)		O
NHR		O
,		O
with		O
R		O
and		O
/		O
or		O
R'		O
=		O
H		O
or		O
(		O
CH		O
(		O
2		O
)		O
)		O
(		O
2		O
)		O
Cl		O
.		O
The		O
conformational		O
characteristics		O
of		O
two		O
series		O
of		O
5		B-IUPAC
-		I-IUPAC
hydroxytryptamine		I-IUPAC
(		O
5		O
-		O
HT		O
)		O
receptor		O
agonists		O
,		O
monophenolic		B-IUPAC
N		I-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dialkylated		B-MODIFIER
2		B-IUPAC
-		I-IUPAC
aminotetralins		I-IUPAC
and		O
trans		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylcyclopropylamines		I-IUPAC
,		O
have		O
been		O
studied		O
by		O
a		O
combination		O
of		O
experimental		O
(		O
NMR		O
spectroscopy		O
)		O
and		O
theoretical		O
(		O
molecular		O
mechanics		O
and		O
MNDO		O
calculations		O
)		O
methods		O
.		O
The		O
syntheses		O
and		O
anthelmintic		O
activities		O
of		O
31		O
3		B-PARTIUPAC
-		I-PARTIUPAC
and		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
isothiocyanatophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
oxadiazoles		I-IUPAC
are		O
reported		O
.		O
The		O
data		O
showed		O
that		O
endocytosis		O
of		O
the		O
octameric		O
RGD		O
derivative		O
was		O
significantly		O
higher		O
by		O
comparison		O
to		O
other		O
compounds		O
in		O
this		O
study		O
.		O
Attempts		O
to		O
synthesize		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
bromomethyl		I-IUPAC
)		I-IUPAC
homoibotenic		I-IUPAC
acid		I-IUPAC
(		O
4f		O
)		O
,		O
a		O
potential		O
receptor		O
alkylating		O
agent		O
,		O
were		O
unsuccessful		O
.		O
Condensation		O
of		O
5		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
[		I-IUPAC
(		I-IUPAC
trimethylsilyl		I-IUPAC
)		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
with		O
2		B-IUPAC
-		I-IUPAC
acetoxyethyl		I-IUPAC
acetoxymethyl		I-IUPAC
ether		I-IUPAC
(		O
6		O
)		O
in		O
the		O
presence		O
of		O
SnCl4		O
afforded		O
the		O
acetate		O
ester		O
7		O
,		O
which		O
on		O
deprotection		O
with		O
NaOMe		O
gave		O
3		O
in		O
50-60%		O
overall		O
yield		O
.		O
Med.		O
Chem.		O
,		O
preceding		O
papers		O
in		O
this		O
issue		O
)		O
,		O
we		O
found		O
H		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Phe		O
-		O
Trp		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
(		O
OLT		O
-		O
8		O
,		O
2		O
)		O
,		O
H		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Phe		O
-		O
L		O
-		O
threo		O
-		O
beta		O
-		O
MeTrp		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
(		O
4		O
)		O
and		O
H		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Phe		O
-		O
D		O
-		O
threo		O
-		O
beta		O
-		O
MeTrp		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
(		O
5		O
)		O
to		O
have		O
very		O
high		O
affinity		O
for		O
sst		O
(		O
4		O
)		O
(		O
IC		O
(		O
50		O
)		O
=		O
0.7		O
,		O
1.8		O
,		O
and		O
4.0		O
nM		O
,		O
respectively		O
)		O
and		O
5		O
-		O
to		O
10		O
-		O
fold		O
selectivity		O
versus		O
the		O
other		O
sst		O
's		O
.		O
2,4		B-IUPAC
-		I-IUPAC
Diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aryl		I-IUPAC
/		I-IUPAC
aralkyl		I-IUPAC
)		I-IUPAC
thieno		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
with		O
3,4,5		B-IUPAC
-		I-IUPAC
trimethoxy		I-IUPAC
or		O
2,5		B-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
substitution		B-MODIFIER
in		O
the		O
aryl		O
/		O
aralkyl		O
moiety		O
and		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aryl		I-IUPAC
/		I-IUPAC
aralkyl		I-IUPAC
)		I-IUPAC
thieno		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
with		O
2,5		B-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
substitution		B-MODIFIER
in		O
the		O
aryl		O
/		O
aralkyl		O
moiety		O
were		O
obtained		O
by		O
reaction		O
of		O
the		O
corresponding		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
cyanothiophenes		I-IUPAC
with		O
chloroformamidine		O
hydrochloride		O
.		O
The		O
effect		O
of		O
substitution		O
in		O
the		O
acyclic		O
structure		O
of		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
-		I-IUPAC
thymine		I-IUPAC
(		O
HEPT		O
)		O
on		O
anti		O
-		O
HIV		O
-		O
1		O
activity		O
was		O
investigated		O
by		O
synthesizing		O
a		O
series		O
of		O
deoxy		B-IUPAC
analogs		B-MODIFIER
and		O
related		O
compounds		O
.		O
The		O
SAR		O
between		O
compound		O
1		O
and		O
1		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethylamine		I-IUPAC
derivatives		B-MODIFIER
suggested		O
that		O
the		O
alkyl		O
group		O
on		O
the		O
1		O
-		O
position		O
carbon		O
of		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
ethylamine		I-IUPAC
derivatives		B-MODIFIER
played		O
the		O
role		O
of		O
one		O
of		O
the		O
propyl		O
groups		O
on		O
the		O
aminic		O
nitrogen		O
of		O
compound		O
1		O
.		O
On		O
the		O
basis		O
of		O
overall		O
superior		O
affinity		O
,		O
high		O
selectivity		O
for		O
the		O
ETA		O
receptor		O
(		O
Ki		O
,		O
0.46		O
nM		O
for		O
ETA		O
and		O
13000		O
nM		O
for		O
ETB		O
)		O
,		O
and		O
good		O
oral		O
bioavailability		O
(		O
48%		O
in		O
rats		O
)		O
,		O
A		O
-		O
216546		O
(		O
10a		O
)		O
was		O
selected		O
as		O
a		O
potential		O
clinical		O
backup		O
for		O
1		O
.		O
Compounds		O
7a		O
,		O
b		O
,		O
analogues		O
of		O
AMPA		O
bearing		O
a		O
1		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
pyrazolyl		I-IUPAC
moiety		B-MODIFIER
as		O
the		O
distal		O
carboxylic		O
functionality		O
,		O
showed		O
only		O
moderate		O
affinity		O
for		O
[		O
3H		O
]		O
AMPA		O
receptor		O
binding		O
sites		O
(		O
IC		O
(		O
50		O
)		O
=		O
2.7		O
+		O
/		O
-		O
0.4		O
microM		O
and		O
IC		O
(		O
50		O
)		O
=		O
2.6		O
+		O
/		O
-		O
0.6		O
microM		O
,		O
respectively		O
)		O
,		O
correlating		O
with		O
electrophysiological		O
data		O
from		O
the		O
rat		O
cortical		O
wedge		O
model		O
(		O
EC		O
(		O
50		O
)		O
=		O
280		O
+		O
/		O
-		O
48		O
microM		O
and		O
EC		O
(		O
50		O
)		O
=		O
586		O
+		O
/		O
-		O
41		O
microM		O
,		O
respectively		O
)		O
.		O
The		O
compounds		O
8		O
,		O
15a		O
,		O
and		O
15b		O
have		O
no		O
effect		O
as		O
inhibitors		O
of		O
AMPA		O
binding		O
,		O
in		O
agreement		O
with		O
in		O
vivo		O
studies		O
that		O
have		O
shown		O
that		O
8		O
does		O
not		O
affect		O
the		O
firing		O
of		O
central		O
neurons		O
whereas		O
15a		O
and		O
15b		O
are		O
antagonists		O
at		O
NMDA		O
receptors		O
,		O
a		O
subpopulation		O
of		O
excitatory		O
receptors		O
not		O
affected		O
by		O
AMPA		O
.		O
The		O
representative		O
compound		O
,		O
2		B-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
biphenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzimidazole		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
26b		O
,		O
CV		O
-		O
11974		O
)		O
,		O
inhibited		O
the		O
specific		O
binding		O
of		O
[		O
125I		O
]		O
AII		O
to		O
bovine		O
adrenal		O
cortical		O
membrane		O
with		O
an		O
IC50		O
value		O
of		O
1.1		O
x		O
10		O
(		O
-		O
7		O
)		O
M		O
.		O
Evaluation		O
of		O
these		O
analogues		O
for		O
binding		O
to		O
muscarinic		O
and		O
dopamine		O
binding		O
sites		O
in		O
comparison		O
with		O
clozapine		O
and		O
other		O
5H		B-IUPAC
-		I-IUPAC
dibenzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
,		I-IUPAC
e		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1,4		I-IUPAC
]		I-IUPAC
diazepine		I-IUPAC
analogues		B-MODIFIER
of		O
clozapine		O
shows		O
that		O
the		O
dopamine		O
D		O
-		O
1		O
and		O
D		O
-		O
2		O
receptor		O
affinities		O
of		O
both		O
the		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propylidene		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5,11		I-IUPAC
-		I-IUPAC
dicarbo		I-IUPAC
analogue		B-MODIFIER
and		O
its		O
corresponding		O
distal		O
-		O
chloro		O
derivative		O
,		O
2		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propylidene		I-IUPAC
)		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylpiperazino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
dibenzo		I-IUPAC
[		I-IUPAC
a		I-IUPAC
,		I-IUPAC
d		I-IUPAC
]		I-IUPAC
cycloheptene		I-IUPAC
,		O
are		O
retained		O
.		O
All		O
indolo		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
quinolines		I-IUPAC
belonging		O
to		O
the		O
5H		O
series		O
,		O
i.e.		O
,		O
bearing		O
a		O
methyl		B-IUPAC
group		B-MODIFIER
on		O
the		O
pyridine		O
nitrogen		O
,		O
showed		O
significant		O
activity		O
against		O
procaryotic		O
and		O
eucaryotic		O
organisms		O
.		O
Treatment		O
of		O
3		O
with		O
sodium		O
methoxide		O
in		O
methanol		O
provided		O
a		O
good		O
yield		O
of		O
methyl		B-IUPAC
4		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
pyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
formimidate		I-IUPAC
(		O
4		O
)		O
.		O
It		O
is		O
nearly		O
inactive		O
at		O
the		O
time		O
of		O
administration		O
,		O
and		O
therefore		O
can		O
be		O
administered		O
,		O
at		O
high		O
dose		O
,		O
with		O
no		O
concern		O
for		O
hypoglycemia		O
.		O
Syntheses		O
of		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,3,3		I-IUPAC
-		I-IUPAC
trifluoro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
TFPe		O
-		O
dUrd		O
)		O
(		O
1		O
)		O
,		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,3,3		I-IUPAC
-		I-IUPAC
trifluoro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
11		O
)		O
,		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,3,3		I-IUPAC
-		I-IUPAC
trifluoro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
8		O
)		O
,		O
and		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3,3,3		I-IUPAC
-		I-IUPAC
trifluoro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
10		O
)		O
from		O
5		B-IUPAC
-		I-IUPAC
chloromercuri		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
are		O
described		O
.		O
In		O
the		O
present		O
investigation		O
,		O
the		O
last		O
two		O
possible		O
modes		O
of		O
generating		O
conformationally		O
semirigid		O
diacylglycerol		O
(		O
DAG		O
)		O
analogues		O
embedded		O
into		O
five		O
-		O
membered		O
ring		O
lactones		O
as		O
templates		O
III		O
and		O
IV		O
are		O
investigated		O
.		O
H		O
.		O
The		O
sedative		O
effect		O
of		O
20		O
,		O
evaluated		O
in		O
the		O
open		O
field		O
test		O
in		O
rats		O
,		O
appeared		O
at		O
doses		O
twice		O
as		O
high		O
as		O
those		O
inducing		O
a		O
minimal		O
anxiolytic		O
-		O
like		O
effect		O
and		O
was		O
similar		O
to		O
the		O
effects		O
of		O
diazepam		O
.		O
In		O
contrast		O
to		O
other		O
inhibitors		O
of		O
PNMT		O
,		O
it		O
is		O
also		O
highly		O
selective		O
toward		O
PNMT		O
in		O
comparison		O
with		O
its		O
affinity		O
toward		O
the		O
alpha		O
2		O
-		O
adrenoceptor		O
(		O
PNMT		O
Ki		O
=		O
0.55		O
microM		O
,		O
alpha		O
2		O
Ki		O
=		O
100		O
microM		O
,		O
selectivity		O
[		O
alpha		O
2		O
Ki		O
/		O
PNMT		O
Ki		O
]		O
=		O
180		O
)		O
.		O
2		O
-		O
(		O
Aminomethyl		O
)		O
-		O
4		O
-		O
aminobutyric		O
acid		O
(		O
isoornithine		O
)		O
,		O
3		B-IUPAC
-		I-IUPAC
methylisoornithine		I-IUPAC
,		O
and		O
2,3		B-IUPAC
-		I-IUPAC
dimethylisoornithine		I-IUPAC
were		O
not		O
decarboxylated		O
by		O
liver		O
ornithine		O
decarboxylase		O
(		O
ODC		O
,		O
EC		O
4.1.1.17		O
)		O
of		O
thioacetamide		O
-		O
treated		O
rats		O
but		O
were		O
good		O
competitive		O
inhibitors		O
of		O
the		O
enzyme		O
(		O
Ki		O
ranged		O
from		O
0.72		O
to		O
1.79		O
mM		O
)		O
.		O
On		O
the		O
basis		O
of		O
the		O
selective		O
incorporation		O
of		O
deuterium		O
into		O
these		O
products		O
,		O
we		O
provide		O
rational		O
mechanistic		O
interpretations		O
of		O
the		O
disproportionation		O
reaction		O
and		O
the		O
rearrangement		O
of		O
the		O
cyano		O
adducts		O
.		O
A		O
series		O
of		O
8		O
-		O
(		O
trifluoromethyl		O
)		O
-		O
substituted		O
quinolones		O
has		O
been		O
prepared		O
and		O
evaluated		O
for		O
in		O
vitro		O
and		O
in		O
vivo		O
antibacterial		O
activity		O
,		O
and		O
phototolerance		O
in		O
a		O
mouse		O
phototolerance		O
assay		O
.		O
(		O
E		O
)		O
-		O
4		O
-		O
[		O
4		O
-		O
(		O
Methylthio		O
)		O
phenyl		O
]		O
-		O
1		O
-		O
(		O
2		O
-		O
piperidinyl		O
)		O
-		O
3		O
-		O
buten		O
-		O
2		O
-		O
one		O
hydrochloride		O
(		O
44		O
,		O
RMI		O
14		O
133A		O
)		O
was		O
found		O
to		O
inhibit		O
ADP		O
-		O
induced		O
aggregation		O
of		O
blood		O
platelets		O
.		O
The		O
high		O
binding		O
affinity		O
of		O
the		O
1,4		B-IUPAC
-		I-IUPAC
diazabicyclo		I-IUPAC
[		O
4.3.0		O
]		O
nonanes		B-IUPAC
12		O
suggests		O
that		O
these		O
may		O
approximate		O
the		O
methyl		O
and		O
pyrrolidine		O
ring		O
conformations		O
found		O
in		O
1		O
when		O
it		O
is		O
bound		O
to		O
the		O
sigma		O
receptor		O
.		O
Whereas		O
mixtures		O
of		O
regioisomeric		O
5		B-PARTIUPAC
-		I-PARTIUPAC
and		O
7		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
benzothiazoles		I-IUPAC
were		O
formed		O
from		O
the		O
established		O
Jacobsen		O
cyclization		O
of		O
precursor		O
3		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
thiobenzanilides		I-IUPAC
,		O
two		O
modifications		O
to		O
this		O
general		O
process		O
have		O
allowed		O
the		O
synthesis		O
of		O
pure		O
samples		O
of		O
these		O
target		O
compounds		O
.		O
The		O
prodrugs		O
were		O
found		O
to		O
be		O
quite		O
stable		O
at		O
physiological		O
pH		O
and		O
were		O
more		O
than		O
200		O
-		O
fold		O
less		O
active		O
as		O
inactivators		O
of		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
alkylguanine		I-IUPAC
-		O
DNA		O
alkyltransferase		O
(		O
alkyltransferase		O
)		O
than		O
either		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
benzylguanine		I-IUPAC
or		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyguanosine		I-IUPAC
.		O
Compound		O
14		O
interacts		O
selectively		O
with		O
the		O
GABA		O
receptors		O
but		O
less		O
effectively		O
than		O
isonipecotic		O
acid		O
and		O
the		O
cis		O
-		O
isomer		O
22		O
.		O
The		O
replacement		O
of		O
the		O
phenyl		O
ring		O
in		O
etoxadrol		O
by		O
either		O
a		O
2		O
-		O
or		O
3		O
-		O
thienyl		O
ring		O
led		O
to		O
compounds		O
with		O
affinity		O
comparable		O
to		O
etoxadrol		O
,		O
and		O
the		O
replacement		O
of		O
the		O
ethyl		O
moiety		O
on		O
etoxadrol		O
's		O
dioxolane		O
ring		O
with		O
propyl		O
(		O
7		O
)		O
or		O
isopropyl		O
(		O
8		O
)		O
led		O
to		O
compounds		O
which		O
were		O
more		O
potent		O
than		O
etoxadrol		O
or		O
PCP		O
.		O
These		O
findings		O
encouraged		O
us		O
to		O
determine		O
the		O
structural		O
differences		O
between		O
1,2		B-IUPAC
-		I-IUPAC
cyclohexanediamine		I-IUPAC
and		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
cyclohexylamine		I-IUPAC
complexes		B-MODIFIER
.		O
Antibacterial		O
efficacy		O
and		O
pharmacokinetic		O
and		O
physicochemical		O
properties		O
of		O
selected		O
derivatives		O
were		O
compared		O
to		O
the		O
relevant		O
7		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azetidinyl		I-IUPAC
)		I-IUPAC
and		O
7		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azetidinyl		I-IUPAC
)		I-IUPAC
analogues		B-MODIFIER
(		O
for		O
Part		O
1		O
,		O
see		O
:		O
J		O
.		O
The		O
MIC50		O
value		O
for		O
the		O
most		O
potent		O
agents		O
in		O
this		O
study		O
against		O
S		O
.		O
A		O
single		O
scalar		O
11-11		O
a		O
1H		O
NMR		O
coupling		O
in		O
the		O
2D		O
-		O
COSY		O
spectrum		O
is		O
indicative		O
of		O
an		O
adduct		O
species		O
that		O
has		O
an		O
S		O
configuration		O
at		O
the		O
C		O
-		O
11		O
position		O
.		O
A		O
similar		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazol		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
derivative		B-MODIFIER
(		O
4		O
)		O
was		O
obtained		O
from		O
3'		B-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
thymidine		I-IUPAC
by		O
the		O
use		O
of		O
phosphoryl		O
chloride		O
as		O
the		O
condensing		O
agent		O
.		O
Contrary		O
to		O
what		O
has		O
been		O
found		O
with		O
simple		O
primary		O
dialkyl		O
esters		O
,		O
ortho		O
-		O
substituted		O
dibenzyl		O
esters		O
of		O
MTX		O
produce		O
longer		O
survival		O
on		O
a		O
q3dX3		O
schedule		O
than		O
does		O
MTX		O
itself		O
and		O
show		O
a		O
dose		O
-		O
sparing		O
effect		O
comparable		O
to		O
that		O
of		O
MTX		O
at		O
shorter		O
treatment		O
intervals		O
.		O
When		O
evaluated		O
for		O
inhibition		O
of		O
the		O
AII		O
pressor		O
response		O
,		O
the		O
benchmark		O
benzoylsulfonamide		O
9		O
(		O
L		O
-		O
159,913		O
)		O
was		O
efficacious		O
in		O
several		O
species		O
and		O
was		O
superior		O
to		O
losartan		O
(		O
1a		O
)		O
in		O
conscious		O
rhesus		O
monkeys		O
.		O
Furthermore		O
,		O
2,4		B-IUPAC
-		I-IUPAC
oxazolidinediones		I-IUPAC
and		O
hydantoins		O
must		O
either		O
orient		O
differently		O
in		O
the		O
same		O
binding		O
site		O
or		O
interact		O
with		O
different		O
sites		O
on		O
the		O
neuronal		O
voltage		O
-		O
dependent		O
sodium		O
channel		O
.		O
The		O
stereochemistry		O
of		O
a		O
hydroxy		O
group		O
at		O
C		O
-		O
4		O
of		O
compound		O
25		O
and		O
that		O
at		O
C		O
-		O
6		O
of		O
compounds		O
36		O
and		O
37		O
were		O
determined		O
on		O
the		O
basis		O
of		O
(		O
1		O
)		O
H		O
NMR		O
spectroscopy		O
in		O
each		O
case		O
.		O
The		O
catalytic		O
reduction		O
product		O
of		O
2		O
,		O
consisting		O
of		O
a		O
mixture		O
of		O
diastereomers		O
,		O
exhibited		O
powerful		O
antifolate		O
activity		O
against		O
both		O
these		O
organisms		O
.		O
Inhibitors		O
of		O
PARP		O
have		O
clinical		O
potential		O
as		O
resistance		O
-		O
modifying		O
agents		O
capable		O
of		O
potentiating		O
radiotherapy		O
and		O
the		O
cytotoxicity		O
of		O
some		O
forms		O
of		O
cancer		O
chemotherapy		O
.		O
The		O
oxidative		O
hydrolysis		O
of		O
the		O
2		B-IUPAC
-		I-IUPAC
thiouracil		I-IUPAC
derivatives		B-MODIFIER
gave		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
alkyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
arylthio		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
derivatives		B-MODIFIER
(		O
46-57		O
)		O
.		O
Furthermore		O
,		O
alkyl		O
substitution		O
also		O
appears		O
to		O
be		O
important		O
since		O
the		O
stripped		O
down		O
polyamines		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
ethylenediamine		I-IUPAC
(		O
15		O
)		O
and		O
N1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
diethylenetriamine		I-IUPAC
(		O
16		O
)		O
exhibited		O
relatively		O
low		O
binding		O
affinity		O
.		O
Larger		O
N		O
-		O
substituents		O
in		O
both		O
phenylpiperidines		O
and		O
OHBQs		O
increase		O
both		O
pre		O
-		O
and		O
postsynaptic		O
dopaminergic		O
activity		O
.		O
3D		O
QSAR		O
models		O
developed		O
may		O
be		O
used		O
in		O
designing		O
and		O
predicting		O
the		O
uPA		O
inhibitory		O
activity		O
of		O
novel		O
molecules		O
.		O
5		O
-		O
fold		O
more		O
potent		O
than		O
the		O
5		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
analogue		B-MODIFIER
.		O
Based		O
upon		O
the		O
observed		O
results		O
,		O
it		O
is		O
concluded		O
that		O
differential		O
effects		O
of		O
alpha		B-PARTIUPAC
-		I-PARTIUPAC
and		O
beta		B-IUPAC
-		I-IUPAC
naphthoflavone		I-IUPAC
on		O
aryl		O
hydrocarbon		O
skin		O
tumorigenesis		O
may		O
be		O
the		O
result		O
of		O
differential		O
enzyme		O
induction		O
rather		O
than		O
the		O
result		O
of		O
differential		O
enzyme		O
inhibition		O
.		O
Two		O
chemical		O
series		O
derived		O
from		O
the		O
general		O
structures		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
tertioalkylphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthoic		I-IUPAC
acid		I-IUPAC
(		O
series		O
I		O
)		O
and		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
tertioalkylphenyl		I-IUPAC
)		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
series		O
II		O
)		O
were		O
developed		O
.		O
omega		O
-		O
Hydroxylation		O
was		O
a		O
minor		O
metabolic		O
pathway		O
in		O
the		O
microsomal		O
incubation		O
.		O
Nearly		O
complete		O
loss		O
of		O
potency		O
was		O
seen		O
for		O
[		O
Ala1		O
]		O
,		O
[		O
Ala3		O
]		O
,		O
[		O
Ala5		O
]		O
,		O
[		O
Ala6		O
]		O
,		O
[		O
Ala10		O
]		O
,		O
[		O
Ala11		O
]		O
,		O
[		O
Ala13		O
]		O
,		O
[		O
Ala14		O
]		O
,		O
and		O
[		O
Ala23		O
]		O
,		O
whereas		O
[		O
Ala16		O
]		O
,		O
[		O
Ala18		O
]		O
,		O
[		O
Ala24		O
]		O
,		O
[		O
Ala25		O
]		O
,		O
[		O
Ala26		O
]		O
,		O
and		O
[		O
Ala29		O
]		O
yielded		O
equipotent		O
analogues		O
and		O
[		O
Ala7		O
]		O
,		O
[		O
Ala12		O
]		O
,		O
[		O
Ala17		O
]		O
,		O
[		O
Ala20		O
]		O
,		O
[		O
Ala21		O
]		O
,		O
and		O
[		O
Ala27		O
]		O
gave		O
weak		O
agonists		O
with		O
potencies		O
15-40%		O
that		O
of		O
the		O
standard		O
.		O
[		O
(		O
123		O
)		O
I		O
]		O
ZIENT		O
uptake		O
in		O
the		O
diencephalon		O
achieved		O
transient		O
equilibrium		O
at		O
157		O
min		O
.		O
The		O
three		O
most		O
potent		O
compounds		O
in		O
both		O
tests		O
,		O
1		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylpropyl		I-IUPAC
)		I-IUPAC
indan		I-IUPAC
,		O
1		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
,		I-IUPAC
6		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylindan		I-IUPAC
,		O
and		O
1		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2,2,4,6		I-IUPAC
-		I-IUPAC
tetramethylindan		I-IUPAC
were		O
selected		O
for		O
further		O
investigations		O
.		O
The		O
sodium		O
salt		O
of		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
cyanopyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
1		O
)		O
was		O
condensed		O
with		O
(		B-IUPAC
2		I-IUPAC
-		I-IUPAC
acetoxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
bromide		I-IUPAC
(		O
2		O
)		O
to		O
provide		O
the		O
corresponding		O
protected		O
acyclic		O
nucleoside		O
,		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
acetoxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
pyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimid		I-IUPAC
ine		I-IUPAC
(		O
3		O
)		O
.		O
Although		O
all		O
the		O
ligands		O
have		O
high		O
affinity		O
for		O
the		O
wild		O
-		O
type		O
PKCdelta		O
C1b		O
,		O
our		O
site		O
-		O
directed		O
mutagenic		O
results		O
showed		O
that		O
ILV		O
is		O
the		O
ligand		O
most		O
sensitive		O
to		O
structural		O
perturbations		O
of		O
the		O
binding		O
site		O
while		O
ingenol		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzoate		I-IUPAC
is		O
the		O
least		O
sensitive		O
among		O
the		O
four		O
classes		O
of		O
ligands		O
examined		O
here		O
.		O
Acylated		O
derivatives		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
group		B-MODIFIER
and		O
other		O
modifications		O
were		O
prepared		O
in		O
an		O
effort		O
to		O
provide		O
A3		O
subtype		O
selectivity		O
.		O
Survival		O
was		O
prolonged		O
to		O
the		O
same		O
degree		O
as		O
with		O
25		O
mg		O
/		O
kg		O
clindamycin		O
,		O
another		O
widely		O
used		O
drug		O
against		O
toxoplasmosis		O
.		O
We		O
tried		O
to		O
strengthen		O
these		O
properties		O
by		O
introducing		O
the		O
structurally		O
modified		O
tyrosine		O
residue		O
2,6		B-IUPAC
-		I-IUPAC
dimethyltyrosine		I-IUPAC
(		O
Dmt		O
)		O
in		O
place		O
of		O
Tyr1		O
.		O
Consequently		O
,		O
the		O
insertion		O
of		O
appropriate		O
substituents		O
in		O
the		O
phenyl		O
ring		O
of		O
8		O
may		O
represent		O
the		O
basis		O
of		O
designing		O
new		O
selective		O
ligands		O
for		O
alpha1		O
-		O
adrenoreceptor		O
subtypes		O
.		O
Certain		O
derivatives		O
containing		O
the		O
1,2		B-IUPAC
-		I-IUPAC
dihydropyrido		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyrazine		I-IUPAC
(		O
1		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
-		I-IUPAC
7,8		I-IUPAC
-		I-IUPAC
dihydropteridine		I-IUPAC
)		O
ring		B-MODIFIER
system		I-MODIFIER
are		O
active		O
against		O
experimental		O
neoplasms		O
in		O
mice		O
.		O
Concentrations		O
for		O
50%		O
KB		O
/		O
HeLa		O
cells		O
arrested		O
in		O
G2		O
/		O
M		O
after		O
treatment		O
with		O
9h		O
and		O
9l		O
were		O
determined		O
and		O
found		O
to		O
be		O
in		O
the		O
range		O
of		O
0.2		O
microM		O
.		O
Compound		O
4		O
was		O
a		O
dual		O
DHFR		O
-		O
TS		O
inhibitor		O
against		O
the		O
bifunctional		O
enzyme		O
derived		O
from		O
Toxoplasma		O
gondii		O
(		O
tg		O
)		O
.		O
In		O
an		O
imaging		O
experiment		O
with		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
S		O
)		O
-		O
FIPCT		O
in		O
a		O
rhesus		O
monkey		O
with		O
its		O
left		O
hemisphere		O
lesioned		O
with		O
MPTP		O
,		O
radioactivity		O
was		O
reduced		O
to		O
background		O
in		O
the		O
caudate		O
and		O
putamen		O
of		O
the		O
lesioned		O
hemisphere		O
.		O
17		B-IUPAC
beta		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
Alkyl		I-IUPAC
/		I-IUPAC
aryl		I-IUPAC
)		I-IUPAC
alkyl		I-IUPAC
/		I-IUPAC
arylamides		I-IUPAC
]		I-IUPAC
45		O
,		O
46		O
,		O
48		O
,		O
and		O
51		O
exhibited		O
highly		O
potent		O
inhibitory		O
activity		O
for		O
human		O
type		O
I		O
5		O
alpha		O
-		O
reductase		O
with		O
IC50s		O
of		O
1.77		O
,		O
2.42		O
,		O
2.93		O
,		O
and		O
5.44		O
nM		O
,		O
respectively		O
,		O
while		O
moderate		O
to		O
no		O
effect		O
was		O
observed		O
on		O
the		O
type		O
II		O
enzyme		O
(		O
100		O
&		O
lt		O
;		O
IC50s		O
&		O
lt		O
;		O
1000		O
nM		O
)		O
,		O
except		O
for		O
compound		O
48		O
(		O
IC50		O
=		O
3.75		O
nM		O
)		O
.		O
Compounds		O
19b		O
,		O
20b		O
,		O
and		O
the		O
3'		B-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
cyclic		I-IUPAC
)		I-IUPAC
phosphate		I-IUPAC
21b		O
are		O
less		O
active		O
than		O
1		O
.		O
While		O
17		O
(		O
IC50		O
=		O
0.016		O
microM		O
)		O
was		O
somewhat		O
less		O
potent		O
than		O
10		O
,		O
its		O
selectivity		O
,		O
as		O
defined		O
by		O
the		O
ratio		O
IC50		O
(		O
rat		O
liver		O
)		O
/		O
IC50		O
(		O
T		O
.		O
Our		O
aim		O
was		O
to		O
develop		O
an		O
(		O
18		O
)		O
F		O
-		O
labeled		O
acetylcholine		O
analogue		O
useful		O
for		O
brain		O
AChE		O
mapping		O
with		O
PET		O
,		O
since		O
(		O
18		O
)		O
F		O
,		O
with		O
a		O
longer		O
half		O
-		O
life		O
,		O
has		O
advantages		O
over		O
(		O
11		O
)		O
C		O
.		O
The		O
A		O
ring		O
nitrogen		O
analogues		O
(		O
7		B-PARTIUPAC
-		I-PARTIUPAC
,		O
8		B-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
10		B-IUPAC
-		I-IUPAC
aza		I-IUPAC
-		I-IUPAC
5		I-IUPAC
[		I-IUPAC
H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
phenanthridin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
)		O
were		O
an		O
order		O
of		O
magnitude		O
less		O
potent		O
than		O
C		O
ring		O
nitrogen		O
analogues		O
(		O
1		B-PARTIUPAC
-		I-PARTIUPAC
,		O
2		B-PARTIUPAC
-		I-PARTIUPAC
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
4		B-IUPAC
-		I-IUPAC
aza		I-IUPAC
-		I-IUPAC
5		I-IUPAC
[		I-IUPAC
H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
phenanthridin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
)		O
.		O
Single		O
doses		O
(		O
200-400		O
mg		O
/		O
kg		O
)		O
of		O
8a		O
and		O
8b		O
produced		O
significant		O
increase		O
in		O
life		O
span		O
(		O
257-371%		O
)		O
in		O
mice		O
bearing		O
ip		O
implanted		O
L1210/0		O
leukemia		O
.		O
Both		O
compounds		O
are		O
biologically		O
active		O
as		O
inhibitors		O
of		O
the		O
growth		O
of		O
cultured		O
mouse		O
fibroblasts		O
and		O
are		O
able		O
to		O
compete		O
for		O
the		O
specific		O
binding		O
of		O
radiolabeled		O
triamcinolone		O
acetonide		O
to		O
the		O
L929		O
cell		O
receptor		O
.		O
The		O
conjugates		O
can		O
use		O
bacterial		O
iron		O
siderophore		O
uptake		O
routes		O
to		O
penetrate		O
the		O
Gram		O
-		O
negative		O
outer		O
membrane		O
permeability		O
barrier		O
.		O
With		O
use		O
of		O
Heindel		O
's		O
triazene		O
method		O
for		O
introduction		O
of		O
the		O
radionuclide		O
,		O
the		O
iodine		O
-		O
125		O
-		O
labeled		O
substituted		O
benzamide		O
was		O
obtained		O
with		O
a		O
calculated		O
specific		O
activity		O
of		O
136		O
Ci		O
/		O
mmol		O
and		O
14%		O
radiochemical		O
yield		O
.		O
A		O
series		O
of		O
aporphine		O
nitrogen		O
mustards		O
and		O
their		O
congeners		O
(		O
1b		O
-		O
g		O
)		O
has		O
been		O
prepared		O
.		O
These		O
various		O
thiazolidine		O
derivatives		O
are		O
formed		O
by		O
nucleophilic		O
addition		O
of		O
the		O
thiol		O
residues		O
of		O
cysteine		O
or		O
glutathione		O
to		O
the		O
aldehyde		B-IUPAC
group		B-MODIFIER
of		O
5		B-IUPAC
-		I-IUPAC
hydroxyindole		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
acetaldehyde		I-IUPAC
(		O
2		O
)		O
,		O
the		O
primary		O
product		O
of		O
the		O
monoamine		O
oxidase		O
-		O
mediated		O
oxidative		O
deamination		O
of		O
1		O
.		O
We		O
have		O
expanded		O
our		O
structure		O
-		O
activity		O
studies		O
in		O
this		O
series		O
,		O
in		O
an		O
attempt		O
to		O
further		O
increase		O
the		O
ETA		O
selectivity		O
.		O
The		O
conformationally		O
restricted		O
linear		O
tricyclic		O
analogs		O
of		O
5		B-PARTIUPAC
-		I-PARTIUPAC
and		O
8		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
di		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
tetralins		I-IUPAC
were		O
investigated		O
for		O
their		O
serotonergic		O
and		O
dopaminergic		O
properties		O
.		O
It		O
is		O
suggested		O
that		O
van		O
der		O
Waals		O
forces		O
and		O
pi		O
interactions		O
may		O
govern		O
the		O
inhibitor		O
-		O
platelet		O
interaction		O
.		O
In		O
view		O
of		O
the		O
fact		O
that		O
3		O
and		O
its		O
B		O
-		O
ring		O
analogues		O
cannot		O
form		O
polyglutamates		O
,		O
their		O
high		O
cytotoxicity		O
relative		O
to		O
the		O
corresponding		O
B		O
-		O
ring		O
analogues		O
of		O
AMT		O
is		O
noteworthy		O
.		O
The		O
best		O
analogue		O
,		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthalenylsulfonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
thiazolidinedione		I-IUPAC
(		O
AY		O
-		O
31,637		O
)		O
was		O
equipotent		O
to		O
ciglitazone		O
in		O
two		O
animal		O
models		O
of		O
NIDDM		O
.		O
The		O
in		O
vivo		O
antagonistic		O
activity		O
of		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
sarcosine		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methylthreonine		I-IUPAC
]		I-IUPAC
angiotensin		I-IUPAC
II		I-IUPAC
is		O
reduced		O
considerably		O
by		O
shortening		O
the		O
chain		O
length		O
by		O
one		O
carbon		O
atom		O
as		O
is		O
in		O
V		O
.		O
(		O
S		O
)		O
-		O
11a		O
was		O
evaluated		O
as		O
a		O
substrate		O
for		O
P815		O
tryptophan		O
hydroxylase		O
and		O
determined		O
to		O
have		O
an		O
apparent		O
Km		O
of		O
4.31		O
+		O
/		O
-		O
1.07		O
mM		O
,		O
essentially		O
half		O
the		O
value		O
previously		O
reported		O
for		O
the		O
racemic		O
mixture		O
of		O
11a		O
with		O
rat		O
brain		O
stem		O
tryptophan		O
hydroxylase		O
.		O
Metabolic		O
studies		O
of		O
the		O
polyamine		O
-		O
vectored		O
(		O
S		O
)		O
-		O
4'		O
-		O
(		O
HO		O
)		O
-		O
DADFTs		O
in		O
rodents		O
indicated		O
that		O
not		O
only		O
did		O
the		O
expected		O
deaminopropylation		O
step		O
occur		O
,		O
but		O
also		O
a		O
surprisingly		O
high		O
level		O
of		O
oxidative		O
deamination		O
at		O
the		O
terminal		O
primary		O
nitrogens		O
took		O
place		O
.		O
On		O
the		O
other		O
hand		O
,		O
because		O
positive		O
chronotropic		O
actions		O
of		O
substituents		B-MODIFIER
with		O
allyl		B-IUPAC
,		O
aminoalkyl		B-IUPAC
,		O
alkoxyalkyl		B-IUPAC
,		O
and		O
normal		O
alkyl		B-IUPAC
groups		B-MODIFIER
were		O
much		O
less		O
than		O
tracheal		O
muscle		O
became		O
very		O
high		O
with		O
substitutions		B-MODIFIER
of		O
3'		B-IUPAC
-		I-IUPAC
butenyl		I-IUPAC
,		O
(		B-IUPAC
dimethylamino		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
,		O
2'		B-IUPAC
-		I-IUPAC
ethoxyethyl		I-IUPAC
,		O
3'		B-IUPAC
-		I-IUPAC
methoxypropyl		I-IUPAC
,		O
and		O
n		B-IUPAC
-		I-IUPAC
propyl		I-IUPAC
groups		B-MODIFIER
at		O
the		O
1		O
-		O
position		O
and		O
of		O
2'		B-IUPAC
-		I-IUPAC
ethoxyethyl		I-IUPAC
,		O
2'		B-IUPAC
-		I-IUPAC
oxopropyl		I-IUPAC
,		O
and		O
n		B-IUPAC
-		I-IUPAC
propyl		I-IUPAC
groups		B-MODIFIER
at		O
the		O
7		O
-		O
position		O
,		O
compared		O
with		O
theophylline		O
and		O
the		O
corresponding		O
unsubstituted		O
xanthines		O
,		O
3		B-IUPAC
-		I-IUPAC
propylxanthine		I-IUPAC
and		O
1		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
propylxanthine		I-IUPAC
.		O
Compounds		O
3		O
and		O
4		O
were		O
powerful		O
inhibitors		O
of		O
recombinant		O
human		O
FPGS		O
,		O
whereas		O
1		O
and		O
2		O
were		O
exceptionally		O
efficient		O
FPGS		O
substrates		O
,		O
with		O
the		O
reduced		O
compound		O
2		O
giving		O
a		O
K		O
(		O
m		O
)		O
(		O
0.018		O
microM		O
)		O
lower		O
than		O
that		O
of		O
any		O
other		O
substrate		O
identified		O
to		O
date		O
.		O
Increasing		O
fluorine		O
substitution		O
was		O
found		O
to		O
decrease		O
basicity		O
of		O
the		O
formamidino		O
group		O
substantially		O
(		O
3a		O
,		O
pKa		O
=		O
8.65		O
;		O
3b		O
,		O
pKa		O
=		O
8.12		O
;		O
3c		O
,		O
pKa		O
=		O
6.60		O
;		O
3d		O
,		O
pKa		O
=		O
6.14		O
)		O
,		O
while		O
having		O
a		O
modest		O
effect		O
on		O
the		O
imidazole		O
portion		O
.		O
At		O
1		O
mg		O
/		O
kg		O
po		O
in		O
rats		O
,		O
18		O
and		O
92		O
(		O
L		O
-		O
162,234		O
)		O
produced		O
85-87%		O
peak		O
inhibition		O
of		O
the		O
AII		O
pressor		O
response		O
with		O
duration		O
exceeding		O
6		O
h		O
.		O
When		O
the		O
methylputrescines		O
formally		O
derived		O
from		O
the		O
decarboxylation		O
of		O
several		O
isoornithines		O
were		O
assayed		O
on		O
rat		O
liver		O
ODC		O
,		O
it		O
was		O
found		O
that		O
only		O
2,3		B-IUPAC
-		I-IUPAC
dimethylputrescine		I-IUPAC
decreased		O
the		O
enzymatic		O
activity		O
.		O
However		O
the		O
effect		O
of		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
substitution		B-MODIFIER
was		O
less		O
pronounced		O
in		O
the		O
5,8		B-IUPAC
-		I-IUPAC
dideaza		I-IUPAC
analogues		B-MODIFIER
than		O
in		O
the		O
5		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
analogues		B-MODIFIER
.		O
Together		O
with		O
the		O
X		O
-		O
ray		O
structure		O
of		O
phorbol		B-IUPAC
-		I-IUPAC
13		I-IUPAC
-		I-IUPAC
acetate		I-IUPAC
in		O
complex		O
with		O
PKCdelta		O
C1b		O
,		O
the		O
predicted		O
binding		O
models		O
of		O
PDBu		O
,		O
ILV		O
,		O
ingenol		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzoate		I-IUPAC
,		O
and		O
thymeleatoxin		O
in		O
complex		O
with		O
PKC		O
showed		O
that		O
the		O
binding		O
of		O
these		O
ligands		O
to		O
PKC		O
is		O
governed		O
by		O
a		O
combination		O
of		O
several		O
highly		O
specific		O
and		O
optimal		O
hydrogen		O
bonds		O
and		O
hydrophobic		O
contacts		O
.		O
Identification		O
of		O
the		O
structural		O
features		O
that		O
are		O
necessary		O
for		O
activity		O
was		O
accomplished		O
by		O
evaluation		O
of		O
modified		O
1		B-IUPAC
-		I-IUPAC
deazapteridines		I-IUPAC
and		O
ring		O
and		O
ring		O
-		O
opened		O
analogues		O
.		O
1,3,5		B-MODIFIER
-		I-MODIFIER
Substituted		I-MODIFIER
indoles		O
and		O
indazoles		O
have		O
been		O
studied		O
as		O
receptor		O
antagonists		O
of		O
the		O
peptidoleukotrienes		O
.		O
casei		O
dihydrofolate		O
reductase		O
.		O
Competition		O
binding		O
in		O
cells		O
stably		O
expressing		O
the		O
transfected		O
human		O
DAT		O
and		O
serotonin		O
transporter		O
(		O
SERT		O
)		O
labeled		O
by		O
[		O
(		O
3		O
)		O
H		O
]		O
WIN		O
35428		O
and		O
[		O
(		O
3		O
)		O
H		O
]		O
citalopram		O
,		O
respectively		O
,		O
demonstrated		O
the		O
following		O
order		O
of		O
DAT		O
affinity		O
(		O
K		O
(		O
i		O
)		O
in		O
nM		O
)		O
:		O
GBR		O
12909		O
(		O
0.36		O
)		O
&		O
gt		O
;		O
CIT		O
(		O
0.48		O
)		O
&		O
gt		O
;		O
(		O
S		O
)		O
-		O
FIPCT		O
(		O
0.67		O
)		O
&		O
gt		O
;		O
&		O
gt		O
;		O
(		O
R		O
)		O
-		O
FIPCT		O
(		O
3.2		O
)		O
.		O
In		O
cultured		O
L1210		O
leukemia		O
,		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
nitrobenzylaminopurine		I-IUPAC
and		O
the		O
corresponding		O
ribonucleoside		O
were		O
better		O
growth		O
inhibitors		O
than		O
N6		B-IUPAC
-		I-IUPAC
benzyladenosine		I-IUPAC
,		O
while		O
N6		B-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
nitrobenzyladenosine		I-IUPAC
,		O
its		O
2'		O
-		O
deoxy		O
analog		O
,		O
and		O
N6		B-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
fluorobenzyladenosine		I-IUPAC
were		O
as		O
active		O
as		O
N6		B-IUPAC
-		I-IUPAC
benzyladenosine		I-IUPAC
.		O
Various		O
substituted		O
isoquinoline		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
carboxaldehyde		I-IUPAC
thiosemicarbazones		I-IUPAC
(		O
12		O
compounds		O
)		O
have		O
been		O
synthesized		O
and		O
evaluated		O
for		O
antineoplastic		O
activity		O
in		O
mice		O
bearing		O
the		O
L1210		O
leukemia		O
.		O
The		O
absolute		O
configuration		O
of		O
(		O
-		O
)		O
-		O
10		O
and		O
(		O
+		O
)		O
-		O
10		O
was		O
determined		O
by		O
single		O
-		O
crystal		O
X		O
-		O
ray		O
diffractometry		O
of		O
the		O
bis		B-IUPAC
-		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
mandelate		I-IUPAC
salt		B-MODIFIER
.		O
The		O
receptor		O
binding		O
potencies		O
IC50		O
values		O
are		O
48		O
(		O
1		O
)		O
,		O
126		O
(		O
2		O
)		O
,		O
40		O
(		O
3		O
)		O
,		O
19		O
(		O
4		O
)		O
,		O
100		O
(		O
5		O
)		O
,		O
48		O
(		O
6		O
)		O
,		O
2000		O
(		O
7		O
)		O
,		O
52		O
(		O
8		O
)		O
,		O
113		O
(		O
9		O
)		O
,		O
512		O
(		O
10		O
)		O
,		O
128		O
(		O
11		O
)		O
,		O
1000		O
(		O
12		O
)		O
,		O
2000		O
(		O
13		O
)		O
,		O
500		O
(		O
14		O
)		O
,		O
and		O
200		O
nM		O
(		O
15		O
)		O
.		O
6		B-IUPAC
-		I-IUPAC
Hydroxypyrimidines		I-IUPAC
substituted		B-MODIFIER
at		O
positions		O
2		O
and		O
4		O
by		O
hydrogen		O
,		O
methyl		O
,		O
amino		O
,		O
cyclopropylamino		O
,		O
dimethylamino		O
,		O
methylsulfanyl		O
,		O
or		O
hydroxyl		O
group		O
afford		O
by		O
the		O
reaction		O
with		O
diisopropyl		B-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
chloroethoxy		I-IUPAC
)		I-IUPAC
methylphosphonate		I-IUPAC
in		O
the		O
presence		O
of		O
NaH		O
,		O
Cs		O
(		O
2		O
)		O
CO		O
(		O
3		O
)		O
,		O
or		O
DBU		O
a		O
mixture		O
of		O
N		B-PARTIUPAC
(		I-PARTIUPAC
1		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
diisopropylphosphorylmethoxy		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
isomers		B-MODIFIER
which		O
were		O
converted		O
to		O
the		O
free		O
phosphonic		O
acids		O
by		O
treatment		O
with		O
bromotrimethylsilane		O
followed		O
by		O
hydrolysis		O
.		O
More		O
detailed		O
biological		O
studies		O
conducted		O
with		O
the		O
most		O
potent		O
inhibitor		O
NU7163		O
(		O
48		O
;		O
IC		O
(		O
50		O
)		O
=		O
0.19		O
microM		O
)		O
demonstrated		O
ATP		O
-		O
competitive		O
DNA		O
-		O
PK		O
inhibition		O
,		O
with		O
a		O
K		O
(		O
i		O
)		O
value		O
of		O
24		O
nM		O
,		O
and		O
48		O
exhibited		O
selectivity		O
for		O
DNA		O
-		O
PK		O
compared		O
with		O
the		O
related		O
enzymes		O
ATM		O
,		O
ATR		O
,		O
mTOR		O
,		O
and		O
PI		O
3		O
-		O
K		O
(		O
p110alpha		O
)		O
.		O
gondii		O
DHFR		O
,		O
with		O
an		O
IC50		O
of		O
0.0064		O
microM		O
corresponding		O
again		O
to		O
a		O
minor		O
increase		O
in		O
activity		O
over		O
TMQ		O
and		O
PTX		O
.		O
It		O
is		O
apparent		O
that		O
the		O
intrinsic		O
activity		O
of		O
a		O
2		B-IUPAC
-		I-IUPAC
aminotetralin		I-IUPAC
derivative		B-MODIFIER
may		O
be		O
modified		O
by		O
varying		O
the		O
N		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
substituents		B-MODIFIER
.		O
In		O
vivo		O
characterization		O
of		O
[		O
18F		O
]		O
F		O
-		O
A		O
-		O
85380		O
showed		O
promising		O
properties		O
for		O
PET		O
imaging		O
of		O
central		O
nAChRs		O
.		O
Treatment		O
of		O
the		O
tetraacetyl		B-IUPAC
derivative		B-MODIFIER
of		O
4		O
with		O
Lawesson		O
's		O
reagent		O
and		O
subsequent		O
deacetylation		O
furnished		O
a		O
mixture		O
of		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosylpyrazole		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
thiocarboxamide		I-IUPAC
(		O
15		O
)		O
and		O
the		O
corresponding		O
nitrile		B-IUPAC
derivative		B-MODIFIER
(		O
16		O
)		O
.		O
This		O
was		O
confirmed		O
by		O
an		O
X		O
-		O
ray		O
crystallographic		O
analysis		O
of		O
9		O
.		O
The		O
new		O
analogues		O
were		O
all		O
obtained		O
from		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
methoxybenzyl		I-IUPAC
)		I-IUPAC
pyrimidine		I-IUPAC
via		O
a		O
Sonogashira		O
reaction		O
,		O
followed		O
,		O
where		O
appropriate		O
,		O
by		O
catalytic		O
hydrogenation		O
.		O
(		O
ABSTRACT		O
TRUNCATED		O
AT		O
400		O
WORDS		O
)		O
A		O
series		O
of		O
22		B-IUPAC
-		I-IUPAC
hydroxycholesterol		I-IUPAC
derivatives		B-MODIFIER
with		O
a		O
modified		O
side		O
chain		O
terminus		O
was		O
prepared		O
.		O
In		O
studies		O
with		O
L1210		O
cells		O
in		O
vitro		O
,		O
a		O
concentration		O
of		O
200		O
microM		O
8		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylquinazolinone		I-IUPAC
(		O
6		O
,		O
NU1025		O
)		O
(		O
IC50		O
value		O
0.40		O
microM		O
)		O
potentiated		O
the		O
cytotoxicity		O
of		O
the		O
monomethylating		O
agent		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyltriazen		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
imidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
and		O
gamma		O
-		O
radiation		O
3.5		O
-		O
and		O
1.4		O
-		O
fold		O
,		O
respectively		O
,		O
at		O
the		O
10%		O
survival		O
level		O
.		O
Both		O
of		O
these		O
polyamine		O
analogues		O
are		O
shown		O
to		O
be		O
more		O
active		O
against		O
L1210		O
murine		O
leukemia		O
cell		O
growth		O
than		O
either		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
,		I-IUPAC
N		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
-		I-IUPAC
diethylnorspermine		I-IUPAC
(		O
DENSPM		O
)		O
or		O
(		B-IUPAC
2R		I-IUPAC
,		I-IUPAC
10R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
,		I-IUPAC
N		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
-		I-IUPAC
diethyl		I-IUPAC
-		I-IUPAC
2,10		I-IUPAC
-		I-IUPAC
dihydroxynorspermine		I-IUPAC
[		O
(		O
2R		O
,		O
10R		O
)		O
-		O
(		O
HO		O
)		O
(		O
2		O
)		O
DENSPM		O
]		O
after		O
96		O
h		O
of		O
treatment		O
;		O
the		O
activity		O
was		O
comparable		O
to		O
that		O
of		O
(		B-IUPAC
2S		I-IUPAC
,		I-IUPAC
10S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
,		I-IUPAC
N		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
-		I-IUPAC
diethyl		I-IUPAC
-		I-IUPAC
2,10		I-IUPAC
-		I-IUPAC
dihydroxynorspermine		I-IUPAC
[		O
(		O
2S		O
,		O
10S		O
)		O
-		O
(		O
HO		O
)		O
(		O
2		O
)		O
DENSPM		O
]		O
at		O
96		O
h		O
.		O
The		O
monocylic		O
analogue		O
[		O
dPen1		O
,		O
(		O
Glu4		O
,		O
Lys8		O
)		O
]		O
oxytocin		O
was		O
a		O
weak		O
oxytocin		O
antagonist		O
with		O
a		O
pA2		O
value		O
of		O
5.8		O
in		O
the		O
uterotonic		O
assay		O
.		O
(		B-IUPAC
R		I-IUPAC
,		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
Fluoromethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
QNB		I-IUPAC
,		O
and		O
(		O
R		O
,		O
R		O
)		O
-		O
IQNB		O
,		O
and		O
(		B-IUPAC
R		I-IUPAC
,		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
fluoroethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
QNB		I-IUPAC
exhibit		O
selectivity		O
for		O
the		O
M1		O
subtype		O
,		O
and		O
(		B-IUPAC
R		I-IUPAC
,		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
fluoromethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
QNB		I-IUPAC
exhibits		O
selectivity		O
for		O
the		O
M2		O
subtype		O
.		O
In		O
an		O
attempt		O
to		O
increase		O
the		O
combined		O
toxicity		O
of		O
the		O
metabolic		O
end		O
-		O
products		O
[		O
acrolein		O
(		O
4		O
)		O
and		O
phosphoramide		O
mustard		O
(		O
3		O
)		O
]		O
from		O
cyclophosphamide		O
(		O
1		O
)		O
,		O
the		O
analog		B-MODIFIER
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
trifluoromethyl		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1,3,2		I-IUPAC
-		I-IUPAC
oxazaphosphorine		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
(		O
2		O
,		O
6		B-IUPAC
-		I-IUPAC
trifluoromethylcyclophosphamide		I-IUPAC
)		O
was		O
synthesized		O
and		O
its		O
metabolism		O
and		O
antitumor		O
activity		O
studied		O
.		O
Most		O
of		O
the		O
target		O
compounds		O
were		O
more		O
potent		O
than		O
the		O
corresponding		O
secondary		O
amides		O
and		O
had		O
improved		O
therapeutic		O
margins		O
toward		O
CNS		O
toxicity		O
.		O
However		O
,		O
the		O
21		O
-		O
hydroxylated		O
erythromycin		O
A		O
analogue		O
was		O
weaker		O
in		O
potency		O
than		O
the		O
corresponding		O
erythromycin		O
B		O
congener		O
and		O
much		O
weaker		O
than		O
the		O
epoxy		O
derivative		O
.		O
A		O
series		O
of		O
N2		B-PARTIUPAC
(		O
and		O
N4		B-PARTIUPAC
)		O
-		B-PARTIUPAC
aryl		B-PARTIUPAC
-		B-PARTIUPAC
N4		B-PARTIUPAC
(		O
and		O
N2		B-PARTIUPAC
)		O
-		B-PARTIUPAC
[		I-PARTIUPAC
(		I-PARTIUPAC
dialkylamino		I-PARTIUPAC
)		I-PARTIUPAC
alkyl		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
2,4		I-PARTIUPAC
-		I-PARTIUPAC
quinazolinediamines		I-PARTIUPAC
has		O
been		O
synthesized		O
for		O
antimalarial		O
evaluation		O
.		O
Combination		O
of		O
the		O
best		O
substituent		O
in		O
each		O
of		O
these		O
positions		O
enhanced		O
the		O
overall		O
activity		O
.		O
However		O
13		O
was		O
no		O
more		O
potent		O
than		O
PTX		O
against		O
M		O
.		O
The		O
protected		O
intermediates		O
required		O
for		O
the		O
synthesis		O
of		O
all		O
of		O
these		O
peptides		O
were		O
prepared		O
by		O
the		O
solid		O
-		O
phase		O
method		O
and		O
cleaved		O
from		O
the		O
resin		O
by		O
ammonolysis		O
.		O
The		O
4H		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
,		O
the		O
2,3		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
,		O
the		O
4H		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
,		O
and		O
the		O
2,3		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
derivatives		B-MODIFIER
were		O
found		O
to		O
be		O
inactive		O
or		O
only		O
marginally		O
activate		O
as		O
receptor		O
ligands		O
or		O
estrogen		O
agonists		O
-		O
antagonists		O
.		O
Biological		O
tests		O
indicate		O
hexahydro		B-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indeno		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyridines		I-IUPAC
to		O
be		O
potential		O
human		O
antidepressants		O
with		O
additional		O
stimulating		O
properties		O
.		O
Further		O
,		O
the		O
octanol		O
-		O
water		O
partition		O
coefficient		O
of		O
(		O
S		O
)		O
-		O
6b		O
as		O
determined		O
by		O
reverse		O
-		O
phase		O
high		O
-		O
performance		O
liquid		O
chromatography		O
was		O
found		O
to		O
be		O
40		O
times		O
greater		O
than		O
that		O
for		O
sulpiride		O
.		O
These		O
compounds		O
exhibit		O
different		O
affinities		O
for		O
the		O
muscarinic		O
receptor		O
tissue		O
subtypes		O
in		O
vitro		O
.		O
Dimethylamine		O
removed		O
the		O
ester		O
groups		O
and		O
opened		O
the		O
epoxide		O
to		O
give		O
the		O
amino		O
alcohol		O
24		O
.		O
The		O
corresponding		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
alkynyl		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
of		O
5'		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
ethylcarboxamidoadenosine		I-IUPAC
(		O
NECA		O
)		O
and		O
Ado		O
are		O
used		O
as		O
reference		O
compounds		O
.		O
This		O
compound		O
had		O
the		O
following		O
binding		O
affinities		O
:		O
IC50		O
(		O
sigma		O
1		O
)		O
=		O
1200		O
nM		O
,		O
IC50		O
(		O
sigma		O
2		O
)		O
=		O
2.5		O
nM		O
.		O
(		B-PARTIUPAC
Trifluoromethyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
,		O
nitro		B-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
other		O
benzyl		O
esters		O
substituted		O
with		O
electron		O
-		O
withdrawing		O
groups		O
were		O
specific		O
for		O
A3		O
receptors		O
with		O
nanomolar		O
Ki		O
values		O
and		O
selectivity		O
as		O
high		O
as		O
37000		O
-		O
fold		O
.		O
Criteria		O
required		O
for		O
good		O
oral		O
activity		O
in		O
the		O
latter		O
model		O
include		O
an		O
(		B-IUPAC
E		I-IUPAC
,		I-IUPAC
-		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
pentadienamide		I-IUPAC
,		O
a		O
second		O
phenyl		B-PARTIUPAC
or		O
a		O
four		O
-		O
or		O
five		O
-		O
carbon		O
alkyl		B-PARTIUPAC
moiety		B-MODIFIER
in		O
the		O
5		O
-		O
position		O
of		O
the		O
diene		O
,		O
and		O
an		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
butyl		I-IUPAC
]		I-IUPAC
substituent		B-MODIFIER
on		O
the		O
carboxamide		O
nitrogen		O
atom		O
.		O
Conversion		O
of		O
the		O
8		B-IUPAC
-		I-IUPAC
phenolic		I-IUPAC
1,2,3,4,5,6		I-IUPAC
-		I-IUPAC
hexahydro		I-IUPAC
-		I-IUPAC
2,6		I-IUPAC
-		I-IUPAC
methano		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzazocines		I-IUPAC
to		O
the		O
corresponding		O
8		B-IUPAC
-		I-IUPAC
thiophenolic		I-IUPAC
analogues		B-MODIFIER
was		O
achieved		O
by		O
three		O
different		O
routes		O
.		O
Also		O
7		B-IUPAC
-		I-IUPAC
aza		I-IUPAC
and		O
8		B-IUPAC
-		I-IUPAC
aza		I-IUPAC
substitution		B-MODIFIER
on		O
the		O
parent		O
quinazoline		O
ring		O
has		O
a		O
detrimental		O
effect		O
on		O
the		O
interaction		O
with		O
beta		O
-		O
PDGFR		O
.		O
Overall		O
,		O
there		O
was		O
a		O
high		O
degree		O
of		O
correlation		O
of		O
the		O
activities		O
against		O
the		O
different		O
kinases		O
,		O
with		O
c		O
-		O
Src		O
being		O
generally		O
the		O
most		O
sensitive		O
to		O
structural		O
changes		O
.		O
None		O
of		O
the		O
bis		O
(		O
carbamates		O
)		O
prepared		O
was		O
active		O
against		O
murine		O
P388		O
lymphocytic		O
leukemia		O
.		O
Interestingly		O
,		O
the		O
same		O
substitutions		O
at		O
positions		O
2		O
and		O
7		O
,		O
with		O
l		O
-		O
threo		O
-		O
beta		O
-		O
MeTrp		O
at		O
position		O
8		O
,		O
yielded		O
a		O
much		O
less		O
selective		O
analogue		O
(		O
20		O
)		O
.		O
Apparent		O
affinity		O
of		O
the		O
compounds		O
for		O
P2Y		O
-		O
purinoceptors		O
was		O
established		O
by		O
measurement		O
of		O
P2Y		O
-		O
purinoceptor		O
-		O
promoted		O
phospholipase		O
C		O
activity		O
in		O
turkey		O
erythrocyte		O
membranes		O
and		O
relaxation		O
of		O
carbachol		O
-		O
contracted		O
smooth		O
muscle		O
in		O
three		O
different		O
preparations		O
(		O
guinea		O
pig		O
taenia		O
coli		O
,		O
rabbit		O
aorta		O
,		O
and		O
rabbit		O
mesenteric		O
artery		O
)		O
.		O
The		O
position		O
of		O
radiolabeling		O
in		O
the		O
3		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
group		B-MODIFIER
was		O
confirmed		O
by		O
[		O
(		O
11/13		O
)		O
C		O
]		O
colabeling		O
and		O
subsequent		O
carbon		O
-		O
13		O
NMR		O
spectroscopy		O
.		O
This		O
new		O
ligand		O
offers		O
several		O
unique		O
advantages		O
,		O
including		O
high		O
specific		O
activity		O
,		O
high		O
binding		O
affinity		O
,		O
and		O
low		O
nonspecific		O
binding		O
,		O
all		O
of		O
which		O
make		O
it		O
an		O
excellent		O
probe		O
for		O
the		O
investigation		O
and		O
characterization		O
of		O
5		O
-		O
HT1A		O
receptors		O
.		O
Compound		O
27		O
also		O
was		O
converted		O
to		O
5		B-IUPAC
-		I-IUPAC
iodoacetamidomethyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
by		O
treatment		O
with		O
ammonia		O
,		O
chloroacetyl		O
chloride		O
,		O
base		O
saponification		O
,		O
and		O
finally		O
sodium		O
iodide		O
.		O
Benzoate		O
substitutions		O
in		O
the		O
ortho		O
position		O
relative		O
to		O
the		O
terminal		O
carboxylate		O
(		O
9d		O
,		O
k		O
,		O
r		O
)		O
are		O
well		O
-		O
tolerated		O
;		O
however		O
,		O
a		O
methoxy		O
substituent		O
meta		O
relative		O
to		O
the		O
terminal		O
carboxylate		O
gives		O
rise		O
to		O
only		O
weakly		O
active		O
analogues		O
(		O
9x		O
)		O
.		O
Also		O
effective		O
are		O
bis		O
(		O
alkoxymethyl		O
)		O
and		O
mixed		O
alkylalkoxymethyl		O
derivatives		O
of		O
5,5		B-IUPAC
-		I-IUPAC
diphenylhydantoin		I-IUPAC
.		O
The		O
isosteric		O
benzene		O
-		O
thiophene		O
replacement		O
accounts		O
for		O
an		O
enhanced		O
stability		O
of		O
the		O
acyl		O
-		O
enzyme		O
intermediates		O
.		O
These		O
results		O
suggest		O
(		O
a		O
)		O
an		O
alternate		O
pathway		O
for		O
the		O
formation		O
of		O
heptapeptide		O
III		O
,		O
viz		O
.		O
It		O
was		O
found		O
that		O
polar		O
functional		O
groups		O
suitable		O
for		O
the		O
attachment		O
of		O
a		O
prodrug		O
moiety		O
were		O
tolerated		O
on		O
the		O
styryl		O
ring		O
and		O
even		O
better		O
on		O
the		O
3		O
-		O
substituent		O
.		O
These		O
effects		O
of		O
8		O
and		O
9		O
proved		O
to		O
be		O
enantioselective		O
,		O
(		O
R		O
)		O
-		O
(		O
-		O
)		O
-		O
8		O
and		O
(		O
R		O
)		O
-		O
(		O
+		O
)		O
-		O
9		O
being		O
the		O
active		O
inhibitors		O
of		O
both		O
uptake		O
systems		O
.		O
The		O
one		O
exception		O
is		O
3		B-IUPAC
-		I-IUPAC
hydroxymethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
THIQ		I-IUPAC
(		O
9		O
)		O
,		O
which		O
was		O
found		O
to		O
display		O
the		O
opposite		O
stereoselectivity		O
at		O
the		O
alpha		O
(		O
2		O
)		O
-		O
adrenoceptor		O
.		O
For		O
the		O
former		O
complexes		O
,		O
trans		O
isomers		O
are		O
more		O
efficacious		O
than		O
the		O
corresponding		O
cis		O
isomers		O
.		O
These		O
compounds		O
represent		O
conformationally		O
constrained		O
direct		O
analogues		O
of		O
the		O
corresponding		O
potent		O
5		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
pentadienecarboxamides		I-IUPAC
(		O
5		O
)		O
.		O
Elaboration		O
of		O
the		O
required		O
oligo		B-IUPAC
(		I-IUPAC
gamma		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamate		I-IUPAC
)		I-IUPAC
chain		O
was		O
achieved		O
one		O
unit		O
at		O
a		O
time		O
,		O
beginning		O
with		O
the		O
coupling		O
of		O
L		B-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
dibenzyl		I-IUPAC
ester		I-IUPAC
with		O
[		B-IUPAC
(		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyloxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
ester		I-IUPAC
(		O
7		O
)		O
,		O
followed		O
by		O
selective		O
removal		O
of		O
the		O
tert		O
-		O
butyloxycarbonyl		O
grouping		O
and		O
another		O
coupling		O
step		O
with		O
5		O
or		O
7		O
as		O
required		O
.		O
The		O
distribution		O
coefficient		O
values		O
of		O
a		O
range		O
of		O
48		O
hydroxypyridinones		O
and		O
their		O
corresponding		O
iron		O
(		O
III		O
)		O
complexes		O
between		O
1		O
-		O
octanol		O
and		O
MOPS		O
buffer		O
(		O
pH		O
7.4		O
)		O
are		O
reported		O
.		O
Western		O
blotting		O
analysis		O
demonstrated		O
that		O
9h		O
caused		O
a		O
shift		O
in		O
tubulin		O
concentration		O
from		O
the		O
polymerized		O
state		O
found		O
in		O
the		O
cell		O
pellet		O
to		O
the		O
unpolymerized		O
state		O
found		O
in		O
the		O
cell		O
supernatant		O
.		O
avium		O
DHFR		O
(		O
IC		O
(		O
50		O
)		O
=		O
0.47		O
nM		O
,		O
SI		O
=		O
1300		O
)		O
but		O
was		O
not		O
potent		O
or		O
selective		O
against		O
either		O
P		O
.		O
Analysis		O
of		O
DNA		O
and		O
Annexin		O
-		O
V		O
-		O
FLUOS		O
staining		O
indicated		O
that		O
compound		O
4		O
causes		O
cell		O
death		O
by		O
apoptosis		O
.		O
This		O
compound		O
is		O
a		O
homofolate		O
analogue		O
of		O
5,10		B-IUPAC
-		I-IUPAC
methenyltetrahydrofolate		I-IUPAC
which		O
serves		O
as		O
one		O
precursor		O
to		O
the		O
10		O
-		O
formyl		O
one		O
-		O
carbon		O
donor		O
for		O
the		O
first		O
transformylation		O
in		O
de		O
novo		O
purine		O
biosynthesis		O
,		O
namely		O
,		O
the		O
conversion		O
of		O
glycinamide		O
ribonucleotide		O
(		O
GAR		O
)		O
to		O
N		B-IUPAC
-		I-IUPAC
formylglycinamide		I-IUPAC
ribonucleotide		I-IUPAC
(		O
FGAR		O
)		O
,		O
catalyzed		O
by		O
the		O
enzyme		O
glycinamide		O
ribonucleotide		O
transformylase		O
(		O
EC		O
2.1.2.2		O
)		O
.		O
Prazosin		O
-		O
related		O
quinazolines		O
4-20		O
were		O
synthesized		O
,		O
and		O
their		O
biological		O
profiles		O
at		O
alpha1		O
-		O
adrenoreceptor		O
subtypes		O
were		O
assessed		O
by		O
functional		O
experiments		O
in		O
isolated		O
rat		O
vas		O
deferens		O
(		O
alpha1A		O
)		O
,		O
spleen		O
(		O
alpha1B		O
)		O
,		O
and		O
aorta		O
(		O
alpha1D		O
)		O
and		O
by		O
binding		O
assays		O
in		O
CHO		O
cells		O
expressing		O
human		O
cloned		O
alpha1		O
-		O
adrenoreceptor		O
subtypes		O
.		O
Thus		O
we		O
searched		O
for		O
a		O
benzyl		O
ester		O
surrogate		O
that		O
would		O
be		O
more		O
resistant		O
to		O
hydrolytic		O
enzymes		O
.		O
More		O
interestingly		O
,		O
the		O
intermediate		O
compound		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
benzyloxyphenyl		I-IUPAC
)		I-IUPAC
propenoic		I-IUPAC
acid		I-IUPAC
5		O
was		O
equiactive		O
with		O
3		O
.		O
The		O
N9		O
-		O
CH3		O
analogues		O
were		O
synthesized		O
via		O
a		O
regiospecific		O
reductive		O
methylation		O
of		O
the		O
corresponding		O
N9		O
-		O
H		O
precursors		O
.		O
However		O
the		O
Ki		O
of		O
the		O
8		B-IUPAC
-		I-IUPAC
deaza		I-IUPAC
analogue		B-MODIFIER
was		O
27		O
-		O
fold		O
lower		O
than		O
that		O
of		O
1		O
,		O
and		O
that		O
of		O
the		O
5,8		B-IUPAC
-		I-IUPAC
dideaza		I-IUPAC
,		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5,8		I-IUPAC
-		I-IUPAC
dideaza		I-IUPAC
,		O
and		O
5		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
5,8		I-IUPAC
-		I-IUPAC
dideaza		I-IUPAC
analogues		B-MODIFIER
was		O
approximately		O
50		O
-		O
fold		O
lower		O
.		O
Optimization		O
of		O
the		O
structural		O
parameters		O
for		O
this		O
activity		O
yiedled		O
5		B-IUPAC
-		I-IUPAC
[		I-IUPAC
m		I-IUPAC
-		I-IUPAC
trifluorobenzyl		I-IUPAC
)		I-IUPAC
thio		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridinecarboxylic		I-IUPAC
acid		I-IUPAC
(		O
41		O
)		O
and		O
its		O
sulfoxide		O
,		O
42		O
.		O
To		O
examine		O
the		O
relationship		O
between		O
the		O
conformation		O
of		O
the		O
pharmacophore		O
and		O
the		O
level		O
of		O
agonistic		O
activity		O
of		O
this		O
type		O
of		O
ligand		O
,		O
we		O
synthesized		O
a		O
series		O
of		O
3		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
{		I-IUPAC
[		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
H		I-IUPAC
or		I-IUPAC
CH3		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
R		I-IUPAC
-		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
}		I-IUPAC
-		I-IUPAC
piperidin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
-		I-IUPAC
+		I-IUPAC
+		I-IUPAC
+		I-IUPAC
methanone		I-IUPAC
derivatives		B-MODIFIER
and		O
found		O
that		O
the		O
combination		O
of		O
a		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
and		O
a		O
6		B-IUPAC
-		I-IUPAC
methylamino		I-IUPAC
substituent		B-MODIFIER
on		O
the		O
pyridine		O
ring		O
synergistically		O
affected		O
their		O
5		O
-		O
HT1A		O
agonist		O
properties		O
.		O
Principal		O
efforts		O
focused		O
on		O
triazoles		O
bearing		O
an		O
n		O
-		O
alkyl		O
substitutent		O
at		O
C3		O
and		O
a		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxybenzoyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
benzyl		I-IUPAC
,		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
carboxybiphenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
,		O
or		O
[		B-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
biphenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
side		B-MODIFIER
chain		I-MODIFIER
at		O
N4		O
.		O
In		O
addition		O
,		O
39		O
was		O
also		O
found		O
to		O
be		O
active		O
against		O
hookworms		O
in		O
dogs		O
at		O
a		O
single		O
,		O
oral		O
dose		O
of		O
200		O
mg		O
/		O
kg		O
.		O
Compounds		O
with		O
potent		O
receptor		O
binding		O
also		O
potently		O
inhibited		O
the		O
quipazine		O
-		O
induced		O
head		O
twitch		O
syndrome		O
in		O
rats		O
.		O
The		O
C2		O
'		O
-		O
endo		O
-		O
C1		O
'		O
-		O
exo		O
conformation		O
,		O
the		O
anti		O
conformation		O
of		O
thymine		O
in		O
relation		O
to		O
the		O
glycosidic		O
bond		O
,		O
and		O
the		O
gauche+		O
conformation		O
in		O
relation		O
to		O
the		O
C4		O
'		O
-		O
C5		O
'		O
bond		O
are		O
characteristic		O
for		O
the		O
3'		B-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxythymidine		I-IUPAC
structure		O
in		O
the		O
crystals		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deaza		I-IUPAC
analogue		B-MODIFIER
of		O
3		O
was		O
also		O
tested		O
at		O
the		O
National		O
Cancer		O
Institute		O
against		O
a		O
panel		O
of		O
50		O
human		O
tumor		O
cell		O
lines		O
in		O
culture		O
and		O
was		O
consistently		O
more		O
potent		O
than		O
3		O
,		O
with		O
IC50		O
values		O
in		O
the		O
low		O
-		O
nanomolar		O
to		O
subnanomolar		O
range		O
against		O
most		O
of		O
the		O
tumors		O
.		O
The		O
introduction		O
of		O
hydroxyl		B-IUPAC
groups		B-MODIFIER
significantly		O
enhanced		O
the		O
radioprotective		O
properties		O
of		O
nonhydroxylated		O
parent		O
compounds		O
,		O
however		O
,		O
only		O
in		O
the		O
case		O
of		O
intraperitoneally		O
administered		O
.		O
Compounds		O
10		O
and		O
21		O
were		O
also		O
able		O
to		O
reduce		O
neuronal		O
cell		O
death		O
induced		O
by		O
the		O
application		O
of		O
KA		O
(		O
100		O
microM		O
)		O
.		O
avium		O
DHFR		O
,		O
and		O
its		O
SI		O
was		O
no		O
better		O
than		O
that		O
of		O
TMP		O
.		O
The		O
site		O
of		O
glycosylation		O
and		O
the		O
anomeric		O
configuration		O
of		O
these		O
nucleosides		O
have		O
been		O
assigned		O
on		O
the		O
basis		O
of		O
1'		O
NMR		O
and		O
UV		O
spectral		O
characteristics		O
and		O
by		O
single		O
-		O
crystal		O
X		O
-		O
ray		O
analysis		O
for		O
27-29		O
.		O
By		O
contrast		O
,		O
compound		O
8b		O
showed		O
no		O
appreciable		O
affinity		O
for		O
Glu		O
uptake		O
sites		O
,		O
neither		O
synaptosomal		O
nor		O
cloned		O
.		O
Substitutions		O
at		O
positions		O
3		O
(		O
[		B-IUPAC
N		I-IUPAC
(		I-IUPAC
beta		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
)		I-IUPAC
d		I-IUPAC
-		I-IUPAC
Dap		I-IUPAC
(		I-IUPAC
3		I-IUPAC
)		I-IUPAC
]		I-IUPAC
degarelix		I-IUPAC
,		O
IC		O
(		O
50		O
)		O
=		O
2.71		O
nM		O
)		O
(		O
5		O
)		O
,		O
7		O
(		O
[		B-IUPAC
Pra		I-IUPAC
(		I-IUPAC
7		I-IUPAC
)		I-IUPAC
]		I-IUPAC
degarelix		I-IUPAC
,		O
IC		O
(		O
50		O
)		O
=		O
2.11		O
nM		O
)		O
(		O
16		O
)		O
,		O
and		O
8		O
(		O
[		B-IUPAC
N		I-IUPAC
(		I-IUPAC
delta		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
IGly		I-IUPAC
)		I-IUPAC
Orn		I-IUPAC
(		I-IUPAC
8		I-IUPAC
)		I-IUPAC
]		I-IUPAC
degarelix		I-IUPAC
,		O
IC		O
(		O
50		O
)		O
=		O
1.38		O
nM		O
)		O
(		O
20		O
)		O
and		O
N		O
-		O
methylation		O
(		O
[		B-IUPAC
N		I-IUPAC
(		I-IUPAC
alpha		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
Leu		I-IUPAC
(		I-IUPAC
7		I-IUPAC
)		I-IUPAC
]		I-IUPAC
degarelix		I-IUPAC
,		O
IC		O
(		O
50		O
)		O
=		O
1.47		O
nM		O
)		O
(		O
32		O
)		O
yielded		O
analogues		O
that		O
were		O
equipotent		O
to		O
degarelix		O
(		O
2		O
)		O
in		O
vitro		O
(		O
IC		O
(		O
50		O
)		O
=		O
1.64		O
nM		O
)		O
but		O
shorter		O
acting		O
in		O
vivo		O
.		O
Pyrazofurin		O
derivatives		O
modified		O
at		O
the		O
1		O
-		O
,		O
4		O
-		O
,		O
or		O
5		O
-		O
position		O
showed		O
neither		O
antiviral		O
nor		O
cytostatic		O
activity		O
in		O
cell		O
culture		O
.		O
Thus		O
,		O
nine		O
new		O
bis		O
-		O
carbamates		O
:		O
methoxycarbonyl		B-IUPAC
(		O
2		O
)		O
,		O
2,2,2		B-IUPAC
-		I-IUPAC
trichloroethoxycarbonyl		I-IUPAC
(		O
3		O
)		O
,		O
ethylthiocarbonyl		B-IUPAC
(		O
4		O
)		O
,		O
benzyloxycarbonyl		B-IUPAC
(		O
5		O
)		O
,		O
(		B-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
dioxol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methoxycarbonyl		I-IUPAC
(		O
6		O
)		O
,		O
phenoxycarbonyl		B-IUPAC
(		O
7		O
)		O
,		O
4		B-IUPAC
-		I-IUPAC
fluorophenoxycarbonyl		I-IUPAC
(		O
8		O
)		O
,		O
4		B-IUPAC
-		I-IUPAC
methoxyphenoxycarbonyl		I-IUPAC
(		O
9		O
)		O
,		O
and		O
(		B-IUPAC
1		I-IUPAC
-		I-IUPAC
acetoxy		I-IUPAC
)		I-IUPAC
ethoxycarbonyl		I-IUPAC
(		O
10		O
)		O
and		O
a		O
bis		B-IUPAC
-		I-IUPAC
carbonate		I-IUPAC
ethoxycarbonyloxy		I-IUPAC
(		O
11		O
)		O
of		O
the		O
bis		O
-		O
amidine		O
1		O
have		O
been		O
synthesized		O
and		O
evaluated		O
.		O
Acetylacetone		O
was		O
condensed		O
with		O
2,4		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzylidene		I-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
dibenzoyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribose		I-IUPAC
(		O
1		O
)		O
,		O
2,4		B-IUPAC
:		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
dibenzylidene		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribose		I-IUPAC
(		O
6		O
)		O
,		O
2,3,4,5		B-IUPAC
-		I-IUPAC
tetraacetyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribose		I-IUPAC
(		O
7		O
)		O
,		O
and		O
2,3,4,5,6		B-IUPAC
-		I-IUPAC
pentaacetyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
glucose		I-IUPAC
(		O
9		O
)		O
to		O
yield		O
3		B-IUPAC
-		I-IUPAC
ylidene		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
pentanedione		I-IUPAC
derivatives		B-MODIFIER
2		O
,		O
11		O
,		O
12		O
,		O
and		O
13		O
,		O
respectively		O
.		O
Its		O
selectivity		O
is		O
about		O
400		O
-		O
fold		O
over		O
the		O
NET		O
and		O
about		O
1000		O
-		O
fold		O
over		O
the		O
DAT		O
.		O
The		O
inactivation		O
was		O
shown		O
to		O
be		O
stereospecific		O
since		O
a		O
D		O
derivative		O
led		O
to		O
no		O
irreversible		O
inactivation		O
.		O
The		O
product		O
(		O
3a		O
)		O
,		O
of		O
the		O
condensation		O
reaction		O
between		O
6		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
nicotinonitrile		I-IUPAC
and		O
2		O
,		O
undergoes		O
Suzuki		O
coupling		O
with		O
4		B-IUPAC
-		I-IUPAC
cyanophenylboronic		I-IUPAC
acid		I-IUPAC
to		O
furnish		O
4a		O
in		O
good		O
yield		O
.		O
aureus		O
,		O
clearly		O
indicating		O
that		O
the		O
2,6		B-PARTIUPAC
-		I-PARTIUPAC
dimethylpyridinyl		I-PARTIUPAC
group		B-MODIFIER
is		O
optimal		O
.		O
Introduction		O
of		O
substituents		O
at		O
the		O
5		O
-		O
,		O
7		O
-		O
,		O
and		O
5,7		O
-		O
positions		O
resulted		O
in		O
analogues		O
having		O
selective		O
NMDA		O
antagonist		O
action		O
,		O
as		O
a		O
result		O
of		O
blockade		O
of		O
the		O
glycine		O
modulatory		O
(		O
or		O
coagonist		O
)		O
site		O
on		O
the		O
NMDA		O
receptor		O
.		O
A		O
series		O
of		O
C11		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aporphines		I-IUPAC
and		O
C11		B-MODIFIER
-		I-MODIFIER
oxygenated		I-MODIFIER
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
noraporphines		I-IUPAC
has		O
been		O
synthesized		O
and		O
evaluated		O
for		O
central		O
serotonergic		O
and		O
dopaminergic		O
effects		O
in		O
vitro		O
and		O
in		O
vivo		O
.		O
Thus		O
,		O
the		O
synthesis		O
of		O
some		O
3		O
-		O
NH		O
-		O
substituted		O
derivatives		O
(		O
2a		O
,		O
3a		O
,		O
4a		O
)		O
starting		O
from		O
3		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
quinoxalinecarbonitrile		I-IUPAC
1,4		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
(		O
1a		O
)		O
is		O
described		O
.		O
This		O
inactivation		O
was		O
very		O
rapid		O
but		O
reversible		O
,		O
with		O
regeneration		O
of		O
enzyme		O
activity		O
being		O
spontaneous		O
and		O
hydrazine		O
-		O
accelerated		O
,		O
suggestive		O
of		O
the		O
intermediacy		O
of		O
a		O
stable		O
acyl		O
enzyme		O
.		O
In		O
contrast		O
,		O
replacement		O
of		O
the		O
2'		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
group		B-MODIFIER
of		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
dimethylallyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5,9		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
benzomorphan		I-IUPAC
[		O
(		O
+		O
)		O
-		O
1b		O
,		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pentazocine		I-IUPAC
]		O
with		O
a		O
2'		O
-		O
H		O
or		O
2'		O
-		O
F		O
group		O
resulted		O
in		O
a		O
2		O
-		O
fold		O
increase		O
in		O
potency		O
.		O
Some		O
of		O
the		O
reported		O
analogues		O
,		O
namely		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
mercapto		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylcyclohexaneacetic		I-IUPAC
acid		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
arginine		I-IUPAC
-		I-IUPAC
vasopressin		I-IUPAC
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
mercapto		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylcyclohexaneacetic		I-IUPAC
acid		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyltryosine		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
arginine		I-IUPAC
-		I-IUPAC
vasopressin		I-IUPAC
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
mercaptocyclohexaneacetic		I-IUPAC
acid		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyltyrosine		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
arginine		I-IUPAC
-		I-IUPAC
vasopressin		I-IUPAC
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
mercapto		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenylcyclohexaneacetic		I-IUPAC
acid		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
arginine		I-IUPAC
-		I-IUPAC
vasopressin		I-IUPAC
and		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
mercapto		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenylcyclohexaneacetic		I-IUPAC
acid		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyltyrosine		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
arginine		I-IUPAC
-		I-IUPAC
vasopressin		I-IUPAC
,		O
are		O
among		O
the		O
most		O
potent		O
and		O
selective		O
antagonists		O
of		O
the		O
vasopressor		O
response		O
to		O
arginine		O
-		O
vasopressin		O
reported		O
to		O
date		O
.		O
carinii		O
at		O
30		O
mg		O
/		O
kg		O
x		O
5		O
days		O
(		O
ip		O
)		O
and		O
against		O
B		O
.		O
8		B-IUPAC
-		I-IUPAC
(		I-IUPAC
m		I-IUPAC
-		I-IUPAC
Bromostyryl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
,		I-IUPAC
7		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propargylxanthine		I-IUPAC
(		O
BS		O
-		O
DMPX		O
,		O
11		O
)		O
and		O
the		O
analogous		B-MODIFIER
8		B-IUPAC
-		I-IUPAC
(		I-IUPAC
m		I-IUPAC
-		I-IUPAC
methoxystyryl		I-IUPAC
)		I-IUPAC
xanthine		I-IUPAC
derivative		B-MODIFIER
(		O
MS		O
-		O
DMPX		O
,		O
5b		O
)		O
were		O
used		O
as		O
starting		O
points		O
.		O
Two		O
series		O
of		O
peptide		O
analogues		O
,		O
(		O
a		O
)		O
p		O
-		O
substituted		O
analogues		O
,		O
[		O
p		O
-		O
X		O
-		O
Phe		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
,		O
where		O
X		O
=		O
F		O
,		O
Cl		O
,		O
Br		O
,		O
I		O
,		O
NH		O
(		O
2		O
)		O
,		O
NO		O
(		O
2		O
)		O
,		O
and		O
(		O
b		O
)		O
[		O
D		O
-		O
Phe		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
,		O
[		O
Trp		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
,		O
and		O
[		O
Chex		O
-		O
Ala		O
(		O
6		O
)		O
,		O
Nle		O
(		O
10		O
)		O
]		O
NKA		O
(		O
4-10		O
)		O
,		O
were		O
synthesized		O
,		O
and		O
their		O
biological		O
activity		O
was		O
examined		O
.		O
Three		O
series		O
of		O
benzamides		O
of		O
N		B-MODIFIER
,		I-MODIFIER
N		I-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
ethylenediamines		B-IUPAC
(		O
linear		B-MODIFIER
alkane		B-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
diamines		I-IUPAC
)		O
,		O
1		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
pyrrolidines		I-IUPAC
,		O
and		O
1		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
3		B-IUPAC
-		I-IUPAC
aminopyrrolidines		I-IUPAC
(		O
cyclic		B-MODIFIER
alkane		B-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
diamines		I-IUPAC
)		O
were		O
designed		O
and		O
synthesized		O
as		O
potential		O
neuroleptics		O
.		O
Binding		O
studies		O
were		O
performed		O
using		O
[		O
3H		O
]		O
isradipine		O
as		O
a		O
reference		O
ligand		O
.		O
No		O
.		O
These		O
data		O
further		O
support		O
a		O
pharmacophore		O
model		O
in		O
which		O
the		O
region		O
occupied		O
by		O
the		O
aryl		O
ring		O
is		O
a		O
lipophilic		O
pocket		O
with		O
electropositive		O
character		O
.		O
Increasing		O
the		O
chain		O
length		O
and		O
the		O
lipophilicity		O
of		O
the		O
N		O
-		O
substituent		O
result		O
in		O
compounds		O
in		O
which		O
high		O
affinity		O
for		O
sigma		O
2		O
binding		O
sites		O
is		O
retained		O
and		O
with		O
selectivity		O
for		O
sigma		O
2		O
vs		O
sigma		O
1		O
binding		O
sites		O
(		O
e.g.		O
,		O
4		B-IUPAC
-		I-IUPAC
cyclohexyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
:		O
IC50		O
-		O
(		O
sigma		O
1		O
)		O
=		O
1.5		O
nM		O
,		O
IC50		O
(		O
sigma		O
2		O
)		O
=		O
0.07		O
nM		O
)		O
.		O
Similarly		O
,		O
5		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
7,12		I-IUPAC
-		I-IUPAC
benz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthraquinone		I-IUPAC
(		O
8		O
)		O
afforded		O
a		O
mixture		O
of		O
cis		B-PARTIUPAC
-		I-PARTIUPAC
and		O
trans		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
7,12		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
7,12		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
7,12		I-IUPAC
-		I-IUPAC
dimethylbenz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthracenes		I-IUPAC
(		O
9		O
)		O
which		O
yielded		O
7		B-IUPAC
-		I-IUPAC
chloromethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
12		I-IUPAC
-		I-IUPAC
methylbenz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthracene		I-IUPAC
(		O
10		O
)		O
on		O
treatment		O
with		O
HCl		O
.		O
The		O
technique		O
for		O
the		O
separation		O
of		O
3		O
from		O
4		O
is		O
described		O
.		O
Here		O
,		O
we		O
investigated		O
structure		O
-		O
activity		O
relationships		O
of		O
the		O
6,7		B-IUPAC
-		I-IUPAC
dimethoxyquinazolinyl		I-IUPAC
moiety		B-MODIFIER
.		O
Combined		O
in		O
situ		O
with		O
1,3		B-IUPAC
-		I-IUPAC
propanediamine		I-IUPAC
,		O
benzylamine		O
,		O
spermine		O
,		O
spermidine		O
,		O
1,3,5		B-IUPAC
-		I-IUPAC
tris		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
benzene		I-IUPAC
,		O
or		O
desferrioxamine		O
B		O
and		O
excess		O
triethylamine		O
,		O
the		O
latter		O
intermediate		O
gave		O
the		O
corresponding		O
amides		O
in		O
isolated		O
yields		O
ranging		O
from		O
16%		O
to		O
60%		O
.		O
A		O
detailed		O
conformational		O
analysis		O
of		O
(		O
N		O
)		O
-		O
methanocarba		O
-		O
T		O
(		O
2		O
)		O
and		O
(		O
S		O
)		O
-		O
methanocarba		O
-		O
T		O
(		O
12		O
)		O
,		O
as		O
representative		O
examples		O
of		O
conformationally		O
rigid		O
pseudorotational		O
antipodes		O
,		O
revealed		O
that		O
in		O
addition		O
to		O
their		O
different		O
forms		O
of		O
ring		O
pucker		O
,		O
(		O
S		O
)		O
-		O
methanocarba		O
-		O
T		O
appears		O
to		O
be		O
a		O
rather		O
stiff		O
molecule		O
with		O
fewer		O
low		O
-		O
energy		O
conformational		O
states		O
available		O
compared		O
to		O
(		O
N		O
)		O
-		O
methanocarba		O
-		O
T		O
.		O
Further		O
biological		O
studies		O
with		O
these		O
compounds		O
are		O
described		O
.		O
All		O
derivatives		O
of		O
propargylfolate		O
were		O
active		O
against		O
the		O
growth		O
of		O
Streptococcus		O
faecium		O
,		O
but		O
with		O
the		O
exception		O
of		O
7,8		B-IUPAC
-		I-IUPAC
dihydropropargylfolic		I-IUPAC
acid		I-IUPAC
,		O
all		O
were		O
inactive		O
against		O
L		O
.		O
NaH		O
-		O
mediated		O
alkylation		O
of		O
6		B-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
(		O
4		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
(		O
5		O
)		O
with		O
certain		O
alkyl		O
bromides		O
gave		O
N7		O
-		O
and		O
N9		O
-		O
alkylated		O
derivatives		O
(		O
7a		O
-		O
d		O
and		O
6a		O
-		O
d		O
)		O
,		O
the		O
N9		O
-		O
isomer		O
being		O
the		O
major		O
product		O
.		O
In		O
vitro		O
,		O
the		O
fluoro		O
derivative		O
of		O
A		O
-		O
85380		O
(		O
2		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
azetidinylmethoxy		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
or		O
F		O
-		O
A		O
-		O
85380		O
)		O
competitively		O
displaced		O
[		O
3H		O
]		O
cytisine		O
or		O
[		O
3H		O
]		O
epibatidine		O
with		O
Ki		O
values		O
of		O
48		O
and		O
46		O
pM		O
,		O
respectively		O
.		O
Thus		O
,		O
none		O
of		O
the		O
compounds		O
showed		O
an		O
advantage		O
over		O
CGS		O
9896		O
(		O
Yokoyama		O
et		O
al.		O
J		O
.		O
The		O
most		O
active		O
and		O
selective		O
compound		O
we		O
found		O
in		O
the		O
present		O
series		O
is		O
compound		O
8b		O
[		O
(		B-IUPAC
1S		I-IUPAC
,		I-IUPAC
3R		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
acetoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
,		I-IUPAC
4		I-IUPAC
-		I-IUPAC
dichlorophenylmethylene		I-IUPAC
)		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
azatricyclo		I-IUPAC
[		I-IUPAC
4.3.1.0		I-IUPAC
(		I-IUPAC
3,7		I-IUPAC
)		I-IUPAC
]		I-IUPAC
decane		I-IUPAC
]		O
.		O
The		O
trans		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indenes		I-IUPAC
(		O
+		O
)		O
-		O
14b		O
and		O
(		O
+		O
)		O
-		O
15b		O
represent		O
selective		O
D1		O
agonists		O
lacking		O
a		O
catechol		O
group		O
,		O
which		O
should		O
meet		O
the		O
prerequisites		O
for		O
a		O
central		O
nervous		O
system		O
penetration		O
.		O
)		O
.		O
Formylation		O
of		O
6		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
pteridinediamine		I-IUPAC
gave		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
pteridinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
formamide		I-IUPAC
.		O
Using		O
the		O
chemically		O
reactive		O
functional		O
groups		O
on		O
tyrosine		O
and		O
p		O
-		O
aminophenylalanine		O
in		O
position		O
9		O
,		O
we		O
prepared		O
iodinated		O
,		O
photoreactive		O
,		O
and		O
affinity		O
ligands		O
,		O
i.e.		O
,		O
[		O
2		B-IUPAC
-		I-IUPAC
phenylalanine		I-IUPAC
,		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
iodotyrosine		I-IUPAC
)		I-IUPAC
]		O
AVT		O
,		O
1		B-IUPAC
-		I-IUPAC
desamino		I-IUPAC
[		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
azidophenylalanine		I-IUPAC
)		I-IUPAC
]		I-IUPAC
AVT		O
,		O
and		O
1		B-IUPAC
-		I-IUPAC
desamino		I-IUPAC
[		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
biotinylphenylalanine		I-IUPAC
)		I-IUPAC
]		I-IUPAC
AVT		O
,		O
respectively		O
.		O
sigma		O
-		O
Receptor		O
Ki		O
's		O
ranged		O
from		O
0.55		O
nM		O
for		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dichlorophenyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
butylpiperazine		I-IUPAC
(		O
7		O
)		O
to		O
654		O
nM		O
for		O
16		O
.		O
The		O
syntheses		O
of		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
6,7,8,9		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
3H		I-IUPAC
,		I-IUPAC
10H		I-IUPAC
-		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
3,2		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
carbazol		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
amine		I-IUPAC
(		O
8		O
)		O
,		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
7,8,9,10		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
11H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
3,2		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
carbazol		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
amine		I-IUPAC
(		O
9a		O
)		O
,		O
and		O
the		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
,		I-IUPAC
11		I-IUPAC
-		I-IUPAC
trimethyl		I-IUPAC
analogue		B-MODIFIER
(		O
9b		O
)		O
are		O
described		O
.		O
The		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
propargyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
adenine		I-IUPAC
(		O
5		O
)		O
and		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
propargyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
hypoxanthine		I-IUPAC
(		O
12		O
)		O
analogues		B-MODIFIER
were		O
converted		O
to		O
the		O
corresponding		O
5'		B-IUPAC
-		I-IUPAC
tributylstannyl		I-IUPAC
intermediates		B-MODIFIER
(		O
9		O
and		O
13		O
)		O
,		O
respectively		O
,		O
which		O
gave		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
adenine		I-IUPAC
(		O
10		O
)		O
and		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
hypoxanthine		I-IUPAC
(		O
14		O
)		O
,		O
respectively		O
,		O
after		O
iododestannylation		O
.		O
The		O
ribofuranosyl		B-IUPAC
derivative		B-MODIFIER
12		O
showed		O
a		O
significant		O
activity		O
against		O
type		O
1		O
herpes		O
simplex		O
virus		O
.		O
In		O
the		O
8		O
-		O
substituted		O
series		O
(		O
R1		O
in		O
3		O
)		O
,		O
only		O
8		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
allyl		I-IUPAC
analogs		B-MODIFIER
were		O
synthesized		O
and		O
evaluated		O
.		O
X		O
-		O
ray		O
analysis		O
carried		O
out		O
on		O
17		O
and		O
28		O
and		O
molecular		O
modeling		O
investigations		O
extended		O
also		O
to		O
related		O
derivatives		O
allowed		O
a		O
possible		O
rationalization		O
between		O
structure		O
and		O
inotropic		O
activity		O
for		O
this		O
series		O
of		O
compounds		O
.		O
A		O
series		O
of		O
substituted		O
racemic		O
naphthofurans		O
were		O
synthesized		O
as		O
"		O
hybrid		O
"		O
molecules		O
of		O
the		O
two		O
major		O
prototypical		O
hallucinogenic		O
drug		O
classes		O
,		O
the		O
phenethylamines		O
and		O
the		O
tryptamines		O
/		O
ergolines		O
.		O
Based		O
on		O
the		O
toxicological		O
findings		O
,		O
it		O
was		O
decided		O
not		O
to		O
pursue		O
compound		O
65		O
clinically		O
.		O
A		O
number		O
of		O
nucleoside		O
analogues		O
have		O
been		O
either		O
used		O
clinically		O
as		O
anticancer		O
drugs		O
or		O
evaluated		O
in		O
clinical		O
studies		O
,		O
while		O
new		O
nucleoside		O
analogues		O
continue		O
to		O
show		O
promise		O
.		O
Treatment		O
of		O
ethyl		B-IUPAC
3		I-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,3,5		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
arabinofuranosyl		I-IUPAC
)		I-IUPAC
pyrrole		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
6		O
)		O
with		O
hydrazine		O
afforded		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,3,5		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
arabinofuranosyl		I-IUPAC
)		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyridazin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
7		O
)		O
.		O
A		O
new		O
metabolic		O
pathway		O
of		O
terminal		O
hydroxylation		O
(		O
omega		O
-		O
hydroxylation		O
)		O
of		O
the		O
N		B-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
group		B-MODIFIER
of		O
propranolol		O
(		O
1		O
)		O
was		O
established		O
.		O
Specific		O
binding		O
ratios		O
[		O
region		O
of		O
interest		O
(		O
ROI		O
)		O
/		O
cerebellum		O
-		O
1		O
]		O
in		O
control		O
studies		O
for		O
cortex		O
(		O
Ctx		O
)		O
and		O
hippocampus		O
(		O
H		O
)		O
were		O
higher		O
for		O
[		O
carbonyl		O
-		O
11C		O
]		O
4a		O
and		O
[		O
18F		O
]		O
4d		O
compared		O
to		O
[		O
18F		O
]		O
4b		O
and		O
[		O
18F		O
]		O
4c		O
.		O
There		O
is		O
reported		O
the		O
first		O
four		O
members		O
of		O
heteroarotinoids		O
,		O
the		O
names		O
of		O
which		O
are		O
ethyl		B-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethylthiochroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoate		I-IUPAC
(		O
1b		O
)		O
,		O
ethyl		B-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethylchroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoate		I-IUPAC
(		O
1c		O
)		O
,		O
ethyl		B-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxothiochroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoate		I-IUPAC
(		O
1d		O
)		O
,		O
and		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
dimethylchroman		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
1e		O
)		O
.		O
Condensation		O
of		O
19		O
with		O
morpholine		O
followed		O
by		O
catalytic		O
reduction		O
of		O
the		O
nitro		O
group		O
and		O
treatment		O
with		O
thiosemicarbazide		O
afforded		O
5		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
morpholinoisoquinoline		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
carboxaldehyde		I-IUPAC
thiosemicarbazone		I-IUPAC
(		O
22		O
)		O
.		O
Among		O
the		O
more		O
active		O
compounds		O
synthesized		O
are		O
tricyclo		B-IUPAC
[		I-IUPAC
3.3.1.1		I-IUPAC
(		I-IUPAC
3,7		I-IUPAC
)		I-IUPAC
]		I-IUPAC
dec		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
[		I-IUPAC
R		I-IUPAC
-		I-IUPAC
(		I-IUPAC
R		I-IUPAC
*		I-IUPAC
,		I-IUPAC
R		I-IUPAC
*		I-IUPAC
)		I-IUPAC
]		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
isoxazolyl		I-IUPAC
)		I-IUPAC
acetyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxoethyl+		I-IUPAC
+		I-IUPAC
+		I-IUPAC
]		I-IUPAC
carbamate		I-IUPAC
(		O
15		O
)		O
,		O
tricyclo		B-IUPAC
[		I-IUPAC
3.3.1.1		I-IUPAC
(		I-IUPAC
3,7		I-IUPAC
)		I-IUPAC
]		I-IUPAC
dec		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
[		I-IUPAC
R		I-IUPAC
-		I-IUPAC
(		I-IUPAC
R		I-IUPAC
*		I-IUPAC
,		I-IUPAC
R		I-IUPAC
*		I-IUPAC
)		I-IUPAC
]		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
sulfopropyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
carbamate		I-IUPAC
,		O
monosodium		O
salt		O
(		O
27		O
)		O
,		O
and		O
tricyclo		B-IUPAC
[		I-IUPAC
3.3.1.1		I-IUPAC
(		I-IUPAC
3,7		I-IUPAC
)		I-IUPAC
]		I-IUPAC
dec		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
[		I-IUPAC
R		I-IUPAC
-		I-IUPAC
(		I-IUPAC
R		I-IUPAC
*		I-IUPAC
,		I-IUPAC
R		I-IUPAC
*		I-IUPAC
)		I-IUPAC
]		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
indol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ylsulfinyl		I-IUPAC
)		I-IUPAC
acetyl		I-IUPAC
]		I-IUPAC
a		I-IUPAC
mino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylethyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
carbamic		I-IUPAC
acid		I-IUPAC
(		O
34		O
)		O
which		O
have		O
CCK		O
-		O
B		O
binding		O
affinities		O
of		O
IC50		O
=		O
2.6		O
,		O
1.3		O
,		O
and		O
1.7		O
nM		O
,		O
CCK		O
-		O
A		O
/		O
-		O
B		O
ratios		O
of		O
650		O
,		O
780		O
,		O
and		O
550		O
and		O
pK		O
(		O
a		O
)		O
values		O
of		O
6.5		O
,		O
less		O
than		O
1		O
,		O
and		O
7.0		O
,		O
respectively		O
.		O
This		O
investigation		O
was		O
conducted		O
to		O
study		O
the		O
role		O
of		O
phenylalanine		O
at		O
position		O
6		O
on		O
the		O
glucagon		O
mechanism		O
of		O
action		O
.		O
The		O
duration		O
of		O
action		O
was		O
also		O
determined		O
in		O
the		O
castrated		O
male		O
rat		O
assay		O
to		O
measure		O
the		O
extent		O
(		O
efficacy		O
and		O
duration		O
of		O
action		O
)		O
of		O
inhibition		O
of		O
luteinizing		O
hormone		O
(		O
LH		O
)		O
release		O
.		O
Also		O
,		O
the		O
effect		O
of		O
the		O
hydroxyl		B-IUPAC
or		O
OBz		O
group		O
configuration		O
at		O
C3		O
on		O
the		O
condensation		O
stereoselectivity		O
of		O
3		B-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
deoxyfuranosides		I-IUPAC
with		O
silylated		O
thymine		O
has		O
been		O
studied		O
.		O
The		O
insertion		O
of		O
substituents		O
on		O
the		O
benzene		O
ring		O
of		O
8		O
affected		O
,		O
according		O
to		O
the		O
type		O
and		O
the		O
position		O
of		O
the		O
substituent		O
,		O
affinity		O
and		O
selectivity		O
for		O
alpha1		O
-		O
adrenoreceptors		O
.		O
Thus		O
,		O
4b		O
,		O
d		O
,		O
e		O
were		O
evaluated		O
for		O
their		O
affinity		O
at		O
muscarinic		O
M1		O
-		O
M5		O
receptors		O
and		O
also		O
assessed		O
for		O
their		O
functional		O
characteristics		O
at		O
the		O
M1		O
and		O
M2		O
isoforms		O
.		O
By		O
contrast		O
,		O
1H		O
NMR		O
and		O
IR		O
spectra		O
of		O
bromo		O
ester		O
21		O
are		O
indicative		O
of		O
syn		O
-		O
conformation		O
of		O
adenine		O
.		O
Some		O
compounds		O
acted		O
as		O
specific		O
calpain		O
inhibitors		O
,		O
with		O
comparable		O
activity		O
on		O
both		O
calpains		O
I		O
and		O
II		O
and		O
a		O
lack		O
of		O
activity		O
on		O
cathepsin		O
B		O
(		O
e.g.		O
,		O
40		O
,		O
42		O
,		O
48		O
,		O
70		O
)		O
.		O
Since		O
neither		O
11		O
nor		O
12		O
is		O
appreciably		O
carcinogenic		O
,		O
the		O
carcinogenic		O
metabolism		O
of		O
7,12		B-IUPAC
-		I-IUPAC
dimethylbenz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthracene		I-IUPAC
(		O
DMBA		O
)		O
probably		O
does		O
not		O
involve		O
attack		O
at		O
the		O
7		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
group		B-MODIFIER
.		O
Neither		O
the		O
conformation		O
with		O
lowest		O
potential		O
energy		O
nor		O
any		O
other		O
electron		O
-		O
derived		O
parameter		O
correlate		O
with		O
these		O
data		O
.		O
This		O
compound		O
produces		O
a		O
significant		O
increase		O
in		O
cGMP		O
which		O
is		O
likely		O
to		O
cause		O
inhibition		O
at		O
an		O
early		O
stage		O
of		O
the		O
platelet		O
activation		O
pathway		O
.		O
(		B-IUPAC
5		I-IUPAC
-		I-IUPAC
Amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
methanone		I-IUPAC
(		O
21		O
)		O
was		O
the		O
most		O
active		O
compound		O
against		O
pentylenetetrazole		O
-		O
induced		O
convulsions		O
.		O
Derivatives		O
of		O
2		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
23		O
,		O
K		O
(		O
i		O
)		O
=		O
15		O
nM		O
)		O
,		O
in		O
which		O
the		O
phenyl		O
ring		O
contains		O
substituents		O
,		O
have		O
been		O
synthesized		O
.		O
3D		O
contour		O
maps		O
generated		O
from		O
these		O
models		O
were		O
analyzed		O
individually		O
,		O
which		O
provides		O
the		O
regions		O
in		O
space		O
where		O
interactive		O
fields		O
may		O
influence		O
the		O
activity		O
.		O
mol		O
(		O
-		O
1		O
)		O
by		O
comparison		O
with		O
the		O
analogue		O
with		O
the		O
cationic		O
nitrogen		O
atom		O
of		O
the		O
quaternary		O
replaced		O
by		O
an		O
ether		O
oxygen		O
atom		O
.		O
Pirenzepine		O
displayed		O
three		O
energy		O
minima		O
,		O
differing		O
in		O
the		O
relative		O
position		O
of		O
the		O
piperazine		O
ring		O
with		O
respect		O
to		O
the		O
tricyclic		O
system		O
.		O
The		O
glutathione		O
conjugates		O
,		O
S		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phenylethyl		I-IUPAC
]		I-IUPAC
glutathione		I-IUPAC
,		O
S		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phenylethyl		I-IUPAC
]		I-IUPAC
glutathione		I-IUPAC
,		O
S		B-IUPAC
-		I-IUPAC
benzylglutathione		I-IUPAC
,		O
and		O
S		B-IUPAC
-		I-IUPAC
methylglutathione		I-IUPAC
were		O
studied		O
as		O
inhibitors		O
of		O
the		O
transferase		O
A		O
catalyzed		O
conjugation		O
of		O
1		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dinitrobenzene		I-IUPAC
.		O
The		O
rank		O
order		O
of		O
potency		O
was		O
(		O
R		O
,		O
S		O
)		O
-		O
trans		O
-		O
8		O
-		O
OH		O
-		O
PIPAT		O
&		O
gt		O
;		O
(		O
R		O
,		O
S		O
)		O
-		O
8		O
-		O
OH		O
-		O
DPAT		O
&		O
gt		O
;		O
WB4101		O
&		O
gt		O
;		O
5		O
-		O
HT		O
&		O
gt		O
;		O
(		O
R		O
,		O
S		O
)		O
-		O
trans		O
-		O
7		O
-		O
OH		O
-		O
PIPAT		O
&		O
gt		O
;		O
(		O
R		O
,		O
S		O
)		O
-		O
7		O
-		O
OH		O
-		O
DPAT		O
&		O
gt		O
;		O
(		B-IUPAC
R		I-IUPAC
,		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
propranolol		I-IUPAC
&		O
gt		O
;		O
spiperone		O
&		O
gt		O
;		O
&		O
gt		O
;		O
ketanserin		O
&		O
gt		O
;		O
&		O
gt		O
;		O
dopamine		O
&		O
gt		O
;		O
atropine		O
.		O
In		O
the		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
7		I-IUPAC
-		I-IUPAC
alkoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxochroman		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
amide		I-IUPAC
derivatives		B-MODIFIER
,		O
another		O
necessary		O
factor		O
to		O
elicit		O
the		O
potent		O
ACAT		O
inhibitory		O
activity		O
was		O
lipophilicity		O
of		O
the		O
molecules		O
.		O
Several		O
N		O
(		O
1		O
)		O
-		O
substituted		O
polyamines		O
containing		O
various		O
spacer		O
units		O
between		O
nitrogen		O
centers		O
were		O
synthesized		O
as		O
their		O
respective		O
HCl		O
salts		O
.		O
Syntheses		O
and		O
biological		O
activities		O
of		O
26		O
N4		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
4		B-IUPAC
-		I-IUPAC
aminopyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
as		O
analogs		O
of		O
naturally		O
occurring		O
modified		O
nucleic		O
acid		O
bases		O
,		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
purin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
ylcarbamoyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
threonine		I-IUPAC
and		O
N6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
delta2		I-IUPAC
-		I-IUPAC
isopentenyl		I-IUPAC
)		I-IUPAC
adenine		I-IUPAC
,		O
are		O
described		O
.		O
Taken		O
together		O
,		O
these		O
results		O
strongly		O
suggest		O
that		O
the		O
two		O
forms		O
of		O
tomaymycin		O
bound		O
to		O
d		O
(		O
ATGCAT		O
)		O
2		O
are		O
the		O
11S		O
,		O
11aS		O
and		O
11R		O
,		O
11aS		O
species		O
,		O
oriented		O
with		O
their		O
aromatic		O
rings		O
to		O
the		O
3'		O
and		O
5'		O
sides		O
,		O
respectively		O
,		O
of		O
the		O
covalently		O
modified		O
guanines		O
.		O
Numerous		O
3		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylanilino		I-IUPAC
)		I-IUPAC
uracils		I-IUPAC
(		O
EMAU		O
)		O
have		O
been		O
synthesized		O
and		O
screened		O
for		O
their		O
capacity		O
to		O
inhibit		O
the		O
replication		O
-		O
specific		O
bacterial		O
DNA		O
polymerase		O
IIIC		O
(		O
pol		O
IIIC		O
)		O
and		O
the		O
growth		O
of		O
Gram+		O
bacteria		O
in		O
culture		O
.		O
The		O
results		O
indicated		O
that		O
,		O
after		O
a		O
single		O
oral		O
administration		O
,		O
these		O
compounds		O
inhibited		O
immobility		O
in		O
the		O
FST		O
more		O
potently		O
and		O
more		O
extensively		O
than		O
the		O
clinically		O
used		O
antidepressant		O
imipramine		O
.		O
Because		O
of		O
strong		O
cytotoxic		O
effect		O
of		O
compound		O
4		O
on		O
melanoma		O
cells		O
(		O
HBL		O
,		O
ME		O
67.3		O
,		O
and		O
ME		O
67.1		O
)		O
,		O
a		O
potential		O
mechanism		O
of		O
action		O
was		O
examined		O
.		O
The		O
11		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
mesylate		I-IUPAC
of		O
5		O
on		O
LiAlH4		O
reduction		O
followed		O
by		O
mild		O
acid		O
treatment		O
and		O
demethylation		O
under		O
alkaline		O
conditions		O
gave		O
9		O
.		O
None		O
of		O
the		O
compounds		O
improved		O
upon		O
1a		O
in		O
inhibiting		O
the		O
growth		O
of		O
L1210		O
cells		O
in		O
culture		O
.		O
Treatment		O
of		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dicyanopyrrole		I-IUPAC
(		O
1		O
)		O
with		O
triethyl		O
orthoformate		O
followed		O
by		O
alkylation		O
via		O
the		O
sodium		O
salt		O
method		O
with		O
a		O
variety		O
of		O
alkylating		O
agents		O
furnished		O
the		O
corresponding		O
1		O
-		O
substituted		O
pyrroles		O
2a		O
-		O
k		O
.		O
Virtually		O
all		O
tumors		O
which		O
are		O
present		O
as		O
solid		O
masses		O
contain		O
hypoxic		O
cells		O
,		O
while		O
normal		O
cells		O
generally		O
have		O
an		O
adequate		O
supply		O
of		O
oxygen		O
.		O
While		O
exo		B-PARTIUPAC
-		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
amino		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
and		O
exo		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
hydroxybenzonorbornene		I-IUPAC
(		O
7		O
and		O
10		O
,		O
respectively		O
)		O
were		O
prepared		O
from		O
5		B-IUPAC
-		I-IUPAC
methoxybenzonorbornadiene		I-IUPAC
by		O
azidomercuration		O
/		O
demercuration		O
and		O
reduction		O
,		O
it		O
was		O
necessary		O
to		O
employ		O
both		O
normal		O
(		O
inversion		O
of		O
configuration		O
)		O
and		O
abnormal		O
(		O
retention		O
of		O
configuration		O
)		O
Mitsunobu		O
reactions		O
to		O
prepare		O
,		O
stereoselectively		O
,		O
exo		B-PARTIUPAC
-		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
amino		I-PARTIUPAC
-		I-PARTIUPAC
6		I-PARTIUPAC
-		I-PARTIUPAC
and		O
exo		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
hydroxybenzonorbornene		I-IUPAC
(		O
8		O
and		O
9		O
,		O
respectively		O
)		O
from		O
6		B-PARTIUPAC
-		I-PARTIUPAC
and		O
7		B-IUPAC
-		I-IUPAC
methoxybenzonorbornen		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ol		I-IUPAC
.		O
The		O
conclusion		O
was		O
reached		O
that		O
certain		O
conformations		O
,		O
which		O
do		O
not		O
resemble		O
those		O
of		O
lowest		O
potential		O
energy		O
,		O
cannot		O
be		O
adopted		O
by		O
the		O
inactive		O
compounds		O
.		O
Optimized		O
structures		O
of		O
all		O
the		O
synthesized		O
ligands		O
were		O
fitted		O
to		O
the		O
known		O
crystal		O
structure		O
of		O
an		O
AMPA		O
-		O
GluR2		O
construct		O
.		O
A		O
reevaluation		O
of		O
binding		O
orientation		O
for		O
5		B-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carboxymethyloxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthoic		I-IUPAC
acid		I-IUPAC
was		O
therefore		O
undertaken		O
,		O
which		O
indicated		O
a		O
180		O
degrees		O
reversal		O
of		O
the		O
binding		O
orientation		O
within		O
the		O
PTP1B		O
catalytic		O
site		O
.		O
The		O
above		O
esters		O
were		O
hydrolyzed		O
to		O
the		O
relative		O
carboxylic		O
acids		O
21-30		O
,		O
which		O
were		O
decarboxylated		O
to		O
the		O
corresponding		O
2,4		B-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
pyrimidines		B-IUPAC
31-40		O
.		O
The		O
presence		O
of		O
an		O
appropriately		O
situated		O
N		O
-		O
3		O
atom		O
,		O
however		O
,		O
as		O
in		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
isopropylphenyl		I-IUPAC
)		I-IUPAC
imidazole		I-IUPAC
,		O
significantly		O
decreases		O
both		O
the		O
Ki		O
and		O
alphaKi		O
of		O
these		O
mixed		O
type		O
inhibitors		O
.		O
The		O
preclinical		O
development		O
of		O
2		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamides		I-IUPAC
as		O
resistance		O
-		O
modifying		O
agents		O
in		O
cancer		O
chemotherapy		O
is		O
described		O
.		O
AlDH		O
activity		O
was		O
only		O
partially		O
restored		O
on		O
incubation		O
with		O
mercaptoethanol		O
(		O
20		O
mM		O
)		O
for		O
1		O
h		O
.		O
All		O
of		O
these		O
compounds		O
were		O
tested		O
in		O
Vero		O
cell		O
cultures		O
against		O
a		O
spectrum		O
of		O
viruses		O
.		O
The		O
values		O
of		O
delta		O
Tm		O
reached		O
19		O
degrees		O
C		O
and		O
1.6		O
degrees		O
C		O
for		O
the		O
most		O
substituted		O
compounds		O
of		O
both		O
series		O
.		O
From		O
this		O
series		O
of		O
compounds		O
,		O
6		B-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
ethoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
isopropyluracil		I-IUPAC
(		O
33		O
)		O
was		O
selected		O
for		O
clinical		O
evaluation		O
.		O
The		O
use		O
of		O
beta		O
-		O
MePhe		O
as		O
a		O
replacement		O
for		O
Phe3		O
was		O
based		O
upon		O
the		O
desire		O
to		O
reduce		O
the		O
conformational		O
flexibility		O
of		O
the		O
Phe3		O
side		O
chain		O
by		O
imposing		O
a		O
steric		O
rotational		O
constraint		O
in		O
the		O
form		O
of		O
the		O
beta		O
-		O
methyl		O
substituent		O
and		O
to		O
thus		O
deduce		O
the		O
residue		O
3		O
side		O
chain		O
orientation		O
in		O
the		O
delta		O
receptor		O
-		O
bound		O
conformation		O
from		O
the		O
correlation		O
between		O
delta		O
receptor		O
binding		O
affinities		O
and		O
conformational		O
preferences		O
.		O
5,10		B-IUPAC
-		I-IUPAC
Dideazaaminopterins		I-IUPAC
were		O
synthesized		O
by		O
similar		O
alkylation		O
of		O
the		O
carbanions		O
of		O
appropriate		O
4		B-PARTIUPAC
-		I-PARTIUPAC
carboxyphenylacetic		I-PARTIUPAC
,		O
(		B-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
carboxy		I-PARTIUPAC
-		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
thienyl		I-PARTIUPAC
)		I-PARTIUPAC
acetic		I-PARTIUPAC
,		O
or		O
(		B-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
acetic		I-IUPAC
acid		I-IUPAC
dimethyl		I-IUPAC
esters		I-IUPAC
.		O
The		O
order		O
of		O
anti		O
-		O
HIV		O
potency		O
of		O
pyrimidine		O
analogues		O
was		O
as		O
follows		O
:		O
5		B-IUPAC
-		I-IUPAC
fluorocytosine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
cytosine		O
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
5		B-IUPAC
-		I-IUPAC
fluorocytosine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
5		B-IUPAC
-		I-IUPAC
iodocytosine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
cytosine		O
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
5		B-IUPAC
-		I-IUPAC
bromocytosine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
thymine		O
(		O
beta		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
5		B-IUPAC
-		I-IUPAC
methylcytosine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
5		B-IUPAC
-		I-IUPAC
iodocytosine		I-IUPAC
(		O
alpha		O
-		O
isomer		O
)		O
&		O
gt		O
;		O
5		B-IUPAC
-		I-IUPAC
chlorocytosine		I-IUPAC
(		O
beta		O
-		O
isomer		O
)		O
.		O
These		O
compounds		O
were		O
tested		O
as		O
specific		O
inhibitors		O
of		O
the		O
NADH		O
:		O
ubiquinone		O
(		O
UBQ		O
)		O
reductase		O
activity		O
of		O
NADH		O
dehydrogenase		O
in		O
mitochondrial		O
membranes		O
.		O
Previous		O
findings		O
suggesting		O
that		O
5,10		B-IUPAC
-		I-IUPAC
dialkyl		I-IUPAC
-		O
substituted		B-MODIFIER
derivatives		I-MODIFIER
of		O
5,10		B-IUPAC
-		I-IUPAC
dideazaaminopterin		I-IUPAC
warranted		O
study		O
as		O
potential		O
antifolates		O
prompted		O
synthesis		O
of		O
10		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5,10		I-IUPAC
-		I-IUPAC
dideazaaminopterin		I-IUPAC
(		O
12a		O
)		O
.		O
The		O
resulting		O
1		B-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
[		I-PARTIUPAC
(		I-PARTIUPAC
dialkylamino		I-PARTIUPAC
)		I-PARTIUPAC
alkyl		I-PARTIUPAC
]		I-PARTIUPAC
amino		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
methyl		I-PARTIUPAC
-		I-PARTIUPAC
5H		I-PARTIUPAC
-		I-PARTIUPAC
pyrido		I-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
4,3		I-PARTIUPAC
-		I-PARTIUPAC
b		I-PARTIUPAC
]		I-PARTIUPAC
benzo		I-PARTIUPAC
[		I-PARTIUPAC
e		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
and		O
-		B-PARTIUPAC
benzo		I-PARTIUPAC
[		I-PARTIUPAC
g		I-PARTIUPAC
]		I-PARTIUPAC
indoles		I-PARTIUPAC
,		O
as		O
well		O
as		O
hydroxy		O
derivatives		O
obtained		O
by		O
demethylation		O
of		O
methoxylated		O
compounds		O
with		O
hydrobromic		O
acid		O
,		O
were		O
tested		O
for		O
antitumor		O
activity		O
in		O
vitro		O
(		O
leukemic		O
and		O
solid		O
tumor		O
cells		O
)		O
and		O
in		O
vivo		O
on		O
various		O
experimental		O
tumor		O
models		O
using		O
the		O
standard		O
NCI		O
protocols		O
.		O
These		O
compounds		O
are		O
antagonists		O
at		O
the		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
aspartate		I-IUPAC
(		O
NMDA		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propanoic		I-IUPAC
acid		I-IUPAC
(		O
AMPA		O
)		O
subclasses		O
of		O
ligand		O
gated		O
ion		O
channel		O
(		O
ionotropic		O
)		O
EAA		O
receptors		O
.		O
A		O
number		O
of		O
7		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
4		B-IUPAC
-		I-IUPAC
aminopyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carbonitrile		I-IUPAC
,		O
-		B-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
,		O
and		O
-		B-IUPAC
5		I-IUPAC
-		I-IUPAC
thiocarboxamide		I-IUPAC
derivatives		B-MODIFIER
related		O
to		O
the		O
nucleoside		O
antibiotics		O
toyocamycin		O
and		O
sangivamycin		O
were		O
prepared		O
and		O
tested		O
for		O
their		O
activity		O
against		O
human		O
cytomegalovirus		O
(		O
HCMV		O
)		O
and		O
herpes		O
simplex		O
virus		O
type		O
-		O
1		O
(		O
HSV		O
-		O
1		O
)		O
.		O
While		O
FdUMP		O
and		O
6a		O
showed		O
a		O
higher		O
affinity		O
and		O
greater		O
inactivation		O
power		O
with		O
the		O
parental		O
cell		O
than		O
FdUrd		O
-		O
resistant		O
cell		O
enzyme		O
,		O
an		O
opposite		O
relationship		O
could		O
be		O
seen		O
with		O
5		O
-		O
hydroxymethyl		O
-		O
dUMP		O
.		O
5		O
-		O
(		O
2		O
-		O
Acylethynyl		O
)		O
-		O
2,4		O
-		O
dimethoxypyrimidines		O
(		O
3-6		O
)		O
were		O
synthesized		O
in		O
excellent		O
yields		O
from		O
2,4		B-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
trimethylsilyl		I-IUPAC
)		I-IUPAC
ethynyl		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
2		O
)		O
by		O
treatment		O
with		O
acid		O
chlorides		O
in		O
the		O
presence		O
of		O
anhydrous		O
aluminum		O
chloride		O
.		O
Among		O
them		O
,		O
(		B-IUPAC
+		I-IUPAC
/		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
cyclohexyloxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
oxy		I-IUPAC
]		I-IUPAC
ethyl		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
biphenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzimida		I-IUPAC
zole		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
(		O
10s		O
,		O
TCV		O
-		O
116		O
)		O
was		O
selected		O
as		O
a		O
candidate		O
for		O
clinical		O
evaluation		O
.		O
This		O
suggests		O
that		O
both		O
the		O
action		O
on		O
A1		O
receptors		O
or		O
interaction		O
with		O
adenosine		O
and		O
the		O
cyclic		O
AMP		O
-		O
PDE		O
inhibitory		O
activity		O
contribute		O
to		O
the		O
bronchodilator		O
action		O
of		O
1		O
-		O
and		O
7		O
-		O
substituted		O
xanthines		O
.		O
The		O
newly		O
prepared		O
[		O
125I		O
]		O
iodoproxyfan		O
(		O
23		O
)		O
possesses		O
advantageous		O
pharmacological		O
properties		O
and		O
fulfills		O
all		O
criteria		O
of		O
a		O
useful		O
radioligand		O
.		O
Using		O
the		O
combined		O
protection		O
of		O
the		O
1		B-IUPAC
-		I-IUPAC
ethoxymethyl		I-IUPAC
and		O
the		O
5		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
trimethylsilyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
ester		I-IUPAC
groups		B-MODIFIER
,		O
a		O
free		O
carboxylic		O
acid		O
was		O
formed		O
at		O
the		O
5		O
-		O
position		O
allowing		O
various		O
substitutions		O
.		O
This		O
analogue		O
(		O
46		O
)		O
was		O
17		O
times		O
more		O
potent		O
than		O
the		O
standard		O
.		O
Most		O
of		O
these		O
derivatives		O
are		O
more		O
active		O
than		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
7,8		I-IUPAC
-		I-IUPAC
methylenedioxy		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
benzodiazepine		I-IUPAC
(		O
1		O
,		O
GYKI		O
52466		O
)		O
,		O
a		O
well		O
-		O
known		O
noncompetitive		O
AMPA		O
receptor		O
antagonist		O
.		O
The		O
nonapeptide		O
[		O
des		O
-		O
Asp1		O
]		O
angiotensin		O
I		O
(		O
IV		O
)		O
,		O
synthesized		O
by		O
Merrifield		O
's		O
solid		O
-		O
phase		O
procedure		O
,		O
was		O
tested		O
as		O
a		O
possible		O
substrate		O
for		O
the		O
converting		O
enzymes		O
from		O
porcine		O
lung		O
and		O
plasma		O
.		O
The		O
replacement		O
of		O
the		O
[		O
Phe		O
(		O
3		O
)		O
-		O
MePhe		O
(		O
4		O
)		O
-		O
Pro		O
(		O
5		O
)		O
]		O
tripeptide		O
by		O
an		O
8		B-IUPAC
-		I-IUPAC
aminocaprylic		I-IUPAC
acid		I-IUPAC
or		O
the		O
N		O
(		O
7		O
)		O
(		O
)		O
-		O
desmethylation		O
of		O
MeVal		O
(		O
7		O
)		O
led		O
to		O
only		O
a		O
3.3		O
-		O
fold		O
decreased		O
capacity		O
to		O
inhibit		O
Pgp		O
function		O
,		O
suggesting		O
that		O
the		O
Pgp		O
inhibitory		O
potential		O
of		O
aureobasidins		O
,		O
though		O
favored		O
by		O
the		O
establishment		O
of		O
an		O
antiparallel		O
beta		O
-		O
sheet		O
between		O
the		O
[		O
D		O
-		O
Hmp		O
(		O
1		O
)		O
-		O
L		O
-		O
MeVal		O
(		O
2		O
)		O
-		O
L		O
-		O
Phe		O
(		O
3		O
)		O
]		O
and		O
[		O
L		O
-		O
aIle		O
(		O
6		O
)		O
-		O
L		O
-		O
MeVal		O
(		O
7		O
)		O
-		O
L		O
-		O
Leu		O
(		O
8		O
)		O
-		O
]		O
tripeptides		O
,		O
does		O
not		O
critically		O
depend		O
on		O
the		O
occurrence		O
of		O
the		O
[		O
L		O
-		O
Phe		O
(		O
3		O
)		O
-		O
L		O
-		O
MePhe		O
(		O
4		O
)		O
-		O
L		O
-		O
Pro		O
(		O
5		O
)		O
-		O
L		O
-		O
aIle		O
(		O
6		O
)		O
]		O
type		O
II		O
'		O
beta		O
-		O
turn		O
secondary		O
structure		O
.		O
A		O
novel		O
synthesis		O
of		O
L		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminoadipic		I-IUPAC
acid		I-IUPAC
suitable		O
for		O
large		O
-		O
scale		O
preparation		O
is		O
also		O
described		O
.		O
-		O
2		O
cells		O
,		O
but		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
bromoacetamido		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
hypoxanthine		I-IUPAC
displayed		O
in		O
vivo		O
activity		O
against		O
Trypanosoma		O
rhodesiense		O
.		O
The		O
new		O
analogues		O
were		O
tested		O
as		O
inhibitors		O
of		O
DHFR		O
from		O
Pneumocystis		O
carinii		O
(		O
Pc		O
)		O
,		O
Toxoplasma		O
gondii		O
(		O
Tg		O
)		O
,		O
and		O
Mycobacterium		O
avium		O
(		O
Ma		O
)		O
,		O
three		O
life		O
-		O
threatening		O
pathogens		O
often		O
found		O
in		O
AIDS		O
patients		O
and		O
individuals		O
whose		O
immune		O
system		O
is		O
impaired		O
as		O
a		O
result		O
of		O
treatment		O
with		O
immunosuppressive		O
chemotherapy		O
or		O
radiation		O
.		O
A		O
number		O
of		O
compounds		O
bioisosterically		O
derived		O
from		O
10		O
,		O
including		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidyl		I-IUPAC
)		I-IUPAC
isothiazol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ol		I-IUPAC
(		O
11		O
)		O
,		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidyl		I-IUPAC
)		I-IUPAC
isoxazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ol		I-IUPAC
(		O
12		O
)		O
,		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,3,6		I-IUPAC
-		I-IUPAC
tetrahydropyrid		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
isoxazol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ol		I-IUPAC
(		O
13		O
)		O
,		O
and		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1,2,3,6		I-IUPAC
-		I-IUPAC
tetrahydropyrid		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
isothiazol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ol		I-IUPAC
(		O
14		O
)		O
,		O
were		O
synthesized		O
and		O
tested		O
as		O
GABAA		O
receptor		O
ligands		O
.		O
Compound		O
32		O
behaved		O
as		O
a		O
competitive		O
CCK		O
(		O
2		O
)		O
receptor		O
antagonist		O
in		O
vitro		O
as		O
judged		O
by		O
its		O
inhibition		O
of		O
pentagastrin		O
-		O
stimulated		O
acid		O
secretion		O
in		O
an		O
isolated		O
,		O
lumen		O
-		O
perfused		O
,		O
immature		O
rat		O
stomach		O
assay		O
(		O
pK		O
(		O
B		O
)		O
=		O
6.74		O
+		O
/		O
-		O
0.27		O
)		O
and		O
by		O
its		O
displacement		O
of		O
[		O
(		O
125		O
)		O
I		O
]		O
CCK		O
-		O
8S		O
from		O
CCK		O
(		O
2		O
)		O
sites		O
in		O
mouse		O
cortical		O
homogenates		O
(		O
pK		O
(		O
i		O
)		O
=		O
6.99		O
+		O
/		O
-		O
0.05		O
)		O
.		O
Each		O
configurational		O
isomer		O
of		O
1		O
was		O
evaluated		O
for		O
its		O
ability		O
to		O
inhibit		O
the		O
binding		O
of		O
retinoic		O
acid		O
to		O
CRABP		O
(		O
chick		O
skin		O
)		O
and		O
to		O
inhibit		O
the		O
chemical		O
induction		O
of		O
ornithine		O
decarboxylase		O
in		O
mouse		O
skin		O
.		O
Optimization		O
of		O
the		O
4		O
-		O
substituent		O
has		O
provided		O
antagonists		O
having		O
nanomolar		O
affinity		O
,		O
including		O
the		O
urea		O
trans		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
5,7		I-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
phenylamino		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,3		I-IUPAC
,		I-IUPAC
4		I-IUPAC
-		I-IUPAC
tetrahydroquinoline		I-IUPAC
(		O
35		O
;		O
IC50		O
=		O
7.4		O
nM		O
vs		O
[		O
3H		O
]		O
glycine		O
binding		O
;		O
Kb		O
=		O
130		O
nM		O
for		O
block		O
of		O
NMDA		O
responses		O
in		O
the		O
rat		O
cortical		O
slice		O
)		O
,		O
which		O
is		O
one		O
of		O
the		O
most		O
potent		O
NMDA		O
antagonists		O
yet		O
found		O
.		O
In		O
agreement		O
with		O
structure		O
-		O
activity		O
relationships		O
of		O
other		O
chxn		O
-		O
containing		O
platinum		O
(		O
II		O
)		O
complexes		O
both		O
[		B-IUPAC
(		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
phosphonomethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
kappaN		I-IUPAC
)		I-IUPAC
acetato		I-IUPAC
-		I-IUPAC
kappaO		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
)		I-IUPAC
]		I-IUPAC
(		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
cyclohexane		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
diamine		I-IUPAC
)		I-IUPAC
platinum		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
complexes		B-MODIFIER
show		O
superior		O
potency		O
than		O
the		O
corresponding		O
cis		O
-		O
congener		O
whereas		O
the		O
trans		O
-		O
R		O
,		O
R		O
isomer		O
displays		O
the		O
highest		O
activity		O
.		O
Under		O
similar		O
treatment		O
conditions		O
(		O
drug		O
dose		O
:		O
5.0		O
micromol		O
/		O
kg		O
;		O
light		O
dose		O
:		O
135		O
J		O
/		O
cm		O
(		O
2		O
)		O
,		O
tumors		O
were		O
exposed		O
to		O
light		O
for		O
30		O
min		O
at		O
24		O
h		O
postinjection		O
)		O
,		O
the		O
benzobacteriochlorins		O
containing		O
N		O
-		O
substituted		O
-		O
imide		O
ring		O
system		O
produced		O
enhanced		O
photosensitizing		O
efficacy		O
with		O
limited		O
skin		O
phototoxicity		O
.		O
In		O
receptor		O
binding		O
(		O
IC50		O
values		O
)		O
and		O
rat		O
cortical		O
wedge		O
electrophysiological		O
(		O
EC50		O
values		O
)		O
studies		O
,		O
7c		O
(		O
IC50		O
=		O
5.5		O
+		O
/		O
-		O
0.6		O
microM		O
;		O
EC50		O
=		O
96		O
+		O
/		O
-		O
5		O
microM		O
)		O
was		O
shown		O
to		O
be		O
markedly		O
weaker		O
than		O
7a		O
(		O
IC50		O
=		O
0.57		O
+		O
/		O
-		O
0.16		O
microM		O
;		O
EC50		O
=		O
7.4		O
+		O
/		O
-		O
0.2		O
microM		O
)		O
as		O
an		O
AMPA		O
agonist		O
,		O
whereas		O
7b		O
,		O
d		O
,		O
e		O
were		O
inactive		O
.		O
In		O
rat		O
brain		O
membranes		O
,		O
all		O
12		O
compounds		O
displayed		O
poor		O
affinity		O
for		O
[		O
(		O
125		O
)		O
I		O
]		O
-		O
alpha		O
-		O
bunagarotoxin		O
binding		O
sites		O
.		O
The		O
chloromethyl		O
compounds		O
,		O
5		O
and		O
10		O
,		O
yielded		O
7		B-IUPAC
-		I-IUPAC
acetoxymethyl		I-IUPAC
-		I-IUPAC
12		I-IUPAC
-		I-IUPAC
methylbenz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthracene		I-IUPAC
(		O
6		O
)		O
and		O
7		B-IUPAC
-		I-IUPAC
acetoxymethyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
12		I-IUPAC
-		I-IUPAC
methylbenz		I-IUPAC
[		I-IUPAC
a		I-IUPAC
]		I-IUPAC
anthracene		I-IUPAC
(		O
11		O
)		O
on		O
treatment		O
with		O
acetate		O
ion		O
.		O
The		O
syntheses		O
and		O
physical		O
properties		O
of		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aminopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodothiophene		I-IUPAC
and		O
N		B-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aminopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodothiophene		I-IUPAC
are		O
described		O
.		O
Preparation		O
of		O
the		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
alkyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
thymine		I-IUPAC
(		O
26-31		O
)		O
and		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
alkyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
arylthio		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thiouracil		I-IUPAC
(		O
32-45		O
)		O
derivatives		B-MODIFIER
was		O
carried		O
out		O
on		O
the		O
basis		O
of		O
LDA		O
lithiation		O
of		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
alkyloxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
thymine		I-IUPAC
(		O
9-14		O
)		O
and		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
alkyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thiouracil		I-IUPAC
(		O
15-25		O
)		O
followed		O
by		O
reaction		O
with		O
diaryl		O
disulfides		O
.		O
Cytallene		O
(		O
5b		O
)		O
and		O
6'		B-IUPAC
beta		I-IUPAC
-		I-IUPAC
hydroxyaristeromycin		I-IUPAC
(		O
10		O
)		O
exhibited		O
significant		O
activity		O
against		O
Friend		O
and		O
Rauscher		O
murine		O
leukemia		O
viruses		O
.		O
To		O
synthesize		O
potent		O
antagonists		O
of		O
the		O
mu		O
-		O
opioid		O
receptor		O
,		O
we		O
prepared		O
a		O
series		O
of		O
endomorphin		O
-		O
1		O
and		O
endomorphin		O
-		O
2		O
analogues		O
with		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
d		I-IUPAC
-		I-IUPAC
alanine		I-IUPAC
(		O
d		O
-		O
1		O
-		O
Nal		O
)		O
or		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
d		I-IUPAC
-		I-IUPAC
alanine		I-IUPAC
(		O
d		O
-		O
2		O
-		O
Nal		O
)		O
in		O
position		O
4		O
.		O
A		O
series		O
of		O
N		B-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
3		I-PARTIUPAC
-		I-PARTIUPAC
pyridinyl		I-PARTIUPAC
)		I-PARTIUPAC
butyl		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
5,5		I-PARTIUPAC
-		O
disubstituted		B-MODIFIER
-		O
pentadienamides		B-PARTIUPAC
was		O
prepared		O
and		O
evaluated		O
for		O
PAF		O
-		O
antagonist		O
activity		O
.		O
Propargylfolic		O
acid		O
and		O
its		O
reduced		O
derivatives		O
were		O
weak		O
inhibitors		O
of		O
L		O
.		O
Deoxygenation		O
gave		O
the		O
corresponding		O
pyrazines		O
VII		O
.		O
The		O
corresponding		O
beta		O
-		O
aryl		O
-		O
substituted		O
lactones		O
,		O
by		O
contrast		O
,		O
are		O
potent		O
acylating		O
agents		O
that		O
lead		O
to		O
acyl		O
enzymes		O
of		O
high		O
stability		O
.		O
A		O
water		O
soluble		O
derivative		O
,		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
morpholinylbutyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
EMAU		I-IUPAC
hydrochloride		I-IUPAC
,		O
given		O
subcutaneously		O
,		O
prolonged		O
the		O
life		O
of		O
infected		O
mice		O
in		O
a		O
dose		O
dependent		O
manner		O
.		O
Compound		O
3		O
is		O
the		O
first		O
example		O
,		O
to		O
our		O
knowledge		O
,		O
of		O
a		O
2,4		O
-		O
diamino		O
classical		O
antifolate		O
that		O
has		O
potent		O
inhibitory		O
activity		O
against		O
both		O
human		O
dihydrofolate		O
reductase		O
(		O
DHFR		O
)		O
and		O
human		O
thymidylate		O
synthase		O
(		O
TS		O
)		O
.		O
The		O
guanine		O
derivatives		O
(		O
8		O
,		O
21		O
)		O
showed		O
potent		O
and		O
selective		O
activity		O
against		O
herpes		O
simplex		O
virus		O
types		O
1		O
and		O
2		O
and		O
varicella		O
zoster		O
virus		O
in		O
cell		O
cultures		O
and		O
8		O
is		O
more		O
active		O
than		O
acyclovir		O
.		O
Both		O
6		O
and		O
11		O
were		O
found		O
to		O
substitute		O
with		O
high		O
potency		O
in		O
3,4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
methylenedioxy		I-IUPAC
)		I-IUPAC
methamphetamine		I-IUPAC
(		O
1		O
)		O
and		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
benzodioxol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylamino		I-IUPAC
)		I-IUPAC
butane		I-IUPAC
(		O
2		O
)		O
trained		O
rats		O
.		O
The		O
compounds		O
were		O
evaluated		O
for		O
their		O
ability		O
to		O
prevent		O
phosphorylation		O
of		O
a		O
model		O
substrate		O
by		O
c		O
-		O
Src		O
,		O
FGF		O
-		O
1		O
receptor		O
,		O
and		O
PDGF		O
-		O
beta		O
receptor		O
enzymes		O
.		O
Three		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
diaminopteridin		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
omega		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
alkynyl		I-IUPAC
)		I-IUPAC
dibenz		I-IUPAC
[		I-IUPAC
b		I-IUPAC
,		I-IUPAC
f		I-IUPAC
]		I-IUPAC
azepines		I-IUPAC
(		O
19-21		O
)		O
were		O
also		O
synthesized		O
and		O
tested		O
.		O
This		O
suggests		O
that		O
while		O
substitution		O
of		O
a		O
polar		O
functionality		O
at		O
C		O
-		O
21		O
does		O
not		O
abolish		O
antibacterial		O
activity		O
,		O
introduction		O
of		O
vicinal		O
polar		O
groups		O
at		O
both		O
C		O
-		O
12		O
and		O
C		O
-		O
21		O
may		O
lead		O
to		O
reduction		O
in		O
potency		O
.		O
Parallel		O
treatment		O
with		O
a		O
"		O
dibromomethylene		O
Wittig		O
reagent		O
"		O
and		O
deprotection		O
gave		O
9		B-IUPAC
-		I-IUPAC
(		I-IUPAC
6,6		I-IUPAC
-		I-IUPAC
dibromo		I-IUPAC
-		I-IUPAC
5		I-IUPAC
,		I-IUPAC
6		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
d		I-IUPAC
-		I-IUPAC
ribo		I-IUPAC
-		I-IUPAC
hex		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
enofuranosyl		I-IUPAC
)		I-IUPAC
adenine		I-IUPAC
(		O
7		O
)		O
,		O
which		O
also		O
was		O
prepared		O
by		O
successive		O
bromination		O
and		O
dehydrobromination		O
of		O
the		O
6'		B-IUPAC
-		I-IUPAC
bromohomovinyl		I-IUPAC
nucleoside		I-IUPAC
8		O
.		O
Adenine		O
analogue		O
14		O
was		O
active		O
against		O
HBV		O
(		O
IC50		O
2		O
microM		O
)		O
,		O
VZV		O
(		O
IC50		O
2.5		O
microM		O
)		O
,		O
and		O
HHV		O
-		O
6		O
(		O
IC50		O
14		O
microM		O
)		O
.		O
Among		O
numerous		O
variations		O
at		O
C5		O
,		O
benzylthio		O
groups		O
gave		O
the		O
best		O
potency		O
.		O
Acylated		O
derivatives		O
and		O
one		O
alkyl		O
derivative		O
of		O
the		O
5		O
-		O
amino		O
group		O
and		O
other		O
modifications		O
were		O
prepared		O
in		O
an		O
effort		O
to		O
enhance		O
A2B		O
or		O
A3		O
subtype		O
potency		O
.		O
This		O
would		O
give		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
tetrazole		I-IUPAC
(		O
13		O
)		O
,		O
the		O
tetrazole		O
acid		O
analog		O
of		O
glycine		O
;		O
and		O
glycine		O
is		O
involved		O
in		O
NMDA		O
receptor		O
activation		O
.		O
Compounds		O
3a		O
,		O
b		O
are		O
transient		O
intermediates		O
,		O
which		O
in		O
strongly		O
acidic		O
medium		O
are		O
not		O
observed		O
with		O
(		O
31		O
)		O
P		O
NMR		O
.		O
This		O
observation		O
eliminates		O
the		O
last		O
remaining		O
uncertainty		O
regarding		O
conformational		O
features		O
of		O
the		O
pharmacophore		O
elements		O
in		O
the		O
delta		O
receptor		O
-		O
bound		O
state		O
,		O
allowing		O
the		O
proposal		O
of		O
a		O
complete		O
model		O
.		O
An		O
N5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
iodophenyl		I-IUPAC
)		I-IUPAC
acetyl		I-IUPAC
derivative		B-MODIFIER
was		O
highly		O
selective		O
for		O
A2A		O
receptors		O
.		O
At		O
P2X		O
-		O
receptors		O
,		O
no		O
activity		O
was		O
observed		O
in		O
the		O
rabbit		O
saphenous		O
artery		O
,		O
but		O
variable		O
degrees		O
of		O
activity		O
were		O
observed		O
in		O
the		O
guinea		O
pig		O
vas		O
deferens		O
and		O
bladder		O
depending		O
on		O
distal		O
substituents		O
of		O
the		O
thioether		O
moiety		O
.		O
(		O
all		O
-		O
E		O
)		O
-		O
1		O
was		O
further		O
evaluated		O
for		O
its		O
ability		O
to		O
prevent		O
the		O
induction		O
of		O
mouse		O
skin		O
papillomas		O
and		O
to		O
induce		O
signs		O
of		O
vitamin		O
A		O
toxicity		O
in		O
mice		O
.		O
The		O
palladium		O
-		O
catalyzed		O
cross		O
-		O
coupling		O
reaction		O
between		O
5		B-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
and		O
stannylated		O
heteroaromatics		O
was		O
optimized		O
for		O
the		O
synthesis		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
thien		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
and		O
5		B-IUPAC
-		I-IUPAC
furan		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
.		O
The		O
ID50		O
of		O
3		O
against		O
L1210		O
mouse		O
leukemia		O
cells		O
in		O
culture		O
was		O
1.7		O
x		O
10		O
(		O
-		O
5		O
)		O
M		O
,		O
as		O
compared		O
with		O
1		O
x		O
10		O
(		O
-		O
6		O
)		O
M		O
for		O
FU		O
.		O
From		O
the		O
findings		O
of		O
this		O
study		O
,		O
it		O
appears		O
that		O
norepinephrine		O
has		O
a		O
different		O
active		O
site		O
binding		O
orientation		O
than		O
most		O
known		O
substrates		O
and		O
competitive		O
inhibitors		O
of		O
PNMT		O
.		O
The		O
esterase		O
activity		O
of		O
the		O
enzyme		O
was		O
commensurably		O
inhibited		O
.		O
The		O
pyrimidine		O
nucleosides		O
(		O
9a		O
-		O
c		O
,		O
10b		O
,		O
c		O
)		O
exhibited		O
no		O
cytotoxic		O
activity		O
against		O
a		O
panel		O
of		O
60		O
human		O
cancer		O
cell		O
lines		O
.		O
The		O
enantiomeric		O
purity		O
of		O
the		O
stereoisomers		O
was		O
determined		O
by		O
a		O
high		O
-		O
performance		O
liquid		O
chromatography		O
-		O
chiral		O
stationary		O
phase		O
technique		O
(		O
HPLC		O
-		O
CSP		O
)		O
.		O
For		O
this		O
,		O
the		O
uPAR		O
antagonist		O
cyclo		O
[		O
19,31		O
]		O
[		O
D		O
-		O
Cys		O
(		O
19		O
)		O
]		O
-		O
uPA		O
(		O
19		O
)		O
(		O
-		O
)		O
(		O
31		O
)		O
was		O
optimized		O
to		O
efficiently		O
interrupt		O
binding		O
of		O
uPA		O
to		O
cellular		O
uPAR		O
.		O
Conventional		O
functional		O
group		O
transformations		O
involving		O
the		O
5		B-IUPAC
-		I-IUPAC
cyano		I-IUPAC
group		B-MODIFIER
of		O
4		O
furnished		O
the		O
5		B-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
derivatives		B-MODIFIER
5a		O
-		O
1		O
and		O
the		O
5		B-IUPAC
-		I-IUPAC
thio		I-IUPAC
-		I-IUPAC
amide		I-IUPAC
analogs		B-MODIFIER
6a		O
-		O
l		O
.		O
Compound		O
7		O
bound		O
strongly		O
to		O
5		O
-		O
HT1A		O
receptors		O
and		O
would		O
be		O
expected		O
to		O
be		O
a		O
novel		O
anxiolytic		O
.		O
Under		O
similar		O
conditions		O
analogues		O
(		O
[		B-IUPAC
N		I-IUPAC
(		I-IUPAC
gamma		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
IGly		I-IUPAC
)		I-IUPAC
Dab		I-IUPAC
(		I-IUPAC
8		I-IUPAC
)		I-IUPAC
]		I-IUPAC
degarelix		I-IUPAC
,		O
IC		O
(		O
50		O
)		O
=		O
1.56		O
nM		O
)		O
(		O
21		O
)		O
and		O
(		O
[		O
IOrn		O
(		O
8		O
)		O
]		O
degarelix		O
,		O
IC		O
(		O
50		O
)		O
=		O
1.72		O
nM		O
)		O
(		O
18		O
)		O
had		O
a		O
longer		O
duration		O
of		O
action		O
{		O
inhibited		O
LH		O
(		O
&		O
gt		O
;		O
96		O
h		O
)		O
release		O
}		O
than		O
azaline		O
B		O
;		O
however		O
they		O
were		O
shorter		O
acting		O
than		O
degarelix		O
.		O
Two		O
adenosine		O
diphosphate		O
analogues		O
were		O
equipotent		O
to		O
the		O
corresponding		O
ATP		O
analogues		O
.		O
Changing		O
the		O
2'		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
group		B-MODIFIER
of		O
(		O
+		O
)		O
-		O
1f		O
to		O
an		O
H		O
,		O
F		O
,		O
Cl		O
,		O
Br		O
,		O
I		O
,		O
NHAc		O
,		O
or		O
NHSO2CH3		O
resulted		O
in		O
a		O
5		O
-		O
fold		O
or		O
greater		O
loss		O
in		O
potency		O
.		O
However		O
,		O
exo		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
hydroxybenzonorbornene		I-IUPAC
(		O
8		O
)		O
and		O
anti		B-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
hydroxybenzonorbornene		I-IUPAC
(		O
12		O
)		O
displayed		O
significant		O
activity		O
as		O
inhibitors		O
toward		O
PNMT		O
.		O
trans		O
-		O
Catechol		O
analogs		O
had		O
low		O
affinity		O
for		O
[		O
3H		O
]		O
4		O
sites		O
,		O
and		O
although		O
they		O
inhibited		O
TH		O
activity		O
,		O
this		O
effect		O
was		O
not		O
blocked		O
by		O
known		O
sigma		O
or		O
dopamine		O
antagonists		O
.		O
These		O
observations		O
suggest		O
that		O
the		O
introduction		O
of		O
an		O
ethyl		O
group		O
in		O
the		O
N		O
(		O
6		O
)		O
-		O
position		O
and		O
an		O
ethylcarboxamido		O
substituent		O
in		O
the		O
4'		O
-		O
position		O
of		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenylhydroxypropynyladenosine		I-IUPAC
could		O
lead		O
to		O
a		O
compound		O
endowed		O
with		O
high		O
potency		O
at		O
the		O
A		O
(		O
2B		O
)		O
receptor		O
.		O
Compound		O
45		O
[		B-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
cyclopentyloxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylindol		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methoxybenzoyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylbenzenesulfonamide		I-IUPAC
,		O
ICI		O
204,219		O
;		O
pKB		O
=		O
9.67		O
+		O
/		O
-		O
0.13		O
,		O
Ki		O
=		O
0.3		O
+		O
/		O
-		O
0.03		O
nM		O
,		O
po		O
ED50		O
=		O
0.3		O
mg		O
/		O
kg		O
]		O
is		O
currently		O
under		O
clinical		O
investigation		O
for		O
asthma		O
.		O
A		O
phosphorylation		O
method		O
,		O
employing		O
methyl		O
dichlorophosphate		O
,		O
was		O
developed		O
and		O
applied		O
in		O
the		O
synthesis		O
of		O
two		O
analogues		O
of		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
hexadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
palmitoyl		I-IUPAC
-		I-IUPAC
sn		I-IUPAC
-		I-IUPAC
glycero		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phosphoethanolamine		I-IUPAC
poly		I-IUPAC
(		I-IUPAC
ethylene		I-IUPAC
glycol		I-IUPAC
)		I-IUPAC
.		O
Substitution		O
of		O
an		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
benzylidene		I-IUPAC
moiety		B-MODIFIER
onto		O
the		O
7		B-MODIFIER
-		I-MODIFIER
keto		I-MODIFIER
precursor		I-MODIFIER
of		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
morphan		I-IUPAC
,		O
(		O
-		O
)		O
-		O
1		O
,		O
produces		O
compounds		O
(		O
+		O
)		O
-		O
2		O
-		O
(		O
+		O
)		O
-		O
9		O
(		O
6.4-52.6		O
nM		O
,		O
sigma		O
2		O
)		O
,		O
which		O
have		O
at		O
least		O
a		O
475-3906		O
-		O
fold		O
increase		O
in		O
affinity		O
for		O
the		O
sigma		O
2		O
receptor		O
subtype		O
relative		O
to		O
the		O
keto		O
precursor		O
(		O
-		O
)		O
-		O
1		O
(		O
Ki		O
=		O
25		O
x		O
10		O
(		O
3		O
)		O
nM		O
)		O
.		O
The		O
presence		O
of		O
a		O
methyl		B-IUPAC
group		B-MODIFIER
on		O
N		O
(		O
6		O
)		O
of		O
the		O
2		B-IUPAC
-		I-IUPAC
alkynyladenosines		I-IUPAC
,		O
inducing		O
an		O
increase		O
in		O
affinity		O
at		O
the		O
human		O
A		O
(		O
3		O
)		O
receptor		O
and		O
a		O
decrease		O
at		O
the		O
other		O
subtypes		O
,		O
resulted		O
in		O
an		O
increase		O
in		O
A		O
(		O
3		O
)		O
selectivity		O
.		O
These		O
results		O
suggest		O
that		O
the		O
nitrogen		O
substitution		O
enhances		O
the		O
affinity		O
and		O
selectivity		O
for		O
the		O
D		O
-		O
2		O
receptor		O
.		O
It		O
is		O
suggested		O
that		O
nipecotamides		O
interact		O
with		O
anionic		O
platelet		O
sites		O
located		O
7		O
A		O
from		O
each		O
other		O
and		O
connected		O
by		O
a		O
hydrophobic		O
well		O
.		O
On		O
the		O
basis		O
of		O
the		O
general		O
structure		O
-		O
-		O
activity		O
relationship		O
trends		O
found		O
for		O
the		O
acyl		B-IUPAC
substituent		B-MODIFIER
in		O
our		O
earlier		O
series		O
,		O
five		O
groups		O
of		O
compounds		O
were		O
tested		O
,		O
diaryl		B-PARTIUPAC
-		I-PARTIUPAC
or		O
alkylarylpropanoyl		B-IUPAC
derivatives		B-MODIFIER
,		O
their		O
3		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		O
substituted		B-MODIFIER
analogues		I-MODIFIER
,		O
and		O
urea		O
,		O
carbamate		O
and		O
amino		O
acid		O
derivatives		O
.		O
We		O
have		O
prepared		O
the		O
radiolabeled		O
des		O
-		O
AA		O
(		O
1,2,5		O
)		O
-		O
[		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
,		O
(		O
125		O
)		O
ITyr		O
(		O
11		O
)		O
]		O
-		O
SRIF		O
(		O
(		O
125		O
)		O
I		O
-		O
25		O
)		O
and		O
des		O
-		O
AA		O
(		O
1,2,5		O
)		O
-		O
[		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
,		O
(		O
125		O
)		O
ITyr		O
(		O
11		O
)		O
]		O
-		O
Cbm		O
-		O
SRIF		O
(		O
(		O
125		O
)		O
I		O
-		O
27		O
)		O
,		O
used		O
them		O
as		O
in		O
vitro		O
tracers		O
,		O
and		O
found		O
them		O
to		O
be		O
superior		O
to		O
des		O
-		O
AA		O
(		O
1,5		O
)		O
-		O
[		O
(		O
125		O
)		O
ITyr		O
(		O
2		O
)		O
,		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
]		O
-		O
SRIF		O
(		O
(		O
125		O
)		O
I		O
-		O
16		O
)		O
for		O
the		O
detection		O
of		O
sst1		O
tumors		O
in		O
receptor		O
autoradiography		O
studies		O
.		O
Analogue		O
13		O
inhibited		O
the		O
growth		O
of		O
L1210		O
murine		O
leukemic		O
cells		O
with		O
an		O
IC50		O
of		O
6		O
x		O
10		O
(		O
5		O
)		O
M		O
in		O
culture		O
.		O
Two		O
lower		O
homologues		O
of		O
10		O
were		O
weak		O
partial		O
H		O
(		O
1		O
)		O
-		O
receptor		O
agonists		O
while		O
two		O
higher		O
homologues		O
of		O
10		O
were		O
silent		O
antagonists		O
endowed		O
with		O
micromolar		O
affinity		O
for		O
rat		O
and		O
guinea		O
-		O
pig		O
H		O
(		O
1		O
)		O
receptors		O
.		O
The		O
open		O
-		O
chain		O
compounds		O
(		O
1b		O
)		O
were		O
less		O
active		O
than		O
the		O
corresponding		O
aziridine		O
ring		O
compounds		O
(		O
1a		O
)		O
.		O
The		O
NOEs		O
observed		O
between		O
tomaymycin		O
protons		O
and		O
adenine		O
H2		O
protons		O
are		O
in		O
accord		O
with		O
molecular		O
modeling		O
studies		O
.		O
In		O
fact		O
,		O
1		B-IUPAC
-		I-IUPAC
boraadamantane		I-IUPAC
.		I-IUPAC
The		O
capacity		O
of		O
ligand		O
1		O
and		O
its		O
Ga		O
(		O
III		O
)		O
and		O
Fe		O
(		O
III		O
)		O
complexes		O
to		O
destroy		O
the		O
tyrosyl		O
radical		O
of		O
the		O
presumed		O
target		O
ribonucleotide		O
reductase		O
is		O
reported		O
.		O
Although		O
compounds		O
9b		O
and		O
9c		O
at		O
44		O
mg		O
and		O
40		O
mg		O
/		O
kg		O
per		O
day		O
x		O
1		O
showed		O
a		O
T		O
/		O
C		O
of		O
147		O
and		O
149		O
,		O
respectively		O
,		O
this		O
group		O
of		O
compounds		O
was		O
found		O
to		O
be		O
less		O
effective		O
than		O
some		O
of		O
the		O
sulfur		O
-		O
containing		O
drugs		O
that		O
we		O
previously		O
described		O
(		O
e.g.		O
sulfenosine		O
and		O
sulfinosine		O
)		O
.		O
They		O
caused		O
an		O
initial		O
rise		O
in		O
blood		O
pressure		O
(		O
30		O
min		O
of		O
infusion		O
,		O
250		O
ng		O
/		O
kg		O
/		O
min		O
in		O
vagotomized		O
,		O
ganglion		O
-		O
blocked		O
rats		O
)		O
of		O
16.57		O
,		O
9.80		O
,		O
22.80		O
,		O
32.00		O
,		O
7.00		O
,		O
15.06		O
,		O
32.50		O
,		O
and		O
11.42		O
mmHg		O
and		O
showed		O
secretory		O
activity		O
(		O
isolated		O
cat		O
adrenal		O
medulla		O
)		O
of		O
1.0		O
,		O
0.1		O
,		O
0.01		O
,		O
0.1		O
,		O
less		O
than		O
0.01		O
,		O
0.1		O
,		O
less		O
than		O
0.01		O
,		O
and		O
0.05%		O
of		O
angiotensin		O
II		O
.		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
Choroethyl		I-IUPAC
)		I-IUPAC
norapocodeine		I-IUPAC
(		O
1e		O
)		O
was		O
obtained		O
from		O
the		O
chlorination		O
of		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethyl		I-IUPAC
)		I-IUPAC
norapocodeine		I-IUPAC
(		O
9		O
)		O
with		O
SOCl2		O
.		O
Reaction		O
of		O
5		B-IUPAC
-		I-IUPAC
diazoimidazole		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
7		O
)		O
with		O
the		O
novel		O
labeling		O
agent		O
[		B-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
isocyanate		I-IUPAC
(		O
8		O
)		O
gave		O
[		B-IUPAC
3		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
temozolomide		I-IUPAC
(		O
9		O
)		O
in		O
14-20%		O
radiochemical		O
yield		O
from		O
[		B-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
isocyanate		I-IUPAC
(		O
8		O
)		O
(		O
decay		O
corrected		O
)		O
.		O
Ethyl		O
4		B-IUPAC
-		I-IUPAC
benzyloxybenzoate		I-IUPAC
,		O
ethyl		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
benzyloxybenzoic		I-IUPAC
acid		I-IUPAC
,		O
ethyl		B-IUPAC
4		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
bromobenzyloxybenzoates		I-IUPAC
,		O
and		O
4		B-IUPAC
-		I-IUPAC
o		I-IUPAC
-		I-IUPAC
methoxybenzyloxyphenyl		I-IUPAC
acetate		I-IUPAC
exhibited		O
the		O
most		O
favorable		O
spectrum		O
of		O
activity		O
.		O
1-4		O
are		O
analogues		O
of		O
A		O
,		O
5-10		O
are		O
analogues		O
of		O
B		O
,		O
and		O
11-16		O
are		O
analogues		O
of		O
C		O
.		O
Additionally		O
,		O
we		O
introduced		O
CalphaMe		O
-		O
leucine		O
residues		O
in		O
lieu		O
of		O
leucine		O
at		O
positions		O
14		O
,		O
15		O
,		O
19		O
,		O
27		O
,		O
and		O
37		O
in		O
[		O
DHis32		O
]		O
astressin		O
.		O
As		O
part		O
of		O
a		O
program		O
in		O
which		O
we		O
are		O
attempting		O
(		O
a		O
)		O
to		O
delineate		O
the		O
structural		O
features		O
at		O
positions		O
1-9		O
in		O
our		O
previously		O
reported		O
antidiuretic		O
antagonists		O
required		O
for		O
antidiuretic		O
antagonism		O
and		O
(		O
b		O
)		O
to		O
obtain		O
analogues		O
with		O
enhanced		O
antiantidiuretic		O
potency		O
and		O
/		O
or		O
selectivity		O
,		O
we		O
have		O
synthesized		O
14		O
new		O
analogues		O
of		O
the		O
antidiuretic		O
antagonist		O
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
mercapto		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
,		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
cyclopentamethylenepropionic		I-IUPAC
acid		I-IUPAC
)		I-IUPAC
,		I-IUPAC
2		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
phenylalanine		I-IUPAC
,		I-IUPAC
4		I-IUPAC
-		I-IUPAC
valine		I-IUPAC
]		I-IUPAC
arginine		I-IUPAC
-		I-IUPAC
vasopressin		I-IUPAC
[		O
d		O
-		O
(		O
CH2		O
)		O
5		O
-		O
D		O
-		O
Phe2VAVP		O
)		O
,		O
in		O
which		O
the		O
valine		O
residue		O
at		O
position		O
4		O
was		O
replaced		O
by		O
the		O
following		O
L		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
acids		I-IUPAC
and		O
glycine		B-PARTIUPAC
:		O
Ile		O
,		O
Abu		O
,		O
Thr		O
,		O
Ala		O
,		O
Gln		O
,		O
Lys		O
,		O
Cha		O
,		O
Nle		O
,		O
Nva		O
,		O
Phe		O
,		O
Leu		O
,		O
Gly		O
,		O
Tyr		O
,		O
and		O
Pro		O
.		O
When		O
the		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboalkoxy		I-IUPAC
substituent		B-MODIFIER
was		O
replaced		O
with		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ethenyl		I-IUPAC
,		O
the		O
resulting		O
analogue		O
11		O
demonstrated		O
the		O
highest		O
DAT		O
binding		O
affinity		O
in		O
the		O
series		O
(		O
K		O
(		O
i		O
)		O
=		O
1.81		O
nM		O
)		O
with		O
DAT		O
selectivity		O
over		O
serotonin		O
transporters		O
(		O
SERT		O
;		O
989		O
-		O
fold		O
)		O
,		O
norepinephrine		O
transporters		O
(		O
NET		O
;		O
261		O
-		O
fold		O
)		O
and		O
muscarinic		O
receptors		O
(		O
90		O
-		O
fold		O
)		O
.		O
In		O
this		O
study		O
,		O
13		O
heteroarotinoids		O
were		O
synthesized		O
.		O
These		O
reaction		O
sequences		O
involved		O
different		O
reductive		O
processes		O
.		O
Structure		O
-		O
-		O
activity		O
relationships		O
are		O
discussed		O
in		O
terms		O
of		O
cholesterol		O
-		O
lowering		O
activity		O
together		O
with		O
effects		O
on		O
weight		O
gain		O
and		O
liver		O
lipids		O
.		O
4		B-IUPAC
-		I-IUPAC
Ureidopyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
(		O
6-26		O
)		O
were		O
prepared		O
by		O
displacement		O
of		O
the		O
ethoxy		O
group		O
of		O
the		O
carbamate		O
2		O
by		O
amino		O
acids		O
and		O
a		O
variety		O
of		O
amines		O
and		O
by		O
a		O
reaction		O
of		O
4		B-IUPAC
-		I-IUPAC
aminopyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
1		O
)		O
with		O
isocyanates		O
.		O
Series		O
of		O
3		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
9,10		B-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
-		I-IUPAC
3,4,6,7		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
pyrimido		I-IUPAC
[		I-IUPAC
6,1		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
isoquinoline		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
diones		I-IUPAC
and		O
2		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
9,10		B-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
pyrimido		I-IUPAC
[		I-IUPAC
6,1		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
isoquinolin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
were		O
synthesized		O
and		O
tested		O
for		O
blood		O
pressure		O
lowering		O
properties		O
in		O
anesthetized		O
normotensive		O
cats		O
and		O
conscious		O
spontaneously		O
hypertensive		O
rats		O
.		O
Examination		O
of		O
the		O
PTP1B		O
inhibitory		O
potency		O
of		O
an		O
extensive		O
series		O
of		O
phosphotyrosyl		B-IUPAC
(		O
pTyr		O
)		O
mimetics		B-MODIFIER
(		O
Xxx		O
)		O
expressed		O
in		O
the		O
EGFr		O
-		O
derived		O
hexapeptide		O
platform		O
Ac		O
-		O
Asp		O
-		O
Ala		O
-		O
Asp		O
-		O
Xxx		O
-		O
Leu		O
-		O
amide		O
previously		O
led		O
to		O
the		O
finding		O
of		O
high		O
inhibitory		O
potency		O
when		O
Xxx		O
=		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonodifluoromethyl		I-IUPAC
)		I-IUPAC
phenylalanyl		I-IUPAC
(		O
F2Pmp		O
)		O
(		O
K		O
(		O
i		O
)		O
=		O
0.2		O
microM		O
)		O
and		O
when		O
Xxx		O
=		O
3		B-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxymethyloxyphenylalanyl		I-IUPAC
(		O
K		O
(		O
i		O
)		O
=		O
3.6		O
microM		O
)		O
.		O
At		O
the		O
3		O
-		O
position		O
of		O
the		O
dihydropyridine		O
ring		O
,		O
esters		O
were		O
much		O
more		O
selective		O
for		O
A3		O
receptors		O
than		O
closely		O
related		O
thioester		O
,		O
amide		O
,		O
and		O
ketone		O
derivatives		O
.		O
We		O
were		O
unable		O
to		O
reproduce		O
the		O
dedifferentiation		O
effect		O
of		O
reversine		O
,		O
previously		O
reported		O
,		O
or		O
to		O
demonstrate		O
any		O
connection		O
between		O
A		O
(		O
3		O
)		O
AR		O
antagonist		O
effects		O
and		O
dedifferentiation		O
.		O
The		O
structure		O
-		O
activity		O
relationships		O
of		O
these		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxochroman		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
amides		I-IUPAC
and		O
related		O
compounds		O
are		O
discussed		O
on		O
the		O
basis		O
of		O
these		O
two		O
assays		O
.		O
5,5		B-IUPAC
-		I-IUPAC
Bis		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanone		I-IUPAC
and		O
its		O
isomer		O
4,4		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
furanone		I-IUPAC
were		O
investigated		O
as		O
possible		O
templates		O
for		O
the		O
construction		O
of		O
conformationally		O
constrained		O
analogues		O
of		O
the		O
biologically		O
important		O
second		O
messenger		O
,		O
diacylglycerol		O
(		O
DAG		O
)		O
.		O
In		O
vivo		O
antiallergic		O
activity		O
evaluation		O
confirmed		O
efficiency		O
of		O
45		O
in		O
sensitized		O
guinea		O
pig		O
late		O
phase		O
eosinophilia		O
inhibition		O
,		O
after		O
parenteral		O
and		O
oral		O
administration		O
at		O
5		O
and		O
30		O
mg		O
/		O
kg		O
,		O
respectively		O
.		O
A		O
Langendorff		O
guinea		O
pig		O
heart		O
preparation		O
served		O
for		O
the		O
assay		O
of		O
agonist		O
potency		O
of		O
a		O
series		O
of		O
26		O
2		B-IUPAC
-		I-IUPAC
aralkoxyadenosines		I-IUPAC
at		O
the		O
A1		O
and		O
A2		O
receptors		O
of		O
,		O
respectively		O
,		O
the		O
atrioventricular		O
node		O
(		O
conduction		O
block		O
)		O
and		O
coronary		O
arteries		O
(		O
vasodilation		O
)		O
.		O
A		O
number		O
of		O
4,7		B-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
benzopyran		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
were		O
synthesized		O
and		O
evaluated		O
for		O
crude		O
rat		O
lens		O
aldose		O
reductase		O
inhibitory		O
activity		O
.		O
(		O
ABSTRACT		O
TRUNCATED		O
AT		O
400		O
WORDS		O
)		O
A		O
series		O
of		O
2,6		B-PARTIUPAC
-		I-PARTIUPAC
and		O
2,4		B-IUPAC
-		I-IUPAC
dihydroxyphenyl		I-IUPAC
alkyl		I-IUPAC
ketones		I-IUPAC
has		O
been		O
investigated		O
as		O
inhibitors		O
of		O
hepatic		O
microsomal		O
aniline		O
hydroxylase		O
and		O
aminopyrine		O
demethylase		O
activities		O
.		O
Two		O
2,3		B-IUPAC
-		I-IUPAC
dihydrobenzofuran		I-IUPAC
analogues		B-MODIFIER
of		O
hallucinogenic		O
amphetamines		O
were		O
prepared		O
and		O
evaluated		O
for		O
activity		O
in		O
the		O
two		O
-		O
lever		O
drug		O
-		O
discrimination		O
paradigm		O
in		O
rats		O
trained		O
to		O
discriminate		O
saline		O
from		O
LSD		O
tartrate		O
(		O
0.08		O
mg		O
/		O
kg		O
)		O
and		O
for		O
the		O
ability		O
to		O
displace		O
[		O
125I		O
]		O
-		O
(		O
R		O
)		O
-		O
DOI		O
[		B-IUPAC
(		I-IUPAC
125I		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,5		I-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
iodophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminopropane		I-IUPAC
)		I-IUPAC
from		O
rat		O
cortical		O
homogenate		O
5		O
-		O
HT2		O
receptors		O
.		O
Condensation		O
of		O
appropriately		O
substituted		O
(		O
arylmethyl		O
)		O
triphenylphosphoranes		O
with		O
4		B-IUPAC
,		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ethylenedioxycyclohexanone		I-IUPAC
,		O
followed		O
by		O
hydrogenation		O
(		O
H2		O
/		O
Pd		O
-		O
C		O
)		O
and		O
acidolysis		O
,		O
yielded		O
the		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
arylmethyl		I-IUPAC
)		I-IUPAC
cyclohexanones		I-IUPAC
,		O
which		O
were		O
then		O
condensed		O
with		O
cyanoguanidine		O
to		O
form		O
the		O
tetrahydroquinazolines		O
.		O
Tumor		O
cell		O
migration		O
and		O
metastasis		O
in		O
cancer		O
are		O
facilitated		O
by		O
interaction		O
of		O
the		O
serine		O
protease		O
urokinase		O
type		O
plasminogen		O
activator		O
(		O
uPA		O
)		O
with		O
its		O
receptor		O
uPAR		O
(		O
CD		O
87		O
)		O
.		O
Their		O
anti		O
-		O
VZV		O
activity		O
was		O
similar		O
or		O
higher		O
to		O
that		O
of		O
EDU		O
and		O
approximately		O
5-12		O
-		O
fold		O
lower		O
than		O
that		O
of		O
acyclovir		O
.		O
Overall		O
comparison		O
of		O
the		O
results		O
indicate		O
that		O
1		O
is		O
subject		O
to		O
considerable		O
conformational		O
freedom		O
and		O
suggests		O
that		O
the		O
sigma		O
receptor		O
is		O
not		O
subject		O
to		O
rigid		O
stereochemical		O
restraints		O
with		O
1		O
.		O
Compound		O
4		O
was		O
essentially		O
inactive		O
(		O
IC50		O
10		O
(		O
-		O
5		O
)		O
M		O
,		O
CCRF		O
-		O
CEM		O
)		O
.		O
v		O
.		O
The		O
synthesized		O
2		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		O
substituted		B-MODIFIER
anthraquinone		B-IUPAC
derivatives		B-MODIFIER
have		O
first		O
half		O
-		O
wave		O
reduction		O
potentials		O
of		O
-		O
0.52		O
to		O
-		O
0.56		O
V		O
at		O
pH		O
7.0		O
,		O
which		O
are		O
the		O
lowest		O
oxidation		O
-		O
reduction		O
potentials		O
of		O
quinone		O
bioreductive		O
alkylating		O
agents		O
synthesized		O
by		O
this		O
laboratory		O
to		O
date		O
.		O
Hydrolysis		O
with		O
sodium		O
hydroxide		O
solution		O
gave		O
the		O
corresponding		O
N		B-IUPAC
,		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
m		I-IUPAC
-		I-IUPAC
phenylene		I-IUPAC
)		I-IUPAC
dioxamic		I-IUPAC
acids		I-IUPAC
.		O
The		O
following		O
substitutions		O
and		O
deletions		O
,		O
alone		O
or		O
in		O
combination		O
,		O
were		O
employed		O
in		O
A		O
,		O
B		O
,		O
and		O
C		O
:		O
1		B-IUPAC
-		I-IUPAC
deaminopenicillamine		I-IUPAC
(		O
dP		O
)		O
;		O
D		O
-		O
Tyr		O
(		O
Alk		O
)		O
2		O
(		O
where		O
Alk		O
=		O
Me		O
or		O
Et		O
)		O
,		O
D		O
-		O
Phe2		O
;		O
Val4		O
,		O
Thr4		O
;		O
delta		O
3		O
-		O
Pro7		O
;		O
Lys8		O
,		O
Cit8		O
;		O
desGly9		O
,		O
desGly		O
-		O
NH2		O
(		O
9		O
)		O
,		O
Ala		O
-		O
NH2		O
(		O
9		O
)		O
;		O
Leu		O
-		O
NH2		O
(		O
9		O
)		O
;		O
Arg		O
-		O
NH2		O
(		O
9		O
)		O
.		O
The		O
anti		O
-		O
orthopoxvirus		O
activity		O
of		O
pyrimidine		O
may		O
be		O
favored		O
by		O
the		O
introduction		O
of		O
hydrophilic		O
moieties		O
to		O
the		O
5		O
-		O
position		O
side		O
chain		O
.		O
Tissue		O
distribution		O
studies		O
in		O
rats		O
with		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aminopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
[		I-IUPAC
125I		I-IUPAC
]		I-IUPAC
iodothiophene		I-IUPAC
showed		O
high		O
brain		O
uptake		O
(		O
5		O
min		O
,		O
2.77%		O
dose		O
/		O
g		O
;		O
30		O
min		O
,		O
2.51%		O
dose		O
/		O
g		O
)		O
and		O
good		O
brain		O
/		O
blood		O
(		O
B		O
/		O
B		O
)		O
ratios		O
(		O
5		O
min		O
,		O
6/1		O
;		O
30		O
min		O
3.8/1		O
.		O
The		O
title		O
compounds		O
displayed		O
partial		O
agonism		O
on		O
contractile		O
H		O
(		O
1		O
)		O
receptors		O
of		O
the		O
guinea		O
-		O
pig		O
ileum		O
and		O
endothelium		O
-		O
denuded		O
aorta		O
,		O
respectively		O
,		O
except		O
10		O
(		O
histaprodifen		O
;		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
diphenylpropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
ethanamine		I-IUPAC
)		O
which		O
was		O
a		O
full		O
agonist		O
in		O
the		O
ileum		O
assay		O
.		O
Compounds		O
4		O
,		O
7		O
,		O
and		O
15		O
were		O
not		O
inhibitory		O
to		O
a		O
variety		O
of		O
viruses		O
in		O
cell		O
culture		O
,		O
and		O
weak		O
cytotoxicity		O
was		O
observed		O
only		O
for		O
CEM		O
cells		O
.		O
Fluorinated		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminophenyl		I-IUPAC
)		I-IUPAC
benzothiazoles		I-IUPAC
were		O
potently		O
cytotoxic		O
(		O
GI		O
(		O
50		O
)		O
&		O
lt		O
;		O
1		O
nM		O
)		O
in		O
vitro		O
in		O
sensitive		O
human		O
breast		O
MCF		O
-		O
7		O
(		O
ER+		O
)		O
and		O
MDA		O
468		O
(		O
ER		O
-		O
)		O
cell		O
lines		O
but		O
inactive		O
(		O
GI		O
(		O
50		O
)		O
&		O
gt		O
;		O
10		O
microM		O
)		O
against		O
PC		O
3		O
prostate		O
,		O
nonmalignant		O
HBL		O
100		O
breast		O
,		O
and		O
HCT		O
116		O
colon		O
cells		O
.		O
Urokinase		O
-		O
type		O
plasminogen		O
activator		O
(		O
uPA		O
)		O
,		O
a		O
trypsin		O
-		O
like		O
serine		O
protease		O
,		O
has		O
been		O
implicated		O
in		O
large		O
number		O
of		O
malignancies		O
,		O
tumor		O
cell		O
invasion		O
,		O
angiogenesis		O
and		O
metastasis		O
;		O
hence		O
,		O
the		O
potent		O
and		O
selective		O
inhibitors		O
of		O
uPA		O
may		O
therefore		O
be		O
therapeutically		O
useful		O
drugs		O
for		O
treatment		O
of		O
various		O
forms		O
of		O
cancer		O
.		O
Among		O
tricyclic		O
quinazoline		O
derivatives		O
,		O
the		O
2		B-IUPAC
-		I-IUPAC
oxoimidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
e		I-IUPAC
]		I-IUPAC
quinazoline		I-IUPAC
derivative		B-MODIFIER
21a		O
showed		O
potent		O
activity		O
(		O
IC		O
(		O
50		O
)		O
=		O
0.10		O
microM		O
)		O
.		O
A		O
group		O
of		O
racemic		B-MODIFIER
alkyl		B-IUPAC
and		O
2		B-PARTIUPAC
-		I-PARTIUPAC
phenethyl		I-PARTIUPAC
1,4		I-PARTIUPAC
-		I-PARTIUPAC
dihydro		I-PARTIUPAC
-		I-PARTIUPAC
2,6		I-PARTIUPAC
-		I-PARTIUPAC
dimethyl		I-PARTIUPAC
-		I-PARTIUPAC
3		I-PARTIUPAC
-		I-PARTIUPAC
nitro		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
3		B-MODIFIER
-		I-MODIFIER
or		O
6		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
2		B-PARTIUPAC
-		I-PARTIUPAC
pyridyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
pyridinecarboxylates		I-PARTIUPAC
(		O
13a		O
-		O
q		O
)		O
was		O
prepared		O
using		O
a		O
modified		O
Hantzsch		O
reaction		O
that		O
involved		O
the		O
condensation		O
of		O
a		O
3		B-MODIFIER
-		I-MODIFIER
or		O
6		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
2		B-IUPAC
-		I-IUPAC
pyridinecarboxaldehyde		I-IUPAC
(		O
7a		O
-		O
j		O
)		O
with		O
an		O
alkyl		B-IUPAC
or		O
2		B-IUPAC
-		I-IUPAC
phenethyl		I-IUPAC
3		I-IUPAC
-		I-IUPAC
aminocrotonate		I-IUPAC
(		O
11a		O
-		O
d		O
)		O
and		O
nitroacetone		O
(		O
12		O
)		O
.		O
With		O
N		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
3,5		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
benzoquinone		I-IUPAC
imine		I-IUPAC
,		O
water		O
and		O
aniline		O
gave		O
substitution		O
on		O
the		O
imine		O
carbon		O
,		O
yielding		O
2,6		B-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
benzoquinone		I-IUPAC
and		O
3,5		B-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
benzoquinone		I-IUPAC
imine		I-IUPAC
,		O
respectively		O
.		O
DAP		O
was		O
selectively		O
blocked		O
by		O
the		O
carbobenzoxy		O
(		O
Cbz		O
)		O
group		O
to		O
give		O
3		O
-		O
N		O
-		O
Cbz		O
-		O
DAP		O
(		O
2a		O
)		O
.		O
The		O
findings		O
demonstrate		O
differences		O
between		O
various		O
leaving		O
groups		O
in		O
the		O
2		O
position		O
for		O
the		O
expression		O
of		O
differential		O
cytotoxicity		O
.		O
Bicyclization		O
of		O
this		O
analogue		O
yielded		O
[		O
dPen1		O
,		O
cyclo		O
(		O
Glu4		O
,		O
Lys8		O
)		O
]		O
oxytocin		O
,		O
a		O
potent		O
antagonist		O
of		O
oxytocin		O
in		O
the		O
uterotonic		O
assay		O
(		O
pA2		O
8.74		O
)		O
with		O
a		O
potency		O
3		O
times		O
greater		O
than		O
that		O
of		O
[		O
Mpa1		O
,		O
cyclo		O
(		O
Glu4		O
,		O
Lys8		O
)		O
]		O
oxytocin		O
.		O
With		O
the		O
exception		O
of		O
[		O
Sar1		O
,		O
Thr		O
(		O
ObetaMe		O
)		O
8		O
]		O
angiotensin		O
II		O
,		O
which		O
gave		O
lower		O
antagonistic		O
properties		O
,		O
all		O
other		O
analogs		O
had		O
either		O
similar		O
antagonistic		O
properties		O
or		O
were		O
better		O
antagonists		O
in		O
adrenal		O
medulla		O
than		O
in		O
smooth		O
muscle		O
.		O
In		O
order		O
to		O
improve		O
the		O
oral		O
bioavailability		O
(		O
BA		O
)		O
of		O
2		B-IUPAC
-		I-IUPAC
butyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
biphenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzimid		I-IUPAC
azole		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
3		O
:		O
CV		O
-		O
11194		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
biphenyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
benzimidazole		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
4		O
:		O
CV		O
-		O
11974		O
)		O
,		O
novel		O
angiotensin		O
II		O
(		O
AII		O
)		O
receptor		O
antagonists		O
,		O
chemical		O
modification		O
to		O
yield		O
prodrugs		O
has		O
been		O
examined		O
.		O
Specifically		O
,		O
compound		O
4		O
,		O
in		O
which		O
the		O
aminosulfonyl		O
NH		O
group		O
is		O
more		O
acidic		O
than		O
that		O
in		O
1		O
,		O
showed		O
greatly		O
reduced		O
selectivity		O
on		O
account		O
of		O
increased		O
alpha		O
2		O
-		O
adrenoceptor		O
affinity		O
as		O
compared		O
to		O
1		O
(		O
PNMT		O
Ki		O
=		O
2.6		O
microM		O
,		O
alpha		O
2		O
Ki		O
=		O
6.3		O
microM		O
,		O
selectivity		O
=		O
2.4		O
)		O
.		O
Antiparasite		O
activity		O
was		O
not		O
solely		O
determined		O
by		O
inhibition		O
strength		O
against		O
trypanothione		O
reductase		O
,		O
there		O
being		O
a		O
strong		O
contribution		O
from		O
hydrophobicity		O
(		O
for		O
example		O
,		O
benzhydryl		B-IUPAC
-		O
quaternized		B-MODIFIER
chlorpromazime		B-IUPAC
had		O
ED		O
(		O
50		O
)		O
&		O
lt		O
;		O
1		O
microM		O
)		O
.		O
A		O
series		O
of		O
imidazo		B-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
isothiazole		I-IUPAC
nucleosides		B-MODIFIER
related		O
to		O
the		O
antibiotic		O
nebularine		O
and		O
the		O
highly		O
cytotoxic		O
6		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosylpurine		I-IUPAC
have		O
been		O
synthesized		O
from		O
the		O
corresponding		O
heterocycles		O
.		O
The		O
compounds		O
are		O
bioisosteres		O
of		O
beta		O
-		O
carbolines		O
and		O
1,2,3,4		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
carbolines		I-IUPAC
where		O
the		O
indole		O
nitrogen		O
is		O
replaced		O
by		O
sulfur		O
.		O
These		O
results		O
open		O
the		O
way		O
toward		O
a		O
new		O
class		O
of		O
selective		O
NO		O
donors		O
after		O
in		O
situ		O
oxidation		O
by		O
each		O
NOS		O
family		O
.		O
Various		O
6		B-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
[		I-PARTIUPAC
(		I-PARTIUPAC
aryl		I-PARTIUPAC
and		O
aralkyl		B-PARTIUPAC
)		I-PARTIUPAC
amino		I-PARTIUPAC
]		I-PARTIUPAC
methyl		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
2,4		I-PARTIUPAC
-		I-PARTIUPAC
pteridinediamines		I-PARTIUPAC
and		O
their		O
8		B-IUPAC
-		I-IUPAC
oxides		I-IUPAC
have		O
been		O
synthesized		O
for		O
antimalarial		O
evaluation		O
.		O
Thus		O
,		O
40		O
,		O
45		O
,		O
and		O
54		O
are		O
potent		O
,		O
orally		O
active		O
5		O
-		O
HT1A		O
receptor		O
agonists		O
with		O
marked		O
antidepressant		O
potential		O
.		O
(		O
+		O
)		O
-		O
1		O
and		O
(		O
-		O
)		O
-		O
1		O
were		O
synthesized		O
from		O
(		B-IUPAC
+		I-IUPAC
/		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
aminocyclohexanol		I-IUPAC
[		O
(		O
+		O
/		O
-		O
)		O
-		O
3		O
]		O
.		O
The		O
complexes		O
3e		O
-		O
g		O
were		O
almost		O
equally		O
cytotoxic		O
to		O
cisplatin		O
toward		O
human		O
stomach		O
cancer		O
cell		O
lines		O
,		O
KATO		O
-		O
III		O
and		O
MKN		O
-		O
45		O
,		O
and		O
a		O
human		O
non		O
-		O
small		O
cell		O
lung		O
cancer		O
cell		O
line		O
,		O
PC14		O
.		O
These		O
compounds		O
have		O
been		O
evaluated		O
in		O
vitro		O
for		O
activity		O
against		O
Trypanosoma		O
b		O
.		O
Additional		O
substituted		O
phenyl		O
side		O
chains		O
which		O
include		O
2,5		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
,		O
3,4		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
,		O
3,4,5		B-IUPAC
-		I-IUPAC
trichloro		I-IUPAC
,		O
3		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
,		O
and		O
2,5		B-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
analogues		B-MODIFIER
13-17		O
were		O
also		O
synthesized		O
.		O
Likewise		O
,		O
for		O
the		O
enones		O
,		O
the		O
order		O
is		O
delta		O
(		O
22		O
)		O
-		O
24		O
-		O
one		O
&		O
gt		O
;		O
delta		O
(		O
20		O
(		O
22		O
)		O
)		O
-		O
23		O
-		O
one		O
&		O
gt		O
;		O
delta		O
(		O
22		O
)		O
-		O
20		O
-		O
one		O
&		O
gt		O
;		O
delta		O
(		O
23		O
)		O
-		O
22		O
-		O
one		O
.		O
The		O
synthesis		O
and		O
biological		O
evaluation		O
of		O
new		O
histamine		O
H3		O
receptor		O
antagonists		O
with		O
an		O
iodinated		O
aryl		O
partial		O
structure		O
are		O
described		O
as		O
part		O
of		O
an		O
extensive		O
research		O
program		O
to		O
find		O
model		O
compounds		O
for		O
the		O
development		O
of		O
a		O
new		O
radioligand		O
with		O
high		O
H3		O
receptor		O
affinity		O
and		O
specific		O
activity		O
.		O
These		O
results		O
demonstrate		O
that		O
topographical		O
modification		O
alone		O
in		O
a		O
conformationally		O
restricted		O
peptide		O
ligand		O
can		O
significantly		O
modulate		O
both		O
potency		O
and		O
receptor		O
selectivity		O
of		O
peptide		O
ligands		O
that		O
have		O
multiple		O
sites		O
of		O
biological		O
activity		O
and		O
suggest		O
that		O
this		O
approach		O
may		O
have		O
general		O
application		O
to		O
peptide		O
ligand		O
design		O
.		O
Furthermore		O
,		O
the		O
sigma		O
1		O
subtype		O
is		O
highly		O
enantioselective		O
for		O
the		O
levorotatory		O
isomers		O
,		O
(		O
-		O
)		O
-		O
2		O
-		O
(		O
-		O
)		O
-		O
7		O
(		O
41-1034		O
-		O
fold		O
)		O
,		O
whereas		O
the		O
sigma		O
2		O
subtype		O
is		O
only		O
somewhat		O
enantioselective		O
for		O
the		O
dextrorotatory		O
isomers		O
,		O
(		O
+		O
)		O
-		O
2		O
-		O
(		O
+		O
)		O
-		O
7		O
(		O
2.6-9.3		O
-		O
fold		O
)		O
.		O
Tentative		O
stereochemical		O
assignments		O
are		O
based		O
on		O
chemical		O
arguments		O
and		O
are		O
supported		O
by		O
13C		O
NMR		O
chemical		O
shift		O
data		O
.		O
All		O
analogues		O
exhibit		O
potent		O
oxytocic		O
antagonism		O
in		O
vitro		O
and		O
in		O
vivo		O
.		O
The		O
steady		O
-		O
state		O
rate		O
constant		O
,		O
Ki		O
,		O
was		O
determined		O
to		O
be		O
396		O
nM		O
.		O
The		O
importance		O
of		O
this		O
ratio		O
remains		O
unclear		O
in		O
terms		O
of		O
identification		O
of		O
potential		O
cocaine		O
antagonists		O
.		O
Novel		O
arylpiperazines		O
were		O
identified		O
as		O
alpha		O
1		O
-		O
adrenoceptor		O
(		O
AR		O
)		O
subtype		O
-		O
selective		O
antagonists		O
by		O
functional		O
in		O
vitro		O
screening		O
.		O
Both		O
cyclopropyl		B-PARTIUPAC
compounds		B-MODIFIER
reduced		O
putrescine		O
and		O
spermidine		O
pools		O
,		O
but		O
less		O
effectively		O
than		O
did		O
DENSPM		O
and		O
its		O
derivatives		O
.		O
2		O
-		O
[		O
5		O
-		O
(		O
4		O
-		O
Amidinophenyl		O
)		O
-		O
furan		O
-		O
2		O
-		O
yl		O
]		O
-		O
5,6,7,8		O
-		O
tetrahydro		O
-		O
imidazo		O
[		O
1,2		O
-		O
a		O
]		O
pyridine		O
-		O
6		O
-		O
carboxamidine		O
acetate		O
salt		O
(		O
7		O
)		O
was		O
synthesized		O
from		O
2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
cyanophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
furan		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carbonitrile		I-IUPAC
(		O
4a		O
)		O
,		O
through		O
the		O
bis		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetoxyamidoxime		I-IUPAC
followed		O
by		O
hydrogenation		O
in		O
glacial		O
acetic		O
acid		O
.		O
21		B-IUPAC
-		I-IUPAC
Hydroxy		I-IUPAC
-		I-IUPAC
6,19		I-IUPAC
-		I-IUPAC
epithioprogesterone		I-IUPAC
S		I-IUPAC
,		I-IUPAC
S		I-IUPAC
-		I-IUPAC
dioxide		I-IUPAC
had		O
improved		O
activity		O
in		O
both		O
parameters		O
,		O
while		O
21		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
6,19		I-IUPAC
-		I-IUPAC
epithioprogesterone		I-IUPAC
had		O
improved		O
activity		O
only		O
in		O
blocking		O
dexamethasone		O
-		O
induced		O
programmed		O
cell		O
death		O
.		O
Activity		O
among		O
the		O
2,4		B-IUPAC
-		I-IUPAC
pteridinediamines		I-IUPAC
IX		O
was		O
generally		O
poor		O
with		O
the		O
exception		O
of		O
the		O
3,4,5		B-IUPAC
-		I-IUPAC
trimethoxyphenyl		I-IUPAC
and		O
1		B-IUPAC
-		I-IUPAC
naphthalenyl		I-IUPAC
analogues		B-MODIFIER
which		O
showed		O
strong		O
suppressive		O
activity		O
at		O
doses		O
ranging		O
from		O
80		O
to		O
640		O
mg		O
/		O
kg		O
.		O
Tomaymycin		O
is		O
a		O
member		O
of		O
the		O
pyrrolo		B-IUPAC
[		I-IUPAC
1,4		I-IUPAC
]		I-IUPAC
benzodiazepine		I-IUPAC
antitumor		O
-		O
antibiotic		O
group		O
that		O
binds		O
covalently		O
to		O
the		O
exocyclic		B-MODIFIER
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
group		B-MODIFIER
of		O
guanine		O
in		O
DNA		O
.		O
[		O
18F		O
]		O
4d		O
has		O
similar		O
pharmacokinetic		O
properties		O
and		O
comparable		O
specific		O
binding		O
ratios		O
to		O
[		O
carbonyl		O
-		O
11C		O
]		O
4a		O
.		O
Potency		O
showed		O
a		O
marked		O
sensitivity		O
to		O
the		O
introduction		O
of		O
substituents		O
to		O
these		O
aromatic		O
rings		O
and		O
only		O
the		O
bis		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
derivative		B-MODIFIER
9j		O
,		O
IC50		O
=		O
0.34		O
microM		O
,		O
demonstrated		O
enhanced		O
potency		O
compared		O
to		O
the		O
parent		O
structure		O
3		O
,		O
IC50		O
=		O
1.2		O
microM		O
.		O
The		O
formation		O
of		O
nitric		O
oxide		O
(		O
NO		O
)		O
was		O
followed		O
during		O
the		O
oxidation		O
of		O
37		O
N		B-IUPAC
-		I-IUPAC
hydroxyguanidines		I-IUPAC
or		O
related		O
derivatives		O
,		O
including		O
18		O
new		O
N		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
hydroxyguanidines		I-IUPAC
,		O
by		O
recombinant		O
inducible		O
nitric		O
oxide		O
synthase		O
(		O
NOS		O
II		O
)		O
.		O
carinii		O
DHFR		O
and		O
M		O
.		O
4		B-IUPAC
-		I-IUPAC
Methoxybenzeneethanamine		I-IUPAC
and		O
2		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
nitrophenylacetic		I-IUPAC
acid		I-IUPAC
were		O
employed		O
as		O
starting		O
materials		O
for		O
for		O
the		O
synthesis		O
of		O
the		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
aminoethyl		I-IUPAC
)		I-IUPAC
indolones		I-IUPAC
.		O
The		O
findings		O
showed		O
that		O
modifications		O
at		O
the		O
position		O
of		O
the		O
amino		O
acid		O
moiety		O
of		O
1		O
significantly		O
influenced		O
the		O
activity		O
and		O
that		O
the		O
1H		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
one		I-IUPAC
skeleton		B-MODIFIER
was		O
also		O
required		O
for		O
activity		O
to		O
occur		O
.		O
The		O
sequence		O
of		O
enamine		O
formation		O
with		O
pyrrolidine		O
,		O
catalytic		O
reduction		O
,		O
N		O
-		O
deprotection		O
,		O
and		O
optical		O
resolution		O
afforded		O
(		B-IUPAC
1R		I-IUPAC
,		I-IUPAC
2S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cis		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylcyclohexylamine		I-IUPAC
[		O
(		O
-		O
)		O
-		O
10		O
]		O
and		O
(		B-IUPAC
1S		I-IUPAC
,		I-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cis		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyrrolidinyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylcyclohexylamine		I-IUPAC
[		O
(		O
+		O
)		O
-		O
10		O
]		O
.		O
Whereas		O
AMAA		O
(		O
6		O
)		O
and		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propinoic		I-IUPAC
acid		I-IUPAC
(		O
AMPA		O
,		O
7		O
)		O
are		O
potent		O
and		O
highly		O
selective		O
agonists		O
at		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
aspartic		I-IUPAC
acid		I-IUPAC
(		O
NMDA		O
)		O
and		O
AMPA		O
receptors		O
,		O
respectively		O
,		O
the		O
higher		O
homologue		O
of		O
AMPA		O
(		O
7		O
)		O
,		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
butyric		I-IUPAC
acid		I-IUPAC
(		O
homo		O
-		O
AMPA		O
,		O
8		O
)		O
,		O
is		O
inactive		O
at		O
ionotropic		O
excitatory		O
amino		O
acid		O
receptors		O
.		O
In		O
the		O
latter		O
assay		O
,		O
both		O
enantiomers		O
of		O
6		O
had		O
identical		O
potencies		O
,		O
but		O
their		O
dose		O
-		O
response		O
curves		O
were		O
not		O
parallel		O
.		O
These		O
prodrugs		O
of		O
ara		O
-		O
C		O
include		O
ara		B-IUPAC
-		I-IUPAC
CDP		I-IUPAC
-		I-IUPAC
rac		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
S		I-IUPAC
-		I-IUPAC
hexadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
palmitoyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
thioglycerol		I-IUPAC
(		O
8a		O
)		O
,		O
ara		B-IUPAC
-		I-IUPAC
CDP		I-IUPAC
-		I-IUPAC
rac		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
S		I-IUPAC
-		I-IUPAC
octadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
palmitoylthioglycerol		I-IUPAC
(		O
8b		O
)		O
,		O
and		O
ara		B-IUPAC
-		I-IUPAC
CDP		I-IUPAC
-		I-IUPAC
rac		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
S		I-IUPAC
-		I-IUPAC
octadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
(		O
or		O
-		B-PARTIUPAC
ethyl		I-PARTIUPAC
,		O
-		B-PARTIUPAC
hexadecyl		I-PARTIUPAC
)		O
thioglycerols		B-PARTIUPAC
(		O
8c		O
-		O
e		O
)		O
.		O
The		O
k		O
(		O
cat		O
)		O
value		O
for		O
NOS		O
II		O
-		O
catalyzed		O
oxidation		O
of		O
N		B-IUPAC
-		I-IUPAC
para		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
hydroxyguanidine		I-IUPAC
was		O
80%		O
of		O
that		O
found		O
for		O
NOHA		O
,		O
and		O
its		O
k		O
(		O
cat		O
)		O
/		O
K		O
(		O
m		O
)		O
value		O
was		O
only		O
9		O
-		O
fold		O
lower		O
than		O
that		O
of		O
NOHA		O
.		O
beta		O
-		O
(		O
1		O
-		O
Chloro		O
-		O
2		O
-		O
naphthyl		O
)		O
alanine		O
and		O
beta		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
were		O
synthesized		O
by		O
ammonolysis		O
of		O
the		O
corresponding		O
alpha		B-IUPAC
,		I-IUPAC
1		I-IUPAC
-		I-IUPAC
dihalo		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthalenepropanoic		I-IUPAC
acids		I-IUPAC
derived		O
from		O
1		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthylamine		I-IUPAC
by		O
diazotization		O
and		O
condensation		O
with		O
acrylic		O
acid		O
in		O
the		O
presence		O
of		O
cuprous		O
halides		O
.		O
Compounds		O
possessing		O
a		O
3		B-MODIFIER
-		I-MODIFIER
or		O
6		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
2		B-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
moiety		B-MODIFIER
,		O
in		O
conjuction		O
with		O
an		O
i		O
-		O
Pr		O
ester		O
substituent		O
,		O
are		O
novel		O
1,4		B-IUPAC
-		I-IUPAC
dihydropyridine		I-IUPAC
calcium		O
channel		O
modulators		O
that		O
offer		O
a		O
new		O
drug		O
design		O
approach		O
directed		O
to		O
the		O
treatment		O
of		O
congestive		O
heart		O
failure		O
and		O
may		O
also		O
be		O
useful		O
as		O
probes		O
to		O
study		O
the		O
structure		O
-		O
function		O
relationships		O
of		O
calcium		O
channels		O
.		O
Noteworthy		O
are		O
the		O
tissue		O
-		O
selective		O
bronchodilator		O
activity		O
of		O
N		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
PGE2		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
and		O
the		O
selectivity		O
for		O
uterine		O
tissue		O
of		O
N		B-IUPAC
-		I-IUPAC
methanesulfonyl		I-IUPAC
-		I-IUPAC
PGE2		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
,		O
2		B-IUPAC
-		I-IUPAC
decarboxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
16,16		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
PGE2		I-IUPAC
,		O
N		B-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
16,16		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
PGE2		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
,		O
and		O
N		B-IUPAC
-		I-IUPAC
methanesulfonyl		I-IUPAC
-		I-IUPAC
16,16		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
PGE2		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
.		O
Here		O
,		O
we		O
report		O
the		O
synthesis		O
and		O
biological		O
evaluation		O
of		O
additional		O
PAT		O
analogues		O
in		O
order		O
to		O
identify		O
differences		O
in		O
binding		O
at		O
these		O
two		O
sites		O
.		O
This		O
antiviral		O
activity		O
did		O
not		O
appear		O
to		O
be		O
related		O
to		O
the		O
decomposition		O
to		O
the		O
5		B-IUPAC
-		I-IUPAC
formyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
,		O
which		O
was		O
itself		O
devoid		O
of		O
anti		O
-		O
orthopoxvirus		O
activity		O
in		O
these		O
assays		O
.		O
A		O
number		O
of		O
compounds		O
were		O
orally		O
effective		O
at		O
doses		O
less		O
than		O
or		O
equal		O
to		O
1		O
mg		O
/		O
kg		O
in		O
blocking		O
LTD4		O
-		O
induced		O
"		O
dyspnea		O
"		O
in		O
guinea		O
pigs		O
.		O
The		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxyalkyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxypyridin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
are		O
demonstrated		O
to		O
be		O
orally		O
active		O
under		O
the		O
in		O
vivo		O
conditions		O
adopted		O
.		O
01		O
)		O
.		O
We		O
found		O
that		O
the		O
antimicrobial		O
and		O
cytotoxic		O
activity		O
of		O
indolo		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
quinolines		I-IUPAC
was		O
strongly		O
influenced		O
by		O
the		O
position		O
,		O
and		O
the		O
number		O
of		O
methyl		B-IUPAC
substituents		B-MODIFIER
and		O
the		O
presence		O
of		O
methyl		B-IUPAC
group		B-MODIFIER
at		O
pyridine		O
nitrogen		O
was		O
essential		O
for		O
the		O
cytotoxicity		O
of		O
these		O
compounds		O
.		O
For		O
instance		O
,		O
compound		O
34		O
was		O
orally		O
active		O
in		O
the		O
rat		O
catalepsy		O
model		O
at		O
3		O
mg		O
/		O
kg		O
.		O
Thus		O
,		O
the		O
compound		O
series		O
reported		O
herein		O
comprise		O
an		O
important		O
new		O
series		O
of		O
selective		O
A		O
(		O
3		O
)		O
AR		O
antagonists		O
.		O
In		O
this		O
study		O
,		O
we		O
present		O
the		O
synthesis		O
and		O
biological		O
evaluations		O
of		O
six		O
of		O
the		O
possible		O
eight		O
isomers		O
of		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylenedioxy		I-IUPAC
)		I-IUPAC
phenoxy		I-IUPAC
]		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
nortropane		I-IUPAC
+		O
+		O
+		O
(		O
4		O
)		O
.		O
The		O
aromatic		O
substituents		O
included		O
OH		O
,		O
OCH3		O
,		O
OCOCH3		O
,		O
CH2CH3		O
,		O
and		O
Cl		O
.		O
6beta		B-IUPAC
-		I-IUPAC
Acetoxynortropane		I-IUPAC
had		O
K		O
(		O
i		O
)		O
values		O
versus		O
oxotremorine		O
-		O
M		O
binding		O
at		O
m		O
(		O
1		O
)		O
-		O
,		O
m		O
(		O
2		O
)		O
-		O
,		O
and		O
m		O
(		O
4		O
)		O
-		O
receptors		O
ranging		O
from		O
4		O
to		O
7		O
nM		O
.		O
2		O
-		O
(		O
4		O
-		O
Chloro		O
-		O
3		O
-		O
hydroxyphenyl		O
)		O
ethylamine		O
(		O
4		O
)		O
and		O
some		O
derivatives		O
were		O
synthesized		O
as		O
dopamine		O
(		O
DA		O
)		O
receptor		O
ligands		O
.		O
Radiolabeled		O
m		B-IUPAC
-		I-IUPAC
iodobenzylguanidine		I-IUPAC
(		O
MIBG		O
)		O
is		O
a		O
tumor		O
-		O
seeking		O
radioactive		O
drug		O
used		O
in		O
the		O
diagnosis		O
and		O
treatment		O
of		O
pheochromocytomas		O
and		O
neuroblastomas		O
.		O
Friedel		O
-		O
Crafts		O
reaction		O
of		O
5		O
led		O
to		O
2,4		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
chloromethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
acetylbenzylamine		I-IUPAC
(		O
6		O
)		O
which		O
on		O
treatment		O
with		O
KCN		O
,		O
hydrolysis		O
of		O
the		O
resultant		O
nitrile		O
,		O
and		O
subsequent		O
esterification		O
afforded		O
6		B-IUPAC
-		I-IUPAC
carbethoxymethyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroisoquinolin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
9		O
)		O
.		O
The		O
most		O
potent		O
compound		O
was		O
(		B-IUPAC
2S		I-IUPAC
,		I-IUPAC
4S		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
piperidyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dioxolane		I-IUPAC
(		O
11		O
)		O
,		O
where		O
a		O
chlorine		O
moiety		O
was		O
placed		O
in		O
the		O
ortho		O
position		O
in		O
the		O
aromatic		O
ring		O
of		O
etoxadrol		O
.		O
Addition		O
of		O
2		O
to		O
an		O
equimolar		O
amount		O
of		O
the		O
reaction		O
product		O
of		O
HOPO		O
-		O
C		O
and		O
CDI		O
in		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dimethylacetamide		I-IUPAC
(		O
DMAA		O
)		O
,		O
purification		O
of		O
the		O
hexadentate		O
intermediate		O
,		O
subsequent		O
treatment		O
with		O
an		O
equimolar		O
amount		O
of		O
2,3		B-IUPAC
-		I-IUPAC
dimethoxybenzoyl		I-IUPAC
chloride		I-IUPAC
(		O
DMB		O
)		O
,		O
and		O
deprotection		O
with		O
BBr3		O
gave		O
1,5,14		B-IUPAC
-		I-IUPAC
tris		I-IUPAC
(		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydroxybenzoyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridon		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
oyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
,		I-IUPAC
5,10,14		I-IUPAC
-		I-IUPAC
tetraazatetradecane		I-IUPAC
[		O
4		O
,		O
3,4,3		O
-		O
LI		O
(		O
triCAM		O
-		O
HOPO		O
)		O
]		O
in		O
5%		O
yield		O
.		O
Reaction		O
of		O
8		O
with		O
dimethyl		B-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminobenzoyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamate		I-IUPAC
gave		O
the		O
2,4		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
acetylamino		I-IUPAC
)		I-IUPAC
derivative		B-MODIFIER
11		O
,		O
which		O
was		O
hydrolyzed		O
with		O
1		O
N		O
sodium		O
hydroxide		O
to		O
give		O
1		O
;		O
the		O
glycine		O
analogue		O
16		O
was		O
prepared		O
in		O
a		O
similar		O
manner		O
.		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Aminomethyl		I-IUPAC
)		I-IUPAC
cyclohexylamine		I-IUPAC
platinum		I-IUPAC
complexes		B-MODIFIER
exhibited		O
higher		O
activity		O
than		O
1,2		B-IUPAC
-		I-IUPAC
cyclohexanediamine		I-IUPAC
complexes		B-MODIFIER
in		O
this		O
tumor		O
system		O
.		O
The		O
NMR		O
structure		O
of		O
cyclo		O
[		O
21,29		O
]		O
[		O
D		O
-		O
Cys		O
(		O
21		O
)		O
Cys		O
(		O
29		O
)		O
]		O
-		O
uPA		O
(		O
21		O
)		O
(		O
-		O
)		O
(		O
30		O
)		O
is		O
very		O
similar		O
to		O
the		O
previously		O
reported		O
structure		O
of		O
the		O
amino		O
terminal		O
fragment		O
of		O
uPA		O
.		O
Treatment		O
of		O
6a		O
-		O
d		O
and		O
7a		O
-		O
d		O
with		O
thiourea		O
furnished		O
the		O
corresponding		O
6		B-IUPAC
-		I-IUPAC
thio		I-IUPAC
derivatives		B-MODIFIER
(		O
9a		O
-		O
d		O
and		O
8a		O
-		O
d		O
)		O
.		O
Reaction		O
of		O
Z		O
-		O
Lys		O
(		O
Z		O
)		O
-		O
Trp		O
-		O
OMe		O
(		O
3		O
)		O
with		O
PS		O
-		O
,		O
CmPS		O
-		O
,		O
pNPS		O
-		O
,		O
DNPS		O
-		O
,		O
and		O
AacCmES		O
-		O
Cl		O
afforded		O
the		O
corresponding		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
sulfenyl		I-IUPAC
)		I-IUPAC
tryptophan		I-IUPAC
derivatives		B-MODIFIER
,		O
which		O
on		O
treatment		O
with		O
boron		B-IUPAC
-		I-IUPAC
tris		I-IUPAC
(		I-IUPAC
trifluoroacetate		I-IUPAC
)		I-IUPAC
/		O
trifluoroacetic		O
acid		O
or		O
trimethylsilyl		O
iodide		O
in		O
acetonitrile		O
(		O
Me3SiI		O
/		O
CH3CN		O
)		O
provided		O
9-13		O
,		O
respectively		O
.		O
Oxidation		O
was		O
effected		O
with		O
hydrogen		O
peroxide		O
or		O
the		O
bromine		O
complex		O
of		O
1,4		B-IUPAC
-		I-IUPAC
diazabicyclo		I-IUPAC
[		I-IUPAC
2.2.2		I-IUPAC
]		I-IUPAC
octane		I-IUPAC
.		O
While		O
[		O
131I		O
]		O
NGA		O
indicated		O
high		O
radioactivity		O
levels		O
in		O
the		O
murine		O
neck		O
,		O
stomach		O
,		O
and		O
blood		O
,		O
such		O
increases		O
in		O
the		O
radioactivity		O
count		O
were		O
not		O
detectable		O
by		O
the		O
administration		O
of		O
either		O
[		O
131I		O
]		O
MIH		O
-		O
NGA		O
or		O
[		O
131I		O
]		O
ATE		O
-		O
NGA		O
.		O
All		O
analogues		O
,		O
with		O
the		O
exception		O
of		O
the		O
Pro4		O
-		O
containing		O
analogue		O
,		O
are		O
antidiuretic		O
antagonists		O
.		O
More		O
bulky		O
substituents		O
at		O
position		O
9		O
led		O
to		O
less		O
active		O
compounds		O
,		O
although		O
some		O
of		O
them		O
[		O
9		B-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
(		O
rac		O
-		O
22		O
)		O
,		O
9		B-IUPAC
-		I-IUPAC
allyl		I-IUPAC
(		O
rac		O
-		O
23		O
)		O
,		O
and		O
9		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
(		O
rac		O
-		O
26		O
)		O
]		O
show		O
activities		O
similar		O
to		O
that		O
of		O
THA		O
.		O
The		O
acute		O
toxicity		O
usually		O
exhibited		O
by		O
the		O
parent		O
amidine		O
1		O
at		O
a		O
dosage		O
level		O
of		O
22		O
micromol		O
/		O
kg		O
/		O
day		O
on		O
intravenous		O
administration		O
has		O
been		O
significantly		O
reduced		O
by		O
the		O
prodrug		O
modifications		O
,		O
with		O
the		O
exception		O
of		O
compound		O
10		O
which		O
exhibited		O
some		O
toxicity		O
.		O
The		O
mechanism		O
of		O
action		O
of		O
these		O
agents		O
has		O
been		O
attributed		O
to		O
the		O
accumulation		O
of		O
cells		O
at		O
mitosis		O
.		O
The		O
novel		O
benzylidene		B-IUPAC
-		I-IUPAC
9		I-IUPAC
(		I-IUPAC
10H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
anthracenones		I-IUPAC
described		O
in		O
the		O
present		O
study		O
constitute		O
an		O
interesting		O
group		O
of		O
highly		O
active		O
and		O
easily		O
accessible		O
antimitotic		O
agents		O
that		O
inhibit		O
tubulin		O
polymerization		O
.		O
Several		O
of		O
the		O
compounds		O
have		O
CCK		O
-		O
B		O
binding		O
affinities		O
similar		O
to		O
the		O
parent		O
carboxylic		O
acid		O
1		O
(		O
CCK		O
-		O
B		O
,		O
IC50		O
=		O
1.7		O
nM		O
;		O
pK		O
(		O
a		O
)		O
=		O
5.6		O
)		O
and		O
span		O
a		O
pK		O
(		O
a		O
)		O
range		O
of		O
less		O
than		O
1		O
(		O
sulfonic		O
acid		O
27		O
)		O
to		O
greater		O
than		O
9.5		O
(		O
5		B-IUPAC
-		I-IUPAC
thio		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
triazole		I-IUPAC
24		O
)		O
.		O
2		B-IUPAC
-		I-IUPAC
Methoxytetrahydrofuran		I-IUPAC
can		O
be		O
used		O
instead		O
of		O
Thf		O
-		O
OAc		O
for		O
preparation		O
of		O
Thf		O
-		O
FU		O
under		O
similar		O
conditions		O
.		O
The		O
3		B-IUPAC
-		I-IUPAC
isoxazolol		I-IUPAC
amino		I-IUPAC
acid		I-IUPAC
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
AMPA		O
,		O
2		O
)		O
and		O
the		O
isomeric		O
compound		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
4		B-IUPAC
-		I-IUPAC
methylhomoibotenic		I-IUPAC
acid		I-IUPAC
,		O
4a		O
)		O
are		O
potent		O
agonists		O
at		O
the		O
AMPA		O
subtype		O
of		O
central		O
excitatory		O
amino		O
acid		O
receptors		O
.		O
The		O
analogue		O
proved		O
to		O
retard		O
the		O
rate		O
of		O
formation		O
of		O
formylglycinamide		O
ribonucleotide		O
apparently		O
by		O
inhibiting		O
the		O
rate		O
of		O
synthesis		O
of		O
10		B-IUPAC
-		I-IUPAC
formyltetrahydrofolate		I-IUPAC
,		O
the		O
actual		O
cofactor		O
for		O
the		O
transformylase		O
enzyme		O
,		O
from		O
5,10		B-IUPAC
-		I-IUPAC
methenyltetrahydrofolate		I-IUPAC
.		O
Using		O
4a		O
as		O
a		O
lead		O
structure		O
,		O
the		O
amino		O
acids		O
4c		O
-		O
e		O
,		O
in		O
which		O
the		O
4		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
group		B-MODIFIER
of		O
4a		O
is		O
replaced		O
by		O
substituents		O
of		O
different		O
size		O
and		O
polarity		O
,		O
were		O
synthesized		O
.		O
;		O
Thurston		O
,		O
D		O
.		O
These		O
precursors		O
were		O
subjected		O
to		O
a		O
five		O
-		O
step		O
route		O
to		O
obtain		O
thieno2		B-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d1		I-IUPAC
,		I-IUPAC
3		I-IUPAC
\C5		I-IUPAC
\8F		I-IUPAC
xazin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
bearing		O
various		O
substituents		O
at		O
positions		O
5		O
and		O
6		O
.		O
N4		B-IUPAC
-		I-IUPAC
Alkylaminopyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
were		O
generally		O
prepared		O
by		O
displacement		O
of		O
the		O
chlorine		O
from		O
4		B-IUPAC
-		I-IUPAC
chloropyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
with		O
various		O
amines		O
.		O
A		O
series		O
of		O
6		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
4		B-IUPAC
-		I-IUPAC
anilinopyrimido		I-IUPAC
[		I-IUPAC
5,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
has		O
been		O
prepared		O
and		O
shown		O
to		O
be		O
potent		O
inhibitors		O
of		O
the		O
tyrosine		O
kinase		O
activity		O
of		O
the		O
epidermal		O
growth		O
factor		O
receptor		O
(		O
EGFR		O
)		O
.		O
These		O
results		O
suggest		O
that		O
the		O
mitochondrial		O
peripheral		O
benzodiazepine		O
receptor		O
(		O
PBR		O
)		O
is		O
not		O
the		O
cellular		O
binding		O
site		O
for		O
this		O
class		O
of		O
compounds		O
.		O
Clinical		O
studies		O
concerning		O
the		O
role		O
of		O
poly		O
(		O
ADP		O
-		O
ribose		O
)		O
polymerase		O
(		O
PARP		O
)		O
in		O
the		O
repair		O
of		O
drug		O
-		O
and		O
radiation		O
-		O
induced		O
DNA		O
damage		O
have		O
been		O
impeded		O
by		O
the		O
poor		O
solubility		O
,		O
lack		O
of		O
potency		O
,		O
and		O
limited		O
specificity		O
of		O
currently		O
available		O
inhibitors		O
.		O
The		O
dicyclic		O
analogue		O
dicyclo		O
(		O
1-3/4-10		O
)		O
[		O
Ac		O
-		O
DAsp		O
(		O
1		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DLys		O
(		O
3		O
)		O
,		O
Asp		O
(		O
4		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
Dpr		O
(		O
10		O
)		O
]		O
GnRH		O
(		O
26		O
)		O
was		O
fully		O
active		O
at		O
500		O
microgram		O
,		O
with		O
a		O
K		O
(		O
i		O
)		O
value		O
of		O
1		O
nM		O
.		O
Aromatic		O
L		O
-		O
amino		O
acid		O
decarboxylase		O
(		O
AADC		O
)		O
is		O
the		O
enzyme		O
responsible		O
for		O
the		O
final		O
step		O
in		O
the		O
biosynthesis		O
of		O
both		O
dopamine		O
and		O
serotonin		O
via		O
decarboxylation		O
of		O
L		B-IUPAC
-		I-IUPAC
dopa		I-IUPAC
and		O
5		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
tryptophan		I-IUPAC
,		O
respectively		O
.		O
Novel		O
A		O
(		O
1		O
)		O
agonists		O
with		O
potent		O
central		O
nervous		O
system		O
effects		O
and		O
diminished		O
influence		O
on		O
the		O
cardiovascular		O
system		O
are		O
reported		O
and		O
compared		O
to		O
selected		O
reference		O
adenosine		O
agonists		O
.		O
In		O
the		O
presence		O
of		O
2		B-IUPAC
-		I-IUPAC
mercaptoehtanesulfonic		I-IUPAC
acid		I-IUPAC
,		O
an		O
acrolein		O
scavenger		O
,		O
1c		O
was		O
equally		O
effective		O
against		O
a		O
P		O
-		O
388		O
mutant		O
cell		O
line		O
that		O
was		O
resistant		O
to		O
FU		O
.		O
In		O
the		O
[		B-IUPAC
1		I-IUPAC
]		I-IUPAC
benzothieno		I-IUPAC
(		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
series		B-MODIFIER
,		O
the		O
aminoethyl		B-IUPAC
carboxamide		I-IUPAC
(		O
12a		O
)		O
group		B-MODIFIER
at		O
C		O
-		O
3		O
also		O
conferred		O
activity		O
,		O
but		O
other		O
amides		O
studied		O
were		O
not		O
active		O
.		O
In		O
vivo		O
,		O
they		O
are		O
comparable		O
to		O
the		O
6,8		B-IUPAC
-		I-IUPAC
difluoro		I-IUPAC
series		B-MODIFIER
and		O
show		O
up		O
to		O
10		O
-		O
fold		O
improvement		O
in		O
efficacy		O
when		O
compared		O
to		O
their		O
ciprofloxacin		O
counterparts		O
vs		O
Streptococcus		O
pyogenes		O
and		O
Streptococcus		O
pneumonia		O
.		O
Both		O
analogs		O
in		O
which		O
the		O
alpha		O
carbon		O
of		O
the		O
Phe3		O
replacement		O
has		O
L		O
-		O
stereochemistry		O
display		O
high		O
affinity		O
for		O
delta		O
receptors		O
with		O
the		O
(		O
2S		O
,		O
3S		O
)		O
-		O
MePhe3		O
analog		O
exhibiting		O
approximately		O
8		O
-		O
fold		O
higher		O
affinity		O
than		O
the		O
(		O
2S		O
,		O
3R		O
)		O
-		O
MePhe3		O
diastereomer		O
.		O
Compound		O
11		O
was		O
found		O
to		O
have		O
the		O
most		O
significant		O
and		O
selective		O
antiviral		O
activity		O
against		O
herpes		O
simplex		O
virus		O
.		O
A		O
series		O
of		O
28		O
4		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
and		O
4,5		B-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
2		B-IUPAC
-		I-IUPAC
pyridylimidazoles		I-IUPAC
was		O
synthesized		O
and		O
evaluated		O
in		O
vitro		O
for		O
inhibition		O
of		O
xanthine		O
oxidase		O
.		O
It		O
appears		O
that		O
2A		O
displayed		O
a		O
higher		O
lipophilicity		O
than		O
2B		O
(		O
PC		O
=		O
305		O
and		O
229		O
,		O
respectively		O
)		O
,		O
and		O
a		O
similar		O
trend		O
was		O
observed		O
for		O
the		O
initial		O
brain		O
uptake		O
at		O
2		O
min		O
postinjection		O
(		O
0.50%		O
and		O
0.28%		O
dose		O
/		O
organ		O
for		O
2A		O
,		O
B		O
,		O
respectively		O
)		O
.		O
One		O
assay		O
measured		O
the		O
ability		O
of		O
a		O
retinoid		O
to		O
inhibit		O
the		O
phorbol		O
ester		O
induced		O
increase		O
of		O
mouse		O
epidermal		O
ornithine		O
decarboxylase		O
(		O
ODC		O
)		O
activity		O
.		O
Several		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
arylmethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
piperidines		I-IUPAC
display		O
antitetrabenazine		O
activity		O
comparable		O
to		O
imipramine		O
or		O
amitriptyline		O
but		O
are		O
two		O
-		O
to		O
fourfold		O
less		O
active		O
than		O
analogous		O
3		B-IUPAC
-		I-IUPAC
arylspiro		I-IUPAC
[		I-IUPAC
isobenzofuran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
,		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
piperidines		I-IUPAC
]		I-IUPAC
.		O
The		O
dibenzothiophene		O
32		O
{		O
38		O
}		O
sensitized		O
HeLa		O
cells		O
to		O
ionizing		O
radiation		O
in		O
vitro		O
,		O
with		O
dose		O
modification		O
factors		O
of		O
2.5		O
at		O
10%		O
survival		O
being		O
observed		O
at		O
0.5		O
microM		O
.		O
A		O
corresponding		O
series		O
of		O
6		B-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
halo		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
galactose		I-IUPAC
analogues		B-MODIFIER
,		O
which		O
are		O
enantiomers		O
of		O
the		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
halomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
fucose		I-IUPAC
analogues		B-MODIFIER
,		O
has		O
also		O
been		O
synthesized		O
.		O
Molecular		O
mechanics		O
computations		O
revealed		O
,		O
however		O
,		O
that		O
the		O
conformational		O
constraints		O
imposed		O
by		O
the		O
beta		O
-		O
methyl		O
group		O
in		O
the		O
(		O
2S		O
,		O
3S		O
)		O
-		O
MePhe3		O
and		O
(		O
2S		O
,		O
3R		O
)		O
-		O
MePhe3		O
analogs		O
were		O
too		O
modest		O
to		O
allow		O
unequivocal		O
determination		O
of		O
delta		O
receptor		O
-		O
bound		O
residue		O
3		O
side		O
chain		O
conformation		O
.		O
Against		O
the		O
colon		O
38		O
adenocarcinoma		O
,		O
the		O
three		O
compounds		O
17		O
,		O
21		O
,		O
and		O
22		O
were		O
highly		O
efficient		O
.		O
Cyclization		O
of		O
4		O
with		O
3		B-IUPAC
-		I-IUPAC
carbethoxybutane		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
(		O
5e		O
)		O
gave		O
3		B-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
ethoxycarbonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4,6		I-IUPAC
-		I-IUPAC
dimethylpyridine		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
thione		I-IUPAC
(		O
6e		O
)		O
,		O
whereas		O
reaction		O
of		O
4		O
with		O
3		B-IUPAC
-		I-IUPAC
carbethoxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phenylpropane		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dione		I-IUPAC
(		O
5f		O
)		O
yielded		O
two		O
products		O
,		O
3		B-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
ethoxycarbonyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
phenylpyridine		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
thione		I-IUPAC
(		O
6f		O
)		O
and		O
the		O
6		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
isomer		B-MODIFIER
6g		O
.		O
Synadenol		O
(		O
14		O
)		O
was		O
also		O
deaminated		O
by		O
AMP		O
deaminase		O
from		O
aspergillus		O
sp		O
.		O
We		O
have		O
previously		O
reported		O
that		O
a		O
series		O
of		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
substituted		I-IUPAC
(		I-IUPAC
thio		I-IUPAC
)		I-IUPAC
carbamoyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
piperazinyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6,7		I-IUPAC
-		I-IUPAC
dimethoxyquinazoline		I-IUPAC
derivatives		B-MODIFIER
were		O
potent		O
and		O
selective		O
inhibitors		O
of		O
platelet		O
-		O
derived		O
growth		O
factor		O
receptor		O
(		O
PDGFR		O
)		O
phosphorylation		O
and		O
demonstrated		O
several		O
biological		O
effects		O
such		O
as		O
suppression		O
of		O
neointima		O
formation		O
following		O
balloon		O
injury		O
in		O
rat		O
carotid		O
artery		O
by		O
oral		O
administration		O
.		O
A		O
functionalized		O
congener		O
bearing		O
an		O
[		B-IUPAC
(		I-IUPAC
aminoethyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
carbonyl		I-IUPAC
group		B-MODIFIER
was		O
also		O
prepared		O
as		O
an		O
intermediate		O
in		O
the		O
synthesis		O
of		O
biologically		O
active		O
conjugates		O
.		O
gondii		O
enzyme		O
was		O
always		O
more		O
sensitive		O
than		O
the		O
P		O
.		O
Condesations		O
of		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
N10		I-IUPAC
-		I-IUPAC
methylpteroic		I-IUPAC
acid		I-IUPAC
(		O
mAPA		O
)		O
with		O
dimethyl		B-IUPAC
DL		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyleneglutamate		I-IUPAC
in		O
the		O
presence		O
of		O
diethyl		O
phosphorocyanidate		O
(		O
DEPC		O
)		O
followed		O
by		O
alkaline		O
hydrolysis		O
yielded		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
N10		I-IUPAC
-		I-IUPAC
methylpteroyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
DL		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyleneglutamic		I-IUPAC
acid		I-IUPAC
(		O
gamma		O
-		O
methyleneMTX		O
)		O
.		O
They		O
behaved		O
as		O
antagonists		O
,		O
but		O
they		O
proved		O
to		O
be		O
less		O
effective		O
than		O
1		O
and		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aminophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylcarbamoyl		I-IUPAC
-		I-IUPAC
7,8		I-IUPAC
-		I-IUPAC
met		I-IUPAC
hylenedioxy		I-IUPAC
-		I-IUPAC
5H		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
benzodiazepine		I-IUPAC
(		O
2		O
,		O
GYKI		O
53655		O
)		O
to		O
reduce		O
the		O
KA		O
-		O
evoked		O
currents		O
.		O
Substitution		O
of		O
1		O
at		O
the		O
6		O
-		O
position		O
resulted		O
in		O
compounds		O
having		O
selective		O
non		O
-		O
NMDA		O
antagonism		O
and		O
8		O
-		O
substituted		O
compounds		O
were		O
inactive		O
at		O
all		O
receptors		O
.		O
Compound		O
20		O
exhibited		O
the		O
most		O
significant		O
broad		O
-		O
spectrum		O
in		O
vitro		O
antiviral		O
and		O
antitumor		O
activity		O
.		O
A		O
series		O
of		O
7		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
2,3		B-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
-		O
1		B-IUPAC
-		I-IUPAC
azetidinyl		I-IUPAC
)		B-PARTIUPAC
-		I-PARTIUPAC
1,4		I-PARTIUPAC
-		I-PARTIUPAC
dihydro		I-PARTIUPAC
-		I-PARTIUPAC
6		I-PARTIUPAC
-		I-PARTIUPAC
fluoro		I-PARTIUPAC
-		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
oxoquinoline		I-PARTIUPAC
-		I-PARTIUPAC
and		O
-		B-PARTIUPAC
1,8		I-PARTIUPAC
-		I-PARTIUPAC
naphthyridine		I-PARTIUPAC
-		I-PARTIUPAC
3		I-PARTIUPAC
-		I-PARTIUPAC
carboxylic		I-PARTIUPAC
acids		I-PARTIUPAC
,		O
with		O
varied		O
substituents		O
at		O
the		O
1		O
-		O
,		O
5		O
-		O
,		O
and		O
8		O
-		O
positions		O
,		O
was		O
prepared		O
to		O
study		O
the		O
effects		O
on		O
potency		O
and		O
physicochemical		O
properties		O
of		O
the		O
substituent		O
at		O
position		O
2		O
of		O
the		O
azetidine		O
moiety		O
.		O
Furthermore		O
,		O
the		O
greater		O
activity		O
of		O
12		O
,		O
relative		O
to		O
8		O
,		O
is		O
consistent		O
with		O
an		O
active		O
site		O
binding		O
preference		O
for		O
molecules		O
in		O
which		O
a		O
more		O
coplanar		O
relationship		O
exists		O
between		O
the		O
aromatic		O
ring		O
and		O
the		O
amine		O
nitrogen		O
.		O
N		O
-		O
Methylation		O
of		O
8		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylquinazolinone		I-IUPAC
(		O
15		O
)		O
with		O
MeI		O
,		O
followed		O
by		O
O		O
-		O
demethylation		O
by		O
BBr3		O
,		O
afforded		O
the		O
control		O
N3		B-IUPAC
-		I-IUPAC
methylquinazolinones		I-IUPAC
42		O
and		O
43		O
,		O
respectively		O
.		O
The		O
highly		O
active		O
compound		O
9h		O
and		O
the		O
2,4		B-IUPAC
-		I-IUPAC
dimethoxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxybenzylidene		I-IUPAC
analogue		B-MODIFIER
9l		O
were		O
tested		O
against		O
five		O
tumor		O
cell		O
lines		O
using		O
the		O
XTT		O
assay		O
,		O
including		O
multidrug		O
resistant		O
phenotypes		O
.		O
In		O
biodistribution		O
studies		O
using		O
[		O
131I		O
]		O
-		O
MIH		O
-		O
OST7		O
and		O
[		O
131I		O
]		O
ATE		O
-		O
OST7		O
,		O
while		O
both		O
131I		O
-		O
labeled		O
OST7s		O
registered		O
almost		O
identical		O
radioactivity		O
levels		O
in		O
the		O
blood		O
up		O
to		O
6		O
h		O
postinjection		O
,		O
the		O
former		O
demonstrated		O
a		O
lower		O
radioactivity		O
level		O
than		O
[		O
131I		O
]		O
ATE		O
-		O
OST7		O
in		O
nontarget		O
tissues		O
throughout		O
the		O
experiment		O
.		O
These		O
high		O
-		O
potency		O
antagonists		O
are		O
&		O
gt		O
;		O
1000		O
times		O
more		O
potent		O
at		O
the		O
NR1A		O
/		O
2B		O
subtype		O
than		O
at		O
either		O
the		O
NR1A		O
/		O
2A		O
or		O
NR1A		O
/		O
2C		O
subtypes		O
.		O
Their		O
pharmacological		O
activity		O
was		O
evaluated		O
in		O
a		O
water		O
lick		O
conflict		O
test		O
in		O
rats		O
and		O
a		O
passive		O
avoidance		O
test		O
in		O
mice		O
.		O
We		O
have		O
designed		O
and		O
synthesized		O
16		O
new		O
olean		B-PARTIUPAC
-		I-PARTIUPAC
and		O
urs		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
one		I-IUPAC
triterpenoids		I-IUPAC
with		O
various		O
modified		O
rings		O
C		O
as		O
potential		O
antiinflammatory		O
and		O
cancer		O
chemopreventive		O
agents		O
and		O
evaluated		O
their		O
inhibitory		O
activities		O
against		O
production		O
of		O
nitric		O
oxide		O
induced		O
by		O
interferon		O
-		O
gamma		O
in		O
mouse		O
macrophages		O
.		O
Those		O
molecules		O
that		O
showed		O
an		O
excellent		O
in		O
vitro		O
activity		O
as		O
well		O
as		O
high		O
selectivity		O
for		O
the		O
parasite		O
[		O
e.g.		O
1c		O
(		O
IC		O
(		O
50		O
)		O
=		O
49		O
nM		O
;		O
SI		O
&		O
gt		O
;		O
5294		O
)		O
,		O
28b		O
(		O
IC		O
(		O
50		O
)		O
=		O
69		O
nM		O
;		O
SI		O
=		O
3072		O
)		O
,		O
32b		O
(		O
IC		O
(		O
50		O
)		O
=		O
22		O
nM		O
;		O
SI		O
=		O
29.5		O
)		O
,		O
41b		O
(		O
IC		O
(		O
50		O
)		O
=		O
118		O
nM		O
;		O
SI		O
=		O
881		O
)		O
]		O
represent		O
new		O
antitrypanosomal		O
lead		O
compounds		O
.		O
The		O
lipophilic		O
side		O
chain		O
of		O
the		O
naphthyl		B-IUPAC
series		B-MODIFIER
was		O
found		O
to		O
tolerate		O
minor		O
variations		O
,		O
ranging		O
from		O
a		O
phenylmethoxy		B-IUPAC
group		B-MODIFIER
to		O
phenyl		B-IUPAC
and		O
alkyloxy		B-IUPAC
groups		B-MODIFIER
.		O
Their		O
anti		O
-		O
V1		O
pA2		O
values		O
range		O
from		O
7.92		O
to		O
8.45		O
.		O
Acetylation		O
of		O
5beta		B-IUPAC
,		I-IUPAC
6alpha		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
19		I-IUPAC
-		I-IUPAC
acetate		I-IUPAC
30		O
and		O
its		O
5alpha		B-IUPAC
,		I-IUPAC
6beta		I-IUPAC
-		I-IUPAC
analogue		I-IUPAC
31		O
followed		O
by		O
dehydration		O
with		O
SOCl		O
(		O
2		O
)		O
and		O
alkaline		O
hydroxysis		O
gave		O
6alpha		O
,		O
19		O
-		O
diol		O
36		O
and		O
its		O
6beta		O
-		O
isomer		O
37		O
,		O
respectively		O
.		O
In		O
contrast		O
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
alkylamino		I-PARTIUPAC
-		I-PARTIUPAC
7		I-PARTIUPAC
-		I-PARTIUPAC
trifluoromethyl		I-PARTIUPAC
-		I-PARTIUPAC
(		O
20a		O
-		O
c		O
)		O
and		O
3		B-IUPAC
-		I-IUPAC
alkylamino		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
pentyl		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
benzothiadiazine		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxides		I-IUPAC
(		O
11a		O
,		O
b		O
)		O
expressed		O
a		O
marked		O
myorelaxant		O
activity		O
on		O
rat		O
aorta		O
ring		O
.		O
The		O
excitatory		O
activity		O
in		O
rat		O
cortical		O
wedge		O
also		O
showed		O
that		O
ACPA		O
was		O
more		O
potent		O
than		O
AMPA		O
(		O
EC50		O
=		O
1.0		O
microM		O
compared		O
to		O
EC50		O
=		O
3.5		O
microM		O
for		O
AMPA		O
)		O
.		O
Certain		O
intermediates		O
,		O
e.g.		O
the		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
iodoalkyl		I-IUPAC
)		I-IUPAC
compounds		B-MODIFIER
,		O
were		O
converted		O
to		O
a		O
variety		O
of		O
(		O
3		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
alkyl		B-IUPAC
)		O
-		O
EMAUs		O
by		O
displacement		O
.		O
Each		O
of		O
the		O
respective		O
Wittig		O
products		O
8a		O
and		O
8b		O
was		O
obtained		O
in		O
75-80%		O
yield		O
.		O
The		O
reaction		O
of		O
2,4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
-		I-IUPAC
dinitroimidazole		I-IUPAC
(		O
1		O
)		O
with		O
a		O
variety		O
of		O
oxiranes		O
upon		O
heating		O
in		O
absolute		O
ethanol		O
yielded		O
the		O
expected		O
1		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
2,4		B-IUPAC
-		I-IUPAC
dinitroimidazoles		I-IUPAC
(		O
2		O
)		O
and		O
also		O
resulted		O
in		O
the		O
formation		O
of		O
a		O
novel		O
class		O
of		O
isomeric		B-MODIFIER
nitroimidazo		B-IUPAC
[		I-IUPAC
2,1		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
oxazoles		I-IUPAC
3		O
and		O
4		O
)		O
by		O
intramolecular		O
cyclization		O
.		O
From		O
this		O
series		O
,		O
compound		O
45		O
was		O
selected		O
for		O
further		O
evaluation		O
where		O
it		O
was		O
also		O
found		O
to		O
be		O
active		O
against		O
3		B-IUPAC
-		I-IUPAC
mercaptopropionic		I-IUPAC
acid		I-IUPAC
,		O
bicuculline		O
,		O
and		O
quinolinic		O
acid		O
induced		O
seizures		O
in		O
mice		O
.		O
The		O
corresponding		O
bridged		O
analogues		O
of		O
5		B-IUPAC
-		I-IUPAC
deazapteroyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
ornithine		I-IUPAC
and		O
(		B-IUPAC
6R		I-IUPAC
,		I-IUPAC
6S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
deaza		I-IUPAC
-		I-IUPAC
5,6,7		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
tetrahydropteroyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
ornithine		I-IUPAC
were		O
also		O
synthesized		O
as		O
potential		O
inhibitors		O
.		O
Five		O
1		B-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
arabinofuranosylcytosine		I-IUPAC
conjugates		B-MODIFIER
and		O
two		O
cytidine		O
conjugates		O
of		O
thioether		O
lipids		O
(		O
1		B-IUPAC
-		I-IUPAC
S		I-IUPAC
-		I-IUPAC
alkylthioglycerols		I-IUPAC
)		O
linked		O
by		O
a		O
pyrophosphate		O
diester		O
bond		O
have		O
been		O
prepared		O
and		O
their		O
antitumor		O
activity		O
against		O
an		O
ara		O
-		O
C2		O
sensitive		O
(		O
L1210/0		O
)		O
and		O
two		O
ara		O
-		O
C		O
resistant		O
L1210		O
lymphoid		O
leukemia		O
sublines		O
in		O
mice		O
were		O
evaluated		O
.		O
Adenosine		O
monophosphate		O
analogues		O
were		O
full		O
agonists		O
,		O
although		O
generally		O
4		O
orders		O
of		O
magnitude		O
less		O
potent		O
.		O
The		O
DA		O
autoreceptor		O
selectivity		O
of		O
these		O
heterocyclic		O
analogues		O
of		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
piperidinyl		I-IUPAC
)		I-IUPAC
phenol		I-IUPAC
(		O
3		O
-		O
PPP		O
)		O
was		O
also		O
evaluated		O
.		O
Syntheses		O
of		O
the		O
enantiomers		O
of		O
myo		B-IUPAC
-		I-IUPAC
inositol		I-IUPAC
1,3,4		I-IUPAC
-		I-IUPAC
trisphosphate		I-IUPAC
are		O
described		O
.		O
Collectively		O
,		O
these		O
data		O
suggest		O
that		O
1c		O
acts		O
as		O
a		O
membrane		O
-		O
permeable		O
prodrug		O
of		O
FdUMP		O
.		O
We		O
now		O
report		O
the		O
synthesis		O
of		O
2		O
-		O
Py		O
-		O
AMPA		O
(		O
7a		O
)		O
and		O
the		O
isomeric		O
compounds		O
3		O
-		O
Py		O
-		O
AMPA		O
(		O
7b		O
)		O
and		O
4		O
-		O
Py		O
-		O
AMPA		O
(		O
7c		O
)		O
as		O
well		O
as		O
the		O
7a		O
analogues		O
,		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
isoxazolyl		I-IUPAC
]		I-IUPAC
p		I-IUPAC
ropion		I-IUPAC
ic		I-IUPAC
acid		I-IUPAC
(		O
7d		O
)		O
and		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
quinolinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
isoxazolyl		I-IUPAC
]		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
7e		O
)		O
.		O
N		O
-		O
Methylation		O
,		O
followed		O
by		O
treatment		O
with		O
aliphatic		O
diamines		O
,		O
aromatic		O
amines		O
,		O
or		O
their		O
derived		O
lithium		O
anions		O
,		O
gave		O
the		O
desired		O
compounds		O
.		O
IV		O
,		O
[		O
des		O
-		O
Asp1		O
]		O
angiotensin		O
II		O
(		O
III		O
)		O
,		O
[		O
des		O
-		O
(		O
Asp1		O
,		O
Arg2		O
)		O
]		O
angiotensin		O
II		O
(		O
V		O
)		O
,		O
[		O
des		O
-		O
(		O
Asp1		O
,		O
Arg2		O
,		O
Val3		O
)		O
]		O
angiotensin		O
II		O
(		O
VI		O
)		O
,		O
[		O
Sar1		O
,		O
Ile8		O
]		O
angiotensin		O
II		O
(		O
VII		O
)		O
,		O
and		O
[		O
des		O
-		O
Asp1		O
,		O
Ile8		O
]		O
angiotensin		O
II		O
(		O
VIII		O
)		O
possessed		O
0.5		O
,		O
20		O
,		O
2		O
,		O
0		O
less		O
than		O
0.1		O
,		O
and		O
less		O
than		O
0.01%		O
of		O
the		O
inotropic		O
activity		O
(		O
rabbit		O
atria		O
)		O
,		O
1		O
,		O
15		O
,		O
5		O
,		O
0		O
,		O
3		O
,		O
and		O
0%		O
secretory		O
activity		O
of		O
the		O
cat		O
adrenal		O
medulla		O
,		O
and		O
0.0		O
,		O
150		O
,		O
0.5		O
,		O
3		O
,		O
and		O
10%		O
of		O
the		O
adrenal		O
steroidogenic		O
activity		O
of		O
angiotensin		O
II		O
,		O
respectively		O
.		O
In		O
contrast		O
,		O
variation		O
of		O
the		O
heterocycle		O
moiety		O
revealed		O
a		O
much		O
less		O
stringent		O
SAR		O
and		O
many		O
5		O
-		O
and		O
6		O
-		O
membered		O
heterocycles		O
were		O
found		O
to		O
effectively		O
substitute		O
for		O
the		O
oxazole		O
ring		O
of		O
2		O
and		O
3		O
.		O
A		O
series		O
of		O
N		O
-		O
substituted		O
imidazolines		O
and		O
ethylenediamines		O
were		O
synthesized		O
and		O
examined		O
for		O
their		O
activity		O
in		O
alpha		O
-		O
and		O
beta		O
-		O
adrenergic		O
systems		O
.		O
Optimization		O
of		O
6		O
resulted		O
in		O
the		O
preparation		O
of		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
thien		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
)		I-IUPAC
pro		I-IUPAC
p		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
enol		I-IUPAC
33		O
with		O
an		O
IC50		O
of		O
300		O
nM		O
on		O
the		O
ETA		O
receptor		O
.		O
Results		O
presented		O
in		O
this		O
paper		O
confirm		O
the		O
first		O
assignment		O
and		O
establish		O
that		O
,		O
although		O
the		O
proposed		O
6		O
-		O
cyano		O
adduct		O
is		O
initially		O
formed		O
,		O
the		O
product		O
that		O
was		O
isolated		O
from		O
the		O
mitochondrial		O
incubation		O
mixtures		O
of		O
MPTP		O
and		O
sodium		O
cyanide		O
actually		O
is		O
the		O
isomeric		O
2		B-IUPAC
-		I-IUPAC
cyano		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1,2,3,6		I-IUPAC
-		I-IUPAC
tetrahydropyridine		I-IUPAC
.		O
Reinforcement		O
of		O
the		O
characteristics		O
of		O
amphiphilicity		O
,		O
helicity		O
,		O
and		O
peptide		O
dipolar		O
effects		O
,		O
using		O
recognized		O
medicinal		O
chemistry		O
approaches		O
including		O
introduction		O
of		O
conformational		O
constraints		O
,		O
has		O
resulted		O
in		O
several		O
potent		O
GHRH		O
analogues		O
.		O
However		O
,		O
4		O
-		O
AHCP		O
was		O
found		O
to		O
be		O
much		O
weaker		O
than		O
AMPA		O
as		O
an		O
inhibitor		O
of		O
[		O
(		O
3		O
)		O
H		O
]		O
AMPA		O
binding		O
and		O
to		O
have		O
limited		O
effect		O
in		O
a		O
[		O
(		O
3		O
)		O
H		O
]		O
kainic		O
acid		O
binding		O
assay		O
using		O
rat		O
cortical		O
membranes		O
.		O
The		O
deamination		O
of		O
14		O
effectively		O
stopped		O
at		O
50%		O
conversion		O
.		O
Many		O
of		O
these		O
2		B-IUPAC
-		I-IUPAC
pyridinecarboxylic		I-IUPAC
acid		I-IUPAC
derivatives		B-MODIFIER
were		O
potent		O
antihypertensive		O
agents		O
in		O
the		O
spontaneously		O
hypertensive		O
rat		O
(		O
SHR		O
)		O
.		O
Aromatic		O
carboxylic		O
esters		O
of		O
1		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
piperidinol		I-IUPAC
were		O
prepared		O
and		O
evaluated		O
for		O
analgesic		O
activity		O
.		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
Bis		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2,11		I-IUPAC
-		I-IUPAC
dihyroxy		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
methoxynoraporphine		I-IUPAC
(		O
1b		O
)		O
and		O
its		O
mono		O
-		O
and		O
diacetyl		O
ester		O
derivatives		O
(		O
1c		O
-		O
d		O
)		O
were		O
prepared		O
from		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
chloroacetyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,11		I-IUPAC
-		I-IUPAC
diacetoxy		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
methoxynoraporphine		I-IUPAC
(		O
2		O
)		O
.		O
Free		O
energy		O
of		O
binding		O
,		O
derived		O
from		O
radioligand		O
displacement		O
KA		O
values		O
,		O
indicated		O
that		O
addition		O
of		O
the		O
bromine		O
in		O
either		O
series		O
contributes		O
2.4-3.2		O
kcal		O
/		O
mol		O
of		O
binding		O
energy		O
.		O
The		O
compounds		O
were		O
tested		O
for		O
their		O
ability		O
to		O
displace		O
bound		O
[		O
(		O
3		O
)		O
H		O
]		O
WIN		O
35,428		O
(		O
5		O
)		O
from		O
rat		O
caudate		O
putamen		O
tissue		O
and		O
for		O
their		O
ability		O
to		O
inhibit		O
[		O
(		O
3		O
)		O
H		O
]		O
dopamine		O
uptake		O
.		O
IR		O
,		O
1H		O
NMR		O
and		O
13C		O
NMR		O
data		O
have		O
been		O
recorded		O
for		O
each		O
compound		O
and		O
support		O
the		O
structural		O
assignments		O
.		O
A		O
number		O
of		O
1		B-IUPAC
-		I-IUPAC
hydroxyazole		I-IUPAC
derivatives		B-MODIFIER
were		O
synthesized		O
as		O
bioisosteres		O
of		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
(		O
Glu		O
)		O
and		O
as		O
analogues		O
of		O
the		O
AMPA		O
receptor		O
agonist		O
(		B-IUPAC
R		I-IUPAC
,		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
isoxazolyl		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
AMPA		O
,		O
3b		O
)		O
.		O
The		O
protected		O
intermediate		O
above		O
was		O
synthesized		O
from		O
Z		O
-		O
Cys		O
(		O
Bzl		O
)		O
-		O
Pro		O
-		O
Leu		O
-		O
Gly		O
-		O
NH2		O
by		O
the		O
stepwose		O
p		O
-		O
nitrophenyl		O
ester		O
method		O
using		O
Nalpha		O
-		O
Boc		O
protection		O
at		O
the		O
penta		O
-		O
,		O
hexa		O
-		O
,		O
and		O
octapeptide		O
stages		O
.		O
The		O
1H		O
NMR		O
spectra		O
of		O
the		O
Z		O
-		O
analogues		O
14		O
and		O
15		O
are		O
consistent		O
with		O
an		O
anti		O
-		O
like		O
conformation		O
of		O
the		O
nucleobases		O
.		O
N		B-IUPAC
-		I-IUPAC
Methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
phenethylphenylacetamide		I-IUPAC
has		O
been		O
reported		O
to		O
be		O
a		O
key		O
binding		O
domain		O
to		O
LTB4		O
receptors		O
.		O
Fluoride		O
was		O
also		O
found		O
after		O
injection		O
of		O
[		O
18F		O
]		O
4d		O
.		O
5		O
-		O
Alkyl		O
-		O
and		O
5		B-IUPAC
-		I-IUPAC
arylalkyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylenedihydrofuran		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
13a		O
-		O
e		O
,		O
3		B-IUPAC
-		I-IUPAC
alkylidenedihydrofuran		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
18a		O
-		O
c		O
,		O
and		O
3		B-IUPAC
-		I-IUPAC
methylenepyrrolidin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
16a		O
-		O
e		O
were		O
synthesized		O
utilizing		O
ethyl		B-IUPAC
2		I-IUPAC
-		I-IUPAC
diethoxyphosphoryl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
nitroalkanoates		I-IUPAC
9a		O
-		O
e		O
as		O
common		O
intermediates		O
.		O
These		O
new		O
nucleosides		O
were		O
screened		O
for		O
their		O
activity		O
against		O
HIV		O
and		O
feline		O
TLV		O
in		O
vitro		O
.		O
1		B-IUPAC
-		I-IUPAC
Alkyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
thymine		I-IUPAC
(		O
59-61		O
)		O
derivatives		B-MODIFIER
were		O
prepared		O
on		O
the		O
basis		O
of		O
alkylation		O
of		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
thymine		I-IUPAC
(		O
58		O
)		O
.		O
In		O
this		O
case		O
,		O
cleavage		O
of		O
the		O
P		O
-		O
N		O
bond		O
of		O
the		O
type		O
2		O
phosphoramidic		O
acid		O
monoesters		O
leads		O
directly		O
to		O
the		O
type		O
4		O
phosphoric		O
acid		O
monoesters		O
.		O
Further		O
,		O
selected		O
analogues		O
were		O
potent		O
inhibitors		O
of		O
the		O
growth		O
of		O
tumor		O
cells		O
in		O
culture		O
in		O
the		O
in		O
vitro		O
screening		O
program		O
of		O
the		O
National		O
Cancer		O
Institute		O
with		O
GI50s		O
in		O
the		O
nanomolar		O
and		O
subnanomolar		O
range		O
.		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
Naphthyl		I-IUPAC
)		I-IUPAC
alanine		I-IUPAC
hydrazide		I-IUPAC
(		O
3		O
)		O
,		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
)		I-IUPAC
glycine		I-IUPAC
hydrazide		I-IUPAC
(		O
5		O
)		O
,		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthyl		I-IUPAC
)		I-IUPAC
glycine		I-IUPAC
hydrazide		I-IUPAC
(		O
7		O
)		O
,		O
and		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthylamino		I-IUPAC
)		I-IUPAC
butyric		I-IUPAC
acid		I-IUPAC
hydrazide		I-IUPAC
(		O
23		O
)		O
showed		O
potent		O
inhibitory		O
action		O
against		O
Mycobacterium		O
tuberculosis		O
H37Rv		O
in		O
Youman		O
's		O
medium		O
at		O
concentrations		O
ranging		O
from		O
0.5		O
to		O
10.0		O
micrograms		O
/		O
mL		O
.		O
All		O
obtained		O
compounds		O
were		O
tested		O
against		O
L		O
-		O
1210		O
,		O
HL		O
-		O
60		O
,		O
and		O
NALM		O
-		O
6		O
leukemia		O
cells		O
.		O
Treatment		O
of		O
4,5,6		B-IUPAC
-		I-IUPAC
triamino		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
1,2,6		I-IUPAC
-		I-IUPAC
thiadiazine		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxide		I-IUPAC
with		O
N		B-IUPAC
-		I-IUPAC
thionylaniline		I-IUPAC
gave		O
a		O
derivative		O
of		O
another		O
new		O
ring		O
system		O
,		O
7		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1,2,5		I-IUPAC
]		I-IUPAC
thiadiazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
[		I-IUPAC
1,2,6		I-IUPAC
]		I-IUPAC
thiadiazine		I-IUPAC
5,5		I-IUPAC
-		I-IUPAC
dioxide		I-IUPAC
.		O
Using		O
the		O
patch		O
-		O
clamp		O
technique		O
,		O
the		O
capability		O
of		O
derivatives		O
16		O
and		O
21		O
to		O
antagonize		O
KA		O
-		O
evoked		O
currents		O
in		O
primary		O
cultures		O
of		O
granule		O
neurons		O
was		O
tested		O
.		O
(		O
ABSTRACT		O
TRUNCATED		O
AT		O
400		O
WORDS		O
)		O
A		O
series		O
of		O
6		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
decahydroisoquinoline		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acids		I-IUPAC
were		O
prepared		O
as		O
excitatory		O
amino		O
acid		O
(		O
EAA		O
)		O
receptor		O
antagonists		O
.		O
Preliminary		O
evidence		O
suggests		O
that		O
2b		O
is		O
a		O
storage		O
analogue		O
of		O
norepinephrine		O
.		O
The		O
results		O
allow		O
the		O
establishment		O
of		O
a		O
three		O
-		O
dimensional		O
pharmacophore		O
of		O
the		O
glycine		O
receptor		O
antagonist		O
site		O
,		O
incorporating		O
a		O
newly		O
defined		O
bulk		O
tolerance		O
/		O
hydrophobic		O
region		O
.		O
The		O
binding		O
affinity		O
for		O
3		O
was		O
2		O
-		O
fold		O
greater		O
than		O
those		O
observed		O
for		O
cocaine		O
(		O
1		O
)		O
and		O
2		O
,		O
while		O
the		O
binding		O
affinity		O
for		O
4		O
was		O
found		O
to		O
be		O
100		O
-		O
fold		O
less		O
than		O
those		O
of		O
1		O
and		O
2		O
.		O
However		O
,		O
as		O
with		O
these		O
standard		O
agents		O
,		O
10		O
showed		O
no		O
appreciable		O
selectivity		O
for		O
either		O
the		O
P		O
.		O
The		O
absolute		O
bioavailability		O
of		O
5q		O
has		O
been		O
found		O
to		O
be		O
28%		O
in		O
the		O
rat		O
,		O
as		O
compared		O
to		O
68%		O
for		O
ICI		O
204,219		O
,		O
with		O
significant		O
levels		O
of		O
5q		O
observed		O
in		O
the		O
blood		O
of		O
rats		O
up		O
to		O
24		O
h		O
postdose		O
.		O
Thus		O
,		O
the		O
3		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluorophenyl		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
{		I-IUPAC
[		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methylamino		I-IUPAC
-		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
}		I-IUPAC
-		I-IUPAC
piperidin		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
-		I-IUPAC
methanone		I-IUPAC
40		O
behaved		O
as		O
a		O
more		O
potent		O
5		O
-		O
HT1A		O
receptor		O
agonist		O
in		O
vitro		O
and		O
in		O
vivo		O
than		O
its		O
5		O
-		O
unsubstituted		O
analogue		O
38		O
.		O
The		O
RAR		O
gamma		O
selective		O
ligands		O
induce		O
differentiation		O
in		O
F9		O
cells		O
(		O
7		O
,		O
AC50		O
=		O
33		O
nM		O
;		O
19		O
,		O
AC50		O
=		O
66		O
nM		O
)		O
.		O
d		O
.		O
B		O
.		O
In		O
accordance		O
with		O
this		O
disparity		O
,		O
compound		O
8a		O
was		O
found		O
to		O
inhibit		O
synaptosomal		O
[		O
3H		O
]		O
D		O
-		O
aspartic		O
acid		O
uptake		O
(		O
IC		O
(		O
50		O
)		O
=		O
93		O
+		O
/		O
-		O
25		O
microM		O
)		O
,		O
as		O
well		O
as		O
excitatory		O
amino		O
acid		O
transporters		O
(		O
EAATs		O
)		O
EAAT1		O
(		O
IC		O
(		O
50		O
)		O
=		O
100		O
+		O
/		O
-		O
30		O
microM		O
)		O
and		O
EAAT2		O
(		O
IC		O
(		O
50		O
)		O
=		O
300		O
+		O
/		O
-		O
80		O
microM		O
)		O
.		O
The		O
relative		O
amounts		O
of		O
these		O
materials		O
excreted		O
during		O
the		O
24		O
-		O
h		O
period		O
following		O
administration		O
of		O
tolazamide		O
were		O
10		O
,		O
5		O
,		O
5		O
,		O
and		O
80%		O
for		O
1-4		O
,		O
respectively		O
.		O
Evaluation		O
of		O
the		O
compounds		O
was		O
carried		O
out		O
in		O
vitro		O
on		O
human		O
blood		O
platelets		O
.		O
Water		O
gave		O
2,6		B-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
p		I-IUPAC
-		I-IUPAC
benzoquinone		I-IUPAC
.		O
This		O
study		O
shows		O
that		O
the		O
pyrrolo		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
scaffold		B-MODIFIER
is		O
conducive		O
to		O
dual		O
DHFR		O
-		O
TS		O
and		O
tumor		O
inhibitory		O
activity		O
,		O
and		O
the		O
potency		O
is		O
determined		O
by		O
the		O
4		O
-		O
position		O
substituent		O
.		O
Treatment		O
of		O
9		O
with		O
triethyloxonium		O
fluoborate		O
followed		O
by		O
dehydrogenation		O
of		O
the		O
product		O
gave		O
6		B-IUPAC
-		I-IUPAC
carbethoxy		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
methylisoquinoline		I-IUPAC
(		O
14		O
)		O
.		O
Overall		O
the		O
R		O
-		O
enantiomer		O
was		O
usually		O
the		O
more		O
potent		O
enantiomer		O
at		O
both		O
PNMT		O
and		O
the		O
alpha		O
(		O
2		O
)		O
-		O
adrenoceptor		O
for		O
these		O
3		B-PARTIUPAC
-		I-PARTIUPAC
fluoromethyl		I-PARTIUPAC
-		I-PARTIUPAC
,		O
3		B-PARTIUPAC
-		I-PARTIUPAC
hydroxymethyl		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
chloromethyl		I-IUPAC
-		I-IUPAC
THIQs		I-IUPAC
.		O
The		O
(		B-IUPAC
4		I-IUPAC
-		I-IUPAC
aminoalkyl		I-IUPAC
)		I-IUPAC
estrogens		I-IUPAC
were		O
prepared		O
from		O
the		O
hydroxyalkyl		O
derivatives		O
with		O
phthalimide		O
under		O
Mitsunobu		O
conditions		O
.		O
Structure		O
-		O
activity		O
relationship		O
studies		O
showed		O
that		O
two		O
structural		O
factors		O
are		O
crucial		O
for		O
NO		O
formation		O
from		O
compounds		O
containing		O
a		O
C		O
(		O
triple		O
bond		O
)		O
NOH		O
function		O
.		O
These		O
analogues		O
displayed		O
potent		O
T		O
.		O
There		O
is		O
also		O
a		O
correlation		O
between		O
the		O
substitution		O
on		O
the		O
7		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
4		I-PARTIUPAC
-		I-PARTIUPAC
pyridinyl		I-PARTIUPAC
)		I-PARTIUPAC
group		B-MODIFIER
and		O
the		O
Gram		O
positive		O
activity		O
,		O
particularly		O
for		O
S		O
.		O
1c		O
might		O
also		O
penetrate		O
cells		O
directly		O
and		O
undergo		O
the		O
same		O
degradation		O
sequence		O
after		O
hydrolysis		O
by		O
cellular		O
esterases		O
.		O
Analogues		O
with		O
ring		O
sizes		O
of		O
18		O
\C2		O
\BF		O
cyclo		O
(		O
1		O
,		O
1'		O
-		O
3		O
)		O
[		O
Ac		O
-		O
DGlu		O
(		O
1		O
)		O
(		O
Gly		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DLys		O
(		O
3		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
DA		O
la		O
(		O
10		O
)		O
]		O
GnRH		O
(		O
24		O
)		O
\C2		O
\BF		O
and		O
19		O
\C2		O
\BF		O
cyclo		O
(		O
1,1		O
'		O
-		O
3		O
)		O
[		O
Ac		O
-		O
DGlu		O
(		O
1		O
)		O
(		O
betaAla		O
)		O
,		O
DCpa		O
(		O
2		O
)		O
,		O
DLys		O
(		O
3		O
)		O
,		O
DNal		O
(		O
6		O
)		O
,		O
DAla		O
(		O
10		O
)		O
]		O
GnRH		O
(		O
25		O
)		O
\C2		O
\BF		O
atoms		O
were		O
also		O
less		O
potent		O
than		O
21		O
with		O
slightly		O
higher		O
K		O
(		O
i		O
)		O
values		O
(		O
1.5		O
and		O
2.2		O
nM		O
,		O
respectively		O
)		O
.		O
All		O
target		O
compounds		O
were		O
evaluated		O
for		O
antiarrhythmic		O
efficacy		O
against		O
chloroform		O
-		O
induced		O
ventricular		O
tachycardia		O
,		O
as		O
well		O
as		O
for		O
acute		O
CNS		O
toxicity		O
in		O
mice		O
.		O
carinii		O
and		O
M		O
.		O
H		O
-		O
Dmt		O
-		O
Tic		O
-		O
NH		O
-		O
CH		O
(		O
2		O
)		O
-		O
1H		O
-		O
benzimidazole		O
-		O
2		O
-		O
yl		O
(		O
Bid		O
)		O
(		O
2		O
)		O
became		O
a		O
highly		O
potent		O
delta		O
-		O
agonist		O
(		O
pEC		O
(		O
50		O
)		O
,		O
9.90		O
)		O
,		O
slightly		O
greater		O
than		O
deltorphin		O
C		O
(		O
pEC		O
(		O
50		O
)		O
,		O
9.56		O
)		O
,		O
with		O
mu		O
-		O
agonism		O
(		O
pE		O
(		O
50		O
)		O
,		O
7.57		O
)		O
,		O
while		O
H		O
-		O
Dmt		O
-		O
Tic		O
-		O
Gly		O
-		O
NH		O
-		O
CH		O
(		O
2		O
)		O
-		O
Bid		O
(		O
4		O
)		O
retained		O
potent		O
delta		O
-		O
antagonism		O
(		O
pA		O
(		O
2		O
)		O
,		O
9.0		O
)		O
but		O
with		O
an		O
order		O
of		O
magnitude		O
less		O
mu		O
-		O
agonism		O
.		O
The		O
complete		O
abolishment		O
or		O
the		O
significant		O
reduction		O
in		O
PKC		O
-		O
ligand		O
binding		O
observed		O
for		O
these		O
mutants		O
thus		O
reflects		O
the		O
loss		O
of		O
certain		O
direct		O
contacts		O
between		O
the		O
side		O
chain		O
of		O
the		O
mutated		O
residue		O
in		O
PKC		O
and		O
ligands		O
as		O
well		O
as		O
the		O
large		O
conformational		O
alteration		O
to		O
the		O
binding		O
site		O
caused		O
by		O
the		O
mutation		O
.		O
If		O
the		O
antiproliferative		O
effect		O
of		O
these		O
amantidine		O
analogues		O
proves		O
to		O
be		O
an		O
effect		O
of		O
binding		O
and		O
activating		O
CD81		O
,		O
then		O
these		O
compounds		O
may		O
have		O
the		O
potential		O
to		O
prevent		O
or		O
treat		O
HCV		O
infections		O
.		O
034		O
nM		O
and		O
with		O
a		O
2000		O
-		O
fold		O
selectivity		O
for		O
the		O
ETA		O
receptor		O
versus		O
the		O
ETB		O
receptor		O
.		O
Study		O
of		O
P2		O
-		O
purinoceptor		O
subtypes		O
has		O
been		O
difficult		O
due		O
to		O
the		O
lack		O
of		O
potent		O
and		O
selective		O
ligands		O
.		O
Any		O
substitution		O
on		O
the		O
piperazine		O
ring		O
of		O
type		O
7		O
compounds		O
led		O
to		O
a		O
decline		O
in		O
activity		O
,		O
the		O
most		O
active		O
analog		B-MODIFIER
being		O
N		B-IUPAC
,		I-IUPAC
N'		I-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
decylnipecotoyl		I-IUPAC
)		I-IUPAC
piperazine		I-IUPAC
(		O
7a		O
)		O
.		O
Modifications		O
of		O
the		O
4		O
-		O
amide		O
show		O
that		O
bulky		O
substituents		O
are		O
tolerated		O
and		O
reveal		O
the		O
critical		O
importance		O
for		O
activity		O
of		O
correct		O
positioning		O
of		O
the		O
carbonyl		O
group		O
.		O
Stannic		O
chloride		O
catalyzed		O
condensation		O
of		O
the		O
pertrimethylsilyl		O
derivatives		O
of		O
4b		O
and		O
4c		O
with		O
a		O
protected		O
glycosyl		O
halide		O
afforded		O
anomeric		O
mixtures		O
of		O
ketonucleosides		O
3		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
deoxy		I-PARTIUPAC
-		I-PARTIUPAC
3,5		I-PARTIUPAC
-		I-PARTIUPAC
di		I-PARTIUPAC
-		I-PARTIUPAC
O		I-PARTIUPAC
-		I-PARTIUPAC
p		I-PARTIUPAC
-		I-PARTIUPAC
toluoyl		I-PARTIUPAC
-		I-PARTIUPAC
beta		I-PARTIUPAC
-		I-PARTIUPAC
and		O
-		B-PARTIUPAC
alpha		I-PARTIUPAC
-		I-PARTIUPAC
D		I-PARTIUPAC
-		I-PARTIUPAC
erythro		I-PARTIUPAC
-		I-PARTIUPAC
pentofuranosyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
6,7		I-PARTIUPAC
-		I-PARTIUPAC
dihydro		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
methylimidazo		I-PARTIUPAC
[		I-PARTIUPAC
4,5		I-PARTIUPAC
-		I-PARTIUPAC
d		I-PARTIUPAC
]		I-PARTIUPAC
[		I-PARTIUPAC
1,3		I-PARTIUPAC
]		I-PARTIUPAC
diazepin		I-PARTIUPAC
-		I-PARTIUPAC
8		I-PARTIUPAC
(		I-PARTIUPAC
3H		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
one		I-PARTIUPAC
(		O
5b		O
and		O
6b		O
)		O
and		O
3		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
deoxy		I-PARTIUPAC
-		I-PARTIUPAC
3,5		I-PARTIUPAC
-		I-PARTIUPAC
di		I-PARTIUPAC
-		I-PARTIUPAC
O		I-PARTIUPAC
-		I-PARTIUPAC
p		I-PARTIUPAC
-		I-PARTIUPAC
toluoyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
beta		I-PARTIUPAC
-		I-PARTIUPAC
and		O
-		B-PARTIUPAC
alpha		I-PARTIUPAC
-		I-PARTIUPAC
D		I-PARTIUPAC
-		I-PARTIUPAC
erythro		I-PARTIUPAC
-		I-PARTIUPAC
pentofuranosyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
5		I-PARTIUPAC
-		I-PARTIUPAC
ethyl		I-PARTIUPAC
-		I-PARTIUPAC
6,7		I-PARTIUPAC
-		I-PARTIUPAC
dihydroimidazo		I-PARTIUPAC
[		I-PARTIUPAC
4,5		I-PARTIUPAC
-		I-PARTIUPAC
d		I-PARTIUPAC
]		I-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
1,3		I-PARTIUPAC
]		I-PARTIUPAC
diazepin		I-PARTIUPAC
-		I-PARTIUPAC
8		I-PARTIUPAC
(		I-PARTIUPAC
3H		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
one		I-PARTIUPAC
(		O
5c		O
and		O
6c		O
)		O
,		O
respectively		O
.		O
All		O
were		O
thus		O
less		O
inhibitory		O
than		O
1a		O
.		O
Alkylation		O
of		O
2,6		B-IUPAC
-		I-IUPAC
diaminopurine		I-IUPAC
with		O
1,4		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
butyne		I-IUPAC
led		O
to		O
chloro		B-IUPAC
derivative		B-MODIFIER
6a		O
,		O
which		O
was		O
hydrolyzed		O
to		O
alcohol		O
6b		O
.		O
Only		O
CPMENSPM		O
,		O
and		O
not		O
(		O
2R		O
,		O
10S		O
)		O
-		O
(		O
HO		O
)		O
(		O
2		O
)		O
CPMENSPM		O
,		O
lowered		O
spermine		O
pools		O
.		O
In		O
both		O
these		O
assays		O
DL		B-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ylglycine		I-IUPAC
proved		O
to		O
be		O
more		O
potent		O
and		O
efficacious		O
than		O
NMDA		O
and		O
cis		O
-		O
methanoglutamate		O
.		O
The		O
bis		B-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloroethyl		I-IUPAC
)		I-IUPAC
carbamate		I-IUPAC
moiety		B-MODIFIER
is		O
capable		O
of		O
reacting		O
with		O
nucleophilic		O
groups		O
as		O
evidenced		O
by		O
the		O
colorimetric		O
reaction		O
with		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
nitrobenzyl		I-IUPAC
)		I-IUPAC
pyridine		I-IUPAC
.		O
Substituted		B-MODIFIER
-		I-MODIFIER
benzyl		I-MODIFIER
[		B-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4a		I-IUPAC
,		I-IUPAC
10a		I-IUPAC
-		I-IUPAC
dihydrophenothiazin		I-IUPAC
-		I-IUPAC
10		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
]		I-IUPAC
dimethylammonium		I-IUPAC
salts		I-IUPAC
,		O
synthesized		O
by		O
Menschutkin		O
quaternization		O
of		O
the		O
tertiary		O
alkylamine		O
omega		O
-		O
nitrogen		O
atom		O
of		O
chlorpromazine		O
,		O
were		O
linear		O
,		O
competitive		O
inhibitors		O
of		O
recombinant		O
trypanothione		O
reductase		O
from		O
T		O
.		O
These		O
compounds		O
exhibit		O
time		O
-		O
dependent		O
inhibition		O
consistent		O
with		O
mechanism		O
-		O
based		O
inhibition		O
.		O
Protection		O
studies		O
with		O
3		O
in		O
the		O
FaDu		O
squamous		O
cell		O
carcinoma		O
cell		O
line		O
indicated		O
that		O
inhibition		O
was		O
completely		O
reversed		O
by		O
leucovorin		O
[		O
(		O
6R		B-IUPAC
,		I-IUPAC
S		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
formyltetrahydrofolate		I-IUPAC
]		O
or		O
by		O
a		O
combination		O
of		O
thymidine		O
and		O
hypoxanthine		O
,		O
suggesting		O
an		O
antifolate		O
effect		O
directed		O
at		O
DHFR		O
.		O
The		O
relative		O
amounts		O
of		O
these		O
materials		O
excreted		O
in		O
0-24		O
-		O
h		O
urine		O
collections		O
from		O
eight		O
subjects		O
averaged		O
7		O
,		O
17		O
,		O
26		O
,		O
10		O
,		O
25		O
,		O
and		O
15%		O
for		O
1-6		O
,		O
respectively		O
.		O
Methyl		O
and		O
ethyl		O
substituents		O
are		O
most		O
preferred		O
in		O
the		O
tri		O
-		O
and		O
tetrasubstituted		O
diarylguanidines		O
.		O
The		O
synthesis		O
and		O
structure		O
-		O
activity		O
relationship		O
of		O
a		O
series		O
of		O
4		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxobut		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
enoic		I-IUPAC
acids		I-IUPAC
and		O
esters		B-PARTIUPAC
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxobut		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
enoic		I-IUPAC
acids		I-IUPAC
and		O
esters		B-PARTIUPAC
as		O
potent		O
inhibitors		O
of		O
kynurenine		O
-		O
3		O
-		O
hydroxylase		O
are		O
described		O
.		O
Analogues		O
with		O
low		O
nitrogen		O
pKa		O
's		O
such		O
that		O
the		O
nitrogens		O
are		O
poorly		O
protonated		O
at		O
physiological		O
pH		O
do		O
not		O
compete		O
well		O
with		O
spermidine		O
for		O
uptake		O
and		O
,		O
as		O
expected		O
,		O
have		O
high		O
96		O
h		O
IC50		O
values		O
and		O
have		O
little		O
effect		O
on		O
S		B-IUPAC
-		I-IUPAC
adenosylmethionine		I-IUPAC
decarboxylase		O
,		O
ornithine		O
decarboxylase		O
,		O
and		O
spermidine		O
/		O
spermine		O
N1		O
-		O
acetyltransferase		O
activities		O
and		O
on		O
intracellular		O
polyamine		O
pools		O
.		O
A		O
series		O
of		O
1		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
2,4		B-IUPAC
-		I-IUPAC
dinitroimidazole		I-IUPAC
analogues		B-MODIFIER
have		O
been		O
synthesized		O
and		O
tested		O
for		O
their		O
radiosensitizing		O
ability		O
for		O
selectively		O
sensitizing		O
hypoxic		O
mammalian		O
cells		O
to		O
the		O
lethal		O
effect		O
of		O
radiation		O
.		O
2,6		B-IUPAC
-		I-IUPAC
Dimethylacetaminophen		I-IUPAC
,		O
like		O
N		B-IUPAC
-		I-IUPAC
methylacetaminophen		I-IUPAC
,		O
showed		O
very		O
little		O
tissue		O
damage		O
.		O
Such		O
compounds		O
were		O
analyzed		O
as		O
true		O
alternate		O
substrate		O
inhibitors		O
.		O
Attempts		O
at		O
reducing		O
the		O
size		O
of		O
the		O
ring		O
with		O
maintenance		O
of		O
selectivity		O
failed		O
in		O
that		O
des		O
-		O
AA		O
(		O
1,4,5,13		O
)		O
-		O
[		O
Tyr		O
(		O
2		O
)		O
,		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
]		O
-		O
SRIF		O
(		O
33		O
)		O
and		O
des		O
-		O
AA		O
(		O
1,4,5,6,12,13		O
)		O
-		O
[		O
Tyr		O
(		O
2		O
)		O
,		O
DTrp		O
(		O
8		O
)		O
,		O
IAmp		O
(		O
9		O
)		O
]		O
-		O
SRIF		O
(		O
34		O
)		O
progressively		O
lost		O
affinity		O
for		O
all		O
receptors		O
.		O
Synthesis		O
of		O
various		O
substituted		B-MODIFIER
5		B-IUPAC
-		I-IUPAC
thio		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridinecarboxylic		I-IUPAC
acids		I-IUPAC
and		O
their		O
derivatives		O
is		O
described		O
by		O
three		O
methods		O
,		O
i.e.		O
,		O
displacement		O
of		O
nitrite		O
from		O
methyl		B-IUPAC
5		I-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridinecarboxylate		I-IUPAC
(		O
10		O
)		O
by		O
a		O
thiol		O
anion		O
,		O
alkylation		O
of		O
methyl		B-IUPAC
5		I-IUPAC
-		I-IUPAC
thio		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridinecarboxylate		I-IUPAC
derived		O
from		O
reaction		O
of		O
the		O
diazotized		B-MODIFIER
methyl		B-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridinecarboxylate		I-IUPAC
(		O
5		O
)		O
with		O
thiocyanate		O
followed		O
by		O
borohydride		O
reduction		O
of		O
the		O
product		O
,		O
and		O
alkylation		O
of		O
5		B-IUPAC
-		I-IUPAC
thio		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
pyridinecarbonitrile		I-IUPAC
followed		O
by		O
hydrolysis		O
.		O
Condensation		O
of		O
1		O
with		O
dibenzoylmethane		B-IUPAC
gave		O
15		O
.		O
Consequently		O
,		O
the		O
1		B-IUPAC
-		I-IUPAC
boraadamantaneamine		I-IUPAC
derivatives		B-MODIFIER
present		O
a		O
promising		O
lead		O
in		O
the		O
development		O
of		O
small		O
molecules		O
with		O
potential		O
to		O
bind		O
to		O
CD81		O
and		O
treat		O
HCV		O
infections		O
.		O
The		O
optimal		O
ratios		O
of		O
Me3Si		O
-		O
FU		O
,		O
Thf		O
-		O
OAc		O
,		O
and		O
SnCl4		O
or		O
NaI		O
for		O
preparation		O
of		O
Thf		O
-		O
FU		O
and		O
Thf2		O
-		O
FU		O
were		O
determined		O
.		O
The		O
N		B-PARTIUPAC
(		I-PARTIUPAC
1		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
naphthalenylmethyl		I-PARTIUPAC
,		O
N		B-PARTIUPAC
(		I-PARTIUPAC
1		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
anthracenylmethyl		I-PARTIUPAC
,		O
and		O
N		B-IUPAC
(		I-IUPAC
1		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pyrenylmethyl		I-IUPAC
4,4		I-IUPAC
-		I-IUPAC
triamines		I-IUPAC
had		O
similar		O
toxicity		O
(		O
IC		O
(		O
50		O
)		O
s		O
:		O
approximately		O
0.5		O
microM		O
)		O
in		O
CHO		O
cells		O
,		O
which		O
have		O
an		O
active		O
polyamine		O
transporter		O
(		O
PAT		O
)		O
.		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Arylhydroxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
isopropyluracil		I-IUPAC
derivatives		B-MODIFIER
15-18		O
were		O
prepared		O
from		O
the		O
5		B-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
thiouracil		I-IUPAC
derivatives		B-MODIFIER
13		O
and		O
14		O
by		O
the		O
above		O
procedure		O
following		O
oxidative		O
hydrolysis		O
of		O
the		O
thione		O
.		O
The		O
relative		O
efficacy		O
of		O
11		O
,		O
which		O
has		O
a		O
higher		O
receptor		O
affinity		O
(		O
IC50		O
=		O
1.3		O
+		O
/		O
-		O
0.3		O
microM		O
)		O
than		O
10		O
(		O
IC50		O
=		O
9.3		O
+		O
/		O
-		O
2.6		O
microM		O
)		O
,		O
was		O
comparable		O
with		O
that		O
of		O
10		O
(		O
30-35%		O
)		O
.		O
Their		O
potency		O
is		O
similar		O
to		O
that		O
of		O
dexamethasone		O
although		O
they		O
do		O
not		O
act		O
through		O
the		O
glucocorticoid		O
receptor		O
.		O
The		O
eight		O
analogues		O
of		O
DPDPE		O
showed		O
highly		O
variable		O
binding		O
and		O
bioassay		O
activities		O
particularly		O
at		O
the		O
delta		O
opioid		O
receptor		O
(		O
4		O
orders		O
of		O
magnitude		O
)		O
,		O
but		O
also		O
at		O
the		O
mu		O
opioid		O
receptor		O
,		O
which		O
led		O
to		O
large		O
differences		O
(		O
3		O
orders		O
of		O
magnitude		O
)		O
in		O
receptor		O
selectivity		O
.		O
However		O
,		O
the		O
rigid		O
A		O
-		O
tract		O
ODN		O
caused		O
loss		O
of		O
RNase		O
H		O
recruitment		O
.		O
Deblocking		O
of		O
6a		O
-		O
c		O
gave		O
the		O
corresponding		O
amino		B-IUPAC
acids		I-IUPAC
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromoacetamido		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
hydrobromide		I-IUPAC
(		O
7a		O
)		O
,		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
dichloroacetamido		I-IUPAC
)		I-IUPAC
propionic		I-IUPAC
acid		I-IUPAC
(		O
7b		O
)		O
,		O
and		O
ethyl		B-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxyethyl		I-IUPAC
]		I-IUPAC
fumarate		I-IUPAC
(		O
7c		O
)		O
.		O
The		O
most		O
active		O
compound		O
(		O
ED50		O
=		O
8.3		O
x		O
10		O
(		O
-		O
9		O
)		O
M		O
)		O
of		O
the		O
2		B-IUPAC
-		I-IUPAC
pyrazinylcarboxamidobenzoates		I-IUPAC
is		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5,6,7,8		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
5,5,8		I-IUPAC
,		I-IUPAC
8		I-IUPAC
-		I-IUPAC
tetramethylquinoxalyl		I-IUPAC
)		I-IUPAC
carboxamido		I-IUPAC
]		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
9u		O
)		O
,		O
while		O
the		O
most		O
active		O
analogue		O
of		O
the		O
beta		O
-		O
ionylideneacetamidobenzoates		O
is		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
6'		I-IUPAC
,		I-IUPAC
6'		I-IUPAC
-		I-IUPAC
trimethyl		I-IUPAC
-		I-IUPAC
1'		I-IUPAC
-		I-IUPAC
cyclohexen		I-IUPAC
-		I-IUPAC
1'		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2E		I-IUPAC
,		I-IUPAC
4E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
pentadienamido		I-IUPAC
]		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
10a		O
,		O
ED50		O
=		O
3.2		O
x		O
10		O
(		O
-		O
8		O
)		O
M		O
)		O
.		O
The		O
sulfones		O
could		O
be		O
synthesized		O
by		O
a		O
novel		O
,		O
selective		O
C		O
-		O
5		O
sulfonylation		O
of		O
dilithio		B-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
thiazolidinedione		I-IUPAC
with		O
appropriate		O
sulfonyl		O
chlorides		O
.		O
On		O
the		O
basis		O
of		O
X		O
-		O
ray		O
crystallographic		O
analyses		O
,		O
the		O
configuration		O
of		O
oxime		O
22a		O
was		O
shown		O
to		O
be		O
E		O
and		O
the		O
absolute		O
configurations		O
of		O
(		O
-		O
)		O
-		O
8		O
x		O
HCl		O
and		O
(		O
+		O
)		O
-		O
9		O
x		O
HBr		O
were		O
established		O
to		O
be		O
R		O
.		O
By		O
contrast		O
,		O
inhibitors		O
based		O
on		O
the		O
benzochromen		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
coumarin		O
)		O
or		O
2		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
7,8		I-IUPAC
-		I-IUPAC
benzochromen		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
flavone		O
)		O
scaffolds		B-MODIFIER
were		O
less		O
potent		O
.		O
Compounds		O
3		O
and		O
4		O
were		O
obtained		O
from		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylpyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
7		O
and		O
2		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylpyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
12		O
,		O
respectively		O
,		O
in		O
a		O
concise		O
three		O
-		O
step		O
sequence		O
.		O
These		O
results		O
were		O
particularly		O
unexpected		O
in		O
view		O
of		O
the		O
critical		O
role		O
(		O
s		O
)		O
originally		O
ascribed		O
to		O
the		O
side		O
chains		O
of		O
residues		O
1		O
and		O
3		O
.		O
Compound		O
6a		O
produced		O
cures		O
at		O
an		O
oral		O
dosage		O
of		O
5		O
mg		O
/		O
kg		O
.		O
The		O
effect		O
of		O
N		O
-		O
and		O
5		O
-		O
substitution		O
on		O
affinity		O
for		O
the		O
5		O
-		O
HT1A		O
receptor		O
was		O
evaluated		O
in		O
competition		O
experiments		O
using		O
rat		O
hippocampal		O
membranes		O
and		O
[		O
3H		O
]		O
8		O
-		O
OH		O
-		O
DPAT		O
as		O
radioligand		O
.		O
On		O
the		O
other		O
hand		O
,		O
there		O
were		O
certain		O
relationships		O
among		O
the		O
in		O
vitro		O
tracheal		O
relaxant		O
activities		O
of		O
these		O
compounds		O
,		O
their		O
affinities		O
for		O
adenosine		O
(		O
A1		O
)		O
receptors		O
in		O
the		O
brain		O
membrane		O
,		O
and		O
their		O
inhibition		O
of		O
cyclic		O
AMP		O
-		O
phosphodiesterase		O
(		O
PDE		O
)		O
in		O
the		O
tracheal		O
muscle		O
.		O
1,4		B-IUPAC
-		I-IUPAC
Di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
allyl		I-IUPAC
-		I-IUPAC
myo		I-IUPAC
-		I-IUPAC
inositol		I-IUPAC
was		O
regioselectively		O
p		O
-		O
methoxybenzylated		O
at		O
the		O
3		O
-		O
position		O
to		O
give		O
1,4		B-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
allyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
methoxybenzyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
myo		I-IUPAC
-		I-IUPAC
inositol		I-IUPAC
followed		O
by		O
benzylation		O
of		O
the		O
remaining		O
free		O
hydroxyl		B-IUPAC
groups		B-MODIFIER
to		O
give		O
the		O
key		O
intermediate		O
1,4		B-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
allyl		I-IUPAC
-		I-IUPAC
2,5,6		I-IUPAC
-		I-IUPAC
tri		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
methoxybenzyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
myo		I-IUPAC
-		I-IUPAC
inositol		I-IUPAC
.		O
A		O
similar		O
reaction		O
with		O
10		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
chloropropionyl		I-IUPAC
)		I-IUPAC
folic		I-IUPAC
acid		I-IUPAC
(		O
3		O
)		O
gave		O
10		O
-		O
(		O
ClCH2CH2CO		O
)		O
-		O
THF		O
(		O
14		O
)		O
rather		O
than		O
5,10		O
-		O
(		O
CH2CH2CO		O
)		O
-		O
THF		O
(		O
13		O
)		O
.		O
In		O
the		O
thalamus		O
,		O
a		O
nAChR		O
-		O
rich		O
area		O
,		O
uptake		O
of		O
radioactivity		O
reached		O
a		O
maximum		O
at		O
60		O
min		O
(		O
4%		O
I		O
.		O
The		O
inhibitions		O
of		O
cytochrome		O
P		O
-		O
450		O
dependent		O
monooxygenase		O
activity		O
in		O
microsomes		O
from		O
rat		O
liver		O
by		O
1		B-IUPAC
-		I-IUPAC
phenylpyrrole		I-IUPAC
,		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
isopropylphenyl		I-IUPAC
)		I-IUPAC
pyrrole		I-IUPAC
,		O
4		B-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
-		I-IUPAC
phenylimidazole		I-IUPAC
,		O
and		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
isopropylphenyl		I-IUPAC
)		I-IUPAC
imidazole		I-IUPAC
have		O
been		O
compared		O
.		O
Substituents		O
on		O
position		O
4		O
included		O
CH3		O
,		O
CO2H		O
,		O
CH2CO2H		O
,		O
CH		O
=		O
CHCO2H		O
,		O
and		O
CH2CH2CO2H		O
.		O
In		O
each		O
assay		O
(		O
all		O
-		O
E		O
)		O
-		O
1		O
was		O
the		O
most		O
active		O
isomer		O
,		O
and		O
this		O
activity		O
was		O
comparable		O
to		O
or		O
better		O
than		O
that		O
for		O
(		B-IUPAC
all		I-IUPAC
-		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
retinoic		I-IUPAC
acid		I-IUPAC
.		O
The		O
results		O
of		O
this		O
study		O
provide		O
an		O
explanation		O
at		O
the		O
molecular		O
level		O
for		O
observed		O
activity		O
differences		O
between		O
cannabinoids		O
that		O
exhibit		O
shape		O
differences		O
associated		O
with		O
their		O
carbocyclic		O
rings		O
.		O
The		O
structure		O
of		O
compound		O
69		O
is		O
of		O
interest		O
because		O
it		O
provides		O
only		O
a		O
single		O
aromatic		O
unit		O
linked		O
through		O
a		O
chain		O
to		O
a		O
basic		O
nitrogen		O
,		O
while		O
most		O
H1		O
-		O
antihistaminic		O
agents		O
have		O
structures		O
that		O
comprise		O
a		O
double		O
-		O
aromatic		O
unit		O
linked		O
through		O
a		O
chain		O
to		O
a		O
basic		O
tertiary		O
amino		O
group		O
.		O
A		O
compound		O
was		O
prepared		O
in		O
which		O
both		O
the		O
Cys		O
-		O
Val		O
methyleneamine		O
isostere		O
and		O
the		O
Tic		O
replacement		O
were		O
incorporated		O
.		O
The		O
biphasic		O
dose		O
-		O
response		O
relationship		O
characteristically		O
shown		O
by		O
the		O
benzothiazole		O
series		O
against		O
sensitive		O
cell		O
lines		O
was		O
exhibited		O
by		O
the		O
4		B-PARTIUPAC
-		I-PARTIUPAC
and		O
6		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
benzothiazoles		I-IUPAC
(		O
10b		O
,		O
d		O
)		O
but		O
not		O
by		O
the		O
5		B-PARTIUPAC
-		I-PARTIUPAC
and		O
7		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
benzothiazoles		I-IUPAC
(		O
10h		O
,		O
i		O
)		O
.		O
When		O
the		O
MTX		O
-		O
equivalent		O
dose		O
of		O
MTX		O
bis		B-IUPAC
(		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chloropiperonyl		I-IUPAC
)		I-IUPAC
ester		I-IUPAC
was		O
increased		O
to		O
40		O
mg		O
/		O
kg		O
,		O
a		O
+		O
167%		O
ILS		O
was		O
observed		O
,		O
as		O
compared		O
with		O
a		O
+		O
100%		O
ILS		O
with		O
60		O
mg		O
/		O
kg		O
of		O
the		O
parent		O
drug		O
.		O
Spiro		O
[		O
isobenzofuran		O
-		O
1		O
(		O
3H		O
)		O
,		O
4'		O
-		O
piperidines		O
]		O
and		O
the		O
corresponding		O
benzofuran		O
and		O
benzopyran		O
derivatives		O
have		O
been		O
synthesized		O
and		O
evaluated		O
as		O
sigma		O
ligands		O
.		O
The		O
stereoselectivity		O
of		O
the		O
Grignard		O
reagent		O
's		O
attachment		O
to		O
2		B-IUPAC
-		I-IUPAC
deoxyfuranose		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ulosides		I-IUPAC
has		O
been		O
ruled		O
by		O
the		O
substitute		O
configuration		O
at		O
Cl		O
.		O
This		O
compound		O
binds		O
to		O
the		O
ETA		O
receptor		O
with		O
an		O
affinity		O
(		O
Ki		O
)		O
of		O
0		O
.		O
Compounds		O
were		O
designed		O
to		O
investigate		O
the		O
effect		O
on		O
selectivity		O
of		O
the		O
acidity		O
of		O
the		O
NH		O
group		O
[		O
the		O
7		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
(		O
compound		O
5		O
)		O
and		O
7		B-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
p		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
(		O
compound		O
4		O
)		O
derivatives		B-MODIFIER
of		O
1		O
]		O
,		O
the		O
relative		O
spatial		O
position		O
of		O
the		O
acidic		O
hydrogen		B-IUPAC
[		I-IUPAC
7		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylsulfonyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroisoquinoline		I-IUPAC
(		O
6		O
)		O
and		O
7		B-IUPAC
-		I-IUPAC
(		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylsulfonyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroisoquinoline		I-IUPAC
(		O
8		O
)		O
]		O
,		O
or		O
the		O
effect		O
of		O
the		O
substitution		O
of		O
an		O
acidic		O
phenolic		O
group		O
for		O
the		O
aminosulfonyl		B-IUPAC
moiety		B-MODIFIER
[		B-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
hydroxynaphthalene		I-IUPAC
(		O
23		O
)		O
and		O
8		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydrobenz		I-IUPAC
[		I-IUPAC
h		I-IUPAC
]		I-IUPAC
isoquinoline		I-IUPAC
(		O
9		O
)		O
]		O
.		O
Piperidine		O
and		O
cyclohexyl		O
ring		O
homologues		O
of		O
the		O
high		O
-		O
affinity		O
dopamine		O
(		O
DA		O
)		O
uptake		O
inhibitor		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
cyclohexyl		I-IUPAC
]		I-IUPAC
piperidine		I-IUPAC
(		O
BTCP		O
,		O
3		O
)		O
were		O
each		O
prepared		O
in		O
four		O
steps		O
from		O
the		O
appropriate		O
cycloalkanones		O
.		O
Binding		O
studies		O
with		O
rat		O
hippocampal		O
membrane		O
homogenates		O
showed		O
that		O
8		O
exhibited		O
a		O
Ki		O
value		O
of		O
0.92		O
nM		O
against		O
(		O
R		O
,		O
S		O
)		O
-		O
[		O
3H		O
]		O
-		O
8		O
-		O
OH		O
-		O
DPAT		O
.		O
Cyclization		O
of		O
VI		O
and		O
VII		O
with		O
guanidine		O
then		O
produced		O
the		O
desired		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
pteridinediamine		I-IUPAC
N		I-IUPAC
-		I-IUPAC
oxides		I-IUPAC
VIII		O
and		O
teridinediamines		O
IX		O
,		O
respectively		O
.		O
Eleven		O
new		O
12		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6,7,10,11		I-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
7		I-IUPAC
,		I-IUPAC
11		I-IUPAC
-		I-IUPAC
methanocycloocta		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
quinoline		I-IUPAC
derivatives		B-MODIFIER
[		O
tacrine		O
(		O
THA		O
)		O
-		O
huperzine		O
A		O
hybrids		O
,		O
rac		O
-		O
21-31		O
]		O
have		O
been		O
synthesized		O
as		O
racemic		O
mixtures		O
and		O
tested		O
as		O
acetylcholinesterase		O
(		O
AChE		O
)		O
inhibitors		O
.		O
Several		O
4		B-MODIFIER
-		I-MODIFIER
N		I-MODIFIER
-		I-MODIFIER
unsubstituted		I-MODIFIER
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
alkylamino		I-IUPAC
)		I-IUPAC
pyridothiadiazines		I-IUPAC
and		O
some		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
alkylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
chlorobenzothiadiazines		I-IUPAC
were		O
found		O
to		O
be		O
more		O
potent		O
than		O
diazoxide		O
for		O
the		O
inhibition		O
of		O
the		O
insulin		O
-		O
releasing		O
process		O
.		O
Among		O
the		O
phenyl		O
ring		O
-		O
substituted		O
analogs		O
,		O
those		O
containing		O
the		O
smaller		O
and		O
electron		O
-		O
withdrawing		O
halogens		O
were		O
favored		O
over		O
those		O
with		O
larger		O
,		O
electron		O
-		O
releasing		O
methyl		O
groups		O
,		O
although		O
delta		O
opioid		O
binding		O
affinity		O
was		O
reduced		O
in		O
all		O
cases		O
.		O
Strikingly		O
,		O
the		O
most		O
potent		O
compounds		O
for		O
inhibition		O
of		O
[		O
3H		O
]		O
WIN		O
-		O
35,428		O
binding		O
were		O
not		O
the		O
(		O
1R		O
)		O
-		O
2		O
beta		O
,		O
3		O
beta		O
-		O
isomers		O
but		O
rather		O
(		O
1R		O
)		O
-		O
2		O
beta		O
,		O
3		O
alpha		O
-		O
4c		O
and		O
(		O
1S		O
)		O
-		O
2		O
beta		O
,		O
3		O
alpha		O
-		O
4f		O
.		O
In		O
all		O
cases		O
,		O
2-2.5		O
equiv		O
of		O
Thf		O
-		O
OAc		O
with		O
respect		O
to		O
Me3Si		O
-		O
FU		O
gave		O
the		O
best		O
results		O
.		O
Treatment		O
of		O
5		O
and		O
7		O
with		O
methanolic		O
ammonia		O
gave		O
the		O
deprotected		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
pyrazole		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
nucleosides		B-MODIFIER
9		O
.		O
Lu		O
28-179		O
)		O
,		O
with		O
the		O
binding		O
affinities		O
:		O
IC50		O
(		O
sigma		O
1		O
)		O
=		O
17		O
nM		O
,		O
IC50		O
(		O
sigma		O
2		O
)		O
=		O
0.12		O
nM		O
,		O
IC50		O
(		O
5		O
-		O
HT1A		O
)		O
=		O
21,000		O
nM		O
,		O
IC50		O
(		O
5		O
-		O
HT2A		O
)		O
=		O
2000		O
nM		O
,		O
IC50		O
(		O
D2		O
)		O
=		O
800		O
nM		O
,		O
IC50		O
(		O
alpha		O
1		O
)		O
=		O
330		O
nM		O
.		O
Thus		O
replacement		O
of		O
the		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
imidazolidinon		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
side		B-MODIFIER
chain		I-MODIFIER
with		O
a		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
ureido		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
or		O
methyl		B-IUPAC
substituent		B-MODIFIER
resulted		O
in		O
unchanged		O
affinity		O
and		O
selectivity		O
for		O
5		O
-		O
HT2		O
receptors		O
.		O
The		O
enantiomers		O
of		O
8		O
were		O
obtained		O
in		O
high		O
enantiomeric		O
purities		O
(		O
ee		O
&		O
gt		O
;		O
/		O
=		O
99.1%		O
)		O
via		O
the		O
diastereomeric		O
amides		O
32		O
and		O
33		O
,		O
synthesized		O
from		O
the		O
primary		O
amine		O
23b		O
and		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
methoxyphenylacetyl		I-IUPAC
chloride		I-IUPAC
and		O
subsequent		O
separation		O
by		O
preparative		O
HPLC		O
.		O
The		O
inhibition		O
of		O
ASase		O
by		O
7a		O
-		O
c		O
at		O
1		O
mM		O
was		O
93		O
,		O
19		O
,		O
and		O
37%		O
,		O
respectively		O
,		O
while		O
7d		O
was		O
without		O
inhibition		O
at		O
2		O
mM		O
.		O
To		O
provide		O
potential		O
new		O
leads		O
for		O
the		O
treatment		O
of		O
orthopoxvirus		O
infections		O
,		O
the		O
5		O
-		O
position		O
of		O
the		O
pyrimidine		O
nucleosides		O
have		O
been		O
modified		O
with		O
a		O
gem		O
diether		O
moiety		O
to		O
yield		O
the		O
following		O
new		O
nucleosides		O
:		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
dimethoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
2b		O
)		O
,		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
diethoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
3b		O
)		O
,		O
5		B-IUPAC
-		I-IUPAC
formyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
ethylene		I-IUPAC
acetal		I-IUPAC
(		O
4b		O
)		O
,		O
and		O
5		B-IUPAC
-		I-IUPAC
formyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
propylene		I-IUPAC
acetal		I-IUPAC
(		O
5b		O
)		O
.		O
i		O
.		O
The		O
effects		O
of		O
some		O
compounds		O
on		O
hexobarbital		O
sleeping		O
times		O
and		O
zoxazolamine		O
paralysis		O
times		O
in		O
mice		O
were		O
also		O
examined		O
.		O
The		O
radioiodinated		O
agents		O
are		O
of		O
interest		O
because		O
of		O
the		O
high		O
expected		O
uptake		O
and		O
prolonged		O
brain		O
retention		O
that		O
may		O
result		O
from		O
binding		O
to		O
high		O
-		O
capacity		O
,		O
relatively		O
nonspecific		O
amine		O
binding		O
sites		O
.		O
Compounds		O
9a		O
-		O
f		O
were		O
devoid		O
of		O
activity		O
against		O
intraperitoneally		O
implanted		O
L1210		O
leukemia		O
in		O
mice		O
.		O
A		O
selective		O
reduction		O
of		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
bromo		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
allylpyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
-		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carbon		I-IUPAC
ril		I-IUPAC
e		I-IUPAC
(		O
3k		O
)		O
in		O
zinc		O
and		O
acetic		O
acid		O
furnished		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
allylpyrrolo		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carbonitrile		I-IUPAC
(		O
4k		O
)		O
.		O
[		O
(		O
18		O
)		O
F		O
]		O
(		O
R		O
)		O
-		O
FIPCT		O
uptake		O
in		O
the		O
caudate		O
/		O
putamen		O
achieved		O
transient		O
equilibrium		O
at		O
75		O
min		O
.		O
The		O
activity		O
of		O
some		O
THA		O
-		O
huperzine		O
A		O
hybrids		O
(		O
rac		O
-		O
19		O
,		O
rac		O
-		O
20		O
,		O
rac		O
-		O
28		O
,		O
and		O
rac		O
-		O
30		O
)		O
,		O
which		O
were		O
separated		O
into		O
their		O
enantiomers		O
by		O
chiral		O
medium		O
-		O
pressure		O
liquid		O
chromatography		O
(		O
chiral		O
MPLC		O
)		O
,		O
using		O
microcrystalline		O
cellulose		O
triacetate		O
as		O
the		O
chiral		O
stationary		O
phase		O
,		O
showed		O
the		O
eutomer		O
to		O
be		O
always		O
the		O
levorotatory		O
enantiomer		O
,		O
their		O
activity		O
being		O
roughly		O
double		O
that		O
of		O
the		O
corresponding		O
racemic		O
mixture		O
,		O
the		O
distomer		O
being		O
much		O
less		O
active		O
.		O
Against		O
HL60		O
cells		O
,		O
4		O
was		O
about		O
7		O
-		O
fold		O
more		O
cytotoxic		O
than		O
PDDF		O
(		O
IC50		O
values		O
0.72		O
and		O
5.29		O
microM		O
)		O
.		O
Overall		O
,		O
the		O
combination		O
of		O
modified		O
rings		O
A		O
and		O
C		O
increases		O
the		O
potency		O
by		O
about		O
10		O
000		O
times		O
compared		O
with		O
the		O
lead		O
compound		O
,		O
3		B-IUPAC
-		I-IUPAC
oxooleana		I-IUPAC
-		I-IUPAC
1,12		I-IUPAC
-		I-IUPAC
dien		I-IUPAC
-		I-IUPAC
28		I-IUPAC
-		I-IUPAC
oic		I-IUPAC
acid		I-IUPAC
(		O
8		O
)		O
(		O
IC		O
(		O
50		O
)		O
=		O
1		O
microM		O
level		O
)		O
.		O
All		O
compounds		O
were		O
markedly		O
active		O
against		O
P388		O
at		O
doses		O
4-16		O
-		O
fold		O
lower		O
than		O
acronycine		O
itself		O
.		O
The		O
wide		O
differences		O
in		O
the		O
relative		O
abilities		O
of		O
these		O
compounds		O
to		O
displace		O
[		O
3H		O
]		O
BTCP		O
and		O
[		O
3H		O
]		O
cocaine		O
suggests		O
that		O
these		O
two		O
radioligands		O
are		O
labeling		O
different		O
sites		O
on		O
the		O
transporter		O
.		O
Corresponding		O
data		O
were		O
included		O
for		O
analogous		O
,		O
resolved		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
piperidines		I-IUPAC
and		O
a		O
few		O
other		O
substituted		O
,		O
racemic		B-MODIFIER
3		B-IUPAC
-		I-IUPAC
phenylpiperidines		I-IUPAC
.		O
In		O
the		O
second		O
stage		O
of		O
hydrolysis		O
,		O
the		O
remaining		O
P		O
-		O
N		O
bond		O
is		O
cleaved		O
together		O
with		O
an		O
intramolecular		O
attack		O
at		O
the		O
phosphorus		O
atom		O
by		O
the		O
non		O
-		O
P		O
-		O
linked		O
nitrogen		O
of		O
the		O
compounds		O
2a		O
-		O
d		O
.		O
At		O
C		O
-		O
7		O
the		O
introduction		O
of		O
some		O
novel		O
piperazines		O
was		O
made		O
.		O
In		O
particular		O
,		O
we		O
have		O
obtained		O
the		O
RAR		O
gamma		O
selective		O
derivatives		O
6		B-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
adamantyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthoic		I-IUPAC
acid		I-IUPAC
(		O
7		O
)		O
[		O
Ki		O
(		O
RAR		O
alpha		O
)		O
=		O
6500		O
nM		O
,		O
Ki		O
(		O
RAR		O
beta		O
)		O
=		O
2480		O
nM		O
,		O
Ki		O
(		O
RAR		O
gamma		O
)		O
=		O
77		O
nM		O
]		O
and		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
adamantyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
]		I-IUPAC
propenyl		I-IUPAC
]		I-IUPAC
benzoic		I-IUPAC
acid		I-IUPAC
(		O
19		O
)		O
[		O
Ki		O
(		O
RAR		O
alpha		O
)		O
=		O
1,144		O
nM		O
,		O
Ki		O
(		O
RAR		O
beta		O
)		O
=		O
1245		O
nM		O
,		O
Ki		O
(		O
RAR		O
gamma		O
)		O
=		O
53		O
nM		O
]		O
.		O
The		O
steady		O
-		O
state		O
inhibition		O
constants		O
,		O
Ki		O
,		O
for		O
7d		O
and		O
7n		O
were		O
calculated		O
to		O
be		O
60		O
and		O
52		O
nM		O
,		O
respectively		O
.		O
The		O
high		O
affinity		O
of		O
trans		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
5,7		I-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxoimidazolidinyl		I-IUPAC
)		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroquinoline		I-IUPAC
(		O
55		O
;		O
IC50		O
=		O
6		O
nM		O
)		O
suggests		O
that		O
the		O
Z		O
,		O
Z		O
conformer		O
of		O
the		O
phenyl		O
urea		O
moiety		O
in		O
35		O
is		O
recognized		O
by		O
the		O
receptor		O
.		O
Results		O
obtained		O
are		O
discussed		O
in		O
terms		O
of		O
conformational		O
,		O
steric		O
,		O
and		O
electronic		O
requirements		O
for		O
5		O
-		O
HT		O
-		O
receptor		O
activation		O
.		O
A		O
series		O
of		O
1,1		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
2,2,3		I-IUPAC
-		I-IUPAC
triarylcyclopropanes		I-IUPAC
(		O
DTACs		O
)		O
was		O
synthesized		O
and		O
evaluated		O
as		O
pure		O
antiestrogens		O
.		O
Pharmacological		O
profiles		O
of		O
these		O
conformationally		O
restricted		O
analogues		O
were		O
shown		O
to		O
be		O
different		O
depending		O
on		O
the		O
cyclopropane		O
backbones		O
.		O
Affinity		O
was		O
determined		O
at		O
cloned		O
human		O
A3		O
receptors		O
using		O
[		O
125I		O
]		O
AB		O
-		O
MECA		O
(		O
N6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
iodobenzyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methylcarbamoyl		I-IUPAC
)		I-IUPAC
adenosine		I-IUPAC
)		O
.		O
Thiation		O
of		O
5b		O
,		O
followed		O
by		O
deblocking		O
,		O
gave		O
3		B-IUPAC
-		I-IUPAC
cyanothiopurinol		I-IUPAC
ribonucleoside		B-MODIFIER
(		O
20		O
)		O
.		O
In		O
the		O
first		O
instance		O
,		O
further		O
work		O
led		O
from		O
the		O
F2Pmp		O
-		O
containing		O
peptide		O
to		O
monomeric		O
inhibitor		O
,		O
6		B-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonodifluoromethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthoic		I-IUPAC
acid		I-IUPAC
(		O
K		O
(		O
i		O
)		O
=		O
22		O
microM		O
)		O
,		O
and		O
to		O
the		O
pseudo		O
-		O
dipeptide		O
mimetic		O
,		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonodifluoromethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthoyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
(		O
K		O
(		O
i		O
)		O
=		O
12		O
microM		O
)		O
.		O
A		O
series		O
of		O
O'		B-IUPAC
-		I-IUPAC
(		I-IUPAC
epoxyalkyl		I-IUPAC
)		I-IUPAC
tyrosines		I-IUPAC
and		O
a		O
carboxy		O
terminal		O
(		B-IUPAC
epoxyalkyl		I-IUPAC
)		I-IUPAC
tyrosine		I-IUPAC
and		O
-		B-PARTIUPAC
phenylalanine		I-PARTIUPAC
were		O
synthesized		O
as		O
potential		O
serine		O
protease		O
inhibitors		O
.		O
One		O
compound		O
(		O
5l		O
)		O
was		O
tested		O
for		O
antiproliferative		O
activity		O
against		O
P		O
.		O
Four		O
isomers		O
of		O
[		B-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
tetrahydrofuran		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
trimethylammonium		I-IUPAC
iodide		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
deoxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
muscarines		I-IUPAC
)		I-IUPAC
were		O
prepared		O
in		O
enantiomerically		O
and		O
diastereomerically		O
pure		O
form		O
from		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
sulfoxide		I-IUPAC
,		O
ethyl		O
fluoroacetate		O
,		O
and		O
allyl		O
bromide		O
.		O
The		O
three		O
synthesized		O
proAELs		O
were		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
hexadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
palmitoyl		I-IUPAC
-		I-IUPAC
sn		I-IUPAC
-		I-IUPAC
glycero		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phosphocholine		I-IUPAC
(		O
1		O
-		O
O		O
-		O
DPPC		O
)		O
,		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
hexadecyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
palmitoyl		I-IUPAC
-		I-IUPAC
sn		I-IUPAC
-		I-IUPAC
glycero		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
phosphoethanolamine		I-IUPAC
poly		I-IUPAC
(		I-IUPAC
ethylene		I-IUPAC
glycol		I-IUPAC
)		I-IUPAC
(		O
350		O
)		O
(		O
1		O
-		O
O		O
-		O
DPPE		O
-		O
PEG		O
(		O
350		O
)		O
)		O
,		O
and		O
1		O
-		O
O		O
-		O
DPPE		O
-		O
PEG		O
(		O
2000		O
)		O
of		O
which		O
1		O
-		O
O		O
-		O
DPPC		O
was		O
the		O
main		O
liposome		O
component		O
.		O
Their		O
effects		O
were		O
compared		O
to		O
those		O
induced		O
by		O
milrinone		O
in		O
both		O
atria		O
preparations		O
.		O
These		O
data		O
were		O
compared		O
with		O
the		O
earlier		O
reported		O
effects		O
of		O
the		O
compounds		O
on		O
single		O
neurons		O
in		O
the		O
feline		O
spinal		O
cord		O
obtained		O
by		O
microelectrophoretic		O
techniques		O
.		O
The		O
binding		O
data		O
suggests		O
that		O
this		O
conformation		O
in		O
1		O
favors		O
strong		O
binding		O
interaction		O
at		O
sigma		O
-		O
receptors		O
.		O
The		O
relative		O
influx		O
of		O
12a		O
was		O
enhanced		O
about		O
3.2		O
-		O
fold		O
over		O
MTX		O
,		O
but		O
as		O
an		O
inhibitor		O
of		O
dihydrofolate		O
reductase		O
(		O
DHFR		O
)		O
from		O
L1210		O
cells		O
and		O
in		O
the		O
inhibition		O
of		O
L1210		O
cell		O
growth		O
in		O
vitro		O
,		O
this		O
compound		O
was		O
approximately		O
20		O
-		O
fold		O
less		O
effective		O
than		O
MTX		O
(		O
DHFR		O
inhibition		O
,		O
Ki		O
=		O
4.82		O
+		O
/		O
-		O
0.60		O
pM		O
for		O
MTX		O
,		O
100		O
pM		O
for		O
12a		O
;		O
cell		O
growth		O
,		O
IC50		O
=		O
3.4		O
+		O
/		O
-		O
1.0		O
nM		O
for		O
MTX		O
,		O
65		O
+		O
/		O
-		O
18		O
nM		O
for		O
12a		O
)		O
.		O
In		O
particular		O
,		O
the		O
combination		O
of		O
a		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
pentenyl		I-IUPAC
group		B-MODIFIER
and		O
a		O
7		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
benzodioxol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
group		B-MODIFIER
provided		O
hydrophobic		O
compound		O
10b		O
with		O
subnanomolar		O
affinity		O
for		O
human		O
ETA		O
receptor		O
subtype		O
and		O
with		O
an		O
ETB		O
/		O
ETA		O
activity		O
ratio		O
of		O
over		O
130000		O
.		O
The		O
increased		O
rigidity		O
of		O
these		O
spiro		O
-		O
fused		O
compounds		O
,		O
relative		O
to		O
the		O
corresponding		O
simple		O
4		B-IUPAC
-		I-IUPAC
phenylpiperidine		I-IUPAC
derivatives		B-MODIFIER
of		O
vesamicol		O
,		O
is		O
expected		O
to		O
confer		O
greater		O
selectivity		O
for		O
the		O
vesamicol		O
receptor		O
.		O
The		O
antiviral		O
activity		O
was		O
lower		O
if		O
the		O
oxygen		O
at		O
the		O
position		O
6		O
was		O
replaced		O
by		O
a		O
sulfur		O
atom		O
,		O
as		O
in		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phosphonomethoxy		I-IUPAC
)		I-IUPAC
ethylsulfanyl		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
.		O
gondii		O
DHFR		O
inhibition		O
as		O
well		O
as		O
inhibition		O
of		O
the		O
growth		O
of		O
T		O
.		O
in		O
electrophysiological		O
experiments		O
using		O
rat		O
alpha		O
(		O
1		O
)		O
beta		O
(		O
2		O
)		O
gamma		O
(		O
2L		O
)		O
GABA		O
(		O
A		O
)		O
receptors		O
expressed		O
in		O
Xenopus		O
laevis		O
oocytes		O
,		O
and		O
(		O
3		O
)		O
.		O
A		O
few		O
selected		O
examples		O
from		O
each		O
type		O
of		O
the		O
active		O
new		O
compounds		O
showed		O
strong		O
activity		O
against		O
ouabain		O
-		O
induced		O
arrhythmia		O
;		O
for		O
comparison		O
known		O
drugs		O
such		O
as		O
lidocaine		O
,		O
mexiletine		O
,		O
and		O
tocainide		O
were		O
selected		O
.		O
This		O
report		O
describes		O
the		O
synthesis		O
and		O
initial		O
biochemical		O
evaluation		O
of		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxyalkyl		I-IUPAC
)		I-IUPAC
estrogens		I-IUPAC
and		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
aminoalkyl		I-IUPAC
)		I-IUPAC
estradiols		I-IUPAC
.		O
Comparison		O
of		O
the		O
binding		O
data		O
of		O
7-9		O
with		O
that		O
of		O
the		O
previously		O
described		O
methylcyclohexyl		O
-		O
PCP		O
derivatives		O
allowed		O
its		O
rationalization		O
in		O
terms		O
of		O
this		O
model		O
.		O
A		O
novel		O
class		O
of		O
tricyclic		O
tropane		O
analogues		O
has		O
been		O
synthesized		O
by		O
making		O
use		O
of		O
radical		O
cyclization		O
technology		O
in		O
combination		O
with		O
the		O
Stille		O
coupling		O
reaction		O
.		O
Thus		O
,		O
a		O
variety		O
of		O
compounds		O
with		O
different		O
pharmacological		O
profiles		O
have		O
been		O
developed		O
.		O
The		O
results		O
of		O
this		O
study		O
indicate		O
that		O
the		O
ring		O
-		O
expanded		O
analogues		O
of		O
the		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
propananilido		I-IUPAC
)		I-IUPAC
piperidines		I-IUPAC
retain		O
a		O
relatively		O
high		O
degree		O
of		O
analgesic		O
potency		O
,		O
except		O
in		O
the		O
case		O
of		O
the		O
1		B-IUPAC
-		I-IUPAC
phenylethylated		I-IUPAC
analogue		B-MODIFIER
which		O
is		O
approximately		O
150		O
-		O
fold		O
less		O
potent		O
than		O
the		O
correspondingly		O
1		O
-		O
substituted		O
piperidine		O
analgesic		O
.		O
The		O
AdoHcy		O
derivatives		O
as		O
well		O
as		O
the		O
nucleoside		O
precursors		O
were		O
evaluated		O
for		O
their		O
antiviral		O
activity		O
.		O
Dose		O
ratios		O
(		O
ratio		O
of		O
ED20		O
of		O
angiotensin		O
II		O
during		O
infusion		O
of		O
the		O
antagonist		O
and		O
before		O
infusion		O
of		O
the		O
antagonist		O
)		O
in		O
vagotomized		O
,		O
ganglion		O
-		O
blocked		O
rats		O
,		O
infused		O
at		O
250		O
ng		O
/		O
kg		O
/		O
min		O
,		O
were		O
33.43		O
,		O
2.14		O
,		O
3.26		O
,		O
2.99		O
,		O
0.62		O
,		O
62.52		O
,		O
incalculable		O
,		O
and		O
11.15		O
,		O
respectively		O
.		O
The		O
benzothiazolo		B-IUPAC
[		I-IUPAC
3,2		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
were		O
the		O
most		O
potent		O
antagonists		O
,		O
being		O
nearly		O
as		O
potent		O
as		O
theophylline		O
at		O
A1		O
-		O
adenosine		O
receptors		O
and		O
somewhat		O
more		O
potent		O
than		O
theophylline		O
at		O
A2		O
-		O
adenosine		O
receptors		O
.		O
The		O
homologous		O
series		O
of		O
acidic		O
amino		O
acids		O
,		O
ranging		O
from		O
aspartic		O
acid		O
(		O
1		O
)		O
to		O
2		B-IUPAC
-		I-IUPAC
aminosuberic		I-IUPAC
acid		I-IUPAC
(		O
5		O
)		O
,		O
and		O
the		O
corresponding		O
series		O
of		O
3		B-IUPAC
-		I-IUPAC
isoxazolol		I-IUPAC
bioisosteres		B-MODIFIER
of		O
these		O
amino		O
acids		O
,		O
ranging		O
from		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
acetic		I-IUPAC
acid		I-IUPAC
(		O
AMAA		O
,		O
6		O
)		O
to		O
(		B-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylisoxazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
hexanoic		I-IUPAC
acid		I-IUPAC
(		O
10		O
)		O
,		O
were		O
tested		O
as		O
ligands		O
for		O
metabotropic		O
excitatory		O
amino		O
acid		O
receptors		O
(		O
mGlu1		O
alpha		O
,		O
mGlu2		O
,		O
mGlu4a		O
,		O
and		O
mGlu6		O
)		O
.		O
Substitution		O
on		O
the		O
aromatic		O
ring		O
of		O
4b		O
with		O
halogen		O
or		O
increasing		O
the		O
size		O
of		O
the		O
N		B-IUPAC
-		I-IUPAC
alkyl		I-IUPAC
substituent		B-MODIFIER
of		O
4b		O
gave		O
alpha		O
2		O
-		O
adrenergic		O
antagonists		O
without		O
agonist		O
activity		O
.		O
The		O
Z		O
-		O
isomers		O
were		O
always		O
predominant		O
in		O
these		O
mixtures		O
(		O
Z		O
/		O
E		O
approximately		O
2/1		O
)		O
.		O
In		O
addition		O
,		O
radioligand		O
-		O
binding		O
parameters		O
in		O
rat		O
brain		O
homogenate		O
with		O
the		O
5		O
-		O
HT		O
uptake		O
inhibitor		O
[		O
3H		O
]		O
paroxetine		O
were		O
unchanged		O
after		O
subacute		O
dosing		O
with		O
either		O
racemic		O
6		O
or		O
11		O
.		O
The		O
preferred		O
conformation		O
of		O
the		O
trans		B-MODIFIER
-		I-MODIFIER
2,4		I-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
tetrahydroquinoline		B-IUPAC
system		O
,		O
as		O
shown		O
by		O
X		O
-		O
ray		O
crystallography		O
and		O
1H		O
NMR		O
studies		O
,		O
places		O
the		O
2		O
-		O
carboxyl		O
pseudoequatorial		O
and		O
the		O
4		O
-		O
substituent		O
pseudoaxial		O
.		O
We		O
report		O
here		O
an		O
enantiospecific		O
synthesis		O
of		O
alpha		B-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
fluoromethyl		I-IUPAC
)		I-IUPAC
tryptophan		I-IUPAC
[		O
(		O
S		O
)		O
-		O
11a		O
]		O
and		O
alpha		B-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
fluoromethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
hydroxytryptophan		I-IUPAC
[		O
(		O
S		O
)		O
-		O
11b		O
]		O
,		O
as		O
well		O
as		O
the		O
(		O
R		O
)		O
-		O
enantiomers		O
,		O
based		O
upon		O
recent		O
methodology		O
involving		O
the		O
face		O
-		O
selective		O
alkylation		O
of		O
cyclic		O
tryptophan		O
tautomers		O
.		O
None		O
of		O
the		O
compounds		O
showed		O
significant		O
activity		O
at		O
metabotropic		O
Glu		O
receptors		O
.		O
The		O
5		B-PARTIUPAC
-		I-PARTIUPAC
Cl		I-PARTIUPAC
and		O
5		B-IUPAC
-		I-IUPAC
NO		I-IUPAC
(		I-IUPAC
2		I-IUPAC
)		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
indanylamides		I-IUPAC
7b		O
(		O
K		O
(		O
i		O
)		O
80		O
nM		O
)		O
and		O
7c		O
(		O
K		O
(		O
i		O
)		O
28		O
nM		O
)		O
were		O
the		O
most		O
potent		O
among		O
the		O
indoles		O
5-8		O
geometrically		O
constrained		O
about		O
the		O
side		O
chain		O
.		O
The		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methoxypropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
dinitroimidazole		I-IUPAC
(		O
2d		O
)		O
was		O
found		O
to		O
be		O
the		O
most		O
effective		O
radiosensitizer		O
of		O
this		O
series		O
.		O
A		O
series		O
of		O
novel		O
(		B-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dialkyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
pyrazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
arylmethanones		I-IUPAC
was		O
synthesized		O
.		O
These		O
results		O
,		O
indicating		O
that		O
the		O
3		O
-		O
aza		O
atom		O
in		O
the		O
pyrido		B-IUPAC
[		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
(		I-IUPAC
8H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
is		O
mandatory		O
,		O
whereas		O
the		O
1		O
-		O
aza		O
atom		O
is		O
not		O
,		O
support		O
the		O
published		O
binding		O
model		O
for		O
these		O
compounds		O
to		O
c		O
-		O
Src		O
(		O
J		O
.		O
The		O
structure		O
of		O
cis		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
cyclohexylamine		I-IUPAC
complexes		B-MODIFIER
is		O
flexible		O
,		O
and		O
the		O
cyclohexane		O
ring		O
is		O
not		O
perpendicular		O
to		O
the		O
chelate		O
ring		O
.		O
In		O
particular		O
,		O
2		B-IUPAC
-		I-IUPAC
phenylethynyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
Ado		O
(		O
8b		O
)		O
showed		O
an		O
A		O
(		O
3		O
)		O
affinity		O
in		O
the		O
low		O
nanomolar		O
range		O
(		O
K		O
(		O
i		O
)		O
(		O
A		O
(		O
3		O
)		O
)		O
=		O
3.4		O
nM		O
)		O
,		O
with		O
a		O
A		O
(		O
1		O
)		O
/		O
A		O
(		O
3		O
)		O
and		O
A		O
(		O
2A		O
)		O
/		O
A		O
(		O
3		O
)		O
selectivity		O
of		O
about		O
500		O
and		O
2500		O
,		O
respectively		O
.		O
Chain		O
extension		O
of		O
14		O
followed		O
by		O
cyclization		O
led		O
to		O
3		B-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5,6		I-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
7H		I-IUPAC
-		I-IUPAC
cyclopenta		I-IUPAC
[		I-IUPAC
f		I-IUPAC
]		I-IUPAC
isoquinolin		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
19		O
)		O
which		O
on		O
reduction		O
and		O
subsequent		O
dehydration		O
yielded		O
3		B-IUPAC
-		I-IUPAC
ethoxy		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
7		I-IUPAC
(		I-IUPAC
5		I-IUPAC
)		I-IUPAC
H		I-IUPAC
-		I-IUPAC
cyclopenta		I-IUPAC
[		I-IUPAC
f		I-IUPAC
]		I-IUPAC
isoquinoline		I-IUPAC
(		O
4		O
)		O
.		O
The		O
design		O
,		O
synthesis		O
,		O
and		O
biological		O
evaluation		O
of		O
several		O
unsaturated		O
acyclonucleosides		O
related		O
to		O
augustmycin		O
A		O
are		O
described		O
.		O
Negative		O
results		O
obtained		O
with		O
other		O
17		O
alpha		O
-		O
electrophilic		O
estradiol		O
derivatives		O
suggested		O
that		O
affinity		O
labeling		O
of		O
the		O
receptor		O
by		O
such		O
derivatives		O
required		O
a		O
minimal		O
distance		O
,		O
including		O
at		O
least		O
four		O
C		O
-		O
C		O
or		O
C		O
-		O
N		O
bonds		O
,		O
between		O
the		O
steroid		O
and		O
the		O
electrophilic		O
carbon		O
.		O
Following		O
the		O
discovery		O
of		O
moderately		O
potent		O
antagonist		O
activity		O
platelet		O
-		O
activating		O
factor		O
(		O
PAF		O
)		O
in		O
2		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
phenylimidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
c		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
(		O
2		O
)		O
(		O
IC50		O
=		O
840		O
nM		O
)		O
,		O
19		O
derivatives		O
(		O
3-21		O
)		O
were		O
prepared		O
which		O
incorporated		O
various		O
lipophilic		O
groups		O
attached		O
to		O
the		O
phenyl		O
4		O
-		O
position		O
.		O
Ep		O
.		O
The		O
affinity		O
of		O
ZIENT		O
and		O
EIENT		O
for		O
DAT		O
was		O
69		O
and		O
1.6		O
-		O
fold		O
lower		O
,		O
respectively		O
,		O
than		O
for		O
SERT		O
.		O
Nearly		O
all		O
compounds		O
substituted		O
in		O
the		O
amino		O
group		O
either		O
decrease		O
the		O
spontaneous		O
motility		O
in		O
mice		O
or		O
exert		O
no		O
effect		O
on		O
it		O
.		O
(		B-IUPAC
R		I-IUPAC
,		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
Hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
[		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
iodo		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
propenyl		I-IUPAC
)		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
tetralin		I-IUPAC
(		O
trans		O
-		O
8		O
-		O
OH		O
-		O
PIPAT		O
)		O
,		O
8		O
,		O
was		O
synthesized		O
by		O
a		O
10		O
-		O
step		O
reaction		O
.		O
Within		O
the		O
series		O
of		O
complexes		O
under		O
investigation		O
,		O
potency		O
decreases		O
depending		O
on		O
the		O
coordinated		O
amine		O
ligand		O
in		O
the		O
following		O
order		O
:		O
trans		O
-		O
R		O
,		O
R		O
-		O
chxn		O
&		O
gt		O
;		O
trans		O
-		O
S		O
,		O
S		O
-		O
chxn		O
&		O
gt		O
;		O
NH		O
(		O
3		O
)		O
&		O
gt		O
;		O
or		O
=		O
cis		O
-		O
R		O
,		O
S		O
-		O
chxn		O
&		O
gt		O
;		O
en		O
.		O
We		O
have		O
developed		O
a		O
new		O
class		O
of		O
sigma		O
subtype		O
selective		O
receptor		O
ligands		O
that		O
are		O
(		B-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
benzylidene		I-IUPAC
derivatives		B-MODIFIER
of		O
the		O
synthetic		O
opioid		O
(		B-PARTIUPAC
+		I-PARTIUPAC
/		I-PARTIUPAC
-		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
,		O
(		B-PARTIUPAC
+		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
,		O
and		O
(		B-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
morphan		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
1		O
)		O
.		O
Remaining		O
steps		O
were		O
ester		O
hydrolysis		O
of		O
9a		O
,		O
b		O
to		O
give		O
carboxylic		O
acids		O
10a		O
,		O
b		O
followed		O
by		O
standard		O
peptide		O
coupling		O
with		O
diethyl		O
L		O
-		O
glutamate		O
to		O
produce		O
diethyl		O
esters		O
11a		O
,		O
b		O
,		O
which		O
on		O
hydrolysis		O
gave		O
12a		O
and		O
10		O
-		O
EDAM		O
(		O
12b		O
)		O
,		O
respectively		O
.		O
Several		O
6		B-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
analogs		B-MODIFIER
of		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
thymine		I-IUPAC
(		O
1		O
;		O
HEPT		O
)		O
were		O
synthesized		O
and		O
evaluated		O
for		O
their		O
anti		O
-		O
HIV		O
-		O
1		O
activity		O
.		O
The		O
synthesis		O
,		O
physical		O
properties		O
,		O
antitumor		O
activity		O
,		O
structure		O
-		O
activity		O
relationships		O
,		O
and		O
nephrotoxicity		O
of		O
a		O
series		O
of		O
[		O
2		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
4,5		B-IUPAC
-		I-IUPAC
bis		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dioxolane		I-IUPAC
]		I-IUPAC
platinum		I-IUPAC
(		I-IUPAC
II		I-IUPAC
)		I-IUPAC
complexes		B-MODIFIER
are		O
described		O
.		O
The		O
combination		O
of		O
Tyr		O
(		O
2		O
)		O
and		O
dTrp		O
(		O
8		O
)		O
in		O
analogues		O
14		O
and		O
22		O
did		O
not		O
affect		O
the		O
affinity		O
of		O
the		O
analogues		O
for		O
sst		O
(		O
4		O
)		O
(		O
IC		O
(		O
50		O
)		O
=		O
1.2		O
and		O
1.1		O
nM		O
,		O
respectively		O
)		O
but		O
resulted		O
in		O
loss		O
of		O
selectivity		O
,		O
whereas		O
the		O
combination		O
of		O
Tyr		O
(		O
2		O
)		O
and		O
LTrp		O
(		O
8		O
)		O
in		O
H		O
-		O
Tyr		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Aph		O
-		O
Trp		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
(		O
13		O
)		O
and		O
H		O
-		O
Tyr		O
-		O
c		O
[		O
Cys		O
-		O
Phe		O
-		O
Ala		O
-		O
Trp		O
-		O
Lys		O
-		O
Thr		O
-		O
Phe		O
-		O
Cys		O
]		O
-		O
OH		O
(		O
19		O
)		O
retained		O
high		O
affinity		O
(		O
IC		O
(		O
50		O
)		O
=		O
1.9		O
and		O
1.98		O
nM		O
,		O
respectively		O
)		O
and		O
sst		O
(		O
4		O
)		O
selectivity		O
(		O
&		O
gt		O
;		O
50		O
and		O
&		O
gt		O
;		O
250		O
,		O
respectively		O
)		O
.		O
The		O
derivatives		O
can		O
be		O
prepared		O
by		O
reaction		O
of		O
1		O
,		O
(		O
+		O
)		O
-		O
1		O
,		O
and		O
(		O
-		O
)		O
-		O
1		O
with		O
the		O
appropriate		O
benzaldehyde		O
under		O
Claisen		O
-		O
Schmidt		O
conditions		O
.		O
The		O
3		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
methoxybenzylidene		I-IUPAC
analogue		B-MODIFIER
9h		O
was		O
found		O
to		O
be		O
the		O
most		O
active		O
compound		O
(		O
IC		O
(		O
50		O
)		O
K562		O
:		O
20		O
nM		O
)		O
.		O
The		O
isolated		O
DTPA		O
-		O
D		O
-		O
Phe1		O
-		O
octreotide		O
had		O
the		O
correct		O
molecular		O
mass		O
(		O
[		O
M+		O
H		O
]		O
+		O
=		O
1395		O
Da		O
)		O
and		O
was		O
obtained		O
in		O
5%		O
yield		O
at		O
&		O
gt		O
;		O
90%		O
purity		O
.		O
Internalization		O
of		O
the		O
compounds		O
by		O
ABIR		O
-		O
positive		O
tumor		O
cells		O
(		O
A549		O
)		O
was		O
monitored		O
by		O
NIR		O
fluorescence		O
microscopy		O
.		O
Compound		O
195		O
was		O
highly		O
potent		O
in		O
vitro		O
(		O
IC50		O
=		O
5.2		O
x		O
10		O
(		O
-		O
8		O
)		O
M		O
)		O
but		O
did		O
not		O
show		O
oral		O
activity		O
when		O
tested		O
at		O
100		O
mg		O
/		O
kg		O
.		O
These		O
are		O
based		O
on		O
modifications		O
of		O
three		O
peptides		O
:		O
A		O
,		O
B		O
,		O
and		O
C		O
.		O
A		O
still		O
unknown		O
tricyclic		O
heterocyclic		O
system		O
(		O
5		O
)		O
was		O
synthesized		O
from		O
6		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylpyridazin		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
one		I-IUPAC
and		O
its		O
structure		O
identified		O
as		O
2,8		B-IUPAC
-		I-IUPAC
dichloro		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
methylpyrrolo		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
b		I-IUPAC
:		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d'		I-IUPAC
]		I-IUPAC
dipyridazin		I-IUPAC
-		I-IUPAC
5		I-IUPAC
(		I-IUPAC
6H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
by		O
spectroscopic		O
investigations		O
.		O
This		O
suggests		O
that		O
(		O
+		O
)		O
-		O
1f		O
and		O
other		O
N		O
-		O
substituted		O
benzomorphan		O
analogues		O
may		O
be		O
binding		O
to		O
single		O
sigma		O
1		O
receptors		O
in		O
a		O
different		O
way		O
or		O
to		O
different		O
sigma		O
1		O
receptors		O
.		O
In		O
a		O
standardized		O
assay		O
that		O
measures		O
Pgp		O
function		O
by		O
the		O
Pgp		O
-		O
mediated		O
efflux		O
of		O
the		O
calcein		O
-		O
AM		O
Pgp		O
substrate		O
and		O
uses		O
human		O
lymphoblastoid		O
MDR		O
-		O
CEM		O
(		O
VBL		O
(		O
100		O
)		O
)		O
cells		O
as		O
highly		O
resistant		O
Pgp		O
-		O
expressing		O
cells		O
and		O
the		O
cyclic		O
undecapeptide		O
cyclosporin		O
A		O
(		O
CsA		O
)		O
as		O
a		O
reference		O
MDR		O
-		O
reversing		O
agent		O
(		O
IC		O
(		O
50		O
)		O
of		O
3.4		O
microM		O
)		O
,		O
AbA		O
was		O
found		O
to		O
be		O
a		O
more		O
active		O
Pgp		O
inhibitor		O
(		O
IC		O
(		O
50		O
)		O
of		O
2.3		O
microM		O
)		O
.		O
Now		O
we		O
report		O
the		O
details		O
required		O
for		O
its		O
synthesis		O
,		O
together		O
with		O
its		O
potency		O
and		O
efficacy		O
in		O
two		O
assays		O
of		O
functional		O
activation		O
of		O
the		O
NMDA		O
receptor		O
,		O
namely		O
agonist		O
-		O
influenced		O
[		O
3H		O
]		O
MK801		O
binding		O
and		O
agonist		O
-		O
induced		O
release		O
of		O
the		O
neurotransmitter		O
[		O
3H		O
]		O
-		O
norepinephrine		O
from		O
brain		O
slices		O
.		O
The		O
novel		O
semirigid		O
derivatives		O
(		B-IUPAC
+		I-IUPAC
)		I-IUPAC
-		I-IUPAC
cis		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bicyclo		I-IUPAC
[		I-IUPAC
3.1.0		I-IUPAC
]		I-IUPAC
hexyl		I-IUPAC
]		I-IUPAC
piperidine		I-IUPAC
[		O
(		O
+		O
)		O
-		O
8		O
]		O
,		O
its		O
enantiomer		O
(		B-PARTIUPAC
-		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
8		I-PARTIUPAC
,		O
and		O
(		B-IUPAC
+		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bicyclo		I-IUPAC
[		I-IUPAC
3.1.0		I-IUPAC
]		I-IUPAC
hexyl		I-IUPAC
]		I-IUPAC
piperidine		I-IUPAC
[		O
(		O
+		O
/		O
-		O
)		O
-		O
9		O
]		O
were		O
synthesized		O
as		O
probes		O
to		O
investigate		O
the		O
mode		O
of		O
interaction		O
of		O
phencyclidine		O
(		O
PCP		O
)		O
with		O
its		O
binding		O
site		O
on		O
the		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
aspartate		I-IUPAC
receptor		O
complex		O
.		O
An		O
(		B-IUPAC
N		I-IUPAC
)		I-IUPAC
-		I-IUPAC
methanocarba		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylthio		I-IUPAC
-		I-IUPAC
ADP		I-IUPAC
analogue		B-MODIFIER
displayed		O
an		O
EC		O
(		O
50		O
)		O
at		O
the		O
hP2Y		O
(		O
1		O
)		O
receptor		O
of		O
0.40		O
nM		O
and		O
was		O
55		O
-		O
fold		O
more		O
potent		O
than		O
the		O
corresponding		O
triphosphate		O
and		O
16		O
-		O
fold		O
more		O
potent		O
than		O
the		O
riboside		O
5'		B-IUPAC
-		I-IUPAC
diphosphate		I-IUPAC
.		O
The		O
effects		O
of		O
the		O
target		O
compounds		O
on		O
GABA		O
uptake		O
mechanisms		O
in		O
vitro		O
were		O
measured		O
using		O
a		O
rat		O
brain		O
synaptosomal		O
preparation		O
and		O
primary		O
cultures		O
of		O
mouse		O
cortical		O
neurons		O
and		O
glia		O
cells		O
(		O
astrocytes		O
)		O
.		O
In		O
in		O
vivo		O
tests		O
against		O
L1210		O
in		O
mice		O
,		O
4		O
failed		O
to		O
show		O
therapeutic		O
effect		O
.		O
The		O
lead		O
compound		O
1a		O
was		O
inactive		O
in		O
the		O
LE1210		O
and		O
P388		O
systems		O
at		O
the		O
doses		O
tested		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
bromo		I-IUPAC
and		O
5		B-IUPAC
-		I-IUPAC
iodo		I-IUPAC
analogues		B-MODIFIER
10		O
and		O
11		O
,		O
respectively		O
,		O
were		O
obtained		O
similarly		O
.		O
In		O
furtherance		O
of		O
our		O
SAR		O
study		O
on		O
the		O
chemistry		O
and		O
antitumor		O
activity		O
of		O
fused		O
nitrogen		O
heteroaromatic		O
compounds		O
,		O
a		O
series		O
of		O
linear		O
,		O
methyl		B-IUPAC
-		O
substituted		B-MODIFIER
derivatives		B-MODIFIER
of		O
5H		B-PARTIUPAC
-		I-PARTIUPAC
and		O
6H		B-IUPAC
-		I-IUPAC
indolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
quinolines		I-IUPAC
were		O
synthesized		O
according		O
to		O
the		O
modified		O
Graebe		O
-		O
Ullmann		O
reaction		O
.		O
These		O
synthetic		O
steroids		O
would		O
facilitate		O
investigations		O
on		O
the		O
potential		O
biological		O
role		O
of		O
catechol		O
estrogens		O
and		O
also		O
enable		O
further		O
examination		O
of		O
the		O
structural		O
and		O
electronic		O
constraints		O
on		O
the		O
A		O
ring		O
in		O
the		O
interaction		O
of		O
estrogens		O
with		O
the		O
estrogen		O
receptor		O
.		O
Further		O
conjugation		O
of		O
[		O
131I		O
]		O
MIH		O
with		O
a		O
mAb		O
against		O
osteogenic		O
sarcoma		O
(		O
OST7		O
)		O
after		O
reduction		O
of		O
its		O
disulfide		O
bonds		O
was		O
followed		O
up		O
.		O
2		O
-		O
Amino		O
-		O
3		O
-		O
aroylthiophenes		O
are		O
agonist		O
allosteric		O
enhancers		O
(		O
AE		O
)		O
at		O
the		O
A		O
(		O
1		O
)		O
adenosine		O
receptor		O
(		O
A		O
(		O
1		O
)		O
AR		O
)		O
.		O
The		O
templates		O
reported		O
in		O
this		O
work		O
correspond		O
to		O
2,3		B-PARTIUPAC
-		I-PARTIUPAC
dideoxy		I-PARTIUPAC
-		I-PARTIUPAC
L		I-PARTIUPAC
-		I-PARTIUPAC
erythro		I-PARTIUPAC
-		I-PARTIUPAC
or		O
-		B-PARTIUPAC
threo		I-PARTIUPAC
-		I-PARTIUPAC
hexono		I-PARTIUPAC
-		I-PARTIUPAC
1,4		I-PARTIUPAC
-		I-PARTIUPAC
lactone		I-PARTIUPAC
(		O
template		O
III		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
deoxyapiolactone		I-IUPAC
(		O
template		O
IV		O
)		O
.		O
Separation		O
of		O
diastereoisomers		O
was		O
achieved		O
by		O
HPLC		O
or		O
by		O
preparative		O
TLC		O
plates		O
.		O
Compounds		O
3b		O
,		O
3c		O
-		O
f		O
,		O
3h		O
,		O
7a		O
,		O
and		O
7b		O
were		O
found		O
to		O
exert		O
cytostatic		O
activity		O
against		O
malignant		O
cell		O
lines		O
:		O
pancreatic		O
carcinoma		O
(		O
MiaPaCa2		O
)		O
,		O
breast		O
carcinoma		O
(		O
MCF7		O
)		O
,		O
cervical		O
carcinoma		O
(		O
HeLa		O
)		O
,		O
laryngeal		O
carcinoma		O
(		O
Hep2		O
)		O
,		O
colon		O
carcinoma		O
(		O
CaCo		O
-		O
2		O
)		O
,		O
melanoma		O
(		O
HBL		O
)		O
,		O
human		O
fibroblast		O
cell		O
lines		O
(		O
WI		O
-		O
38		O
)		O
.		O
Several		O
of		O
these		O
quaternary		O
phenothiazines		O
completely		O
inhibited		O
T		O
.		O
A		O
novel		O
class		O
of		O
5		O
-		O
substituted		O
acyclic		O
pyrimidine		O
nucleosides		O
,		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azidovinyl		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
(		O
9a		O
)		O
,		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
ethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azidovinyl		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
(		O
9b		O
)		O
,		O
and		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
(		I-IUPAC
hydroxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azidovinyl		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
(		O
9c		O
)		O
,		O
were		O
synthesized		O
by		O
regiospecific		O
addition		O
of		O
bromine		O
azide		O
to		O
the		O
5		B-IUPAC
-		I-IUPAC
vinyl		I-IUPAC
substituent		B-MODIFIER
of		O
the		O
respective		O
5		B-IUPAC
-		I-IUPAC
vinyluracils		I-IUPAC
(		O
2a		O
-		O
c		O
)		O
followed		O
by		O
treatment		O
of		O
the		O
obtained		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azido		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromoethyl		I-IUPAC
)		I-IUPAC
compounds		B-MODIFIER
(		O
3a		O
-		O
c		O
)		O
with		O
t		O
-		O
BuOK		O
,		O
to		O
affect		O
the		O
base		O
-		O
catalyzed		O
elimination		O
of		O
HBr		O
.		O
Fifteen		O
glucagon		O
analogues		O
have		O
been		O
designed		O
and		O
synthesized		O
by		O
incorporating		O
structural		O
changes		O
in		O
the		O
N		O
-		O
terminal		O
region		O
of		O
glucagon		O
,		O
in		O
particular		O
histidine		O
-		O
1		O
,		O
phenylalanine		O
-		O
6		O
,		O
and		O
aspartic		O
acid		O
-		O
9		O
.		O
Following		O
deblocking		O
with		O
Na		O
in		O
NH3		O
and		O
oxidizing		O
with		O
K3		O
[		O
Fe		O
(		O
CN		O
)		O
6		O
]		O
,		O
each		O
peptide		O
was		O
purified		O
on		O
Sephadex		O
G		O
-		O
15		O
in		O
a		O
two		O
-		O
step		O
procedure		O
using		O
50%		O
HOAc		O
and		O
0.2		O
M		O
HOAc		O
as		O
eluants		O
.		O
,		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2RS		I-IUPAC
,		I-IUPAC
3SR		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydroxybutylladenine		I-IUPAC
,		O
9		B-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
(		I-PARTIUPAC
RS		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
or		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
dihydroxybutyl		I-IUPAC
]		I-IUPAC
adenine		I-IUPAC
,		O
9		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2S		I-IUPAC
,		I-IUPAC
3R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2,3,4		I-IUPAC
-		I-IUPAC
trihydroxybutyl		I-IUPAC
]		I-IUPAC
adenine		I-IUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
adenin		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
alanine		I-IUPAC
,		O
an		O
antiviral		O
effect		O
was		O
noted		O
at		O
a		O
concentration		O
of		O
0.5-1		O
mM		O
.		O
These		O
results		O
provide		O
the		O
first		O
experimental		O
evidence		O
that		O
peptides		O
can		O
carry		O
pyrimidines		O
into		O
a		O
eukaryote		O
.		O
Substitution		O
with		O
a		O
cyclopropylmethyl		O
or		O
benzyl		O
group		O
resulted		O
in		O
reduced		O
activity		O
.		O
Therefore		O
,		O
this		O
paper		O
describes		O
the		O
synthesis		O
and		O
characterization		O
of		O
two		O
types		O
of		O
carbonic		O
anhydrase		O
inhibitors		O
;		O
the		O
N		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		O
substituted		B-MODIFIER
sulfonamides		B-IUPAC
are		O
reversible		O
competitive		O
inhibitors		O
of		O
carbonic		O
anhydrase		O
,		O
while		O
the		O
N		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		O
substituted		B-MODIFIER
sulfonamides		B-IUPAC
are		O
irreversible		O
inhibitors		O
.		O
A		O
selected		O
number		O
of		O
previously		O
known		O
2,4		B-IUPAC
-		I-IUPAC
diaminothieno		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
lacking		O
the		O
3,4,5		B-IUPAC
-		I-IUPAC
trimethoxyphenyl		I-IUPAC
and		O
2,5		B-IUPAC
-		I-IUPAC
dimethoxyphenyl		I-IUPAC
substitution		B-MODIFIER
pattern		I-MODIFIER
of		O
TMQ		O
and		O
PTX		O
,		O
respectively		O
,		O
were		O
also		O
tested		O
for		O
comparison		O
.		O
N3		B-IUPAC
-		I-IUPAC
Methylquinazolinones		I-IUPAC
42		O
and		O
43		O
were		O
essentially		O
devoid		O
of		O
activity		O
(		O
IC50		O
values		O
&		O
gt		O
;		O
100		O
microM		O
)		O
.		O
The		O
data		O
provide		O
a		O
basis		O
for		O
identifying		O
muscarinic		O
receptor		O
subtypes		O
(		O
as		O
defined		O
through		O
cloning		O
procedures		O
)		O
with		O
selective		O
ligands		O
.		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
Hydroxymethyl		I-IUPAC
)		I-IUPAC
estradiol		I-IUPAC
1		O
did		O
not		O
stimulate		O
the		O
growth		O
of		O
MCF		O
-		O
7		O
cells		O
at		O
concentrations		O
up		O
to		O
1		O
microM		O
.		O
Most		O
compounds		O
were		O
orally		O
active		O
in		O
blocking		O
the		O
conditioned		O
avoidance		O
response		O
(		O
CAR		O
)		O
but		O
did		O
not		O
antagonize		O
apomorphine		O
-		O
induced		O
stereotyped		O
behavior		O
.		O
The		O
most		O
active		O
compound		O
in		O
the		O
functional		O
test		O
(		O
-		O
log		O
Ki		O
=		O
8.3		O
)		O
and		O
in		O
binding		O
studies		O
with		O
[		B-IUPAC
3H		I-IUPAC
]		I-IUPAC
-		I-IUPAC
(		I-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
methylhistamine		I-IUPAC
on		O
rat		O
cerebral		O
cortex		O
(		O
-		O
log		O
Ki		O
=		O
9.0		O
)		O
in		O
vitro		O
was		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
imidazol		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
propyl		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
iodophenyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
ether		I-IUPAC
(		O
iodoproxyfan		O
,		O
19		O
)		O
exhibiting		O
no		O
central		O
H3		O
receptor		O
antagonist		O
activity		O
in		O
vivo		O
.		O
5		B-IUPAC
-		I-IUPAC
Deazaaminopterins		I-IUPAC
bearing		O
an		O
alkyl		O
substituent		O
at		O
the		O
5		O
-		O
position		O
were		O
generally		O
quite		O
effective		O
as		O
antiinflammatory		O
agents		O
.		O
Of		O
a		O
series		O
of		O
58		O
aliphatic		O
nucleoside		O
analogues		O
,		O
(		B-IUPAC
S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
dihydroxypropyl		I-IUPAC
)		I-IUPAC
adenine		I-IUPAC
[		O
(		O
S		O
)		O
-		O
DHPA		O
]		O
proved		O
to		O
be		O
the		O
most		O
active		O
congener		O
,		O
when		O
assayed		O
for		O
antiviral		O
activity		O
in		O
primary		O
rabbit		O
kidney		O
cell		O
cultures		O
challenged		O
with		O
either		O
vaccinia		O
or		O
vesicular		O
stomatitis		O
virus		O
.		O
4		B-MODIFIER
-		I-MODIFIER
N		I-MODIFIER
-		I-MODIFIER
Substituted		B-MODIFIER
and		O
-		B-MODIFIER
unsubstituted		I-MODIFIER
3		B-PARTIUPAC
-		I-PARTIUPAC
alkyl		I-PARTIUPAC
-		I-PARTIUPAC
and		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
alkylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
4,3		I-IUPAC
-		I-IUPAC
e		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
thiadiazine		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxides		I-IUPAC
were		O
synthesized		O
and		O
tested		O
vs		O
diazoxide		O
and		O
selected		O
3		B-PARTIUPAC
-		I-PARTIUPAC
alykl		I-PARTIUPAC
-		I-PARTIUPAC
and		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
alkylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
4H		I-IUPAC
-		I-IUPAC
1,2,4		I-IUPAC
-		I-IUPAC
benzothiadiazine		I-IUPAC
1,1		I-IUPAC
-		I-IUPAC
dioxides		I-IUPAC
as		O
potassium		O
channel		O
openers		O
on		O
pancreatic		O
and		O
vascular		O
tissues		O
.		O
These		O
analogues		O
were		O
compared		O
to		O
the		O
corresponding		O
series		O
of		O
6,8		B-PARTIUPAC
-		I-PARTIUPAC
difluoro		I-PARTIUPAC
-		I-PARTIUPAC
and		O
6		B-IUPAC
-		I-IUPAC
fluoro		I-IUPAC
-		I-IUPAC
8H		I-IUPAC
-		I-IUPAC
quinolones		I-IUPAC
(		O
ciprofloxacin		O
type		O
)		O
.		O
Further		O
modification		O
of		O
this		O
series		O
produced		O
benzoic		O
acid		O
derivative		O
(		B-IUPAC
1		I-IUPAC
,		I-IUPAC
1		I-IUPAC
-		I-IUPAC
dioxido		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
benzisothiazol		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
(		I-IUPAC
phenylmethoxy		I-IUPAC
)		I-IUPAC
carbonyl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
benzoate		I-IUPAC
(		O
7n		O
)		O
which		O
is		O
the		O
most		O
potent		O
inhibitor		O
identified		O
in		O
this		O
series		O
(		O
IC50		O
=		O
0.064		O
microM		O
)		O
.		O
A		O
hemolysis		O
investigation		O
was		O
conducted		O
on		O
human		O
red		O
blood		O
cells		O
,		O
and		O
the		O
results		O
demonstrate		O
that		O
proAEL		O
liposomes		O
display		O
a		O
very		O
low		O
hemotoxicity		O
,		O
which		O
has		O
been		O
a		O
major		O
obstacle		O
for		O
using		O
AELs		O
in		O
cancer		O
therapy		O
.		O
Among		O
the		O
3		O
-		O
substituted		O
allopurinol		O
nucleosides		O
,		O
18b		O
and		O
18c		O
showed		O
significant		O
activity		O
against		O
Para		O
3		O
virus		O
and		O
were		O
found		O
to		O
be		O
potent		O
inhibitors		O
of		O
growth		O
of		O
L1210		O
and		O
P388		O
leukemia		O
.		O
Hydrolysis		O
of		O
the		O
lactone		O
ring		O
of		O
the		O
1H		B-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzopyran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
one		I-IUPAC
skeleton		B-MODIFIER
,		O
to		O
give		O
6		B-IUPAC
-		I-IUPAC
[		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylhex		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
yl		I-IUPAC
]		I-IUPAC
amino		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4		I-IUPAC
,		I-IUPAC
5		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
ammoniohexanoate		I-IUPAC
(		O
5		O
)		O
,		O
led		O
to		O
a		O
considerable		O
decrease		O
in		O
activity		O
.		O
Of		O
the		O
four		O
gem		O
diether		O
nucleosides		O
,		O
only		O
the		O
dimethyl		O
gem		O
diether		O
congener		O
showed		O
significant		O
antiviral		O
activity		O
against		O
both		O
viruses		O
.		O
By		O
these		O
approaches		O
eight		O
new		O
diamidines		O
and		O
four		O
potential		O
prodrugs		O
were		O
prepared		O
.		O
The		O
binding		O
of		O
selective		O
muscarinic		O
receptor		O
antagonists		O
to		O
regions		O
of		O
rat		O
brain		O
was		O
examined		O
through		O
quantitative		O
autoradiographic		O
techniques		O
.		O
Compound		O
2		O
was		O
obtained		O
from		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
hydroxypyrimidine		I-IUPAC
and		O
1		B-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
dichloroacetone		I-IUPAC
.		O
Beta		O
-		O
glucuronidase		O
from		O
both		O
Escherichia		O
coli		O
and		O
bovine		O
liver		O
cleaved		O
the		O
prodrugs		O
efficiently		O
to		O
release		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
benzylguanine		I-IUPAC
and		O
O		B-IUPAC
(		I-IUPAC
6		I-IUPAC
)		I-IUPAC
-		I-IUPAC
benzyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyguanosine		I-IUPAC
,		O
respectively		O
.		O
However		O
,		O
the		O
intrinsic		O
receptor		O
-		O
alkylating		O
activities		O
of		O
these		O
compounds		O
were		O
probably		O
very		O
hampered		O
by		O
their		O
poor		O
hydrolytic		O
stability		O
in		O
estrogen		O
receptor		O
-		O
containing		O
tissue		O
extracts		O
.		O
Compound		O
5h		O
was		O
also		O
active		O
against		O
T		O
.		O
This		O
agrees		O
with		O
a		O
recent		O
binding		O
model		O
that		O
suggests		O
this		O
general		O
class		O
of		O
compounds		O
binds		O
to		O
EGFR		O
with		O
the		O
6		O
-		O
position		O
located		O
in		O
an		O
area		O
of		O
comparative		O
bulk		O
tolerance		O
at		O
the		O
entrance		O
to		O
the		O
ATP		O
-		O
binding		O
pocket		O
.		O
N5		B-IUPAC
-		I-IUPAC
Acetyl		I-IUPAC
-		I-IUPAC
N5		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
ornithine		I-IUPAC
(		O
1		O
)		O
,		O
the		O
key		O
constituent		O
of		O
several		O
microbial		O
siderophores		O
,		O
has		O
been		O
synthesized		O
in		O
23%		O
yield		O
overall		O
from		O
N		O
-		O
Cbz		O
-		O
L		O
-		O
glutamic		O
acid		O
1		B-IUPAC
-		I-IUPAC
tert		I-IUPAC
-		I-IUPAC
butyl		I-IUPAC
ester		I-IUPAC
(		O
6		O
)		O
derived		O
from		O
L		B-IUPAC
-		I-IUPAC
glutamic		I-IUPAC
acid		I-IUPAC
.		O
For		O
example		O
,		O
[		O
(		O
2S		O
,		O
3S		O
)		O
-		O
beta		O
-		O
MePhe4		O
]		O
DPDPE		O
(		O
2		O
)		O
is		O
1800		O
-		O
fold		O
selective		O
in		O
binding		O
to		O
the		O
delta		O
vs		O
mu		O
receptor		O
,		O
making		O
it		O
one		O
of		O
the		O
most		O
selective		O
delta		O
opioid		O
receptor		O
ligands		O
in		O
the		O
enkephalin		O
series		O
as		O
assessed		O
by		O
the		O
rat		O
brain		O
binding		O
assay		O
,		O
whereas		O
the		O
corresponding		O
(		O
2R		O
,		O
3R		O
)		O
-		O
beta		O
-		O
Me		O
-		O
p		O
-		O
NO2Phe		O
-		O
containing		O
analogue		O
9		O
is		O
only		O
4.5		O
-		O
fold		O
selective		O
(		O
nonselective		O
)		O
in		O
this		O
same		O
assay		O
.		O
Thus		O
,		O
MTX		O
bis		B-IUPAC
(		I-IUPAC
6		I-IUPAC
-		I-IUPAC
chloropiperonyl		I-IUPAC
)		I-IUPAC
ester		I-IUPAC
at		O
an		O
MTX		O
-		O
equivalent		O
dose		O
of		O
5.5		O
mg		O
/		O
kg		O
gave		O
a		O
+		O
88%		O
increase		O
in		O
median		O
life		O
span		O
(		O
ILS		O
)		O
,		O
whereas		O
for		O
MTX		O
a		O
+		O
88%		O
ILS		O
required		O
30		O
mg		O
/		O
kg		O
.		O
Analyses		O
of		O
urine		O
samples		O
indicated		O
that		O
m		O
-		O
iodohippuric		O
acid		O
was		O
the		O
sole		O
radiolabeled		O
metabolite		O
.		O
2beta		B-IUPAC
-		I-IUPAC
Carbomethoxy		I-IUPAC
-		I-IUPAC
3beta		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
(		I-IUPAC
Z		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
iodoethenyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
)		I-IUPAC
nortropane		I-IUPAC
(		O
ZIENT		O
)		O
(		O
6		O
)		O
and		O
2beta		B-IUPAC
-		I-IUPAC
carbomethoxy		I-IUPAC
-		I-IUPAC
3beta		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
(		I-IUPAC
E		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
iodoethenyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
)		I-IUPAC
nortropane		I-IUPAC
(		O
EIENT		O
)		O
(		O
10		O
)		O
were		O
prepared		O
and		O
evaluated		O
in		O
vitro		O
and		O
in		O
vivo		O
for		O
serotonin		O
transporter		O
(		O
SERT		O
)		O
selectivity		O
and		O
specificity		O
.		O
Four		O
compounds		O
(		O
5a		O
,		O
h		O
,		O
k		O
,		O
l		O
)		O
were		O
tested		O
against		O
T		O
.		O
The		O
compounds		O
were		O
evaluated		O
as		O
inhibitors		O
against		O
DHFR		O
from		O
P		O
.		O
Where		O
substantial		O
reduction		O
or		O
abolition		O
of		O
affinity		O
at		O
AMPA		O
receptors		O
was		O
observed		O
,		O
this		O
could		O
be		O
rationalized		O
on		O
the		O
basis		O
of		O
the		O
ability		O
of		O
the		O
ligand		O
to		O
fit		O
the		O
construct		O
.		O
Several		O
of		O
the		O
compounds		O
showed		O
much		O
lower		O
levels		O
of		O
cross		O
-		O
resistance		O
to		O
the		O
P388		O
/		O
AMSA		O
line		O
than		O
classical		O
DNA		O
-		O
intercalating		O
agents		O
,		O
which		O
suggests		O
that		O
their		O
primary		O
mechanism		O
of		O
action		O
may		O
not		O
be		O
via		O
interference		O
with		O
topoisomerase		O
II		O
alpha		O
.		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
Arylmethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,3,6		I-IUPAC
-		I-IUPAC
tetrahydropyridine		I-IUPAC
derivatives		B-MODIFIER
,		O
at		O
best		O
,		O
exhibit		O
modest		O
antitetrabenazine		O
activity		O
,		O
with		O
the		O
exception		O
of		O
4		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylmethyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
1,2,3,6		I-IUPAC
-		I-IUPAC
tetrahydropyridine		I-IUPAC
which		O
is		O
approximately		O
equipotent		O
with		O
amitriptyline		O
.		O
Subsequently		O
,		O
we		O
have		O
designed		O
and		O
synthesized		O
novel		O
olean		B-PARTIUPAC
-		I-PARTIUPAC
and		O
urs		B-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
one		I-IUPAC
derivatives		B-MODIFIER
with		O
nitrile		B-IUPAC
and		O
carboxyl		B-IUPAC
groups		B-MODIFIER
at		O
C		O
-		O
2		O
in		O
ring		O
A		O
and		O
with		O
9		B-IUPAC
(		I-IUPAC
11		I-IUPAC
)		I-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
12		I-IUPAC
-		I-IUPAC
one		I-IUPAC
and		O
12		B-IUPAC
-		I-IUPAC
en		I-IUPAC
-		I-IUPAC
11		I-IUPAC
-		I-IUPAC
one		I-IUPAC
functionalities		B-MODIFIER
in		O
ring		O
C		O
.		O
Most		O
compounds		O
showed		O
slower		O
on		O
-		O
set		O
and		O
longer		O
duration		O
of		O
action		O
relative		O
to		O
cocaine		O
.		O
Radioiodine		O
was		O
introduced		O
into		O
the		O
5		O
-		O
position		O
of		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aminopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodothiophene		I-IUPAC
and		O
N		B-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
(		I-IUPAC
RS		I-IUPAC
)		I-IUPAC
-		I-IUPAC
aminopropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
iodothiophene		I-IUPAC
by		O
radioiodination		O
of		O
the		O
corresponding		O
5		B-IUPAC
-		I-IUPAC
boronic		I-IUPAC
acid		I-IUPAC
or		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
trimethylstannyl		I-IUPAC
)		I-IUPAC
derivatives		B-MODIFIER
.		O
Structure		O
-		O
activity		O
relationships		O
for		O
inhibition		O
of		O
DNA		O
-		O
dependent		O
protein		O
kinase		O
(		O
DNA		O
-		O
PK		O
)		O
have		O
been		O
defined		O
for		O
substituted		B-MODIFIER
chromen		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
.		O
Both		O
of		O
these		O
retinoids		O
had		O
ID50		O
values		O
(		O
dose		O
required		O
for		O
half		O
-		O
maximal		O
inhibition		O
of		O
phorbol		O
ester		O
induced		O
ODC		O
activity		O
)		O
of		O
about		O
0.3		O
nmol		O
.		O
(		O
R		O
)		O
-		O
11a		O
was		O
not		O
a		O
substrate		O
for		O
P815		O
tryptophan		O
hydroxylase		O
.		O
Bicyclic		O
hydantoin		O
4		O
was		O
nevertheless		O
a		O
good		O
anti		O
-		O
MES		O
anticonvulsant		O
in		O
mice		O
(		O
ED50		O
=		O
86		O
mg		O
/		O
kg		O
)		O
,		O
although		O
this		O
activity		O
likely		O
results		O
from		O
mechanisms		O
other		O
than		O
interactions		O
at		O
the		O
neuronal		O
voltage		O
-		O
dependent		O
sodium		O
channel		O
.		O
This		O
compound		O
was		O
inactive		O
against		O
Brugia		O
pahangi		O
at		O
a		O
dosage		O
of		O
100		O
mg		O
/		O
kg		O
x		O
5		O
days		O
.		O
6beta		B-IUPAC
-		I-IUPAC
Acyloxy		I-IUPAC
(		I-IUPAC
nor		I-IUPAC
)		I-IUPAC
tropanes		I-IUPAC
and		O
classical		O
muscarinic		O
agonists		O
,		O
such		O
as		O
muscarine		O
and		O
oxotremorine		O
,		O
had		O
higher		O
affinity		O
versus		O
oxotremorine		O
-		O
M		O
binding		O
compared		O
to		O
quinuclidinyl		O
benzilate		O
binding		O
at		O
native		O
M		O
(		O
2		O
)		O
-		O
muscarinic		O
receptors		O
of		O
heart		O
,		O
but		O
not		O
at		O
transfected		O
m		O
(		O
2		O
)		O
-		O
muscarinic		O
receptors		O
.		O
Protolytic		O
properties		O
of		O
compounds		O
7a		O
,		O
b		O
,		O
8b		O
,		O
and		O
9b		O
were		O
determined		O
by		O
titration		O
,		O
and		O
a		O
correlation		O
between		O
the		O
pK		O
(		O
a		O
)		O
values		O
and		O
the		O
activity		O
at		O
AMPA		O
receptors		O
was		O
apparent		O
.		O
Two		O
additional		O
7		O
-		O
oxa		O
-		O
7,8		O
-		O
dihydro		O
-		O
RAs		O
exhibited		O
modest		O
activity		O
in		O
the		O
papilloma		O
assay		O
.		O
The		O
key		O
intermediate		O
,		O
hemiaminal		O
8		O
,		O
was		O
prepared		O
in		O
four		O
stages		O
from		O
3		B-IUPAC
-		I-IUPAC
chloropropionaldehyde		I-IUPAC
diethyl		I-IUPAC
acetal		I-IUPAC
.		O
Indolo		B-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
quinolines		I-IUPAC
with		O
the		O
highest		O
number		O
of		O
methyl		B-IUPAC
groups		B-MODIFIER
had		O
the		O
greatest		O
contribution		O
to		O
the		O
increase		O
in		O
the		O
Tm		O
of		O
calf		O
thymus		O
DNA		O
.		O
Convenient		O
procedures		O
are		O
described		O
for		O
the		O
synthesis		O
of		O
5		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
N		B-IUPAC
(		I-IUPAC
4		I-IUPAC
)		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxycytidines		I-IUPAC
5a		O
,		O
b		O
,		O
d		O
-		O
h		O
via		O
transformation		O
of		O
the		O
respective		O
5		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
3'		B-IUPAC
,		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
di		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
acetyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridines		I-IUPAC
1a		O
-		O
c		O
,		O
e		O
-		O
h		O
.		O
Although		O
less		O
potent		O
than		O
PDDF		O
,		O
marked		O
inhibition		O
of		O
thymidylate		O
synthase		O
by		O
2		O
was		O
observed		O
in		O
permeabilized		O
L1210		O
cells		O
.		O
The		O
results		O
also		O
indicate		O
that		O
the		O
microsomal		O
monooxygenase		O
activities		O
induced		O
in		O
rat		O
liver		O
by		O
alpha		B-IUPAC
-		I-IUPAC
naphthoflavone		I-IUPAC
,		O
beta		B-IUPAC
-		I-IUPAC
naphthoflavone		I-IUPAC
,		O
and		O
3		B-IUPAC
-		I-IUPAC
methylcholanthrene		I-IUPAC
are		O
not		O
equivalent		O
.		O
The		O
5		B-IUPAC
-		I-IUPAC
fluorocytosine		I-IUPAC
analogue		B-MODIFIER
12		O
was		O
inactive		O
at		O
up		O
to		O
1		O
x		O
10		O
(		O
-		O
4		O
)		O
M		O
,		O
and		O
the		O
other		O
halogenated		O
derivatives		O
10		O
and		O
11		O
had		O
no		O
effect		O
even		O
at		O
1		O
x		O
10		O
(		O
-		O
3		O
)		O
M		O
.		O
Several		O
7		B-IUPAC
-		I-IUPAC
hydroxypyrazolo		I-IUPAC
[		I-IUPAC
1,5		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
(		O
1-21		O
)		O
,		O
7		B-IUPAC
-		I-IUPAC
mercaptopyrazolo		I-IUPAC
[		I-IUPAC
1,5		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyrimidines		I-IUPAC
(		O
37-49		O
)		O
,		O
and		O
4		B-IUPAC
-		I-IUPAC
alkylpyrazolo		I-IUPAC
[		I-IUPAC
1,5		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyrimidin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
(		O
50-55		O
)		O
and		O
the		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
alkylpyrazolo		I-IUPAC
[		I-IUPAC
1,5		I-IUPAC
-		I-IUPAC
a		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
thiones		I-IUPAC
(		O
56-60		O
)		O
were		O
synthesized		O
and		O
tested		O
for		O
antischistosomal		O
activity		O
against		O
Schistosoma		O
mansoni		O
.		O
Thus		O
both		O
1		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
hydroxyalkyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
and		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
carboxyalkyl		I-IUPAC
)		I-IUPAC
pyridinones		I-IUPAC
are		O
able		O
to		O
remove		O
iron		O
from		O
the		O
liver		O
.		O
Fifty		O
nanomoles		O
of		O
4a		O
blocked		O
only		O
30%		O
of		O
the		O
specific		O
binding		O
of		O
[		O
18F		O
]		O
4d		O
,		O
while		O
complete		O
blockade		O
was		O
obtained		O
from		O
co		O
-		O
injection		O
of		O
200		O
nmol		O
of		O
4a		O
(		O
H		O
/		O
Cb		O
-		O
1		O
from		O
17.2		O
to		O
0.6		O
)		O
.		O
Optimization		O
of		O
the		O
spatial		O
alignment		O
of		O
the		O
RGD		O
moieties		O
through		O
careful		O
molecular		O
design		O
and		O
library		O
construction		O
could		O
induce		O
multivalent		O
ligand		O
-		O
receptor		O
interactions		O
useful		O
for		O
in		O
vivo		O
tumor		O
imaging		O
and		O
tumor		O
-		O
targeted		O
therapy		O
.		O
To		O
elucidate		O
the		O
structural		O
requirements		O
for		O
selective		O
activation		O
of		O
the		O
site		O
/		O
conformation		O
of		O
AMPA		O
receptors		O
recognized		O
by		O
2		O
,		O
a		O
number		O
of		O
isosteric		O
analogues		O
of		O
2		O
have		O
now		O
been		O
synthesized		O
and		O
pharmacologically		O
characterized		O
.		O
Subacute		O
toxicity		O
evaluation		O
in		O
dogs		O
and		O
guinea		O
pigs		O
showed		O
it		O
to		O
have		O
an		O
unfavorable		O
therapeutic		O
ratio		O
.		O
Inhibition		O
of		O
macromolecular		O
synthesis		O
with		O
compounds		O
4c		O
,		O
4d		O
,		O
6e		O
,		O
9c		O
,		O
and		O
9d		O
follows		O
the		O
order		O
:		O
DNA		O
greater		O
than		O
RNA		O
greater		O
than		O
or		O
equal		O
to		O
protein		O
.		O
The		O
activity		O
of		O
ring		O
-		O
substituted		O
(		O
F		O
,		O
Cl		O
,		O
CH3		O
,		O
and		O
OCH3		O
)		O
2		B-IUPAC
-		I-IUPAC
phenethoxyadenosines		I-IUPAC
increases		O
ortho		O
less		O
than		O
meta		O
less		O
than		O
para		O
.		O
The		O
inhibition		O
constants		O
,		O
alpha		O
(		O
the		O
ratio		O
of		O
the		O
molar		O
I50		O
of		O
theophylline		O
to		O
the		O
molar		O
I50		O
of		O
the		O
test		O
compounds		O
)		O
,		O
were		O
subjected		O
to		O
a		O
Hansch		O
correlation		O
analysis		O
.		O
Two		O
control		O
compounds		O
were		O
also		O
evaluated		O
:		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
anthracen		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
butylamine		I-IUPAC
and		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
anthracen		I-IUPAC
-		I-IUPAC
9		I-IUPAC
-		I-IUPAC
ylmethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
butanediamine		I-IUPAC
.		O
The		O
Pgp		O
-		O
inhibitory		O
activity		O
was		O
increased		O
about		O
2		O
-		O
fold		O
by		O
some		O
minor		O
modifications		O
such		O
as		O
those		O
found		O
in		O
the		O
naturally		O
occurring		O
aureobasidins		O
AbB		O
(		O
[		O
D		O
-		O
Hiv		O
(		O
1		O
)		O
]		O
-		O
AbA		O
)		O
,		O
AbC		O
(		O
[		O
Val		O
(		O
6		O
)		O
]		O
-		O
AbA		O
)		O
,		O
and		O
AbD		O
[		O
gammaHOMeVal		O
(		O
9		O
)		O
]		O
-		O
AbA		O
)		O
.		O
The		O
potency		O
pattern		O
due		O
to		O
substituents		O
of		O
the		O
phenyl		B-IUPAC
ring		B-MODIFIER
was		O
found		O
to		O
parallel		O
that		O
found		O
in		O
a		O
previously		O
reported		O
1,3		B-IUPAC
-		I-IUPAC
dialkyl		I-IUPAC
-		I-IUPAC
8		I-IUPAC
-		I-IUPAC
phenylxanthine		I-IUPAC
series		B-MODIFIER
.		O
The		O
enantiomerically		O
pure		O
key		O
intermediate		O
8		O
has		O
been		O
synthesized		O
in		O
six		O
steps		O
from		O
1,6		B-IUPAC
-		I-IUPAC
anhydro		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
gulose		I-IUPAC
(		O
2		O
)		O
,		O
and		O
compound		O
8		O
was		O
condensed		O
with		O
5		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
pyrimidines		B-IUPAC
,		O
6		B-IUPAC
-		I-IUPAC
chloropurine		I-IUPAC
,		O
and		O
2,6		B-MODIFIER
-		I-MODIFIER
disubstituted		I-MODIFIER
purine		B-IUPAC
to		O
obtain		O
various		O
dioxolanylpyrimidine		B-IUPAC
and		O
-		B-PARTIUPAC
purine		I-PARTIUPAC
nucleosides		I-PARTIUPAC
,		O
respectively		O
.		O
A		O
conformationally		O
defined		O
retinoic		O
acid		O
analog		O
(		O
1		O
)		O
which		O
contains		O
a		O
dimethylene		O
bridge		O
to		O
maintain		O
the		O
6		O
-		O
s		O
-		O
trans		O
orientation		O
for		O
two		O
terminal		O
double		O
bonds		O
in		O
the		O
polyene		O
chain		O
was		O
synthesized		O
.		O
The		O
4		B-IUPAC
-		I-IUPAC
phenylfuranone		I-IUPAC
(		O
1		O
and		O
2		O
)		O
and		O
the		O
5		B-IUPAC
-		I-IUPAC
phenylpyranone		I-IUPAC
(		O
4		O
)		O
proved		O
to		O
be		O
only		O
reversible		O
,		O
competitive		O
inhibitors		O
.		O
We		O
also		O
obtained		O
the		O
following		O
order		O
for		O
thrombin		O
binding		O
:		O
p		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxo		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
benzamidine		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
ethylbenzamidine		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
propyl		I-IUPAC
)		I-IUPAC
benzamidine		I-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
methylbenzamidine		I-IUPAC
&		O
gt		O
;		O
benzamidine		B-IUPAC
&		O
gt		O
;		O
p		B-IUPAC
-		I-IUPAC
amidinophenylpyruvate		I-IUPAC
.		O
Syntheses		O
of		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methoxyapomorphine		I-IUPAC
(		O
R		O
-		O
8		O
)		O
,		O
its		O
antipode		O
S		O
-		O
8		O
,		O
and		O
its		O
(		B-PARTIUPAC
R		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
-		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
N		I-PARTIUPAC
-		I-PARTIUPAC
n		I-PARTIUPAC
-		I-PARTIUPAC
propyl		I-PARTIUPAC
R		O
-		O
9		O
derivatives		B-MODIFIER
are		O
described		O
.		O
Evidence		O
incicating		O
that		O
effective		O
in		O
vivo		O
inhibition		O
of		O
hypoxanthine		O
-		O
guanine		O
phosphoribosyltransferase		O
(		O
HGPRT		O
,		O
EC		O
2.4.2.8		O
)		O
should		O
produce		O
antiprotozoal		O
activity		O
without		O
significant		O
toxic		O
effects		O
on		O
mammalian		O
hosts		O
prompted		O
syntheses		O
of		O
1		O
-		O
substituted		O
hypoxanthines		O
bearing		O
functionalized		O
side		O
chains		O
whose		O
groupings		O
might		O
interact		O
with		O
appropriate		O
groupings		O
of		O
HGPRT		O
to		O
form		O
covalent		O
bonds		O
or		O
strong		O
hydrophobic		O
bonds		O
.		O
These		O
findings		O
indicate		O
that		O
[		O
99mTc		O
]		O
CpTT		O
-		O
PA		O
was		O
recognized		O
,		O
transported		O
,		O
and		O
metabolized		O
as		O
a		O
long		O
chain		O
fatty		O
acid		O
analogue		O
for		O
energy		O
production		O
in		O
the		O
myocardium		O
.		O
However		O
,		O
evaluation		O
in		O
sheep		O
indicated		O
that		O
its		O
anthelmintic		O
spectrum		O
was		O
inferior		O
to		O
methyl		B-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylsulfinyl		I-IUPAC
)		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
1,2		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
]		I-IUPAC
pyridine		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
carbamate		I-IUPAC
.		O
Direct		O
alkylation		O
of		O
2		B-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyrimidone		I-IUPAC
produced		O
the		O
N3		O
-		O
substituted		O
derivatives		O
,		O
which		O
were		O
separated		O
from		O
the		O
byproduct		O
4		B-IUPAC
-		I-IUPAC
alkoxy		I-IUPAC
analogues		B-MODIFIER
.		O
Finally		O
these		O
two		O
compounds		O
have		O
been		O
evaluated		O
against		O
Brugia		O
malayi		O
.		O
The		O
heterocyclic		O
systems		O
studied		O
were		O
based		O
on		O
2		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
methylfuran		I-IUPAC
(		O
2-4		O
)		O
,		O
1		B-IUPAC
-		I-IUPAC
phenylpyrazole		I-IUPAC
(		O
5-7		O
)		O
,		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylpyrazole		I-IUPAC
(		O
9-11		O
)		O
,		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methylthiophene		I-IUPAC
(		O
13		O
)		O
,		O
1		B-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
1,2,3		I-IUPAC
-		I-IUPAC
triazole		I-IUPAC
(		O
14		O
)		O
,		O
3		B-IUPAC
-		I-IUPAC
phenylisoxazole		I-IUPAC
(		O
15		O
)		O
,		O
3		B-IUPAC
-		I-IUPAC
phenylisothiazole		I-IUPAC
(		O
16		O
)		O
,		O
2		B-IUPAC
-		I-IUPAC
phenylthiazole		I-IUPAC
(		O
17		O
)		O
,		O
and		O
2		B-IUPAC
-		I-IUPAC
phenyloxazole		I-IUPAC
(		O
18		O
)		O
.		O
We		O
were		O
able		O
to		O
confirm		O
the		O
substantial		O
cardioselectivity		O
of		O
1		B-PARTIUPAC
-		I-PARTIUPAC
(		I-PARTIUPAC
3,4		I-PARTIUPAC
-		I-PARTIUPAC
dimethoxyphenethyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
3		I-PARTIUPAC
-		I-PARTIUPAC
[		I-PARTIUPAC
(		I-PARTIUPAC
4		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
aryl		B-IUPAC
)		B-PARTIUPAC
oxy		I-PARTIUPAC
]		I-PARTIUPAC
propan		I-PARTIUPAC
-		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
ols		I-PARTIUPAC
when		O
compared		O
to		O
those		O
with		O
a		O
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
hydroxyphenethyl		I-IUPAC
)		I-IUPAC
group		B-MODIFIER
.		O
Biodistribution		O
of		O
the		O
purified		O
diastereomers		O
2A		O
,		O
B		O
was		O
evaluated		O
in		O
rats		O
.		O
The		O
optical		O
purity		O
(		O
greater		O
than		O
99.5%		O
)		O
of		O
(		O
-		O
)		O
-		O
10		O
and		O
(		O
+		O
)		O
-		O
10		O
was		O
determined		O
by		O
HPLC		O
analysis		O
of		O
the		O
diastereomeric		O
ureas		O
formed		O
by		O
reaction		O
with		O
optically		O
pure		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
methylbenzyl		I-IUPAC
isocyanate		I-IUPAC
.		O
The		O
first		O
one		O
is		O
the		O
presence		O
of		O
a		O
monosubstituted		B-MODIFIER
N		B-IUPAC
-		I-IUPAC
hydroxyguanidine		I-IUPAC
function		O
,		O
since		O
disubstituted		B-MODIFIER
N		B-IUPAC
-		I-IUPAC
hydroxyguanidines		I-IUPAC
,		O
amidoximes		O
,		O
ketoximes		O
,		O
and		O
aldoximes		O
failed		O
to		O
produce		O
NO		O
.		O
Deprotection		O
with		O
sodium		O
in		O
liquid		O
ammonia		O
was		O
followed		O
by		O
sulfhydryl		O
oxidation		O
with		O
I2		O
to		O
give		O
the		O
hormone		O
analogue		O
.		O
2		O
cells		O
in		O
culture		O
except		O
the		O
parent		O
base		O
,		O
8		B-IUPAC
-		I-IUPAC
aza		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
methylthio		I-IUPAC
)		I-IUPAC
purine		I-IUPAC
(		O
1		O
)		O
and		O
the		O
8		O
-		O
isomers		O
(		O
3,12		O
,		O
and		O
13		O
)		O
.		O
Nine		O
of		O
these		O
heterocycles		O
contained		O
a		O
thiochroman		O
group		O
,		O
two		O
had		O
a		O
chroman		O
group		O
,		O
and		O
two		O
others		O
had		O
a		O
benzothienyl		O
system		O
.		O
Both		O
of		O
these		O
series		O
display		O
much		O
higher		O
no		O
effect		O
doses		O
(		O
greater		O
tolerance		O
)		O
than		O
the		O
corresponding		O
6,8		B-IUPAC
-		I-IUPAC
difluoroquinolones		I-IUPAC
.		O
Compounds		O
11		O
(		O
n		O
equals		O
3		O
)		O
,		O
20		O
,		O
26		O
,		O
and		O
49		O
were		O
highly		O
protective		O
when		O
administered		O
intraperitoneally		O
but		O
were		O
generally		O
ineffective		O
when		O
given		O
perorally		O
,		O
as		O
were		O
the		O
other		O
hydroxylated		O
phosphorothioates		O
prepared		O
.		O
Meanwhile		O
,		O
synthetic		O
efforts		O
en		O
route		O
to		O
olefinic		O
compounds		O
led		O
to		O
the		O
discovery		O
that		O
2		B-IUPAC
-		I-IUPAC
pyridylethyl		I-IUPAC
(		O
9o		O
)		O
and		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
oxopyrrolidinyl		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
(		O
9u		O
)		O
replacement		B-MODIFIER
of		O
the		O
p		O
-		O
anisyl		O
group		O
of		O
1yielded		O
very		O
hydrophilic		O
ETA		O
antagonists		O
with		O
potency		O
and		O
selectivity		O
equal		O
to		O
those		O
of		O
10b		O
.		O
All		O
of		O
the		O
analogues		O
are		O
weak		O
agonists		O
at		O
the		O
A1		O
receptor		O
,		O
requiring		O
concentrations		O
greater		O
than		O
9		O
microM		O
to		O
cause		O
second		O
degree		O
heart		O
block		O
.		O
Biochemical		O
evaluation		O
of		O
the		O
enantiomers		O
of		O
these		O
compounds		O
at		O
both		O
PNMT		O
and		O
the		O
alpha		O
(		O
2		O
)		O
-		O
adrenoceptor		O
indicates		O
that		O
both		O
sites		O
display		O
similar		O
stereoselectivity		O
.		O
These		O
materials		O
were		O
obtained		O
by		O
reacting		O
4		B-IUPAC
-		I-IUPAC
nitro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
picoline		I-IUPAC
N		I-IUPAC
-		I-IUPAC
oxide		I-IUPAC
,		O
either		O
directly		O
or		O
after		O
conversion		O
to		O
the		O
corresponding		O
4		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
derivative		B-MODIFIER
,		O
with		O
a		O
variety		O
of		O
secondary		O
amines		O
.		O
A		O
combination		O
of		O
a		O
cyclopropyl		O
or		O
a		O
substituted		O
phenyl		B-IUPAC
group		B-MODIFIER
at		O
N		O
-		O
1		O
and		O
a		O
trans		B-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azetidinyl		I-IUPAC
group		B-MODIFIER
at		O
C		O
-		O
7		O
conferred		O
the		O
best		O
overall		O
antibacterial		O
,		O
pharmacokinetic		O
,		O
and		O
physicochemical		O
properties		O
to		O
the		O
azetidinylquinolones		O
studied		O
.		O
8		B-PARTIUPAC
-		I-PARTIUPAC
Methoxy		I-PARTIUPAC
-		I-PARTIUPAC
and		O
8		B-IUPAC
-		I-IUPAC
methylquinazolinones		I-IUPAC
(		O
14-34		O
)		O
were		O
readily		O
prepared		O
by		O
acylation		O
of		O
3		O
-		O
substituted		O
anthranilamides		O
with		O
the		O
appropriate		O
acid		O
chloride		O
,		O
followed		O
by		O
base		O
-		O
catalyzed		O
cyclization		O
.		O
An		O
examination		O
of		O
nitrogen		O
substitution		O
(		O
R2		O
in		O
3		O
)		O
revealed		O
that		O
analogs		O
with		O
either		O
an		O
allyl		O
or		O
an		O
n		B-IUPAC
-		I-IUPAC
propyl		I-IUPAC
group		B-MODIFIER
displayed		O
equipotent		O
activities		O
.		O
In		O
the		O
linear		O
series		O
(		O
analogues		O
of		O
metoclopramide		O
)		O
,		O
introduction		O
of		O
a		O
benzyl		B-IUPAC
group		B-MODIFIER
on		O
the		O
terminal		O
nitrogen		O
,		O
rather		O
than		O
an		O
ethyl		B-IUPAC
group		B-MODIFIER
,		O
and		O
a		O
methyl		B-IUPAC
group		B-MODIFIER
on		O
the		O
p		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
group		B-MODIFIER
of		O
metoclopramide		O
both		O
enhanced		O
the		O
activity		O
.		O
This		O
research		O
has		O
identified		O
the		O
4		B-MODIFIER
-		I-MODIFIER
substituted		I-MODIFIER
-		O
3		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
adamantyl		I-IUPAC
)		I-IUPAC
phenyl		I-IUPAC
moiety		B-MODIFIER
as		O
a		O
new		O
pharmacophore		O
which		O
can		O
replace		O
the		O
beta		B-IUPAC
-		I-IUPAC
cyclogeranylidene		I-IUPAC
ring		B-MODIFIER
of		O
the		O
naturally		O
occurring		O
all		B-IUPAC
-		I-IUPAC
trans		I-IUPAC
-		I-IUPAC
retinoic		I-IUPAC
acid		I-IUPAC
.		O
8a		O
,		O
8b		O
,		O
and		O
14b		O
exhibited		O
IC		O
(		O
50		O
)		O
values		O
less		O
than		O
10		O
nM		O
.		O
When		O
the		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
group		B-MODIFIER
of		O
27		O
and		O
31		O
was		O
replaced		O
by		O
an		O
ethyl		B-IUPAC
or		O
an		O
isopropyl		B-IUPAC
group		B-MODIFIER
,		O
the		O
anti		O
-		O
HIV		O
-		O
1		O
activity		O
was		O
improved		O
remarkably		O
[		O
EC50		O
:		O
5		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
ethoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
-		I-IUPAC
uracil		I-IUPAC
(		O
46		O
)		O
,		O
0.019		O
microM		O
;		O
5		B-IUPAC
-		I-IUPAC
ethyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
(		O
52		O
)		O
,		O
0.0059		O
microM		O
;		O
5		B-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
ethoxymethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
(		O
55		O
)		O
,		O
0.012		O
microM		O
;		O
5		B-IUPAC
-		I-IUPAC
isopropyl		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
benzyloxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
phenylthio		I-IUPAC
)		I-IUPAC
uracil		I-IUPAC
(		O
56		O
)		O
,		O
0.0027		O
microM		O
]		O
.		O
The		O
Gewald		O
thiophene		O
synthesis		O
was		O
utilized		O
to		O
obtain		O
several		O
ethyl		B-IUPAC
2		I-IUPAC
-		I-IUPAC
aminothiophene		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylates		I-IUPAC
.		O
The		O
pA2		O
values		O
(		O
rabbit		O
aortic		O
strips		O
)		O
obtained		O
were		O
7.68		O
,		O
7.53		O
,		O
7.23		O
,		O
7.53		O
,		O
and		O
9.66		O
,		O
and		O
the		O
dose		O
ratios		O
(		O
in		O
vagotomized		O
ganglion		O
-		O
blocked		O
rats		O
infused		O
at		O
250		O
ng		O
/		O
kg		O
/		O
min		O
)		O
obtained		O
were		O
2.37		O
,		O
4.49		O
,		O
1.02		O
,		O
1.47		O
,		O
and		O
24.04		O
,		O
respectively		O
.		O
Structurally		O
,		O
this		O
series		O
of		O
analogues		O
has		O
novel		O
substitutions		O
at		O
positions		O
3		O
,		O
7		O
,		O
and		O
8		O
and		O
N		O
(		O
alpha		O
)		O
-		O
methylation		O
at		O
positions		O
6		O
,		O
7		O
,		O
and		O
8		O
in		O
the		O
structure		O
of		O
degarelix		O
.		O
The		O
insulin		O
constituent		O
of		O
the		O
(		O
FMS		O
)		O
(		O
3		O
)		O
-		O
insulin		O
conjugate		O
undergoes		O
a		O
slow		O
,		O
spontaneous		O
activation		O
in		O
the		O
circulatory		O
system		O
,		O
manifesting		O
a		O
prolonged		O
glucose		O
-		O
lowering		O
action		O
in		O
vivo		O
.		O
The		O
lead		O
structure		O
19		O
has		O
been		O
selected		O
for		O
in		O
-		O
depth		O
pharmacological		O
evaluation		O
.		O
In		O
addition		O
,		O
replacement		O
of		O
the		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
group		B-MODIFIER
with		O
other		O
substituents		O
destroyed		O
activity		O
.		O
Small		O
libraries		O
of		O
6		B-PARTIUPAC
-		I-PARTIUPAC
and		O
7		B-IUPAC
-		I-IUPAC
alkoxy		I-IUPAC
-		O
substituted		B-MODIFIER
chromen		B-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
showed		O
that		O
a		O
number		O
of		O
7		B-IUPAC
-		I-IUPAC
alkoxy		I-IUPAC
-		O
substituted		B-MODIFIER
chromenones		B-IUPAC
displayed		O
improved		O
activity		O
.		O
In		O
contrast		O
,		O
conjugates		O
8c		O
-		O
e		O
were		O
less		O
effective		O
(		O
ILS		O
19-75%		O
)		O
and		O
cytidine		O
conjugates		O
(		O
9a		O
and		O
9b		O
)		O
were		O
ineffective		O
.		O
Tumorigenicity		O
assays		O
indicate		O
that		O
the		O
9,10		B-IUPAC
-		I-IUPAC
dihydrodiol		I-IUPAC
derivatives		B-MODIFIER
of		O
cholanthrene		O
and		O
its		O
3		B-PARTIUPAC
-		I-PARTIUPAC
and		O
6		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
derivatives		B-MODIFIER
are		O
all		O
potent		O
tumor		O
initiators		O
on		O
mouse		O
skin		O
.		O
SPECT		O
brain		O
imaging		O
studies		O
in		O
monkeys		O
demonstrated		O
high		O
[		O
(		O
123		O
)		O
I		O
]		O
ZIENT		O
uptake		O
in		O
the		O
diencephalon		O
,		O
which		O
resulted		O
in		O
diencephalon		O
-		O
to		O
-		O
cerebellum		O
ratios		O
of		O
2.12		O
at		O
190		O
min		O
.		O
Chlorination		O
with		O
phosphorus		O
oxychloride		O
and		O
condensation		O
with		O
a		O
requisite		O
arylamine		O
provided		O
the		O
N2		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
dialkylamino		I-IUPAC
)		I-IUPAC
alkyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
N4		I-IUPAC
-		I-IUPAC
phenyl		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
quinazolinediamines		I-IUPAC
(		O
X		O
)		O
.		O
Interestingly		O
,		O
the		O
related		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
azido		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
bromoethyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
deoxyuridine		I-IUPAC
(		O
1n		O
)		O
analogue		O
proved		O
to		O
be		O
markedly		O
inhibitory		O
to		O
DHBV		O
replication		O
(		O
EC		O
(		O
50		O
)		O
=		O
2.6-6.6		O
microM		O
)		O
.		O
aureus		O
(		O
Smith		O
)		O
when		O
given		O
by		O
the		O
ip		O
route		O
.		O
From		O
incubations		O
of		O
the		O
enantiomers		O
of		O
1		O
and		O
pseudoracemic		O
propranolol		O
[		O
equimolar		O
(		B-IUPAC
2R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
propranolol		I-IUPAC
-		I-IUPAC
3,3		I-IUPAC
-		I-IUPAC
d2		I-IUPAC
and		O
(		B-IUPAC
2S		I-IUPAC
)		I-IUPAC
-		I-IUPAC
propranolol		I-IUPAC
-		I-IUPAC
d0		I-IUPAC
]		O
in		O
the		O
presence		O
of		O
the		O
rat		O
liver		O
microsomal		O
fraction		O
,		O
we		O
established		O
that		O
the		O
diastereomeric		O
products		O
were		O
formed		O
in		O
the		O
order		O
(		O
2S		O
,		O
2		O
"		O
S		O
)		O
-		O
2		O
approximately		O
equal		O
to		O
(		O
2S		O
,		O
2		O
"		O
R		O
)		O
-		O
2		O
greater		O
than		O
(		O
2R		O
,		O
2		O
"		O
R		O
)		O
-		O
2		O
greater		O
than		O
(		O
2R		O
,		O
2		O
"		O
S		O
)		O
-		O
2		O
.		O
These		O
agents		O
were		O
tested		O
for		O
their		O
ability		O
to		O
sensitize		O
hypoxic		O
Escherichia		O
coli		O
cells		O
to		O
killing		O
by		O
ionizing		O
radiation		O
.		O
Compound		O
4		O
was		O
synthesized		O
by		O
the		O
nucleophilic		O
displacement		O
of		O
5		O
with		O
diethyl		B-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
4		I-IUPAC
-		I-IUPAC
(		I-IUPAC
aminomethyl		I-IUPAC
)		I-IUPAC
benzoyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
glutamate		I-IUPAC
(		O
15		O
)		O
and		O
saponification		O
.		O
Similarly		O
,		O
replacement		O
of		O
the		O
carboxyl		B-IUPAC
group		B-MODIFIER
of		O
3b		O
by		O
isosteric		O
tetrazolyl		B-IUPAC
or		O
1,2,4		B-IUPAC
-		I-IUPAC
triazolyl		I-IUPAC
groups		B-MODIFIER
to		O
give		O
5		O
and		O
6		O
,		O
respectively		O
,		O
or		O
conversion		O
of		O
3b		O
into		O
analogue		O
7		O
,		O
in		O
which		O
the		O
diaminosquaric		O
acid		O
group		O
has		O
been		O
bioisosterically		O
substituted		O
for		O
the		O
alpha		B-IUPAC
-		I-IUPAC
aminocarboxylic		I-IUPAC
acid		I-IUPAC
unit		O
,		O
provided		O
compounds		O
completely		O
devoid		O
of		O
effect		O
at		O
AMPA		O
receptors		O
.		O
However		O
,		O
the		O
new		O
compounds		O
we		O
describe		O
exhibit		O
diminished		O
cardiovascular		O
effects		O
in		O
both		O
anesthetized		O
and		O
awake		O
rats		O
when		O
compared		O
to		O
reference		O
A		O
(		O
1		O
)		O
agonists		O
such		O
as		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
phenylisopropyladenosine		I-IUPAC
(		O
R		O
-		O
PIA		O
,		O
5		O
)		O
,		O
N		B-IUPAC
-		I-IUPAC
cyclopentyladenosine		I-IUPAC
(		O
CPA		O
,		O
2		O
)		O
,		O
4		O
,		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
1S		I-IUPAC
,		I-IUPAC
trans		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxycyclopentyl		I-IUPAC
]		I-IUPAC
adenosine		I-IUPAC
(		O
GR		O
79236		O
,		O
26		O
)		O
,		O
N		B-IUPAC
-		I-IUPAC
cyclohexyl		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
methyladenosine		I-IUPAC
(		O
SDZ		O
WAG		O
994		O
,		O
27		O
)		O
,		O
and		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methylphenyl		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
adenosine		I-IUPAC
(		O
Metrifudil		O
,		O
28		O
)		O
.		O
Most		O
of		O
the		O
new		O
compounds		O
were		O
active		O
in		O
a		O
PAF		O
-		O
binding		O
assay		O
employing		O
whole		O
,		O
washed		O
dog		O
platelets		O
as		O
the		O
receptor		O
source		O
and		O
inhibited		O
PAF		O
-		O
induced		O
bronchoconstriction		O
in		O
guinea		O
pigs		O
after		O
intravenous		O
administration		O
.		O
These		O
same		O
five		O
compounds		O
,		O
as		O
well		O
as		O
the		O
lead		O
compound		O
Analog		O
II		O
,		O
were		O
active		O
in		O
vitro		O
against		O
the		O
estrogen		O
-		O
dependent		O
MCF		O
-		O
7		O
human		O
breast		O
tumor		O
cell		O
line		O
in		O
a		O
dose		O
-		O
dependent		O
fashion		O
.		O
These		O
results		O
suggest		O
that		O
latent		O
alkyl		B-IUPAC
isocyanates		I-IUPAC
are		O
inhibitors		O
of		O
AlDH		O
,		O
giving		O
further		O
support		O
to		O
the		O
hypothesis		O
that		O
the		O
inhibition		O
of		O
AlDH		O
in		O
vivo		O
by		O
the		O
hypoglycemic		O
agent		O
chlorpropamide		O
may		O
be		O
due		O
to		O
the		O
release		O
of		O
n		B-IUPAC
-		I-IUPAC
propyl		I-IUPAC
isocyanate		I-IUPAC
following		O
metabolic		O
bioactivation		O
.		O
The		O
most		O
active		O
cytotoxic		O
agent		O
(		O
16		O
)		O
,		O
possessing		O
a		O
5		B-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
2,2		I-IUPAC
-		I-IUPAC
diiodoethyl		I-IUPAC
)		I-IUPAC
substituent		B-MODIFIER
(		O
ED50		O
=		O
0.77		O
micrograms		O
/		O
mL		O
)		O
,		O
exhibited		O
an		O
activity		O
approaching		O
that		O
of		O
melphalan		O
(		O
ED50		O
=		O
0.15		O
micrograms		O
/		O
mL		O
)		O
.		O
Most		O
importantly		O
,		O
three		O
compounds		O
from		O
this		O
series		O
demonstrated		O
statistically		O
significant		O
protective		O
effects		O
in		O
rat		O
models		O
of		O
stroke		O
and		O
heart		O
ischemia		O
.		O
The		O
ring		O
-		O
opened		O
3		B-IUPAC
-		I-IUPAC
acylamino		I-IUPAC
analogues		B-MODIFIER
46		O
and		O
47		O
were		O
prepared		O
via		O
nitration		O
of		O
the		O
phenethylamine		O
43		O
derived		O
from		O
4		B-IUPAC
-		I-IUPAC
methoxyphenylacetic		I-IUPAC
acid		I-IUPAC
.		O
Unit		O
cell		O
dimensions		O
(		O
at		O
15		O
degrees		O
C		O
)		O
are		O
as		O
follows		O
:		O
for		O
1b		O
,		O
a		O
=		O
20.568		O
(		O
6		O
)		O
A		O
,		O
b		O
=		O
14.760		O
(		O
3		O
)		O
A		O
,		O
c		O
=		O
7.679		O
(		O
2		O
)		O
A		O
,		O
alpha		O
=		O
113.33		O
(		O
2		O
)		O
degrees		O
,		O
beta		O
=		O
79.45		O
(		O
2		O
)		O
degrees		O
,		O
gamma		O
=		O
79.98		O
(		O
2		O
)		O
degrees		O
,		O
Z		O
=		O
4		O
;		O
for		O
18		O
,		O
a		O
=		O
9.292		O
(		O
5		O
)		O
A		O
,		O
b		O
=		O
9.291		O
(		O
5		O
)		O
A		O
,		O
c		O
=		O
7.951		O
(		O
3		O
)		O
A		O
,		O
alpha		O
=		O
102.16		O
(		O
3		O
)		O
degrees		O
,		O
beta		O
=		O
77.49		O
(		O
3		O
)		O
degrees		O
,		O
gamma		O
=		O
79.60		O
(		O
4		O
)		O
degrees		O
,		O
Z		O
=		O
2		O
.		O
We		O
have		O
found		O
that		O
alpha		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		O
substituted		B-MODIFIER
halo		B-IUPAC
enol		I-IUPAC
lactones		I-IUPAC
(		O
I		O
and		O
II		O
)		O
are		O
effective		O
mechanism		O
-		O
based		O
inactivators		O
for		O
chymotrypsin		O
.		O
The		O
original		O
synthetic		O
procedure		O
for		O
the		O
preparation		O
of		O
21		O
of		O
these		O
compounds		O
is		O
also		O
reported		O
.		O
The		O
synthesis		O
and		O
pharmacological		O
properties		O
of		O
several		O
racemic		B-MODIFIER
6,7,8,9		B-IUPAC
-		I-IUPAC
tetrahydro		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
1H		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
benzazepine		I-IUPAC
-		I-IUPAC
2,5		I-IUPAC
-		I-IUPAC
diones		I-IUPAC
(		O
THHBADs		O
)		O
are		O
described		O
.		O
A		O
series		O
of		O
2		B-IUPAC
-		I-IUPAC
(		I-IUPAC
diethylamino		I-IUPAC
)		I-IUPAC
thieno1		I-IUPAC
,		I-IUPAC
3		I-IUPAC
\C5		I-IUPAC
\8F		I-IUPAC
xazin		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
ones		I-IUPAC
was		O
synthesized		O
and		O
evaluated		O
in		O
vitro		O
for		O
inhibitory		O
activity		O
toward		O
human		O
leukocyte		O
elastase		O
(		O
HLE		O
)		O
.		O
In		O
this		O
article		O
,		O
we		O
report		O
synthesis		O
and		O
cytotoxicity		O
of		O
a		O
series		O
of		O
new		O
pyrido		B-IUPAC
[		I-IUPAC
2		I-IUPAC
,		I-IUPAC
3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
nucleosides		B-MODIFIER
.		O
All		O
the		O
furoxan		O
and		O
furazan		O
derivatives		O
showed		O
activity		O
as		O
inhibitors		O
of		O
platelet		O
aggregation		O
.		O
The		O
potencies		O
of		O
the		O
complexes		O
3		O
and		O
4		O
correlated		O
well		O
with		O
the		O
structure		O
-		O
activity		O
relationships		O
of		O
other		O
2beta		B-IUPAC
-		I-IUPAC
carbomethoxy		I-IUPAC
-		I-IUPAC
3beta		I-IUPAC
-		I-IUPAC
aryltropane		I-IUPAC
derivatives		B-MODIFIER
.		O
The		O
insertion		O
of		O
substituents		O
on		O
the		O
furan		O
ring		O
of		O
3		O
,		O
as		O
in		O
compounds		O
4		O
and		O
5		O
,		O
did		O
not		O
improve		O
the		O
selectivity		O
profile		O
.		O
gondii		O
cells		O
in		O
culture		O
.		O
This		O
rather		O
surprising		O
and		O
unexpected		O
finding		O
may		O
be		O
explained		O
by		O
considering		O
neutral		O
and		O
negative		O
antagonism		O
.		O
Prolonging		O
such		O
treatment		O
was		O
found		O
to		O
result		O
in		O
the		O
formation		O
of		O
N		B-IUPAC
-		I-IUPAC
[		I-IUPAC
2		I-IUPAC
-		I-IUPAC
(		I-IUPAC
chloroethoxy		I-IUPAC
)		I-IUPAC
ethyl		I-IUPAC
]		I-IUPAC
norapocodeine		I-IUPAC
(		O
1f		O
)		O
at		O
the		O
expense		O
of		O
1e		O
.		O
The		O
aim		O
of		O
this		O
study		O
was		O
to		O
label		O
the		O
potent		O
PBR		O
agonist		O
N		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
phenoxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
isopropoxybenzyl		I-IUPAC
)		I-IUPAC
acetamide		I-IUPAC
(		O
3		O
)		O
and		O
its		O
ethyl		B-IUPAC
(		O
7		O
)		O
and		O
methyl		B-IUPAC
(		O
8		O
)		O
homologues		B-MODIFIER
with		O
(		O
11		O
)		O
C		O
and		O
to		O
evaluate		O
them		O
as		O
PET		O
ligands		O
for		O
PBR		O
with		O
mice		O
,		O
rats		O
,		O
and		O
monkeys		O
.		O
The		O
pyridopyrimidine		O
with		O
the		O
best		O
combination		O
of		O
potency		O
and		O
selectivity		O
was		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
butynyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
]		I-IUPAC
benzyl		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
13		O
)		O
,		O
with		O
an		O
IC		O
(		O
50		O
)		O
value		O
of		O
0.65		O
nM		O
against		O
P		O
.		O
albicans		O
in		O
the		O
intact		O
form		O
.		O
4		O
-		O
(		O
Dimethylamino		O
)		O
-		O
and		O
4		B-IUPAC
-		I-IUPAC
(		I-IUPAC
methylamino		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
arylspiro		I-IUPAC
[		I-IUPAC
cyclohexane		I-IUPAC
-		I-IUPAC
1,1		I-IUPAC
'		I-IUPAC
(		I-IUPAC
3'		I-IUPAC
H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
isobenzofuran		I-IUPAC
]		I-IUPAC
derivatives		B-MODIFIER
were		O
prepared		O
as		O
analogues		O
of		O
previously		O
reported		O
3		B-IUPAC
-		I-IUPAC
arylspiro		I-IUPAC
[		I-IUPAC
isobenzofuran		I-IUPAC
-		I-IUPAC
1		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
,		I-IUPAC
4'		I-IUPAC
-		I-IUPAC
piperidines		I-IUPAC
]		I-IUPAC
.		O
Although		O
active		O
against		O
Leishmania		O
donovani		O
,		O
none		O
of		O
the		O
analogues		O
showed		O
major		O
improvement		O
in		O
this		O
activity		O
relative		O
to		O
chlorpromazine		O
or		O
other		O
nonquaternized		O
phenothiazines		O
.		O
Most		O
notably		O
,		O
1		B-IUPAC
-		I-IUPAC
[		I-IUPAC
1		I-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
benzo		I-IUPAC
[		I-IUPAC
b		I-IUPAC
]		I-IUPAC
thienyl		I-IUPAC
)		I-IUPAC
cyclohexyl		I-IUPAC
]		I-IUPAC
pyrrolidine		I-IUPAC
(		O
7		O
)		O
exhibited		O
a		O
3.4		O
-		O
fold		O
greater		O
affinity		O
for		O
these		O
sites		O
compared		O
with		O
BTCP		O
and		O
a		O
9		O
-		O
fold		O
greater		O
affinity		O
at		O
these		O
sites		O
than		O
cocaine		O
.		O
The		O
binding		O
compatibility		O
of		O
the		O
most		O
active		O
compounds		O
with		O
a		O
model		O
of		O
ACE		O
active		O
site		O
was		O
evaluated		O
by		O
molecular		O
modeling		O
techniques		O
.		O
The		O
pA2		O
values		O
for		O
VII		O
and		O
VIII		O
were		O
8.31		O
and		O
10.0		O
in		O
the		O
adrenal		O
cortex		O
and		O
9.31		O
and		O
9.16		O
in		O
the		O
adrenal		O
medulla		O
,		O
respectively		O
.		O
Cold		O
monoiodination		O
of		O
19		O
yielded		O
21		O
,		O
with		O
retention		O
of		O
high		O
sst		O
(		O
4		O
)		O
selectivity		O
and		O
affinity		O
(		O
IC		O
(		O
50		O
)		O
=		O
3.5		O
nM		O
)		O
.		O
These		O
compounds		O
are		O
not		O
inhibitors		O
of		O
thrombin		O
,		O
plasmin		O
t		O
-		O
PA		O
,		O
urokinase		O
,		O
and		O
factor		O
Xa		O
(		O
IC50		O
&		O
gt		O
;		O
33		O
microM		O
)		O
.		O
The		O
conformationally		O
restricted		O
,		O
cyclic		O
disulfide		O
-		O
containing		O
delta		O
opioid		O
receptor		O
selective		O
enkephalin		O
analogue		O
[		O
D		O
-		O
Pen2		O
,		O
D		O
-		O
Pen5		O
]		O
enkephalin		O
(		O
1		O
,		O
DPDPE		O
)		O
was		O
systematically		O
modified		O
topographically		O
by		O
addition		O
of		O
a		O
methyl		B-IUPAC
group		B-MODIFIER
at		O
either		O
the		O
pro		O
-		O
S		O
or		O
pro		O
-		O
R		O
position		O
of		O
the		O
beta		O
carbon		O
of		O
an		O
L		O
-		O
Phe4		O
or		O
D		O
-		O
Phe4		O
residue		O
to		O
give		O
[		O
(		O
2S		O
,		O
3S		O
)		O
-		O
beta		O
-		O
MePhe4		O
]		O
DPDPE		O
(		O
2		O
)		O
,		O
[		O
(		O
2R		O
,		O
3R		O
)		O
-		O
beta		O
-		O
MePhe4		O
]		O
DPDPE		O
(		O
3		O
)		O
,		O
[		O
(		O
2S		O
,		O
3R		O
)		O
-		O
beta		O
-		O
MePhe4		O
]		O
DPDPE		O
(		O
4		O
)		O
,		O
and		O
[		O
(		O
2R		O
,		O
3S		O
)		O
-		O
beta		O
-		O
MePhe4		O
]		O
DPDPE		O
(		O
5		O
)		O
.		O
In		O
contrast		O
,		O
the		O
chiral		O
cis		O
compounds		O
(		O
+		O
)		O
-		O
1		O
and		O
(		O
-		O
)		O
-		O
1		O
showed		O
high		O
affinity		O
for		O
sigma		O
receptors		O
and		O
negligible		O
affinity		O
for		O
kappa		O
opioid		O
receptors		O
in		O
the		O
[		O
3H		O
]		O
BREM		O
assay		O
.		O
The		O
structural		O
basis		O
of		O
protein		O
kinase		O
C		O
(		O
PKC		O
)		O
binding		O
to		O
several		O
classes		O
of		O
high		O
-		O
affinity		O
ligands		O
has		O
been		O
investigated		O
through		O
complementary		O
computational		O
and		O
experimental		O
methods		O
.		O
In		O
the		O
female		O
rat		O
,		O
79%		O
of		O
an		O
orally		O
administered		O
dose		O
of		O
tritiated		O
tolazamide		O
was		O
excreted		O
in		O
urine		O
during		O
a		O
5		O
-		O
day		O
period		O
as		O
1-4		O
.		O
Compound		O
4		O
was		O
prepared		O
from		O
3i		O
by		O
alkylation		O
with		O
3		B-IUPAC
-		I-IUPAC
dimethylaminopropyl		I-IUPAC
chloride		I-IUPAC
in		O
the		O
presence		O
of		O
NaH		O
.		O
Intracerebroventricular		O
administration		O
of		O
10		O
elicited		O
a		O
naloxone		O
-		O
reversible		O
antinociceptive		O
effect		O
in		O
mice		O
similar		O
to		O
that		O
of		O
H		O
-		O
Lys		O
-		O
Trp		O
(		O
NPS		O
)		O
-		O
OMe		O
.		O
Contribution		O
of		O
both		O
an		O
N		B-PARTIUPAC
-		I-PARTIUPAC
n		I-PARTIUPAC
-		I-PARTIUPAC
propyl		I-PARTIUPAC
and		O
a		O
2		B-PARTIUPAC
-		I-PARTIUPAC
hydroxy		I-PARTIUPAC
in		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylnorapomorphine		I-IUPAC
(		O
R		O
(		O
-		O
)		O
-		O
2		O
-		O
OH		O
-		O
NPA		O
,		O
R		O
-		O
7		O
)		O
or		O
a		O
methoxy		O
group		O
in		O
(		B-IUPAC
R		I-IUPAC
)		I-IUPAC
-		I-IUPAC
(		I-IUPAC
-		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
n		I-IUPAC
-		I-IUPAC
propylnorapomorphine		I-IUPAC
(		O
R		O
(		O
-		O
)		O
-		O
2		O
-		O
OCH3		O
-		O
NPA		O
,		O
R		O
-		O
9		O
)		O
produced		O
the		O
highest		O
D2		O
affinity		O
(		O
0.053		O
and		O
0.17		O
nM		O
)		O
and		O
D2		O
over		O
D1		O
selectivity		O
(		O
17,300		O
and		O
10,500		O
times		O
)		O
of		O
the		O
compounds		O
evaluated		O
.		O
Serial		O
measurements		O
of		O
tumor		O
size		O
,		O
and		O
evaluation		O
of		O
increased		O
life		O
span		O
,		O
in		O
response		O
to		O
drug		O
treatment		O
also		O
revealed		O
potentially		O
1,4		B-PARTIUPAC
-		I-PARTIUPAC
bis		I-PARTIUPAC
(		O
alkylating		O
)		O
(		B-PARTIUPAC
bromomethyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
1,4		I-PARTIUPAC
-		I-PARTIUPAC
quinone		I-PARTIUPAC
7		O
and		O
1,3		B-PARTIUPAC
-		I-PARTIUPAC
bis		I-PARTIUPAC
(		O
alkylating		O
)		O
(		B-PARTIUPAC
hydroxymethyl		I-PARTIUPAC
)		I-PARTIUPAC
-		I-PARTIUPAC
1,4		I-PARTIUPAC
-		I-PARTIUPAC
quinone		I-PARTIUPAC
10		O
to		O
have		O
variable		O
activity		O
,		O
but		O
none		O
of		O
the		O
potentially		O
bis		O
(		O
alkylating		O
)		O
bis		O
(		O
quinones		O
)		O
showed		O
antitumor		O
properties		O
in		O
this		O
model		O
.		O
Compounds		O
1		O
[		O
especially		O
1s		O
[		O
R1		O
=		O
(		B-PARTIUPAC
CH2		I-PARTIUPAC
)		I-PARTIUPAC
2N		I-PARTIUPAC
(		I-PARTIUPAC
benzyl		I-PARTIUPAC
)		I-PARTIUPAC
(		I-PARTIUPAC
2		I-PARTIUPAC
-		I-PARTIUPAC
naphthylmethyl		I-PARTIUPAC
)		O
,		O
R2		O
=		O
i		O
-		O
Pr		O
,		O
X		O
=		O
0		O
-		O
NO2		O
]		O
and		O
1t		O
[		O
R1		O
=		O
(		B-PARTIUPAC
CH2		I-PARTIUPAC
)		I-PARTIUPAC
2N		I-PARTIUPAC
(		I-PARTIUPAC
benzyl		I-PARTIUPAC
)		I-PARTIUPAC
(		I-PARTIUPAC
3,4		I-PARTIUPAC
-		I-PARTIUPAC
dichlorobenzyl		I-PARTIUPAC
)		O
,		O
R2		O
=		O
i		O
-		O
Pr		O
,		O
X		O
=		O
0		O
-		O
NO2		O
]		O
]		O
exhibited		O
not		O
only		O
more		O
potent		O
and		O
longer		O
lasting		O
vasodilative		O
action		O
but		O
also		O
a		O
hypotensive		O
activity		O
with		O
slow		O
onset		O
as		O
compared		O
with		O
dihydropyridines		O
.		O
Some		O
functional		O
groups		O
were		O
introduced		O
that		O
were		O
hypothesized		O
to		O
influence		O
the		O
phamacokinetic		O
properties		O
of		O
the		O
analogues		O
such		O
as		O
bioavailability		O
,		O
solubility		O
,		O
intra		O
-		O
or		O
intermolecular		O
hydrogen		O
bond		O
forming		O
capacity		O
,		O
and		O
ability		O
to		O
bind		O
carrier		O
proteins		O
.		O
Aqueous		O
base		O
transformed		O
4		O
into		O
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyethoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
pyrazolo		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
6		O
)		O
in		O
good		O
yield		O
.		O
The		O
simultaneous		O
replacement		O
of		O
both		O
piperazine		O
and		O
furan		O
rings		O
of		O
1		O
gave		O
8		O
which		O
resulted		O
in		O
a		O
potent		O
,		O
selective		O
alpha1B		O
-		O
adrenoreceptor		O
antagonist		O
(		O
85		O
-		O
and		O
15		O
-		O
fold		O
more		O
potent		O
than		O
at		O
alpha1A		O
-		O
and		O
alpha1D		O
-		O
subtypes		O
,		O
respectively		O
)		O
.		O
However		O
,		O
no		O
correlation		O
between		O
the		O
binding		O
constant		O
values		O
and		O
photosensitizing		O
efficacy		O
was		O
observed		O
.		O
The		O
transformation		O
of		O
milrinone		O
to		O
1,3		B-IUPAC
-		I-IUPAC
dihydro		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
2H		I-IUPAC
-		I-IUPAC
imidazo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
13a		O
)		O
,		O
5		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
thiazolo		I-IUPAC
[		I-IUPAC
4,5		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
pyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
3H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
51		O
)		O
,		O
and		O
7		B-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
pyridinyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,8		I-IUPAC
-		I-IUPAC
naphthyridin		I-IUPAC
-		I-IUPAC
2		I-IUPAC
(		I-IUPAC
1H		I-IUPAC
)		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
22		O
)		O
resulted		O
in		O
very		O
potent		O
cAMP		O
PDE		O
III		O
inhibitors		O
with		O
in		O
vitro		O
activity		O
in		O
the		O
nanomolar		O
range		O
.		O
A		O
competitive		O
intracellular		O
localization		O
study		O
of		O
these		O
novel		O
structures		O
with		O
Rhodamine		O
-		O
123		O
(		O
a		O
mitochondrial		O
probe		O
)		O
indicated		O
their		O
preferential		O
localization		O
in		O
mitochondria		O
,		O
without		O
producing		O
any		O
specific		O
displacement		O
of		O
(		O
3		O
)		O
H		O
-		O
PK11195		O
(		O
PBR		O
probe		O
,		O
(		B-MODIFIER
3		I-MODIFIER
)		I-MODIFIER
H		I-MODIFIER
-		I-MODIFIER
labeled		I-MODIFIER
1		B-IUPAC
-		I-IUPAC
(		I-IUPAC
2		I-IUPAC
-		I-IUPAC
chlorophenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
methyl		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
(		I-IUPAC
1		I-IUPAC
-		I-IUPAC
methylpropyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
isoquinoline		I-IUPAC
carboxamide		I-IUPAC
)		O
.		O
A		O
number		O
of		O
nucleoside		O
and		O
nucleotide		O
derivatives		O
of		O
4		B-IUPAC
-		I-IUPAC
hydroxy		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
beta		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
ribofuranosylpyrazole		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
carboxamide		I-IUPAC
(		O
pyrazofurin		O
,		O
1		O
)		O
were		O
prepared		O
and		O
tested		O
for		O
their		O
antiviral		O
and		O
cytostatic		O
activity		O
in		O
cell		O
culture		O
.		O
Five		O
of		O
these		O
analogues		O
(		O
1		O
,		O
2		O
,		O
3		O
,		O
6		O
,		O
and		O
7		O
)		O
exhibit		O
enhanced		O
antiantidiuretic		O
/		O
antivasopressor		O
selectivity		O
.		O
Condensation		O
of		O
the		O
appropriate		O
2,4		B-IUPAC
-		I-IUPAC
dichloroquinazoline		I-IUPAC
(		O
IV		O
)		O
with		O
the		O
requisite		O
N		B-IUPAC
,		I-IUPAC
N		I-IUPAC
-		I-IUPAC
dialkylalkylenediamine		I-IUPAC
afforded		O
a		O
series		O
of		O
2		B-IUPAC
-		I-IUPAC
chloro		I-IUPAC
-		I-IUPAC
N		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
dialkylamino		I-IUPAC
)		I-IUPAC
alkyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
4		I-IUPAC
-		I-IUPAC
quinazolinamines		I-IUPAC
(		O
V		O
)		O
which		O
were		O
condensed		O
with		O
the		O
appropriate		O
arylamine		O
to		O
provide		O
the		O
corresponding		O
N2		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
N4		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
dialkylamino		I-IUPAC
)		I-IUPAC
alkyl		I-IUPAC
]		I-IUPAC
-		I-IUPAC
2,4		I-IUPAC
-		I-IUPAC
quinazolinediamines		I-IUPAC
(		O
VI		O
)		O
.		O
The		O
antitumor		O
activity		O
of		O
3		O
-		O
Thf		O
-		O
FU		O
is		O
also		O
reported		O
.		O
In		O
the		O
first		O
approach		O
,		O
17		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
azido		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyphenyl		I-IUPAC
)		I-IUPAC
-		I-IUPAC
18,19,20		I-IUPAC
-		I-IUPAC
trinorprostaglandin		I-IUPAC
F2		I-IUPAC
alpha		I-IUPAC
,		O
16		B-IUPAC
-		I-IUPAC
(		I-IUPAC
5		I-IUPAC
-		I-IUPAC
azido		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
hydroxyphenoxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
17,18,19,20		I-IUPAC
-		I-IUPAC
tetranorprostaglandin		I-IUPAC
F2		I-IUPAC
alpha		I-IUPAC
,		O
and		O
16		B-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
azido		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
hydroxyphenoxy		I-IUPAC
)		I-IUPAC
-		I-IUPAC
17,18,19,20		I-IUPAC
-		I-IUPAC
tetranorprostaglandin		I-IUPAC
F2		I-IUPAC
alpha		I-IUPAC
were		O
prepared		O
by		O
using		O
the		O
Corey		O
synthesis		O
,		O
but		O
were		O
biologically		O
inactive		O
presumably		O
as		O
a		O
result		O
of		O
the		O
hydrophilic		O
phenolic		O
hydroxyl		O
group		O
.		O
N		O
-		O
Methylation		O
(		O
9y		O
)		O
results		O
in		O
loss		O
of		O
activity		O
.		O
Although		O
it		O
had		O
2.5		O
-		O
fold		O
lower		O
potency		O
than		O
28		O
against		O
Ma		O
DHFR		O
(		O
IC		O
(		O
50		O
)		O
=		O
3.7		O
nM		O
)		O
and		O
was		O
substantially		O
weaker		O
against		O
Pc		O
and		O
Tg		O
DHFR		O
,		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
[		I-IUPAC
2'		I-IUPAC
-		I-IUPAC
methoxy		I-IUPAC
-		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
(		I-IUPAC
4		I-IUPAC
-		I-IUPAC
carboxyphenyl		I-IUPAC
)		I-IUPAC
ethynylbenzyl		I-IUPAC
]		I-IUPAC
pyrimidine		I-IUPAC
(		O
29		O
)		O
,		O
with		O
the		O
carboxy		B-IUPAC
group		B-MODIFIER
at		O
the		O
para		O
rather		O
than		O
the		O
meta		O
position		O
,		O
displayed		O
2200		O
-		O
fold		O
selectivity		O
against		O
the		O
Ma		O
enzyme		O
and		O
was		O
the		O
most		O
selective		O
2,4		B-IUPAC
-		I-IUPAC
diamino		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
(		O
5'		B-MODIFIER
-		O
substituted		I-MODIFIER
benzyl		B-PARTIUPAC
)		O
pyrimidine		B-PARTIUPAC
inhibitor		O
of		O
this		O
enzyme		O
we		O
have		O
encountered		O
to		O
date		O
.		O
Analogues		O
of		O
the		O
2'		B-IUPAC
,		I-IUPAC
6'		I-IUPAC
-		I-IUPAC
dimethyl		I-IUPAC
-		I-IUPAC
L		I-IUPAC
-		I-IUPAC
tyrosine		I-IUPAC
(		I-IUPAC
Dmt		I-IUPAC
)		I-IUPAC
-		I-IUPAC
1,2,3,4		I-IUPAC
-		I-IUPAC
tetrahydroisoquinoline		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylic		I-IUPAC
acid		I-IUPAC
(		O
Tic		O
)		O
pharmacophore		O
were		O
prepared		O
to		O
test		O
the		O
hypothesis		O
that		O
a		O
"		O
spacer		O
"		O
and		O
a		O
third		O
aromatic		O
center		O
in		O
opioid		O
peptides		O
are		O
required		O
to		O
convert		O
a		O
delta		O
-		O
antagonist		O
into		O
ligands		O
with		O
delta		O
-		O
agonist		O
or		O
with		O
mixed		O
delta		O
-		O
antagonist		O
/		O
mu		O
-		O
agonist		O
properties		O
.		O
Compounds		O
constructed		O
with		O
the		O
2		B-IUPAC
-		I-IUPAC
deoxyapiolactone		I-IUPAC
template		O
were		O
synthesized		O
stereoselectively		O
from		O
di		B-IUPAC
-		I-IUPAC
O		I-IUPAC
-		I-IUPAC
isopropylidene		I-IUPAC
-		I-IUPAC
alpha		I-IUPAC
-		I-IUPAC
D		I-IUPAC
-		I-IUPAC
apiose		I-IUPAC
.		O
Treatment		O
of		O
the		O
latter		O
in		O
dilute		O
hydrochloric		O
acid		O
with		O
sodium		O
iodide		O
-		O
125		O
and		O
chloramine		O
-		O
T		O
gave		O
[		O
125I		O
]		O
(		O
S		O
)		O
-		O
6b		O
in		O
56%		O
radiochemical		O
yield		O
and		O
at		O
least		O
97%		O
radiochemical		O
purity		O
.		O
Subnanomolar		O
IC50		O
values		O
at		O
the		O
AT1		O
receptor		O
subtype		O
were		O
observed		O
for		O
a		O
variety		O
of		O
acylsulfonamides		O
,		O
including		O
aroyl		O
,		O
heteroaroyl		O
,		O
and		O
cycloalkylcarbonyl		B-IUPAC
derivatives		B-MODIFIER
.		O
The		O
selected		O
oleanane		O
triterpenoid		O
,		O
CDDO		O
(		O
26		O
)		O
,		O
was		O
found		O
to		O
be		O
a		O
potent		O
,		O
multifunctional		O
agent		O
in		O
various		O
in		O
vitro		O
assays		O
and		O
to		O
show		O
antiinflammatory		O
activity		O
against		O
thioglycollate		O
-		O
interferon		O
-		O
gamma		O
-		O
induced		O
mouse		O
peritonitis		O
.		O
(		O
We		O
considered		O
the		O
possibility		O
that		O
some		O
decarboxylation		O
of		O
DL		B-IUPAC
-		I-IUPAC
tetrazol		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
ylglycine		I-IUPAC
may		O
have		O
occurred		O
during		O
testing		O
.		O
In		O
pursuit		O
of		O
radiolabeled		O
monoclonal		O
antibodies		O
(		O
mAbs		O
)		O
with		O
rapid		O
urinary		O
excretion		O
of		O
radioactivity		O
from		O
nontarget		O
tissues		O
,		O
radioiodinated		O
mAbs		O
releasing		O
a		O
m		B-IUPAC
-		I-IUPAC
iodohippuric		I-IUPAC
acid		I-IUPAC
from		O
the		O
mAbs		O
in		O
nontarget		O
tissues		O
were		O
designed		O
.		O
The		O
intermediate		O
adducts		O
on		O
1,8		B-IUPAC
-		I-IUPAC
diazabicyclo		I-IUPAC
[		I-IUPAC
5.4.0		I-IUPAC
]		I-IUPAC
undec		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
ene		I-IUPAC
(		O
DBU		O
)		O
treatment		O
rearranged		O
to		O
the		O
corresponding		O
stable		O
benzobacteriochlorins		O
,		O
exhibiting		O
the		O
longest		O
wavelength		O
absorption		O
in		O
the		O
range		O
of		O
737		O
to		O
805		O
nm		O
.		O
All		O
the		O
double		O
-		O
armed		O
aporphine		O
amide		O
nitrogen		O
mustards		O
(		O
ab		O
-		O
d		O
)		O
were		O
found		O
to		O
have		O
antitumor		O
activity		O
.		O
Indeed		O
,		O
when		O
5		B-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthoic		I-IUPAC
acid		I-IUPAC
itself		O
was		O
examined		O
at		O
neutral		O
pH		O
for		O
inhibitory		O
potency		O
,		O
it		O
was		O
found		O
to		O
have		O
K		O
(		O
i		O
)		O
=		O
31		O
+		O
/		O
-		O
7		O
microM		O
,		O
which		O
is		O
lower		O
than		O
parent		O
5		B-IUPAC
-		I-IUPAC
carboxy		I-IUPAC
-		I-IUPAC
6		I-IUPAC
-		I-IUPAC
carboxymethyloxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
naphthoic		I-IUPAC
acid		I-IUPAC
.		O
In		O
contrast		O
,		O
3'		B-IUPAC
-		I-IUPAC
C		I-IUPAC
-		I-IUPAC
methylidene		I-IUPAC
-		I-IUPAC
2'		I-IUPAC
,		I-IUPAC
3'		I-IUPAC
-		I-IUPAC
dideoxy		I-IUPAC
-		I-IUPAC
5		I-IUPAC
-		I-IUPAC
methyluridine		I-IUPAC
5'		I-IUPAC
-		I-IUPAC
triphosphate		I-IUPAC
was		O
found		O
to		O
be		O
incorporated		O
at		O
the		O
3'		O
-		O
end		O
of		O
the		O
DNA		O
chain		O
by		O
HIV		O
-		O
1		O
reverse		O
transcriptase		O
,		O
albeit		O
with		O
very		O
low		O
efficiency		O
.		O
Next		O
,		O
cyclo		O
[		O
21,29		O
]		O
[		O
D		O
-		O
Cys		O
(		O
21		O
)		O
Cys		O
(		O
29		O
)		O
]		O
-		O
uPA		O
(		O
21		O
)		O
(		O
-		O
)		O
(		O
30		O
)		O
was		O
yielded		O
by		O
changing		O
the		O
chirality		O
of		O
Cys		O
(		O
21		O
)		O
to		O
D		O
-		O
Cys		O
(		O
21		O
)		O
.		O
The		O
pKa		O
values		O
of		O
respective		O
ligands		O
and		O
the		O
stability		O
constants		O
of		O
their		O
iron		O
(		O
III		O
)		O
complexes		O
are		O
presented		O
.		O
The		O
AII		O
-		O
induced		O
contraction		O
of		O
rabbit		O
aortic		O
strips		O
was		O
antagonized		O
by		O
CV		O
-		O
11974		O
(		O
IC50		O
value		O
,		O
3.0		O
x		O
10		O
(		O
-		O
10		O
)		O
M		O
)		O
.		O
This		O
has		O
led		O
to		O
syntheses		O
and		O
macrofilaricidal		O
evaluations		O
of		O
a		O
number		O
of		O
1		B-IUPAC
-		I-IUPAC
aryl		I-IUPAC
-		I-IUPAC
9H		I-IUPAC
-		I-IUPAC
pyrido		I-IUPAC
[		I-IUPAC
3,4		I-IUPAC
-		I-IUPAC
b		I-IUPAC
]		I-IUPAC
indole		I-IUPAC
-		I-IUPAC
3		I-IUPAC
-		I-IUPAC
carboxylate		I-IUPAC
derivatives		B-MODIFIER
(		O
3-7		O
)		O
.		O
Certain		O
other		O
acidic		O
sulfonamides		O
,		O
such		O
as		O
sulfonylcarbamates		O
and		O
disulfimides		O
also		O
displayed		O
high		O
affinity		O
for		O
the		O
AT1		O
receptor		O
.		O
Analogues		O
4b		O
,		O
4c		O
,		O
and		O
9b		O
at		O
1		O
x		O
10		O
(		O
-		O
3		O
)		O
M		O
specifically		O
inhibited		O
the		O
incorporation		O
of		O
L		B-IUPAC
-		I-IUPAC
[		I-IUPAC
3H		I-IUPAC
]		I-IUPAC
fucose		I-IUPAC
into		O
macromolecular		O
components		O
of		O
SW613		O
human		O
mammary		O
tumor		O
cells		O
.		O
Most		O
of		O
these		O
analogues		O
demonstrated		O
high		O
affinity		O
binding		O
to		O
the		O
dopamine		O
transporter		O
(		O
DAT		O
;		O
K		O
(		O
i		O
)		O
=		O
1.8-40		O
nM		O
)		O
,		O
and		O
selectivity		O
over		O
the		O
other		O
monoamine		O
transporters		O
and		O
muscarinic		O
M		O
(		O
1		O
)		O
receptors		O
.		O
Thus		O
,		O
IV		O
is		O
a		O
good		O
substrate		O
for		O
converting		O
enzymes		O
from		O
lung		O
and		O
plasma		O
while		O
all		O
other		O
compounds		O
were		O
inhibitors		O
of		O
these		O
enzymes		O
.		O
A		O
series		O
of		O
synthetic		O
estrogens		O
containing		O
hydroxyalkyl		O
side		O
chains		O
at		O
the		O
C		O
-		O
4		O
position		O
of		O
the		O
A		O
ring		O
were		O
designed		O
as		O
metabolically		O
stable		O
analogs		O
of		O
4		B-IUPAC
-		I-IUPAC
hydroxyestradiol		I-IUPAC
,		O
a		O
catechol		O
estrogen		O
.		O
carinii		O
pneumonia		O
in		O
AIDS		O
patients		O
.		O
The		O
acyclic		B-MODIFIER
analog		I-MODIFIER
4		B-IUPAC
-		I-IUPAC
amino		I-IUPAC
-		I-IUPAC
1		I-IUPAC
-		I-IUPAC
[		I-IUPAC
(		I-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
]		I-IUPAC
pyrrolo		I-IUPAC
[		I-IUPAC
2,3		I-IUPAC
-		I-IUPAC
d		I-IUPAC
]		I-IUPAC
pyridazin		I-IUPAC
-		I-IUPAC
7		I-IUPAC
-		I-IUPAC
one		I-IUPAC
(		O
24		O
)		O
was		O
prepared		O
via		O
the		O
sodium		O
salt		O
glycosylation		O
of		O
5		O
with		O
(		B-IUPAC
1,3		I-IUPAC
-		I-IUPAC
dihydroxy		I-IUPAC
-		I-IUPAC
2		I-IUPAC
-		I-IUPAC
propoxy		I-IUPAC
)		I-IUPAC
methyl		I-IUPAC
bromide		I-IUPAC
(		O
22		O
)		O
followed		O
by		O
a		O
ring		O
annulation		O
with		O
hydrazine		O
.		O
